CUMULATIVE SUPPLEMENT 7
July 2026



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

46th EDITION

Department of Health and Human Services
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

2026

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

46th EDITION

Cumulative Supplement 7
July 2026

CONTENTS

PAGE

Contents

1.0 INTRODUCTION v
1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT vi
1.2 CUMULATIVE SUPPLEMENT CONTENT vi
1.3 LEVOTHYROXINE SODIUM vii
1.4 AVAILABILITY OF THE EDITION viii
1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST ix
1.6 CUMULATIVE SUPPLEMENT LEGEND x

DRUG PRODUCT LISTS
Prescription Drug Product List 1-1
OTC Drug Product List 2-1
Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List 3-1
Orphan Products Designations and Approvals List 4-1
Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution 5-1

PATENT AND EXCLUSIVITY INFORMATION ADDENDUM
A. Patent and Exclusivity Lists A-1
B. Patent and Exclusivity Terms B-1

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

46th EDITION

CUMULATIVE SUPPLEMENT 7
July 2026

1.0 INTRODUCTION

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section

2., How To Use The Drug Product Lists, describes the layout and usage of the List.

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>A>**. The Patent and Exclusivity List new additions are indicated by the symbol **>A>** to the left of Patent Number or Exclusivity Code. The **>A>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month’s second work week (e.g., November’s supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
  o Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes
- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.

- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Division of Orange Book Publication and Regulatory Assessment (DOBPRA) of any changes or corrections. The DOBPRA can be contacted by email at orangebook@fda.hhs.gov.

1.3 LEVOTHYROXINE SODIUM[1]

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.[2]

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).

- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS

[1] In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

[2] Please consult the Active Section of the Orange Book for information on other strengths.

AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN INC	0.3MG	N021116	RLD	–
AB4	LEVOTHYROXINE SODIUM[3]	MYLAN	0.3MG	A076187	–	RS

1.4 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions.

There are historical lists of Orange Book cumulative supplement product monthly changes at http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,
Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,
https://www.fda.gov/about-fda/reports-manuals-forms/forms.

[3] Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

The current listing of the Orphan Product Designations and Approvals is available at https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.

1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2025	MAR 2026	JUN 2026	SEP 2026	DEC 2026
DRUG PRODUCTS	24120	24441	24637		
LISTED SINGLE SOURCE	2765 (11.5%)	2813 (11.5%)	2807 (11.4%)		
MULTISOURCE	21355 (88.5%)	21628 (88.5%)	21830 (88.6%)		
THERAPEUTICALLY EQUIVALENT	21260 (87.1%)	21534 (88.1%)	21763 (88.3%)		
NOT THERAPEUTICALLY EQUIVALENT	95 (0.4%)	94 (0.4%)	67 (0.3%)		

EXCEPTIONS[4]	47 (0.2%)	47 (0.2%)	47 (0.2%)
NEW MOLECULAR ENTITIES APPROVED	19	41	36
NUMBER OF APPLICANTS	1198	1198	1195

1.6 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by “N” is a New Drug Application (NDA or innovator). The application number preceded by an “A” is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN[5]	Applicant holder firm name has changed
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration
CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMKT	Change. RX to OTC marketing status switch.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.

[4] Amino acid containing products of varying composition (see Introduction, page xx of the List).
[5] The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug
CHRS	Change. Reference Standard
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

ABAMETAPIR

LOTION;TOPICAL
XEGLYZE

@	+	LNHC	0.74%	N	206966	001	Jul 24, 2020	Apr CAHN

ABARELIX

POWDER;INTRAMUSCULAR
PLENAXIS

@		SPECIALITY EUROPEAN	100MG/VIAL	N	021320	001	Nov 25, 2003	Jan CDFR

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE;ORAL
ACAMPROSATE CALCIUM

AB		APPCO	333MG	A	218984	001	Mar 16, 2026	Mar NEWA

ACARBOSE

TABLET;ORAL
ACARBOSE

>D> AB		AVET LIFESCIENCES	25MG	A	202271	001	Feb 07, 2012	Jul DISC
>A>	@		25MG	A	202271	001	Feb 07, 2012	Jul DISC
>D> AB			50MG	A	202271	002	Feb 07, 2012	Jul DISC
>A>	@		50MG	A	202271	002	Feb 07, 2012	Jul DISC
>D> AB			100MG	A	202271	003	Feb 07, 2012	Jul DISC
>A>	@		100MG	A	202271	003	Feb 07, 2012	Jul DISC
	@	NATCO PHARMA USA	25MG	A	091053	001	Jan 06, 2011	Mar CAHN
	@		50MG	A	091053	002	Jan 06, 2011	Mar CAHN
	@		100MG	A	091053	003	Jan 06, 2011	Mar CAHN

ACETAMINOPHEN

SOLUTION;INTRAVENOUS
ACETAMINOPHEN

AP1		APOTEX	1GM/100ML (10MG/ML)	A	205746	001	Apr 18, 2023	May CAHN

ACETAMINOPHEN; BUTALBITAL

TABLET;ORAL
BUTAPAP

AA	!	MIKART	325MG;50MG	A	089987	001	Oct 26, 1992	Mar CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AA		INGENUS PHARMS LLC	300MG;50MG;40MG	A	215047	001	Nov 17, 2021	Feb CAHN

TABLET;ORAL
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AA	!	ABHAI LLC	325MG;50MG;40MG	A	211106	001	Sep 26, 2018	Jun CHRS
	@	STRIDES PHARMA INTL	325MG;50MG;40MG	A	040511	001	Aug 27, 2003	Jun DISC

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

@		QUAGEN	325MG;50MG;40MG;30MG	A	204649	001	Jul 08, 2020	Apr CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA		LANNETT CO INC	300MG;5MG	A	207171	001	Jun 20, 2017	Mar CMFD
AA			300MG;7.5MG	A	207171	002	Jun 20, 2017	Mar CMFD
AA			300MG;10MG	A	207171	003	Jun 20, 2017	Mar CMFD
AA			325MG;5MG	A	207172	001	Jun 22, 2017	Mar CMFD
AA			325MG;7.5MG	A	207172	002	Jun 22, 2017	Mar CMFD
AA			325MG;10MG	A	207172	003	Jun 22, 2017	Mar CMFD
	@	STRIDES PHARMA INTL	325MG;5MG	A	040655	001	Jan 19, 2006	Jan DISC
	@		325MG;7.5MG	A	040656	001	Jan 19, 2006	Jan DISC
	@		325MG;10MG	A	040355	001	May 31, 2000	Jan DISC

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXYCODONE AND ACETAMINOPHEN

AA		LANNETT CO INC	325MG;5MG	A207333	001	Sep 25, 2017	Feb	CMFD
AA			325MG;10MG	A207333	002	Sep 25, 2017	Feb	CMFD

PERCOCET

AA	!	OZANTRI	325MG;2.5MG	A040330	001	Jun 25, 1999	Apr	CAHN
AA	!		325MG;5MG	A040330	002	Jun 25, 1999	Apr	CAHN
	@ +		325MG;5MG	A085106	002		Apr	CAHN
AA	!		325MG;7.5MG	A040330	003	Nov 23, 2001	Apr	CAHN
AA	!		325MG;10MG	A040330	004	Nov 23, 2001	Apr	CAHN

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

	@	MICRO LABS LTD INDIA	325MG;37.5MG	A201952	001	Dec 14, 2012	Jun	DISC
	@	SENORES PHARMS	325MG;37.5MG	A078778	001	Apr 07, 2014	Jun	CAHN

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS;OTIC

HYDROCORTISONE AND ACETIC ACID

AT		COSETTE PHARMS NC	2%;1%	A040609	001	Feb 06, 2006	May	CAHN

ACETYLCYSTEINE

INJECTABLE;INTRAVENOUS

ACETADOTE

>A> AP	+!	APOTEX	6GM/30ML (200MG/ML)	N021539	001	Jan 23, 2004	Jul	CAHN
>D> AP	+!	CUMBERLAND PHARMS	6GM/30ML (200MG/ML)	N021539	001	Jan 23, 2004	Jul	CAHN

ACLIDINIUM BROMIDE

POWDER, METERED;INHALATION

TUDORZA PRESSAIR

	+!	AZURITY	0.4MG/INH	N202450	001	Jul 23, 2012	Jun	CAHN
	+!		0.4MG/INH	N202450	001	Jul 23, 2012	Mar	CAHN

ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE

POWDER, METERED;INHALATION

DUAKLIR PRESSAIR

>D>	+!	AZURITY	0.4MG/INH;0.012MG/INH	N210595	001	Mar 29, 2019	Jul	CAHN
>A>	+!		0.4MG/INH;0.012MG/INH	N210595	001	Mar 29, 2019	Jul	CAHN
	+!		0.4MG/INH;0.012MG/INH	N210595	001	Mar 29, 2019	Mar	CAHN

ACYCLOVIR

OINTMENT;TOPICAL

ACYCLOVIR

	@	COSETTE PHARMS NC	5%	A205591	001	Nov 13, 2017	May	CAHN

TABLET;ORAL

ACYCLOVIR

	@	STRIDES PHARMA INTL	400MG	A074946	001	Nov 19, 1997	Jan	DISC
	@		800MG	A074946	002	Nov 19, 1997	Jan	DISC

ACYCLOVIR SODIUM

INJECTABLE;INJECTION

ACYCLOVIR SODIUM

>A> AP		HAINAN POLY	EQ 50MG BASE/ML	A218111	001	Jan 08, 2024	Jul	CAHN
>D> AP		SLATE RUN PHARMA	EQ 50MG BASE/ML	A218111	001	Jan 08, 2024	Jul	CAHN

ADAPALENE

SOLUTION;TOPICAL

ADAPALENE

AB		WAYLIS THERAP	0.1%	A203981	001	Sep 23, 2016	Jan	CAHN
AB			0.1%	A204593	001	Jan 05, 2016	Jan	CAHN

ADAPALENE; BENZOYL PEROXIDE

GEL;TOPICAL

ADAPALENE AND BENZOYL PEROXIDE

>A> AB		AUROBINDO PHARMA LTD	0.3%;2.5%	A217384	001	Jul 22, 2026	Jul	NEWA
AB	!	SUN PHARMA CANADA	0.1%;2.5%	A206959	001	Jan 24, 2018	Jun	CHRS

EPIDUO

	@ +	GALDERMA LABS LP	0.1%;2.5%	N022320	001	Dec 08, 2008	Jun	DISC

AFATINIB DIMALEATE

TABLET;ORAL

AFATINIB DIMALEATE

>A>			APOTEX	EQ 20MG BASE	A210725	001	Jul 14, 2026	Jul NFTG
>A>	AB			EQ 30MG BASE	A210725	002	Jul 14, 2026	Jul NFTG
>A>	AB			EQ 40MG BASE	A210725	003	Jul 14, 2026	Jul NFTG
>A>	AB		HETERO LABS LTD V	EQ 20MG BASE	A210750	001	Jul 14, 2026	Jul NFTG
>A>	AB			EQ 30MG BASE	A210750	002	Jul 14, 2026	Jul NFTG
>A>	AB			EQ 40MG BASE	A210750	003	Jul 14, 2026	Jul NFTG

GILOTRIF

>D>		+	BOEHRINGER INGELHEIM	EQ 20MG BASE	N201292	001	Jul 12, 2013	Jul CFTG
>A>	AB	+		EQ 20MG BASE	N201292	001	Jul 12, 2013	Jul CFTG
>D>		+		EQ 30MG BASE	N201292	002	Jul 12, 2013	Jul CFTG
>A>	AB	+		EQ 30MG BASE	N201292	002	Jul 12, 2013	Jul CFTG
>D>		+!		EQ 40MG BASE	N201292	003	Jul 12, 2013	Jul CFTG
>A>	AB	+!		EQ 40MG BASE	N201292	003	Jul 12, 2013	Jul CFTG

ALBUTEROL SULFATE

AEROSOL, METERED;INHALATION

ALBUTEROL SULFATE

	AB3		CIPLA	EQ 0.09MG BASE/INH	A219409	001	Apr 22, 2026	Apr NFTG

VENTOLIN HFA

	AB3	+!	GLAXOSMITHKLINE	EQ 0.09MG BASE/INH	N020983	001	Apr 19, 2001	Apr CFTG

SYRUP;ORAL

ALBUTEROL SULFATE

		@	COSETTE PHARMS NC	EQ 2MG BASE/5ML	A074454	001	Sep 25, 1995	May CAHN

TABLET;ORAL

ALBUTEROL SULFATE

>D>	BX		AIZANT	EQ 2MG BASE	A210948	001	Mar 15, 2019	Jul DISC
>A>		@		EQ 2MG BASE	A210948	001	Mar 15, 2019	Jul DISC
>D>	BX			EQ 4MG BASE	A210948	002	Mar 15, 2019	Jul DISC
>A>		@		EQ 4MG BASE	A210948	002	Mar 15, 2019	Jul DISC
		@	NATCO PHARMA USA	EQ 2MG BASE	A072894	002	Jan 17, 1991	Jun DISC
	AB			EQ 2MG BASE	A072894	002	Jan 17, 1991	Mar CAHN
		@		EQ 4MG BASE	A072894	001	Jan 17, 1991	Jun DISC
	AB	!		EQ 4MG BASE	A072894	001	Jan 17, 1991	Mar CAHN
	AB	!	ZYDUS PHARMS	EQ 4MG BASE	A208884	002	Oct 22, 2020	Jun CHRS

ALCLOMETASONE DIPROPIONATE

CREAM;TOPICAL

ACLOVATE

>A>		@ +	FOUGERA	0.05%	N018707	001	Dec 14, 1982	Jul CAHN
>D>		@ +	FOUGERA PHARMS	0.05%	N018707	001	Dec 14, 1982	Jul CAHN

OINTMENT;TOPICAL

ACLOVATE

>A>		@ +	FOUGERA	0.05%	N018702	001	Dec 14, 1982	Jul CAHN
>D>		@ +	FOUGERA PHARMS	0.05%	N018702	001	Dec 14, 1982	Jul CAHN

ALENDRONATE SODIUM

TABLET, EFFERVESCENT;ORAL

BINOSTO

		@ +	RADIUS	EQ 70MG BASE	N202344	001	Mar 12, 2012	Jun DISC

ALISKIREN HEMIFUMARATE

TABLET;ORAL

TEKTURNA

	AB	+	LXO IRELAND	EQ 150MG BASE	N021985	001	Mar 05, 2007	Jan CAHN
	AB	+!		EQ 300MG BASE	N021985	002	Mar 05, 2007	Jan CAHN

ALLOPURINOL

TABLET;ORAL

LOPURIN

>A>	AB		DR REDDYS	100MG	A071587	002	Apr 02, 1987	Jul CMS1

ALOSETRON HYDROCHLORIDE

TABLET;ORAL

LOTRONEX

	AB	+	LEGACY	EQ 0.5MG BASE	N021107	002	Dec 23, 2003	Jun CAHN
	AB	+!		EQ 1MG BASE	N021107	001	Feb 09, 2000	Jun CAHN

ALPELISIB

GRANULE;ORAL

VIJOICE

		+!	NOVARTIS	50MG/PACKET	N218466	001	Apr 24, 2024	Apr CDFR

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

SOLUTION;INTRAVENOUS

INFUVITE ADULT

	AP	+!	SANDOZ CANADA INC	2 IU/ML;40MG/ML;12MCG/ML;40 IU/ML;1MCG/ML;3MG/ML;120MCG/ML;8MG/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;660 IU/ML;0.03MG/ML	N021163	001	May 18, 2000	Apr CFTG
	AP	+!		2 IU/ML;40MG/ML;12MCG/ML;40 IU/ML;1MCG/ML;3MG/ML;120MCG/ML;8MG/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;660 IU/ML;30MCG/ML	N021163	002	Jun 16, 2003	Apr CFTG

MULTIPLE VITAMINS INJECTION ADULT

	AP		APOTEX	2 IU/ML;40MG/ML;12MCG/ML;40 IU/ML;1MCG/ML;3MG/ML;120MCG/ML;8MG/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;660 IU/ML;0.03MG/ML	A210273	001	Apr 09, 2026	Apr NFTG
	AP			2 IU/ML;40MG/ML;12MCG/ML;40 IU/ML;1MCG/ML;3MG/ML;120MCG/ML;8MG/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;660 IU/ML;30MCG/ML	A210672	001	Apr 09, 2026	Apr NFTG

ALPRAZOLAM

TABLET;ORAL

ALPRAZOLAM

		@	STRIDES PHARMA INTL	0.25MG	A090248	001	Sep 17, 2010	Jan DISC
		@		0.5MG	A090248	002	Sep 17, 2010	Jan DISC
		@		1MG	A090248	003	Sep 17, 2010	Jan DISC
		@		2MG	A090248	004	Sep 17, 2010	Jan DISC
>A>	AB		UNICHEM	0.25MG	A213204	001	Jul 13, 2026	Jul NEWA
>A>	AB			0.5MG	A213204	002	Jul 13, 2026	Jul NEWA
>A>	AB			1MG	A213204	003	Jul 13, 2026	Jul NEWA
>A>	AB			2MG	A213204	004	Jul 13, 2026	Jul NEWA

AMANTADINE HYDROCHLORIDE

CAPSULE;ORAL

AMANTADINE HYDROCHLORIDE

>A>	AB		ONESOURCE	100MG	A211354	001	Feb 18, 2022	Jul CAHN
>D>	AB		ONESOURCE SPECIALTY	100MG	A211354	001	Feb 18, 2022	Jul CAHN

SYRUP;ORAL

AMANTADINE HYDROCHLORIDE

	AA		POM PHARMA	50MG/5ML	A214178	001	Aug 20, 2021	Apr CAHN

TABLET;ORAL

AMANTADINE HYDROCHLORIDE

	AB		POM PHARMA	100MG	A210215	001	Mar 10, 2020	Apr CAHN
>D>	AB		WATSON LABS INC	100MG	A208096	001	Dec 15, 2016	Jul DISC
>A>		@		100MG	A208096	001	Dec 15, 2016	Jul DISC

AMBRISENTAN

TABLET;ORAL

AMBRISENTAN

		@	SUN PHARM	5MG	A210784	001	Mar 28, 2019	May DISC
		@		10MG	A210784	002	Mar 28, 2019	Jun DISC

AMCINONIDE

CREAM;TOPICAL

AMCINONIDE

		@	GENUS LIFESCIENCES	0.1%	A076065	001	May 15, 2003	Jun DISC
		!	TARO PHARM INDS	0.1%	A076229	001	May 31, 2002	Jun CTEC
	AB	!		0.1%	A076229	001	May 31, 2002	Jun CHRS

AMIFOSTINE

INJECTABLE;INJECTION

ETHYOL

@	LEGACY	375MG/VIAL	N020221	002	Sep 10, 1999	Jun	CAHN
+!		500MG/VIAL	N020221	001	Dec 08, 1995	Jun	CAHN
@	LEGACY PHARMA	375MG/VIAL	N020221	002	Sep 10, 1999	Mar	CAHN
@ +		500MG/VIAL	N020221	001	Dec 08, 1995	Mar	CAHN
+!		500MG/VIAL	N020221	001	Dec 08, 1995	Mar	CMFD

AMINOCAPROIC ACID

INJECTABLE;INJECTION

AMINOCAPROIC ACID

AP	ZENARA	250MG/ML	A215374	001	Aug 28, 2025	Mar	CAHN

SOLUTION;ORAL

AMINOCAPROIC ACID

>A> AA	APOZEAL PHARMS	0.25GM/ML	A213216	001	May 19, 2025	Jul	CAHN
AA	CARNEGIE	0.25GM/ML	A214140	001	Jan 26, 2021	Feb	CAHN
>D> AA	SCIEGEN PHARMS	0.25GM/ML	A213216	001	May 19, 2025	Jul	CAHN

TABLET;ORAL

AMINOCAPROIC ACID

AB	CARNEGIE	500MG	A213928	001	Feb 12, 2021	Feb	CAHN
AB		1GM	A213928	002	Feb 12, 2021	Feb	CAHN
AB	RISING	500MG	A213944	001	Sep 14, 2022	May	CAHN
AB		1GM	A213944	002	Sep 14, 2022	May	CAHN

AMINOPHYLLINE

SUPPOSITORY;RECTAL

TRUPHYLLINE

@	COSETTE PHARMS NC	250MG	A085498	001	Mar 23, 1983	May	CAHN
@		500MG	A085498	002	Jan 03, 1983	May	CAHN

AMISULPRIDE

SOLUTION;INTRAVENOUS

BARHEMSYS

+!	LXO IRELAND	5MG/2ML (2.5MG/ML)	N209510	001	Feb 26, 2020	Jun	CAHN
+!		10MG/4ML (2.5MG/ML)	N209510	002	Sep 01, 2020	Jun	CAHN

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

AB	AUROBINDO PHARMA USA	10MG	A086009	002			Mar CMFD
AB		25MG	A086009	003			Mar CMFD
AB		50MG	A086009	001			Mar CMFD
AB		75MG	A086009	004			Mar CMFD
AB		100MG	A086009	005			Mar CMFD
AB		150MG	A086009	006			Mar CMFD
AB	RUBICON RESEARCH	10MG	A215376	001	May 01, 2023	May	CTEC
AB		25MG	A215376	002	May 01, 2023	May	CTEC
AB		50MG	A215376	003	May 01, 2023	May	CTEC
AB		75MG	A215376	004	May 01, 2023	May	CTEC
AB		100MG	A215376	005	May 01, 2023	May	CTEC
AB		150MG	A215376	006	May 01, 2023	May	CTEC

AMLODIPINE BESYLATE

FOR SOLUTION;ORAL

SDAMLO

+!	BRILLIAN PHARMA	EQ 2.5MG BASE/BOT	N219531	001	Jul 24, 2025	Jan	CMFD
+!		EQ 5MG BASE/BOT	N219531	002	Jul 24, 2025	Jan	CMFD
+!		EQ 10MG BASE/BOT	N219531	003	Jul 24, 2025	Jan	CMFD

TABLET;ORAL

AMLODIPINE BESYLATE

AB	GRAVITI PHARMS	EQ 2.5MG BASE	A201380	003	Feb 17, 2026	Feb	NEWA
@	STRIDES PHARMA	EQ 2.5MG BASE	A077516	001	Jul 11, 2007	Jun	DISC
@		EQ 5MG BASE	A077516	002	Jul 11, 2007	Jun	DISC
@		EQ 10MG BASE	A077516	003	Jul 11, 2007	Jun	DISC
AB	TEVA PHARMS INC	EQ 2.5MG BASE	A219686	001	Jan 22, 2026	Jan	NEWA
AB		EQ 5MG BASE	A219686	002	Jan 22, 2026	Jan	NEWA
AB		EQ 10MG BASE	A219686	003	Jan 22, 2026	Jan	NEWA

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET;ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

AB		APDM PHARMS	EQ 2.5MG BASE;EQ 10MG BASE	A207762	001	Jan 11, 2019	Jun	CAHN
AB			EQ 2.5MG BASE;EQ 20MG BASE	A207762	002	Jan 11, 2019	Jun	CAHN
AB			EQ 2.5MG BASE;EQ 40MG BASE	A207762	003	Jan 11, 2019	Jun	CAHN
AB			EQ 5MG BASE;EQ 10MG BASE	A207762	004	Jan 11, 2019	Jun	CAHN
AB			EQ 5MG BASE;EQ 20MG BASE	A207762	005	Jan 11, 2019	Jun	CAHN
AB			EQ 5MG BASE;EQ 40MG BASE	A207762	006	Jan 11, 2019	Jun	CAHN
AB			EQ 5MG BASE;EQ 80MG BASE	A207762	007	Jan 11, 2019	Jun	CAHN
AB			EQ 10MG BASE;EQ 10MG BASE	A207762	008	Jan 11, 2019	Jun	CAHN
AB			EQ 10MG BASE;EQ 20MG BASE	A207762	009	Jan 11, 2019	Jun	CAHN
AB			EQ 10MG BASE;EQ 40MG BASE	A207762	010	Jan 11, 2019	Jun	CAHN
AB			EQ 10MG BASE;EQ 80MG BASE	A207762	011	Jan 11, 2019	Jun	CAHN

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE;ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

AB	!	LUPIN PHARMS	EQ 10MG BASE;40MG	A078466	006	Jul 05, 2011	May	CHRS

LOTREL

@ +		SANDOZ	EQ 2.5MG BASE;10MG	N020364	002	Mar 03, 1995	May	DISC
@ +			EQ 5MG BASE;10MG	N020364	003	Mar 03, 1995	May	DISC
@ +			EQ 5MG BASE;20MG	N020364	004	Mar 03, 1995	May	DISC
@ +			EQ 5MG BASE;40MG	N020364	007	Apr 11, 2006	May	DISC
@ +			EQ 10MG BASE;20MG	N020364	005	Jun 20, 2002	May	DISC
@ +			EQ 10MG BASE;40MG	N020364	006	Apr 11, 2006	May	DISC

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

@		LUPIN	EQ 5MG BASE;12.5MG;160MG	A200797	001	Jun 03, 2015	Jun	DISC
@			EQ 5MG BASE;25MG;160MG	A200797	002	Jun 03, 2015	Jun	DISC
@			EQ 10MG BASE;12.5MG;160MG	A200797	003	Jun 03, 2015	Jun	DISC
@			EQ 10MG BASE;25MG;160MG	A200797	004	Jun 03, 2015	Jun	DISC
@			EQ 10MG BASE;25MG;320MG	A200797	005	Jun 03, 2015	Jun	DISC

AMLODIPINE BESYLATE; INDAPAMIDE; TELMISARTAN

TABLET;ORAL

WIDAPLIK

@ +		AZURITY	EQ 1.25MG BASE;0.625MG;10MG	N219423	001	Jun 05, 2025	Jun	DISC
+!			EQ 1.25MG BASE;0.625MG;10MG	N219423	001	Jun 05, 2025	May	CHRS
+			EQ 1.25MG BASE;0.625MG;10MG	N219423	001	Jun 05, 2025	Mar	CMFD
@ +			EQ 2.5MG BASE;1.25MG;20MG	N219423	002	Jun 05, 2025	Jun	DISC
+			EQ 2.5MG BASE;1.25MG;20MG	N219423	002	Jun 05, 2025	Mar	CMFD
@ +			EQ 5MG BASE;2.5MG;40MG	N219423	003	Jun 05, 2025	Jun	DISC
+!			EQ 5MG BASE;2.5MG;40MG	N219423	003	Jun 05, 2025	Mar	CMFD

AMLODIPINE BESYLATE; TELMISARTAN

TABLET;ORAL

TELMISARTAN AND AMLODIPINE

@		LUPIN	EQ 5MG BASE;40MG	A201586	001	Jan 08, 2014	Jan	DISC
@			EQ 5MG BASE;80MG	A201586	003	Jan 08, 2014	Jan	DISC
@			EQ 10MG BASE;40MG	A201586	002	Jan 08, 2014	Jan	DISC
@			EQ 10MG BASE;80MG	A201586	004	Jan 08, 2014	Jan	DISC
		MYLAN	EQ 5MG BASE;40MG	A202516	001	Aug 26, 2014	Feb	CMFD
@			EQ 5MG BASE;40MG	A202516	001	Aug 26, 2014	Jan	DISC
			EQ 5MG BASE;80MG	A202516	003	Aug 26, 2014	Feb	CMFD
@			EQ 5MG BASE;80MG	A202516	003	Aug 26, 2014	Jan	DISC
			EQ 10MG BASE;40MG	A202516	002	Aug 26, 2014	Feb	CMFD
@			EQ 10MG BASE;40MG	A202516	002	Aug 26, 2014	Jan	DISC
!			EQ 10MG BASE;80MG	A202516	004	Aug 26, 2014	Feb	CMFD
@			EQ 10MG BASE;80MG	A202516	004	Aug 26, 2014	Jan	DISC

AMLODIPINE BESYLATE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE AND VALSARTAN

@		LUPIN	EQ 5MG BASE;160MG	A090245	001	Mar 30, 2015	Apr	DISC
@			EQ 5MG BASE;320MG	A090245	003	Mar 30, 2015	Apr	DISC
@			EQ 10MG BASE;160MG	A090245	002	Mar 30, 2015	Apr	DISC
@			EQ 10MG BASE;320MG	A090245	004	Mar 30, 2015	Apr	DISC

AMMONIA N-13

INJECTABLE;INTRAVENOUS

AMMONIA N 13

	@	NUKEMED	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204455	001	Apr 23, 2015	Apr DISC
	!	WA UNIV SCH MED	37.5mCi-800mCi/10ML (3.75-80mCi/ML)	A204506	002	Feb 13, 2026	Feb NFTG

AMMONIUM LACTATE

CREAM;TOPICAL

AMMONIUM LACTATE

AB		PADAGIS ISRAEL	EQ 12% BASE	A075774	001	May 01, 2002	Jan CHRS
AB	!	SUN PHARMA CANADA	EQ 12% BASE	A075883	001	Apr 10, 2003	Jan CHRS
AB		ZYDUS LIFESCIENCES	EQ 12% BASE	A217815	001	Feb 12, 2026	Feb NEWA

LOTION;TOPICAL

AMMONIUM LACTATE

AB		ZYDUS LIFESCIENCES	EQ 12% BASE	A217758	001	May 15, 2026	May NEWA

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET, EXTENDED RELEASE;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	!	SANDOZ	1GM;EQ 62.5MG BASE	A090227	001	Apr 21, 2010	Jan CTEC

AUGMENTIN XR

AB	+	US ANTIBIOTICS	1GM;EQ 62.5MG BASE	N050785	001	Sep 25, 2002	Jan CMFD

AMPHETAMINE SULFATE

TABLET;ORAL

AMPHETAMINE SULFATE

	@	INGENUS PHARMS LLC	5MG	A213763	001	Aug 24, 2020	Feb CAHN
	@		10MG	A213763	002	Aug 24, 2020	Feb CAHN

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE;INJECTION

AMPICILLIN AND SULBACTAM

	@	EUROFARMA	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065316	001	Jun 29, 2007	Feb CAHN
	@		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065316	002	Jun 29, 2007	Feb CAHN

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

FOR SUSPENSION;ORAL

PROBAMPACIN

	@	COSETTE PHARMS NC	EQ 3.5GM BASE/BOT;1GM/BOT	A061741	001		May CAHN

APALUTAMIDE

TABLET;ORAL

APALUTAMIDE

AB		ZYDUS LIFESCIENCES	60MG	A217113	001	Mar 17, 2025	May CAHN

APREPITANT

EMULSION;INTRAVENOUS

APONVIE

	+!	HERON THERAPS INC	32MG/4.4ML (7.2MG/ML)	N216457	001	Sep 16, 2022	Mar CTEC
AB	+!		32MG/4.4ML (7.2MG/ML)	N216457	001	Sep 16, 2022	Feb CFTG

APREPITANT

	+!	AZURITY	130MG/18ML (7.2MG/ML)	N218754	001	Jun 16, 2026	Jun NEWA
	@	MYLAN	32MG/4.4ML (7.2MG/ML)	A218851	001	Mar 05, 2026	Mar DISC
AB			32MG/4.4ML (7.2MG/ML)	A218851	001	Mar 05, 2026	Feb NFTG

ARFORMOTEROL TARTRATE

SOLUTION;INHALATION

ARFORMOTEROL TARTRATE

	@	TEVA PHARMS USA	EQ 0.015MG BASE/2ML	A200293	001	Nov 09, 2021	Jun DISC

ARIPIPRAZOLE

TABLET;ORAL

ARIPIPRAZOLE

	@	APOTEX	2MG	A078583	001	Jul 24, 2015	Apr DISC
	@		5MG	A078583	002	Jul 24, 2015	Apr DISC
	@		10MG	A078583	003	Jul 24, 2015	Apr DISC
	@		15MG	A078583	004	Jul 24, 2015	Apr DISC

TABLET;ORAL
ARIPIPRAZOLE

	@		20MG	A078583	005	Jul 24, 2015	Apr	DISC
	@		30MG	A078583	006	Jul 24, 2015	Apr	DISC

TABLET, ORALLY DISINTEGRATING;ORAL
ARIPIPRAZOLE

AB		AUROBINDO PHARMA	10MG	A216208	001	Feb 18, 2026	Feb	NEWA
AB			15MG	A216208	002	Feb 18, 2026	Feb	NEWA

ARMODAFINIL

TABLET;ORAL
ARMODAFINIL

AB		COREPHARMA	50MG	A201514	001	Mar 25, 2019	Jan	CMFD
AB			150MG	A201514	002	Mar 25, 2019	Jan	CMFD
AB			250MG	A201514	003	Mar 25, 2019	Jan	CMFD
	@	LUPIN	50MG	A200751	001	Nov 28, 2016	Jun	DISC
	@		150MG	A200751	003	Nov 28, 2016	Jun	DISC
	@		200MG	A200751	004	Nov 28, 2016	Jun	DISC
	@		250MG	A200751	005	Nov 28, 2016	Jun	DISC

ARSENIC TRIOXIDE

INJECTABLE;INJECTION
ARSENIC TRIOXIDE

AP		INGENUS PHARMS LLC	1MG/ML	A209315	001	Nov 15, 2018	Feb	CAHN
	@		2MG/ML	A209315	002	Jan 14, 2021	Feb	CAHN
AP		J MOLNER	1MG/ML	A210802	001	Nov 13, 2018	Jun	CAHN

ARTICAINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
CYKLX

	@ +	AM GENOMICS	EQ 8% BASE	N218643	001	Aug 15, 2025	Feb	DISC
	@ +	THEA PHARMA	EQ 8% BASE	N218643	001	Aug 15, 2025	Apr	CAHN

ASCORBIC ACID

SOLUTION;INTRAVENOUS
ASCORBIC ACID

>A> AP		STIRA	25,000MG/50ML (500MG/ML)	A220172	001	Jul 30, 2026	Jul	NEWA

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE;INTRAVENOUS
INFUVITE PEDIATRIC

AP	+!	SANDOZ CANADA INC	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL; 0.14MG/VIAL;17MG/VIAL;1MG/VIAL ;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N021265	001	Feb 21, 2001	Apr	CFTG

INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)

AP	+!	SANDOZ CANADA INC	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL; 0.14MG/VIAL;17MG/VIAL;1MG/VIAL ;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N021265	002	Jan 29, 2004	Apr	CFTG

MULTIPLE VITAMINS INJECTION PEDIATRIC

AP		APOTEX	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL; 0.14MG/VIAL;17MG/VIAL;1MG/VIAL ;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	A210671	001	Apr 21, 2026	Apr	NFTG

MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE)

AP		APOTEX	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL; 0.14MG/VIAL;17MG/VIAL;1MG/VIAL ;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	A210456	001	Apr 21, 2026	Apr	NFTG

ASENAPINE MALEATE

TABLET;SUBLINGUAL

SAPHRIS

AB		+	ABBVIE	EQ 2.5MG BASE	N022117	003	Mar 12, 2015	Mar CAHN
AB		+		EQ 5MG BASE	N022117	001	Aug 13, 2009	Mar CAHN
AB		+!		EQ 10MG BASE	N022117	002	Aug 13, 2009	Mar CAHN

ASPIRIN; CARISOPRODOL

TABLET;ORAL

CARISOPRODOL AND ASPIRIN

	@		INGENUS PHARMS LLC	325MG;200MG	A040832	001	Jan 07, 2010	May CAHN

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXYCODONE AND ASPIRIN

	@		EPIC PHARMA LLC	325MG;4.8355MG	A040910	001	Jul 16, 2020	Apr DISC

PERCODAN

	@	+	ENDO OPERATIONS	325MG;4.8355MG	N007337	007	Aug 05, 2005	Apr DISC

ATENOLOL

TABLET;ORAL

ATENOLOL

AB			IPCA LABS LTD	25MG	A077877	001	Dec 27, 2006	Jan CMFD
AB				50MG	A077877	002	Dec 27, 2006	Jan CMFD
AB				100MG	A077877	003	Dec 27, 2006	Jan CMFD

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL

ATENOLOL AND CHLORTHALIDONE

AB		!	UNICHEM	100MG;25MG	A213302	002	Nov 25, 2020	Apr CHRS

TENORETIC 100

	@	+	TWI PHARMS	100MG;25MG	N018760	001	Jun 08, 1984	Apr DISC

TENORETIC 50

	@	+	TWI PHARMS	50MG;25MG	N018760	002	Jun 08, 1984	Apr DISC

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

AB			CREEKWOOD PHARMS	EQ 10MG BASE	A218875	001	Jun 16, 2026	Jun NEWA
AB				EQ 18MG BASE	A218875	002	Jun 16, 2026	Jun NEWA
AB				EQ 25MG BASE	A218875	003	Jun 16, 2026	Jun NEWA
AB				EQ 40MG BASE	A218875	004	Jun 16, 2026	Jun NEWA
AB				EQ 60MG BASE	A218875	005	Jun 16, 2026	Jun NEWA
AB				EQ 80MG BASE	A218875	006	Jun 16, 2026	Jun NEWA
AB				EQ 100MG BASE	A218875	007	Jun 16, 2026	Jun NEWA

SOLUTION;ORAL

ATONCY

		+!	MAP77	EQ 4MG BASE/ML	N220320	001	Mar 20, 2026	Mar NEWA

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

AB			UMEDICA	EQ 10MG BASE	A213853	001	Aug 19, 2020	Jun CTEC
AB				EQ 20MG BASE	A213853	002	Aug 19, 2020	Jun CTEC
AB				EQ 40MG BASE	A213853	003	Aug 19, 2020	Jun CTEC
AB				EQ 80MG BASE	A213853	004	Aug 19, 2020	Jun CTEC

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET;ORAL

LYPQOZET

>D>			PHARMOBEDIENT	EQ 10MG BASE;10MG	A206084	001	Apr 26, 2017	Jul DISC
>A>		@		EQ 10MG BASE;10MG	A206084	001	Apr 26, 2017	Jul DISC
>D>				EQ 20MG BASE;10MG	A206084	002	Apr 26, 2017	Jul DISC
>A>		@		EQ 20MG BASE;10MG	A206084	002	Apr 26, 2017	Jul DISC
>D>				EQ 40MG BASE;10MG	A206084	003	Apr 26, 2017	Jul DISC
>A>		@		EQ 40MG BASE;10MG	A206084	003	Apr 26, 2017	Jul DISC
>D>		!		EQ 80MG BASE;10MG	A206084	004	Apr 26, 2017	Jul DISC
>A>		@		EQ 80MG BASE;10MG	A206084	004	Apr 26, 2017	Jul DISC

ATROPINE SULFATE

SOLUTION;INTRAVENOUS

ATROPINE SULFATE

>D>		@ +	ACCORD HLTHCARE	0.4MG/ML (0.4MG/ML)	N214652	001	Sep 29, 2020	Jul CMFD
>A>	AP	+		0.4MG/ML (0.4MG/ML)	N214652	001	Sep 29, 2020	Jul CMFD

SOLUTION/DROPS;OPHTHALMIC

ATROPINE SULFATE

	AT1		EDENBRIDGE PHARMS	1%	A219013	001	Apr 15, 2026	Apr NEWA
>A>	AT1		GLAND	1%	A219996	001	Jul 31, 2026	Jul NEWA

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET;ORAL

MOTOFEN

		+!	LEGACY	0.025MG;1MG	N017744	002		Jun CAHN

MOTOFEN HALF-STRENGTH

		@	LEGACY	0.025MG;0.5MG	N017744	001		Jun CAHN

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

		@	QUAGEN	0.025MG;2.5MG	A085762	001		Apr CAHN
		@		0.025MG;2.5MG	A210571	001	Aug 31, 2018	Feb CAHN

AURANOFIN

CAPSULE;ORAL

RIDAURA

		+!	LEGACY	3MG	N018689	001	May 24, 1985	Jun CAHN

AXITINIB

TABLET;ORAL

AXITINIB

		@	APOTEX	1MG	A211650	001	Oct 30, 2025	Apr DISC
		@		5MG	A211650	002	Oct 30, 2025	Apr DISC

INLYTA

		+	PF PRISM CV	1MG	N202324	001	Jan 27, 2012	Apr CTEC
		+!		5MG	N202324	002	Jan 27, 2012	Apr CTEC

AZACITIDINE

POWDER;INTRAVENOUS, SUBCUTANEOUS

AZACITIDINE

		@	AMNEAL	100MG/VIAL	A211549	001	Feb 03, 2022	Apr DISC

AZATHIOPRINE

TABLET;ORAL

IMURAN

		@ +	LEGACY	25MG	N016324	002		Jun CAHN
	AB	+!		50MG	N016324	001		Jun CAHN

AZILSARTAN KAMEDOXOMIL

TABLET;ORAL

AZILSARTAN MEDOXOMIL

	AB		LUPIN	EQ 40MG MEDOXOMIL	A214489	001	Jul 20, 2022	Apr CMFD
	AB			EQ 80MG MEDOXOMIL	A214489	002	Jul 20, 2022	Apr CMFD

EDARBI

	AB	+	AZURITY	EQ 40MG MEDOXOMIL	N200796	001	Feb 25, 2011	Apr CTEC
	AB	+!		EQ 80MG MEDOXOMIL	N200796	002	Feb 25, 2011	Apr CTEC

AZITHROMYCIN

INJECTABLE;INJECTION

AZITHROMYCIN

>D>	AP		EUGIA PHARMA	EQ 500MG BASE/VIAL	A203294	001	Jun 19, 2015	Jul CHRS
>A>	AP	!		EQ 500MG BASE/VIAL	A203294	001	Jun 19, 2015	Jul CHRS
>A>	AP		HAINAN POLY	EQ 500MG BASE/VIAL	A203412	001	Oct 09, 2018	Jul CAHN
>D>	AP		SLATE RUN PHARMA	EQ 500MG BASE/VIAL	A203412	001	Oct 09, 2018	Jul CAHN
>D>								

ZITHROMAX

>D>	AP	+!	PFIZER	EQ 500MG BASE/VIAL	N050733	001	Jan 30, 1997	Jul DISC
>A>		@ +		EQ 500MG BASE/VIAL	N050733	001	Jan 30, 1997	Jul DISC

TABLET;ORAL

AZITHROMYCIN

		@	CARLSBAD	EQ 250MG BASE	A211317	001	Jul 26, 2022	Feb CAHN

TABLET;ORAL
AZITHROMYCIN

AB			EQ 600MG BASE	A211068	001	May 08, 2020	Feb	CAHN
	@	STRIDES PHARMA	EQ 250MG BASE	A215772	001	Jul 15, 2022	Jun	DISC
	@		EQ 500MG BASE	A215773	001	Jul 12, 2022	Jun	DISC

AZTREONAM

INJECTABLE;INJECTION
AZACTAM

	@	LABS DELBERT	500MG/VIAL	N050580	001	Dec 31, 1986	May	CAHN
AP	+!		1GM/VIAL	N050580	002	Dec 31, 1986	May	CAHN
AP	+!		2GM/VIAL	N050580	003	Dec 31, 1986	May	CAHN

AZTREONAM

	@	HIKMA	1GM/VIAL	A207069	001	Feb 05, 2026	Feb	DISC
AP			1GM/VIAL	A207069	001	Feb 05, 2026	Jan	NEWA
	@		2GM/VIAL	A207069	002	Feb 05, 2026	Feb	DISC
AP			2GM/VIAL	A207069	002	Feb 05, 2026	Jan	NEWA

BACITRACIN

OINTMENT;OPHTHALMIC
BACITRACIN

	@	PADAGIS US	500 UNITS/GM	A061212	001		Mar	DISC

BACITRACIN ZINC; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

	@	PADAGIS US	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062166	002		Mar	DISC

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC
NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE

	!	BAUSCH AND LOMB INC	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A064068	001	Oct 30, 1995	May	CAHN

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

AT	!	BAUSCH AND LOMB INC	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A064064	001	Oct 30, 1995	May	CAHN
	@	PADAGIS US	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A060764	002		Mar	DISC

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC
BACITRACIN ZINC AND POLYMYXIN B SULFATE

	!	BAUSCH AND LOMB	500 UNITS/GM;10,000 UNITS/GM	A064046	001	Jan 26, 1995	Mar	CTEC
	!	BAUSCH AND LOMB INC	500 UNITS/GM;10,000 UNITS/GM	A064046	001	Jan 26, 1995	May	CAHN
	@	PADAGIS US	500 UNITS/GM;10,000 UNITS/GM	A065022	001	Feb 27, 2002	Mar	DISC

BACLOFEN

GRANULE;ORAL
LYVISPAH

	@ +	STRIDES PHARMA INTL	5MG/PACKET	N215422	001	Nov 22, 2021	Apr	CDFR
	@ +		10MG/PACKET	N215422	002	Nov 22, 2021	Apr	CDFR
	@ +		20MG/PACKET	N215422	003	Nov 22, 2021	Apr	CDFR

GRANULES;ORAL
LYVISPAH

	@ +	STRIDES PHARMA INTL	5MG/PACKET	N215422	001	Nov 22, 2021	Jan	CAHN
	@ +		10MG/PACKET	N215422	002	Nov 22, 2021	Jan	CAHN
	@ +		20MG/PACKET	N215422	003	Nov 22, 2021	Jan	CAHN

TABLET;ORAL
BACLOFEN

AB		HIBROW HLTHCARE	5MG	A211555	003	Nov 30, 2021	May	CTEC
AB			10MG	A211555	001	Feb 01, 2019	May	CTEC
AB			20MG	A211555	002	Feb 01, 2019	May	CTEC
AB		RUBICON RESEARCH	5MG	A209102	001	Nov 28, 2017	Jan	CHRS

BALOXAVIR MARBOXIL

TABLET;ORAL

BALOXAVIR MARBOXIL

AB		NORWICH	40MG	A217449	001	Jun 17, 2026	Jun NFTG
AB			80MG	A217449	002	Jun 17, 2026	Jun NFTG

XOFLUZA

AB	+	GENENTECH INC	40MG	N210854	002	Oct 24, 2018	Jun CFTG
AB	+!		80MG	N210854	003	Mar 18, 2021	Jun CFTG

BALSALAZIDE DISODIUM

CAPSULE;ORAL

BALSALAZIDE DISODIUM

AB		CARNEGIE	750MG	A219422	001	Apr 03, 2025	Feb CAHN

BAXDROSTAT

TABLET;ORAL

BAXFENDY

	+	ASTRAZENECA AB	1MG	N219878	001	May 15, 2026	May NEWA
	+!		2MG	N219878	002	May 15, 2026	May NEWA

BECLOMETHASONE DIPROPIONATE; FORMOTEROL FUMARATE; GLYCOPYRROLATE

AEROSOL, METERED;INHALATION

TRIMBOW

	+!	CHIESI	0.086MG/INH;0.0049MG/INH;0.010 6MG/INH	N219622	001	May 14, 2026	May NEWA
	+!		0.172MG/INH;0.0049MG/INH;0.010 6MG/INH	N219622	002	May 14, 2026	May NEWA

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

	@	APOTEX	5MG;6.25MG	A078794	001	Aug 21, 2014	Mar DISC
	@		10MG;12.5MG	A078794	002	Aug 21, 2014	Mar DISC
	@		20MG;12.5MG	A078794	003	Aug 21, 2014	Mar DISC
	@		20MG;25MG	A078794	004	Aug 21, 2014	Mar DISC
AB	!	SANDOZ	20MG;25MG	A076631	004	Feb 11, 2004	Jan CHRS

LOTENSIN HCT

AB	+	VALIDUS PHARMS	20MG;25MG	N020033	003	May 19, 1992	Jan CHRS

BENDAMUSTINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

BENDAMUSTINE HYDROCHLORIDE

	+!	AVYXA HOLDINGS	100MG/4ML (25MG/ML)	N219014	001	Jul 03, 2025	Mar CAHN
	+!	DR REDDYS	100MG/4ML (25MG/ML)	N219014	001	Jul 03, 2025	Apr CMFD

BENZONATATE

CAPSULE;ORAL

BENZONATATE

AA		ASCENT PHARMS INC	150MG	A211518	002	Feb 22, 2019	Apr CMFD
AA		MARKSANS PHARMA	100MG	A220298	001	Mar 30, 2026	Mar NEWA
AA			200MG	A220298	002	Mar 30, 2026	Mar NEWA
AA	!	THEPHARMANETWORK LLC	150MG	A040627	003	Sep 24, 2014	Apr CTEC

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

>D>	AB		ACTAVIS LABS UT INC	2.5%;EQ 1.2% BASE	A205128	001	Jun 19, 2015	Jul DISC
>A>		@		2.5%;EQ 1.2% BASE	A205128	001	Jun 19, 2015	Jul DISC
>A>	AB			3.75%;EQ 1.2% BASE	A208757	001	Aug 07, 2026	Jul NEWA

BENZPHETAMINE HYDROCHLORIDE

TABLET;ORAL

BENZPHETAMINE HYDROCHLORIDE

AA		AVET LIFESCIENCES	50MG	A202061	001	Jan 27, 2012	Jun CMFD

BEPOTASTINE BESILATE

SOLUTION/DROPS;OPHTHALMIC

BEPOTASTINE BESILATE

	@	APOTEX	1.5%	A206066	001	Mar 05, 2019	Apr DISC

BETAMETHASONE DIPROPIONATE

CREAM;TOPICAL

BETAMETHASONE DIPROPIONATE

	AB		AUROBINDO PHARMA LTD	EQ 0.05% BASE	A219348	001	Jan 26, 2026	Jan	NEWA
	AB		COSETTE PHARMS NC	EQ 0.05% BASE	A210217	001	Oct 12, 2018	May	CAHN
>A>	AB	+!	FOUGERA	EQ 0.05% BASE	N019137	001	Jun 26, 1984	Jul	CAHN
>D>	AB	+!	FOUGERA PHARMS	EQ 0.05% BASE	N019137	001	Jun 26, 1984	Jul	CAHN

LOTION;TOPICAL

BETAMETHASONE DIPROPIONATE

	AB		COSETTE PHARMS NC	EQ 0.05% BASE	A071467	001	Aug 10, 1987	May	CAHN
		@		EQ 0.05% BASE	A071882	001	Jun 06, 1988	May	CAHN

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

SUSPENSION;TOPICAL

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

	AB		COSETTE PHARMS NC	0.064%;0.005%	A210765	001	May 11, 2020	May	CAHN

BETAMETHASONE VALERATE

AEROSOL, FOAM;TOPICAL

BETAMETHASONE VALERATE

		@	INGENUS PHARMS LLC	0.12%	A207144	001	May 24, 2017	Feb	CAHN

LUXIQ

>D>		@ +	PHARMOBEDIENT	0.12%	N020934	001	Feb 28, 1999	Jul	CAHN
>A>		@ +	QUAGEN	0.12%	N020934	001	Feb 28, 1999	Jul	CAHN

CREAM;TOPICAL

BETA-VAL

	AB		COSETTE PHARMS NC	EQ 0.1% BASE	N018642	001	Mar 24, 1983	May	CAHN

BETAMETHASONE VALERATE

>A>	AB	+!	FOUGERA	EQ 0.1% BASE	N018861	001	Aug 31, 1983	Jul	CAHN
>D>	AB	+!	FOUGERA PHARMS INC	EQ 0.1% BASE	N018861	001	Aug 31, 1983	Jul	CAHN

LOTION;TOPICAL

BETA-VAL

		@	COSETTE PHARMS NC	EQ 0.1% BASE	A070072	001	Jun 27, 1985	May	CAHN

BETAMETHASONE VALERATE

>A>	AB	+!	FOUGERA	EQ 0.1% BASE	N018866	001	Aug 31, 1983	Jul	CAHN
>D>	AB	+!	FOUGERA PHARMS INC	EQ 0.1% BASE	N018866	001	Aug 31, 1983	Jul	CAHN

OINTMENT;TOPICAL

BETA-VAL

	AB		COSETTE PHARMS NC	EQ 0.1% BASE	A070069	001	Dec 19, 1985	May	CAHN

BETAMETHASONE VALERATE

>A>	AB	+!	FOUGERA	EQ 0.1% BASE	N018865	001	Aug 31, 1983	Jul	CAHN
>D>	AB	+!	FOUGERA PHARMS INC	EQ 0.1% BASE	N018865	001	Aug 31, 1983	Jul	CAHN

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

	AT		EUROFARMA	EQ 0.5% BASE	A075630	001	Apr 12, 2001	Feb	CAHN

BIMATOPROST

SOLUTION/DROPS;TOPICAL

BIMATOPROST

		@	APOTEX	0.03%	A201894	001	Dec 01, 2014	Apr	DISC

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE

	AB		INGENUS PHARMS LLC	140MG;125MG;125MG	A217511	001	Jul 03, 2023	Feb	CAHN

BISOPROLOL FUMARATE

TABLET;ORAL

BISOPROLOL FUMARATE

	AB		MICRO LABS	5MG	A218303	001	Mar 09, 2026	Feb	NEWA
	AB			10MG	A218303	002	Mar 09, 2026	Feb	NEWA
		@	NATCO PHARMA USA	5MG	A075831	001	Dec 14, 2005	Mar	CAHN
		@		10MG	A075831	002	Dec 14, 2005	Mar	CAHN

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

	AB		AUROBINDO PHARMA LTD	2.5MG;6.25MG	A217922	001	Jan 21, 2026	Jan NEWA
	AB			5MG;6.25MG	A217922	002	Jan 21, 2026	Jan NEWA
	AB			10MG;6.25MG	A217922	003	Jan 21, 2026	Jan NEWA
	AB		UNIQUE PHARM	2.5MG;6.25MG	A219489	001	Mar 24, 2026	Mar NEWA
	AB			5MG;6.25MG	A219489	002	Mar 24, 2026	Mar NEWA
	AB			10MG;6.25MG	A219489	003	Mar 24, 2026	Mar NEWA

BIVALIRUDIN

INJECTABLE;INTRAVENOUS

BIVALIRUDIN

>A>	AP		HAINAN POLY	250MG/VIAL	A213078	001	May 28, 2021	Jul CAHN
>D>	AP		SLATE RUN PHARMA	250MG/VIAL	A213078	001	May 28, 2021	Jul CAHN

BORTEZOMIB

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

BORTEZOMIB

		@	CAPLIN ONE LABS	3.5MG/VIAL	A203654	001	Jul 26, 2022	Mar DISC
	AP			3.5MG/VIAL	A203654	001	Jul 26, 2022	Jan CAHN

BOSENTAN

TABLET, FOR SUSPENSION;ORAL

BOSENTAN

	AB		ZYDUS PHARMS	32MG	A213981	001	Feb 17, 2026	Feb NEWA

BOSUTINIB MONOHYDRATE

TABLET;ORAL

BOSULIF

	AB	+	PF PRISM CV	EQ 400MG BASE	N203341	003	Oct 27, 2017	Jun CFTG

BOSUTINIB MONOHYDRATE

	AB		MSN	EQ 400MG BASE	A209624	001	Jun 12, 2026	Jun NFTG

BREXANOLONE

SOLUTION;INTRAVENOUS

ZULRESSO

		@ +	SAGE THERAP SUPERNUS	100MG/20ML (5MG/ML)	N211371	001	Jun 17, 2019	Jun CAHN

BRIGATINIB

TABLET;ORAL

ALUNBRIG

		+!	TAKEDA PHARMS USA	90MG	N208772	002	Apr 28, 2017	Jan CHRS
		+		180MG	N208772	003	Oct 02, 2017	Jan CHRS

BRIMONIDINE TARTRATE

SOLUTION/DROPS;OPHTHALMIC

BRIMONIDINE TARTRATE

	AT	!	BAUSCH AND LOMB INC	0.2%	A076260	001	May 28, 2003	May CAHN
	AB		GLAND	0.1%	A219219	001	Mar 11, 2026	Feb NEWA
	AB		MANKIND PHARMA	0.1%	A220398	001	Apr 16, 2026	Apr NEWA
	AB		MICRO LABS	0.1%	A218558	001	May 07, 2026	Apr NEWA

BRIMONIDINE TARTRATE; CARBACHOL

SOLUTION/DROPS;OPHTHALMIC

YUVEZZI

		+!	VISUS	0.1%;2.75%	N220142	001	Jan 28, 2026	Jan NEWA

BRIMONIDINE TARTRATE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

BRIMONIDINE TARTRATE AND TIMOLOL MALEATE

	AB		GLAND	0.2%;EQ 0.5% BASE	A219166	001	Jun 11, 2026	Jun NEWA
	AB		SABA ILAC SANAYIVE	0.2%;EQ 0.5% BASE	A217934	001	Jul 01, 2026	Jun NEWA

BRIVARACETAM

SOLUTION;INTRAVENOUS

BRIVARACETAM

	AP		HAINAN POLY	50MG/5ML (10MG/ML)	A218249	001	Feb 23, 2026	Feb NFTG
	AP		MICRO LABS	50MG/5ML (10MG/ML)	A214880	001	Feb 23, 2026	Feb NFTG
	AP		MSN	50MG/5ML (10MG/ML)	A214924	001	Feb 23, 2026	Feb NFTG
>A>	AP		SHANDONG	50MG/5ML (10MG/ML)	A219766	001	Jul 13, 2026	Jul NEWA

		SOLUTION;INTRAVENOUS						
		BRIVIACT						
	AP	+! UCB INC	50MG/5ML (10MG/ML)	N205837	001	May 12, 2016	Feb	CFTG
		SOLUTION;ORAL						
		BRIVARACETAM						
	AA	ALKEM LABS LTD	10MG/ML	A219772	001	Feb 23, 2026	Feb	NEWA
>A>	AA	AUROBINDO PHARMA	10MG/ML	A220288	001	Aug 10, 2026	Jul	NEWA
	AA	INDOCO	10MG/ML	A220385	001	Feb 23, 2026	Feb	NEWA
	AA	LUPIN	10MG/ML	A220164	001	Feb 23, 2026	Feb	NEWA
	AA	MSN	10MG/ML	A214922	001	Feb 19, 2026	Feb	NFTG
	AA	REGCON HOLDINGS	10MG/ML	A220385	001	Feb 23, 2026	Mar	CAHN
	AA	ZHEJIANG POLY PHARM	10MG/ML	A218494	001	Feb 23, 2026	Feb	NEWA
		BRIVIACT						
	AA	+! UCB INC	10MG/ML	N205838	001	May 12, 2016	Feb	CFTG
		TABLET;ORAL						
		BRIVARACETAM						
	AB	APOTEX	10MG	A214875	001	Feb 23, 2026	Feb	NEWA
	AB		25MG	A214875	002	Feb 23, 2026	Feb	NEWA
	AB		50MG	A214875	003	Feb 23, 2026	Feb	NEWA
	AB		75MG	A214875	004	Feb 23, 2026	Feb	NEWA
	AB		100MG	A214875	005	Feb 23, 2026	Feb	NEWA
>A>	AB	AUROBINDO PHARMA LTD	10MG	A214848	003	Jul 13, 2026	Jul	NEWA
>A>	AB		25MG	A214848	004	Jul 13, 2026	Jul	NEWA
	AB		50MG	A214848	001	Jan 06, 2023	Jan	CMFD
>A>	AB		75MG	A214848	005	Jul 13, 2026	Jul	NEWA
	AB		100MG	A214848	002	Jan 06, 2023	Jan	CMFD
	AB	CENTAUR PHARMS PVT	10MG	A220470	001	Feb 23, 2026	Feb	NEWA
	AB		25MG	A220470	002	Feb 23, 2026	Feb	NEWA
	AB		50MG	A220470	003	Feb 23, 2026	Feb	NEWA
	AB		75MG	A220470	004	Feb 23, 2026	Feb	NEWA
	AB		100MG	A220470	005	Feb 23, 2026	Feb	NEWA
	AB	SCIEGEN PHARMS	10MG	A219952	001	Jul 01, 2026	Jun	NEWA
	AB		25MG	A219952	002	Jul 01, 2026	Jun	NEWA
	AB		50MG	A219952	003	Jul 01, 2026	Jun	NEWA
	AB		75MG	A219952	004	Jul 01, 2026	Jun	NEWA
	AB		100MG	A219952	005	Jul 01, 2026	Jun	NEWA
	AB	SUNSHINE	10MG	A214748	001	Jun 09, 2022	Jan	CMFD
	AB		25MG	A214748	002	Jun 09, 2022	Jan	CMFD
	AB		50MG	A214748	003	Jun 09, 2022	Jan	CMFD
	AB		75MG	A214748	004	Jun 09, 2022	Jan	CMFD
	AB		100MG	A214748	005	Jun 09, 2022	Jan	CMFD
	AB	ZYDUS PHARMS	10MG	A214501	001	Oct 03, 2022	May	CMFD
	AB		25MG	A214501	002	Oct 03, 2022	May	CMFD
	AB		50MG	A214501	003	Oct 03, 2022	May	CMFD
	AB		75MG	A214501	004	Oct 03, 2022	May	CMFD
	AB		100MG	A214501	005	Oct 03, 2022	May	CMFD
		BROMFENAC SODIUM						
		SOLUTION/DROPS;OPHTHALMIC						
		BROMFENAC SODIUM						
>D>		@ AMRING PHARMS	EQ 0.09% ACID	A202030	001	Jan 09, 2013	Jul	CAHN
>A>		@ J MOLNER	EQ 0.09% ACID	A202030	001	Jan 09, 2013	Jul	CAHN
		BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE						
		SYRUP;ORAL						
		BROMFED-DM						
		@ + PHARMOBEDIENT	2MG/5ML;10MG/5ML;30MG/5ML	A088811	001	Jun 07, 1985	Jan	DISC
		BUDESONIDE						
		SUSPENSION;INHALATION						
		PULMICORT RESPULES						
	AN	+! ASTRAZENECA	0.25MG/2ML	N020929	001	Aug 08, 2000	Jan	CHRS
	AN	+!	0.5MG/2ML	N020929	002	Aug 08, 2000	Jan	CHRS
		BUDESONIDE; FORMOTEROL FUMARATE						
		AEROSOL, METERED;INHALATION						
		SYMBICORT AEROSPHERE						
		+! ASTRAZENECA	0.08MG/INH;0.0048MG/INH	N216579	002	Apr 27, 2026	Apr	NEWA

BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE

AEROSOL, METERED;INHALATION

BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE

AB		TEVA PHARMS USA INC	0.08MG/INH;0.0045MG/INH	A	212212	001	Apr 23, 2026	Apr NEWA
AB			0.16MG/INH;0.0045MG/INH	A	212212	002	Apr 23, 2026	Apr NEWA

BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE

AEROSOL, METERED;INHALATION

BREZTRI AEROSPHERE

+!		ASTRAZENECA AB	0.16MG/INH;0.0048MG/INH;0.018MG/INH	N	212122	002	Apr 27, 2026	Apr NEWA

BUMETANIDE

INJECTABLE;INJECTION

BUMETANIDE

AP		ANTHEA PHARMA	0.25MG/ML	A	220427	001	Feb 26, 2026	Feb NEWA

TABLET;ORAL

BUMETANIDE

AB		MSN	0.5MG	A	215362	001	Feb 05, 2026	Jan NEWA
AB			1MG	A	215362	002	Feb 05, 2026	Jan NEWA
AB			2MG	A	215362	003	Feb 05, 2026	Jan NEWA

BUPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

BUPIVACAINE HYDROCHLORIDE

AP		ANTHEA PHARMA	0.25%	A	220493	001	Apr 22, 2026	Apr NEWA
AP			0.5%	A	220493	002	Apr 22, 2026	Apr NEWA
AP			0.75%	A	220493	003	Apr 22, 2026	Apr NEWA
>D> AP		MEITHEAL	0.25%	A	216039	001	Jun 23, 2023	Jul DISC
>A>	@		0.25%	A	216039	001	Jun 23, 2023	Jul DISC
>D> AP			0.25%	A	216040	001	Dec 27, 2023	Jul DISC
>A>	@		0.25%	A	216040	001	Dec 27, 2023	Jul DISC
>D> AP			0.5%	A	216039	002	Jun 23, 2023	Jul DISC
>A>	@		0.5%	A	216039	002	Jun 23, 2023	Jul DISC
>D> AP			0.5%	A	216040	002	Dec 27, 2023	Jul DISC
>A>	@		0.5%	A	216040	002	Dec 27, 2023	Jul DISC
>D> AP			0.75%	A	216040	003	Dec 27, 2023	Jul DISC
>A>	@		0.75%	A	216040	003	Dec 27, 2023	Jul DISC

BUPRENORPHINE

FILM, EXTENDED RELEASE;TRANSDERMAL

BUTRANS

AB	+	KNOA PHARMA	5MCG/HR	N	021306	001	Jun 30, 2010	May CAHN
AB	+		7.5MCG/HR	N	021306	005	Jun 30, 2014	May CAHN
AB	+		10MCG/HR	N	021306	002	Jun 30, 2010	May CAHN
AB	+		15MCG/HR	N	021306	004	Jul 25, 2013	May CAHN
AB	+!		20MCG/HR	N	021306	003	Jun 30, 2010	May CAHN

SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS

BRIXADI

+!		BRAEBURN	8MG/0.16ML (50MG/ML)	N	210136	001	May 23, 2023	Mar CHRS
+!			16MG/0.32ML (50MG/ML)	N	210136	002	May 23, 2023	Mar CHRS
+!			24MG/0.48ML (50MG/ML)	N	210136	003	May 23, 2023	Mar CHRS
+!			32MG/0.64ML (50MG/ML)	N	210136	004	May 23, 2023	Mar CHRS
+!			64MG/0.18ML (356MG/ML)	N	210136	005	May 23, 2023	Mar CHRS
+!			96MG/0.27ML (356MG/ML)	N	210136	006	May 23, 2023	Mar CHRS

BUPRENORPHINE HYDROCHLORIDE

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

@		QUAGEN	EQ 2MG BASE	A	201066	001	Mar 06, 2015	Jun CAHN
@			EQ 8MG BASE	A	201066	002	Mar 06, 2015	Jun CAHN
>A>	!	RUBICON RESEARCH	EQ 4MG BASE	A	090279	003	Jul 10, 2026	Jul NFTG
>A>	!		EQ 12MG BASE	A	090279	004	Jul 10, 2026	Jul NFTG

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM;BUCCAL, SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB		ASCENT PHARMS INC	EQ 2MG BASE;EQ 0.5MG BASE	A	219850	001	Jan 21, 2026	Jan NEWA
AB			EQ 4MG BASE;EQ 1MG BASE	A	219850	002	Jan 21, 2026	Jan NEWA
AB			EQ 8MG BASE;EQ 2MG BASE	A	219850	003	Jan 21, 2026	Jan NEWA
AB			EQ 12MG BASE;EQ 3MG BASE	A	219850	004	Jan 21, 2026	Jan NEWA

BUPROPION HYDROCHLORIDE

TABLET;ORAL
BUPROPION HYDROCHLORIDE

	AB		SENORES PHARMS	75MG	A075584	001	Feb 07, 2000	Feb CAHN
	AB			100MG	A075584	002	Feb 07, 2000	Feb CAHN

TABLET, EXTENDED RELEASE;ORAL
BUPROPION HYDROCHLORIDE

>A>	AB3		AUROBINDO PHARMA LTD	150MG	A216051	001	Jul 21, 2026	Jul NEWA
>A>	AB3			300MG	A216051	002	Jul 21, 2026	Jul NEWA
	AB1		MACLEODS PHARMS	100MG	A218567	001	Jun 23, 2026	Jun NEWA
	AB1			150MG	A218567	002	Jun 23, 2026	Jun NEWA
	AB1			200MG	A218567	003	Jun 23, 2026	Jun NEWA
	AB1		YICHANG HUMANWELL	100MG	A220529	001	May 04, 2026	Apr NEWA
	AB1			150MG	A220529	002	May 04, 2026	Apr NEWA
	AB1			200MG	A220529	003	May 04, 2026	Apr NEWA

BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL
AUVELITY

		+	AXSOME	105MG;30MG	N215430	002	Apr 30, 2026	Apr NEWA

BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
CONTRAVE

>A>		+!	AZURITY	90MG;8MG	N200063	001	Sep 10, 2014	Jul CAHN
>D>		+!	NALPROPION	90MG;8MG	N200063	001	Sep 10, 2014	Jul CAHN

BUSPIRONE HYDROCHLORIDE

CAPSULE;ORAL
BUCAPSOL

			EPIC PHARMA LLC	5MG	A218628	004	Apr 29, 2026	Apr NFTG

TABLET;ORAL
BUSPIRONE HYDROCHLORIDE

			EPIC PHARMA LLC	2.5MG	A208972	006	May 13, 2026	May NEWA
	AB			5MG	A208972	001	Apr 16, 2019	May CTEC
	AB			7.5MG	A208972	002	Apr 16, 2019	May CTEC
	AB			10MG	A208972	003	Apr 16, 2019	May CTEC
				12.5MG	A208972	007	May 13, 2026	May NEWA
	AB			15MG	A208972	004	Apr 16, 2019	May CTEC
	AB			30MG	A208972	005	Apr 16, 2019	May CTEC
>D>	BX		INVENTIA HLTHCARE	5MG	A209696	001	May 03, 2018	Jul CTEC
>A>	AB			5MG	A209696	001	May 03, 2018	Jul CTEC
>D>	BX			7.5MG	A209696	002	May 03, 2018	Jul CTEC
>A>	AB			7.5MG	A209696	002	May 03, 2018	Jul CTEC
>D>	BX			10MG	A209696	003	May 03, 2018	Jul CTEC
>A>	AB			10MG	A209696	003	May 03, 2018	Jul CTEC
>D>	BX			15MG	A209696	004	May 03, 2018	Jul CTEC
>A>	AB			15MG	A209696	004	May 03, 2018	Jul CTEC
>D>	BX			30MG	A209696	005	May 03, 2018	Jul CTEC
>A>	AB			30MG	A209696	005	May 03, 2018	Jul CTEC
		@	MYLAN	7.5MG	A076008	002	Jul 08, 2013	Feb DISC

BUSULFAN

INJECTABLE;INJECTION
BUSULFAN

>D>		@	ARTHUR GRP	6MG/ML	A205106	001	Sep 21, 2018	Jul CAHN
		@	MYLAN INSTITUTIONAL	6MG/ML	A208536	001	Nov 20, 2017	Jun DISC
>A>		@	PRAXGEN	6MG/ML	A205106	001	Sep 21, 2018	Jul CAHN

CABERGOLINE

TABLET;ORAL
CABERGOLINE

	AB		RENATA	0.5MG	A220309	001	Jun 15, 2026	Jun NEWA

CABOTEGRAVIR; RILPIVIRINE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
CABENUVA KIT

		+	VIIV HLTHCARE	400MG/2ML (200MG/ML);600MG/2ML (300MG/ML)	N212888	001	Jan 21, 2021	May CHRS

CAFFEINE; ERGOTAMINE TARTRATE

TABLET;ORAL

ERGOTAMINE TARTRATE AND CAFFEINE

	!	MIKART	100MG;1MG	A040590	001	Sep 16, 2005	Mar	CAHN

CALCIPOTRIENE

SOLUTION;TOPICAL

CALCIPOTRIENE

AT	!	COSETTE PHARMS NC	0.005%	A078468	001	Mar 24, 2011	May	CAHN

CALCITONIN SALMON

INJECTABLE;INJECTION

CALCITONIN-SALMON

AP		ZYDUS PHARMS	200 IU/ML	A215864	001	Mar 04, 2026	Feb	NEWA

SPRAY, METERED;NASAL

MIACALCIN

>D>	@ +	ALLIED	200 IU/SPRAY	N020313	002	Aug 17, 1995	Jul	CAHN
	@ +		200 IU/SPRAY	N020313	002	Aug 17, 1995	Jun	CAHN
>A>	@ +	SAPTALIS PHARMS	200 IU/SPRAY	N020313	002	Aug 17, 1995	Jul	CAHN

CALCITRIOL

CAPSULE;ORAL

CALCITRIOL

AB		HUMANWELL PURACAP	0.25MCG	A219796	001	Feb 27, 2026	Feb	NEWA
AB			0.5MCG	A219796	002	Feb 27, 2026	Feb	NEWA

CALCIUM ACETATE

CAPSULE;ORAL

CALCIUM ACETATE

	@	LUPIN	667MG	A202127	001	Jul 09, 2015	Mar	DISC

TABLET;ORAL

CALCIUM ACETATE

	@	PADAGIS US	667MG	A091561	001	Apr 13, 2011	Mar	DISC

CALCIUM CHLORIDE

INJECTABLE;INJECTION

CALCIUM CHLORIDE 10%

AP		SQUARE PHARMS PLC	100MG/ML	A217463	001	Sep 29, 2025	May	CMFD
	@		100MG/ML	A217463	001	Sep 29, 2025	Mar	DISC

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 5% AND LACTATED RINGER'S

AP		FRESENIUS KABI USA	20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML	A210332	001	Mar 28, 2022	May	CMFD

DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	+!	OTSUKA ICU MEDCL	20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N017608	001		May	CHRS

CALCIUM GLUCONATE

SOLUTION;INTRAVENOUS

CALCIUM GLUCONATE

AP		CAPLIN	1GM/10ML (100MG/ML)	A218840	001	May 04, 2026	Apr	NEWA
AP			5GM/50ML (100MG/ML)	A218840	002	May 04, 2026	Apr	NEWA
AP			10GM/100ML (100MG/ML)	A218840	003	May 04, 2026	Apr	NEWA
	+!	HQ SPCLT PHARMA	10GM/100ML (100MG/ML)	N210906	004	Nov 18, 2025	May	NEWA

CANAGLIFLOZIN

TABLET;ORAL

CANAGLIFLOZIN

AB		APOTEX	100MG	A210449	001	Apr 14, 2026	Apr	NFTG
AB			300MG	A210449	002	Apr 14, 2026	Apr	NFTG
	@	AUROBINDO PHARMA LTD	100MG	A210386	001	Apr 20, 2026	Apr	DISC
AB			100MG	A210386	001	Apr 20, 2026	Apr	NEWA
	@		300MG	A210386	002	Apr 20, 2026	Apr	DISC
AB			300MG	A210386	002	Apr 20, 2026	Apr	NEWA

INVOKANA

AB	+	JANSSEN PHARMS	100MG	N204042	001	Mar 29, 2013	Apr	CFTG
AB	+!		300MG	N204042	002	Mar 29, 2013	Apr	CFTG

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

>D>	AB		PHARMOBEDIENT	32MG;12.5MG	A090704	002	Dec 04, 2012	Jul	DISC
>A>		@		32MG;12.5MG	A090704	002	Dec 04, 2012	Jul	DISC
	AB		SENORES PHARMS	16MG;12.5MG	A202965	001	Jun 03, 2013	Jan	CAHN
	AB			32MG;12.5MG	A202965	002	Jun 03, 2013	Jan	CAHN
	AB			32MG;25MG	A202965	003	Jun 03, 2013	Jan	CAHN

CANGRELOR

POWDER;INTRAVENOUS

CANGRELOR

	AP		MSN	50MG/VIAL	A213703	001	Jun 04, 2026	May	NEWA

CAPECITABINE

TABLET;ORAL

CAPECITABINE

	AB	!	DR REDDYS	500MG	A204345	002	Dec 04, 2020	Jan	CHRS

XELODA

		@ +	CHEPLAPHARM	150MG	N020896	001	Apr 30, 1998	Jan	DISC
		@ +		500MG	N020896	002	Apr 30, 1998	Jan	DISC

CAPTOPRIL

TABLET;ORAL

CAPTOPRIL

		@	COSETTE PHARMS NC	12.5MG	A074433	001	Feb 13, 1996	May	CAHN
		@		12.5MG	A074462	001	Feb 13, 1996	May	CAHN
		@		12.5MG	A074483	001	Feb 13, 1996	May	CAHN
		@		25MG	A074433	002	Feb 13, 1996	May	CAHN
		@		25MG	A074462	002	Feb 13, 1996	May	CAHN
		@		25MG	A074483	002	Feb 13, 1996	May	CAHN
		@		50MG	A074433	003	Feb 13, 1996	May	CAHN
		@		50MG	A074462	003	Feb 13, 1996	May	CAHN
		@		50MG	A074483	003	Feb 13, 1996	May	CAHN
		@		100MG	A074433	004	Feb 13, 1996	May	CAHN
		@		100MG	A074462	004	Feb 13, 1996	May	CAHN
		@		100MG	A074483	004	Feb 13, 1996	May	CAHN

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

		@	COSETTE PHARMS NC	25MG;15MG	A074827	001	Dec 29, 1997	May	CAHN
		@		25MG;25MG	A074827	002	Dec 29, 1997	May	CAHN
		@		50MG;15MG	A074827	004	Dec 29, 1997	May	CAHN
		@		50MG;25MG	A074827	003	Dec 29, 1997	May	CAHN

CARBAMAZEPINE

TABLET, EXTENDED RELEASE;ORAL

CARBAMAZEPINE

	AB		INGENUS PHARMS LLC	100MG	A216404	001	Dec 02, 2022	Feb	CAHN
	AB			200MG	A216404	002	Dec 02, 2022	Feb	CAHN
	AB			400MG	A216404	003	Dec 02, 2022	Feb	CAHN

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET;ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

	AB		ALEMBIC	12.5MG;200MG;50MG	A218535	001	Feb 05, 2026	Jan	NEWA
	AB			18.75MG;200MG;75MG	A218535	002	Feb 05, 2026	Jan	NEWA
	AB			25MG;200MG;100MG	A218535	003	Feb 05, 2026	Jan	NEWA
	AB			31.25MG;200MG;125MG	A218535	004	Feb 05, 2026	Jan	NEWA
	AB			37.5MG;200MG;150MG	A218535	005	Feb 05, 2026	Jan	NEWA
	AB			50MG;200MG;200MG	A218535	006	Feb 05, 2026	Jan	NEWA

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE;ORAL

CARBIDOPA AND LEVODOPA

		@	SUN PHARM INDS	25MG;100MG	A077828	001	Aug 23, 2007	Feb	DISC
		@		50MG;200MG	A077828	002	Aug 23, 2007	Feb	DISC

CARBINOXAMINE MALEATE

TABLET;ORAL

CARBINOXAMINE MALEATE

>D>	AA	!	GENUS	4MG	A040442	001	Mar 19, 2003	Jul	DISC
>A>		@		4MG	A040442	001	Mar 19, 2003	Jul	DISC
	AB		LEADING	6MG	A215476	001	Dec 19, 2024	Jun	CTEC
	AB	!	MIKART	6MG	A207484	001	May 31, 2016	Jun	CTEC
>D>	AA		MISSION PHARMACAL	4MG	A090756	001	May 27, 2011	Jul	CHRS
>A>	AA	!		4MG	A090756	001	May 27, 2011	Jul	CHRS
>A>		!		4MG	A090756	001	May 27, 2011	Jul	CTEC

CARBOPLATIN

INJECTABLE;INTRAVENOUS

CARBOPLATIN

		@	INGENUS PHARMS LLC	50MG/5ML (10MG/ML)	A208487	001	Apr 26, 2017	May	CAHN
		@		150MG/15ML (10MG/ML)	A208487	002	Apr 26, 2017	May	CAHN
		@		450MG/45ML (10MG/ML)	A208487	003	Apr 26, 2017	May	CAHN
		@		600MG/60ML (10MG/ML)	A208487	004	Apr 26, 2017	May	CAHN
		@	NOVAST LABS	50MG/5ML (10MG/ML)	A208487	001	Apr 26, 2017	Feb	DISC
		@		150MG/15ML (10MG/ML)	A208487	002	Apr 26, 2017	Feb	DISC
		@		450MG/45ML (10MG/ML)	A208487	003	Apr 26, 2017	Feb	DISC
		@		600MG/60ML (10MG/ML)	A208487	004	Apr 26, 2017	Feb	DISC
	AP		QILU PHARM HAINAN	50MG/5ML (10MG/ML)	A219999	001	Feb 04, 2026	Jan	NEWA
	AP			150MG/15ML (10MG/ML)	A219999	002	Feb 04, 2026	Jan	NEWA
	AP			450MG/45ML (10MG/ML)	A219999	003	Feb 04, 2026	Jan	NEWA
	AP			600MG/60ML (10MG/ML)	A219999	004	Feb 04, 2026	Jan	NEWA

CARBOPROST TROMETHAMINE

INJECTABLE;INJECTION

CARBOPROST TROMETHAMINE

	AP		SOMERSET THERAPS LLC	EQ 0.25MG BASE/ML	A219529	001	May 27, 2026	May	NEWA

CARFILZOMIB

POWDER;INTRAVENOUS

CARFILZOMIB

>A>	AP		MSN	60MG/VIAL	A209526	001	Jul 20, 2026	Jul	NEWA

CARIPRAZINE HYDROCHLORIDE

CAPSULE;ORAL

CARIPRAZINE HYDROCHLORIDE

		@	AUROBINDO PHARMA LTD	EQ 1.5MG BASE	A213982	001	Dec 16, 2025	Jan	DISC
		@		EQ 3MG BASE	A213982	002	Dec 16, 2025	Jan	DISC
		@		EQ 6MG BASE	A213982	003	Dec 16, 2025	Jan	DISC

VRAYLAR

		+!	ABBVIE	EQ 1.5MG BASE	N204370	001	Sep 17, 2015	Jan	CTEC
		+		EQ 3MG BASE	N204370	002	Sep 17, 2015	Jan	CTEC
		+		EQ 6MG BASE	N204370	004	Sep 17, 2015	Jan	CTEC

CARISOPRODOL

TABLET;ORAL

CARISOPRODOL

	AA		INGENUS PHARMS LLC	350MG	A040823	001	Oct 22, 2008	Feb	CAHN

CARMUSTINE

INJECTABLE;INJECTION

CARMUSTINE

		@	INGENUS PHARMS LLC	100MG/VIAL	A211011	001	Jun 21, 2022	May	CAHN

CARVEDILOL

TABLET;ORAL

CARVEDILOL

>D>		@	ALLIED	3.125MG	A077316	001	Sep 05, 2007	Jul	CAHN
		@		3.125MG	A077316	001	Sep 05, 2007	Jun	CAHN
>D>		@		6.25MG	A077316	002	Sep 05, 2007	Jul	CAHN
		@		6.25MG	A077316	002	Sep 05, 2007	Jun	CAHN
>D>		@		12.5MG	A077316	003	Sep 05, 2007	Jul	CAHN
		@		12.5MG	A077316	003	Sep 05, 2007	Jun	CAHN
>D>		@		25MG	A077316	004	Sep 05, 2007	Jul	CAHN
		@		25MG	A077316	004	Sep 05, 2007	Jun	CAHN
		@	LUPIN	3.125MG	A078217	001	Sep 05, 2007	Feb	DISC
		@		6.25MG	A078217	002	Sep 05, 2007	Feb	DISC

TABLET;ORAL
CARVEDILOL

	@		12.5MG	A078217	003	Sep 05, 2007	Feb	DISC
	@		25MG	A078217	004	Sep 05, 2007	Feb	DISC
>A>	@	SCIEGEN PHARMS	3.125MG	A077316	001	Sep 05, 2007	Jul	CAHN
>A>	@		6.25MG	A077316	002	Sep 05, 2007	Jul	CAHN
>A>	@		12.5MG	A077316	003	Sep 05, 2007	Jul	CAHN
>A>	@		25MG	A077316	004	Sep 05, 2007	Jul	CAHN

CASPOFUNGIN ACETATE
POWDER;INTRAVENOUS
CASPOFUNGIN ACETATE

AP	!	GLAND	50MG/VIAL	A207092	001	Sep 29, 2017	May	CHRS
AP	!		70MG/VIAL	A207092	002	Sep 29, 2017	May	CHRS
	@	HENGRUI PHARMA	50MG/VIAL	A200833	001	Jun 28, 2018	May	DISC
	@		70MG/VIAL	A200833	002	Jun 28, 2018	May	DISC

CEFAZOLIN SODIUM
POWDER;INTRAVENOUS
CEFAZOLIN SODIUM

	+!	HQ SPCLT PHARMA	EQ 3GM BASE/VIAL	N211413	002	Mar 08, 2024	Feb	NEWA

CEFEPIME HYDROCHLORIDE; ZIDEBACTAM
POWDER;INTRAVENOUS
ZAYNICH

	+!	WOCKHARDT BIO AG	EQ 2GM BASE/VIAL;1GM/VIAL	N220787	001	May 29, 2026	May	NEWA

CEFIXIME
CAPSULE;ORAL
CEFIXIME

AB		AUROBINDO PHARMA LTD	400MG	A217607	001	Mar 23, 2026	Mar	NEWA

FOR SUSPENSION;ORAL
CEFIXIME

AB		FDC LTD	100MG/5ML	A218691	001	May 14, 2026	May	NEWA
AB			200MG/5ML	A218691	002	May 14, 2026	May	NEWA

TABLET;ORAL
CEFIXIME

	!	FDC LTD	400MG	A206358	001	Dec 17, 2024	Jan	CMFD

CEFTAROLINE FOSAMIL
POWDER;INTRAVENOUS
CEFTAROLINE FOSAMIL

AP		APOTEX	400MG/VIAL	A208075	001	Sep 21, 2021	Jan	CMFD
AP			600MG/VIAL	A208075	002	Sep 21, 2021	Jan	CMFD

TEFLARO

AP	+!	ABBVIE	400MG/VIAL	N200327	001	Oct 29, 2010	Jan	CTEC
AP	+!		600MG/VIAL	N200327	002	Oct 29, 2010	Jan	CTEC

CEFTRIAXONE SODIUM
INJECTABLE;INJECTION
CEFTRIAXONE

	@	SANDOZ INC	EQ 1GM BASE/VIAL	A065204	001	May 03, 2005	Apr	DISC
	@		EQ 2GM BASE/VIAL	A065204	002	May 03, 2005	Apr	DISC

CELECOXIB
CAPSULE;ORAL
CELECOXIB

>D>	@	ALLIED	50MG	A078857	001	May 30, 2014	Jul	CAHN
	@		50MG	A078857	001	May 30, 2014	Jun	CAHN
>D>	@		100MG	A078857	002	Feb 11, 2015	Jul	CAHN
	@		100MG	A078857	002	Feb 11, 2015	Jun	CAHN
>D>	@		200MG	A078857	003	Feb 11, 2015	Jul	CAHN
	@		200MG	A078857	003	Feb 11, 2015	Jun	CAHN
>D>	@		400MG	A078857	004	Feb 11, 2015	Jul	CAHN
	@		400MG	A078857	004	Feb 11, 2015	Jun	CAHN
>A>	@	SENORES PHARMS	50MG	A078857	001	May 30, 2014	Jul	CAHN
>A>	@		100MG	A078857	002	Feb 11, 2015	Jul	CAHN
>A>	@		200MG	A078857	003	Feb 11, 2015	Jul	CAHN
>A>	@		400MG	A078857	004	Feb 11, 2015	Jul	CAHN

CEPHALEXIN

FOR SUSPENSION;ORAL

CEPHALEXIN

AB			AUROBINDO PHARMA	EQ 125MG BASE/5ML	A213568	001	Jun 09, 2026	May NEWA
AB				EQ 250MG BASE/5ML	A213568	002	Jun 09, 2026	May NEWA

TABLET;ORAL

CEPHALEXIN

AB			TEVA	EQ 250MG BASE	A063024	002	Jan 12, 1989	Jun CTEC
AB		!		EQ 500MG BASE	A063024	001	Jan 12, 1989	Jun CTEC

CETIRIZINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

QUZYTTIR

		+!	ESTEVE	10MG/ML (10MG/ML)	N211415	001	Oct 04, 2019	Apr CAHN

SOLUTION;ORAL

CETIRIZINE HYDROCHLORIDE

AA			RUBICON RESEARCH	5MG/5ML	A220335	001	Feb 25, 2026	Feb NEWA
		@	TIME CAP LABS	5MG/5ML	A078757	001	Aug 28, 2009	Mar CAHN

CETRORELIX ACETATE

POWDER;SUBCUTANEOUS

CETRORELIX ACETATE

AP			EPIC PHARMA LLC	EQ 0.25MG BASE/VIAL	A218740	001	Apr 29, 2026	May CAHN
AP			HUMANWELL	EQ 0.25MG BASE/VIAL	A218740	001	Apr 29, 2026	Apr NEWA
>D> AP			TEVA PHARMS INC	EQ 0.25MG BASE/VIAL	A215737	001	Aug 12, 2022	Jul DISC
>A>		@		EQ 0.25MG BASE/VIAL	A215737	001	Aug 12, 2022	Jul DISC

CEVIMELINE HYDROCHLORIDE

CAPSULE;ORAL

CEVIMELINE HYDROCHLORIDE

AB			ZYDUS LIFESCIENCES	30MG	A220267	001	Mar 11, 2026	Feb NEWA

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE;ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE

AB		+	BARR	5MG	A084768	001		Mar CRLD
AB		+		10MG	A083116	001		Mar CRLD
AB		+!		25MG	A084769	001		Mar CRLD

LIBRIUM

AB		+	BAUSCH	5MG	A085461	001		Feb CAHN
AB		+		10MG	A085472	001		Feb CAHN

CHLORHEXIDINE GLUCONATE

SOLUTION;DENTAL

PERIDEX

AT		+!	SOLVENTUM	0.12%	N019028	001	Aug 13, 1986	May CAHN

CHLOROTHIAZIDE

SUSPENSION;ORAL

DIURIL

	@	+	SALIX PHARMS	250MG/5ML	N011870	001		Jan DISC

CHLOROTHIAZIDE; RESERPINE

TABLET;ORAL

CHLOROTHIAZIDE AND RESERPINE

>A>		@	HIKMA	250MG;0.125MG	A088365	002	Dec 22, 1983	Jul CMS1

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

>A>		@	APOZEAL PHARMS	4MG/5ML;5MG/5ML;60MG/5ML	A206660	001	May 15, 2017	Jul CAHN
		@	PADAGIS US	4MG/5ML;5MG/5ML;60MG/5ML	A204627	001	Apr 29, 2014	Mar DISC
>D>		@	SCIEGEN PHARMS	4MG/5ML;5MG/5ML;60MG/5ML	A206660	001	May 15, 2017	Jul CAHN

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE;ORAL

CHLORPROMAZINE HYDROCHLORIDE

AA		!	GENUS	30MG/ML	A214542	001	Jun 02, 2021	Mar CTEC
AA		!		100MG/ML	A214542	002	Jun 02, 2021	Mar CTEC
AA			RUBICON	30MG/ML	A216678	001	Oct 10, 2025	Mar CTEC
AA				100MG/ML	A216678	002	Oct 10, 2025	Mar CTEC

CONCENTRATE;ORAL
CHLORPROMAZINE HYDROCHLORIDE

AA		RUBICON RESEARCH	30MG/ML	A216678	001	Oct 10, 2025	May CAHN
AA			100MG/ML	A216678	002	Oct 10, 2025	May CAHN

SONAZINE

AA		SAPTALIS PHARMS	30MG/ML	A080983	004		Mar CMFD
AA			100MG/ML	A080983	005		Mar CMFD

INJECTABLE;INJECTION
CHLORPROMAZINE HYDROCHLORIDE

AP		MSN	25MG/ML	A216092	001	Jan 26, 2026	Jan NEWA

TABLET;ORAL
CHLORPROMAZINE HYDROCHLORIDE

AB		ZAMEER PHARMS	10MG	A212630	001	Nov 29, 2021	Jan CAHN
AB			25MG	A212630	002	Nov 29, 2021	Jan CAHN
AB			50MG	A212630	003	Nov 29, 2021	Jan CAHN
AB			100MG	A212630	004	Nov 29, 2021	Jan CAHN
AB			200MG	A212630	005	Nov 29, 2021	Jan CAHN

CHLORTHALIDONE

TABLET;ORAL
CHLORTHALIDONE

AB	!	ALKEM LABS LTD	50MG	A213412	002	Feb 11, 2020	Mar CHRS
	@	COSETTE PHARMS NC	50MG	A088651	001	May 30, 1985	May CAHN
AB		INGENUS PHARMS LLC	25MG	A206904	001	Mar 30, 2017	May CAHN
AB			50MG	A206904	002	Mar 30, 2017	May CAHN
AB		MACLEODS PHARMS	25MG	A212229	001	Jul 01, 2026	Jun NEWA
AB			50MG	A212229	002	Jul 01, 2026	Jun NEWA

THALITONE

	@ +	CASPER PHARMA LLC	25MG	N019574	002	Feb 12, 1992	Jun DISC

CHLORZOXAZONE

TABLET;ORAL
CHLORZOXAZONE

AA		SENORES PHARMS	500MG	A210961	001	Jan 22, 2024	Jan CAHN

CHOLESTYRAMINE

POWDER;ORAL
CHOLESTYRAMINE

AB		AIPING PHARM INC	EQ 4GM RESIN/PACKET	A214877	001	Jan 21, 2022	Jun CMFD
AB			EQ 4GM RESIN/SCOOPFUL	A214877	002	Jan 21, 2022	Jun CMFD
AB		MICRO LABS	EQ 4GM RESIN/PACKET	A219318	001	Mar 05, 2026	Feb NEWA
AB		PHARMOBEDIENT	EQ 4GM RESIN/PACKET	A209597	001	Mar 09, 2021	Jan CAHN
AB			EQ 4GM RESIN/SCOOPFUL	A209597	002	Mar 09, 2021	Jan CAHN

CHOLESTYRAMINE LIGHT

AB		ZYDUS PHARMS	EQ 4GM RESIN/PACKET	A202902	002	Apr 25, 2017	Mar NEWA

CHROMIC CHLORIDE

INJECTABLE;INJECTION
CHROMIC CHLORIDE

AP		SOMERSET THERAPS LLC	EQ 0.004MG CHROMIUM/ML	A218538	001	Nov 18, 2024	Feb CAHN

CICLESONIDE

AEROSOL, METERED;INHALATION
ALVESCO

	+!	AZURITY	0.08MG/INH	N021658	002	Jan 10, 2008	Jun CAHN
	+!		0.16MG/INH	N021658	003	Jan 10, 2008	Jun CAHN

AEROSOL, METERED;NASAL
ZETONNA

	@ +	AZURITY	0.037MG/INH	N202129	001	Jan 20, 2012	Jun CAHN
	@ +		0.037MG/INH	N202129	001	Jan 20, 2012	Mar CAHN

SPRAY, METERED;NASAL
OMNARIS

	+!	AZURITY	0.05MG/SPRAY	N022004	001	Oct 20, 2006	Jun CAHN
	+!		0.05MG/SPRAY	N022004	001	Oct 20, 2006	Mar CAHN

CICLOPIROX

CREAM;TOPICAL
CICLOPIROX

AB		COSETTE PHARMS NC	0.77%	A078463	001	Dec 20, 2010	May CAHN

LOPROX

AB	+!	EUROFARMA	0.77%	N018748	001	Dec 30, 1982	Feb CAHN

		SOLUTION;TOPICAL							
		CICLOPIROX							
		@	COSETTE PHARMS NC	8%	A078233	001	Sep 18, 2007	May	CAHN
		SUSPENSION;TOPICAL							
		LOPROX							
	AB	+!	EUROFARMA	0.77%	N019824	001	Dec 30, 1988	Feb	CAHN
		CIMETIDINE HYDROCHLORIDE							
		INJECTABLE;INJECTION							
		CIMETIDINE HYDROCHLORIDE							
		@	HOSPIRA	EQ 300MG BASE/2ML	A074296	001	Mar 28, 1997	May	CAHN
		CINACALCET HYDROCHLORIDE							
		TABLET;ORAL							
		CINACALCET HYDROCHLORIDE							
		@	HETERO LABS LTD V	EQ 30MG BASE	A209403	001	Oct 07, 2020	Feb	DISC
		@		EQ 60MG BASE	A209403	002	Oct 07, 2020	Feb	DISC
		@		EQ 90MG BASE	A209403	003	Oct 07, 2020	Feb	DISC
		@	STEVENS J	EQ 30MG BASE	A204364	001	Dec 02, 2021	Feb	CPOT
		@		EQ 60MG BASE	A204364	002	Dec 02, 2021	Feb	CPOT
		@		EQ 90MG BASE	A204364	003	Dec 02, 2021	Feb	CPOT
>D>	AB		SUN PHARM	EQ 60MG BASE	A207008	002	Oct 11, 2018	Jul	DISC
>A>		@		EQ 60MG BASE	A207008	002	Oct 11, 2018	Jul	DISC
		CIPROFLOXACIN HYDROCHLORIDE							
		SOLUTION/DROPS;OPHTHALMIC							
		CIPROFLOXACIN HYDROCHLORIDE							
>D>		@	AMRING PHARMS	EQ 0.3% BASE	A078598	001	Jan 16, 2008	Jul	CAHN
>A>		@	J MOLNER	EQ 0.3% BASE	A078598	001	Jan 16, 2008	Jul	CAHN
		SOLUTION/DROPS;OTIC							
		CIPROFLOXACIN HYDROCHLORIDE							
	AB		ALEMBIC THERAP	EQ 0.2% BASE	A217887	001	Nov 05, 2024	May	CAHN
		TABLET;ORAL							
		CIPROFLOXACIN HYDROCHLORIDE							
		@	AMNEAL	EQ 250MG BASE	A075939	002	Jun 09, 2004	Mar	DISC
		@		EQ 500MG BASE	A075939	003	Jun 09, 2004	Mar	DISC
		@		EQ 750MG BASE	A075939	004	Jun 09, 2004	Mar	DISC
		@	HIKMA	EQ 250MG BASE	A076558	002	Jun 09, 2004	Jun	DISC
		@		EQ 500MG BASE	A076558	003	Jun 09, 2004	Jun	DISC
		@		EQ 750MG BASE	A076558	004	Jun 09, 2004	Jun	DISC
		CISATRACURIUM BESYLATE							
		INJECTABLE;INJECTION							
		CISATRACURIUM BESYLATE							
		@	HENGRUI PHARMA	EQ 2MG BASE/ML	A204960	003	Aug 30, 2017	Feb	DISC
	AP		PIRAMAL	EQ 2MG BASE/ML	A212432	001	Mar 11, 2022	Apr	CMFD
	AP			EQ 10MG BASE/ML	A212432	002	Mar 11, 2022	Apr	CMFD
		CISATRACURIUM BESYLATE PRESERVATIVE FREE							
	AP		HAINAN POLY	EQ 2MG BASE/ML	A216539	001	Aug 27, 2024	Apr	CMFD
	AP			EQ 10MG BASE/ML	A216539	002	Aug 27, 2024	Apr	CMFD
		@	HENGRUI PHARMA	EQ 2MG BASE/ML	A204960	001	Jan 27, 2017	Feb	DISC
		@		EQ 10MG BASE/ML	A204960	002	Sep 19, 2017	Feb	DISC
		CITALOPRAM HYDROBROMIDE							
		CAPSULE;ORAL							
		CITALOPRAM HYDROBROMIDE							
	AB	+!	ALMATICA	EQ 30MG BASE	N215428	001	Jan 31, 2022	Mar	CFTG
	AB		AUROBINDO PHARMA LTD	EQ 30MG BASE	A219985	001	Mar 13, 2026	Mar	NFTG
		TABLET;ORAL							
		CITALOPRAM HYDROBROMIDE							
		@	AMNEAL PHARMS NY	EQ 10MG BASE	A077289	001	Nov 30, 2006	Feb	DISC
		@		EQ 20MG BASE	A077289	002	Nov 30, 2006	Feb	DISC
		@		EQ 40MG BASE	A077289	003	Nov 30, 2006	Feb	DISC
		@	COSETTE PHARMS NC	EQ 10MG BASE	A077048	001	Nov 16, 2004	May	CAHN
		@		EQ 20MG BASE	A077048	002	Nov 16, 2004	May	CAHN
		@		EQ 40MG BASE	A077048	003	Nov 16, 2004	May	CAHN

CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE

GEL;VAGINAL

PHEXX

	+!	EVOFEM INC	1%;1.8%;0.4%	N208352	001	May 22, 2020	May CTNA

CLADRIBINE

TABLET;ORAL

CLADRIBINE

AB		HOPEWELL PHARMA	10MG	A215547	001	Mar 27, 2026	Mar NEWA

CLINDAMYCIN HYDROCHLORIDE

CAPSULE;ORAL

CLINDAMYCIN HYDROCHLORIDE

	@	COSETTE PHARMS NC	EQ 150MG BASE	A063029	001	Sep 20, 1989	Jun CAHN
	@		EQ 300MG BASE	A063029	002	Aug 05, 2005	Jun CAHN

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION;ORAL

CLINDAMYCIN PALMITATE HYDROCHLORIDE

	@	AMNEAL PHARMS	EQ 75MG BASE/5ML	A203513	001	Mar 13, 2014	Apr DISC
AA		APPCO	EQ 75MG BASE/5ML	A207047	001	May 11, 2018	May CAHN
	@	PADAGIS US	EQ 75MG BASE/5ML	A090902	001	Jul 07, 2010	Mar DISC

CLINDAMYCIN PHOSPHATE

AEROSOL, FOAM;TOPICAL

EVOCLIN

>D>	@ +	NORVIUM BIOSCIENCE	1%	N050801	001	Oct 22, 2004	Jul CAHN
>A>	@ +	QUAGEN	1%	N050801	001	Oct 22, 2004	Jul CAHN

GEL;TOPICAL

CLINDAMYCIN PHOSPHATE

AB1		AUROBINDO PHARMA LTD	EQ 1% BASE	A218942	001	Mar 18, 2026	Mar NEWA
AB1		SOLARIS PHARMA CORP	EQ 1% BASE	A211872	001	Jul 29, 2020	Feb CAHN

SOLUTION;TOPICAL

CLINDA-DERM

	@	PADAGIS US	EQ 1% BASE	A063329	001	Sep 30, 1992	Mar DISC

CLINDAMYCIN PHOSPHATE

	@	INGENUS PHARMS LLC	EQ 1% BASE	A064108	001	Sep 27, 1996	Feb CAHN
>D> AT		RISING	EQ 1% BASE	A218300	001	Mar 23, 2026	Jul CDFR
AT			EQ 1% BASE	A218300	001	Mar 23, 2026	Mar NEWA

>A> SWAB;TOPICAL

>A> CLINDAMYCIN PHOSPHATE

>A> AT		RISING	EQ 1% BASE	A218300	001	Mar 23, 2026	Jul CDFR

CLINDETS

	@	PERRIGO CO	EQ 1% BASE	A064136	001	Sep 30, 1996	Mar DISC

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL;TOPICAL

VELTIN

AB2	+!	CHARTWELL RX	1.2%;0.025%	N050803	001	Jul 16, 2010	Jun CAHN

CLOBAZAM

FILM;ORAL

SYMPAZAN

	+	COSETTE	5MG	N210833	001	Nov 01, 2018	Jun CAHN
	+		10MG	N210833	002	Nov 01, 2018	Jun CAHN
	+!		20MG	N210833	003	Nov 01, 2018	Jun CAHN

CLOBETASOL PROPIONATE

AEROSOL, FOAM;TOPICAL

CLOBETASOL PROPIONATE

	@	INGENUS PHARMS LLC	0.05%	A206805	001	Jul 31, 2017	May CAHN

OLUX

>D>	@ +	PHARMOBEDIENT	0.05%	N021142	001	May 26, 2000	Jul CAHN
>A>	@ +	QUAGEN	0.05%	N021142	001	May 26, 2000	Jul CAHN

OLUX E

>D>	@ +	PHARMOBEDIENT	0.05%	N022013	001	Jan 12, 2007	Jul CAHN
>A>	@ +	QUAGEN	0.05%	N022013	001	Jan 12, 2007	Jul CAHN

CREAM;TOPICAL

CLOBETASOL PROPIONATE

	@	COSETTE PHARMS NC	0.05%	A074139	001	Aug 03, 1994	Jun CAHN

GEL;TOPICAL
CLOBETASOL PROPIONATE
@ ENCUBE 0.05% A208881 001 Mar 06, 2017 May CAHN
OINTMENT;TOPICAL
CLOBETASOL PROPIONATE
AB COSETTE PHARMS NC 0.05% A074089 001 Feb 16, 1994 May CAHN
SOLUTION;TOPICAL
CLOBETASOL PROPIONATE
@ COSETTE PHARMS NC 0.05% A074331 001 Dec 15, 1995 Jun CAHN
SPRAY;TOPICAL
CLOBETASOL PROPIONATE
@ PADAGIS US 0.05% A090898 001 Jun 16, 2011 Mar DISC

CLOCORTOLONE PIVALATE
CREAM;TOPICAL
CLODERM
AB +! LEGACY 0.1% N017765 001 Jun CAHN

CLOFARABINE
SOLUTION;INTRAVENOUS
CLOFARABINE
@ INGENUS PHARMS LLC 20MG/20ML (1MG/ML) A210270 001 Sep 14, 2018 May CAHN
@ PHARMOBEDIENT 20MG/20ML (1MG/ML) A208860 001 Nov 06, 2017 May DISC

CLOMIPHENE CITRATE
TABLET;ORAL
>A> CLOMID
>A> AB ! COSETTE 50MG A075528 001 Aug 30, 1999 Jul CTNA
CLOMIPHENE CITRATE
AB ASCENT PHARMS INC 50MG A220673 001 May 15, 2026 May NEWA
>D> AB ! COSETTE 50MG A075528 001 Aug 30, 1999 Jul CTNA
AB RUBICON RESEARCH 50MG A216545 001 Nov 12, 2024 May CAHN

CLOMIPRAMINE HYDROCHLORIDE
CAPSULE;ORAL
CLOMIPRAMINE HYDROCHLORIDE
>D> AB TP ANDA HOLDINGS 25MG A210653 001 Apr 03, 2020 Jul DISC
>A> @ 25MG A210653 001 Apr 03, 2020 Jul DISC
>D> AB 50MG A210653 002 Apr 03, 2020 Jul DISC
>A> @ 50MG A210653 002 Apr 03, 2020 Jul DISC
>D> AB 75MG A210653 003 Apr 03, 2020 Jul DISC
>A> @ 75MG A210653 003 Apr 03, 2020 Jul DISC

CLONAZEPAM
TABLET;ORAL
CLONAZEPAM
AB CHARTWELL RX 0.5MG A074925 001 Sep 30, 1997 Jan CMFD
AB 1MG A074925 002 Sep 30, 1997 Jan CMFD
AB 2MG A074925 003 Sep 30, 1997 Jan CMFD
@ QUAGEN 0.5MG A074940 001 Oct 30, 1997 Apr CAHN
@ 1MG A074940 002 Oct 30, 1997 Apr CAHN
@ 2MG A074940 003 Oct 30, 1997 Apr CAHN
>A> RUBICON RESEARCH 0.25MG A075468 004 Jun 12, 2026 Jul NFTG
TABLET, ORALLY DISINTEGRATING;ORAL
CLONAZEPAM
AB RUBICON RESEARCH 0.125MG A216988 001 May 21, 2026 May NEWA
AB 0.25MG A216988 002 May 21, 2026 May NEWA
AB 0.5MG A216988 003 May 21, 2026 May NEWA
AB 1MG A216988 004 May 21, 2026 May NEWA
AB 2MG A216988 005 May 21, 2026 May NEWA

CLONIDINE
SYSTEM;TRANSDERMAL
CLONIDINE
@ DIFGEN PHARMS 0.1MG/24HR A076157 001 Aug 18, 2009 Feb CAHN
@ 0.2MG/24HR A076157 002 Aug 18, 2009 Feb CAHN
@ 0.3MG/24HR A076157 003 Aug 18, 2009 Feb CAHN
TABLET, EXTENDED RELEASE;ORAL
NEXICLON XR
ROSEMONT EQ 0.17MG BASE N022500 001 Dec 03, 2009 Mar CAHN
@ EQ 0.26MG BASE N022500 002 Dec 03, 2009 Mar CAHN

CLONIDINE HYDROCHLORIDE

SOLUTION;ORAL

>A>		QLONILIK						
>A>	+!	CMP DEV LLC	0.05MG/ML	N221094	001	Jul 29, 2026	Jul	NEWA

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

	!	TP ANDA HOLDINGS	0.05MG	A070923	004	Apr 06, 2026	Mar	NFTG

CLORAZEPATE DIPOTASSIUM

CAPSULE;ORAL

CLORAZEPATE DIPOTASSIUM

@		NATCO PHARMA USA	3.75MG	A071509	001	Oct 19, 1987	Mar	CAHN
@			7.5MG	A071510	001	Oct 19, 1987	Mar	CAHN
@			15MG	A071511	001	Oct 19, 1987	Mar	CAHN

COBICISTAT

TABLET;ORAL

TYBOST

@ +		GILEAD SCIENCES INC	150MG	N203094	001	Sep 24, 2014	Mar	DISC

COBICISTAT; DARUNAVIR ETHANOLATE

TABLET;ORAL

PREZCOBIX

	+!	JANSSEN PRODS	150MG;EQ 675MG BASE	N205395	002	Mar 21, 2025	Mar	CHRS

TABLET, FOR SUSPENSION;ORAL

PREZCOBIX PED

	+!	JANSSEN PRODS	90MG;EQ 600MG BASE	N220092	001	Feb 27, 2026	Feb	NEWA

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETH HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE

AA	!	PAI HOLDINGS	10MG/5ML;5MG/5ML;6.25MG/5ML	A040660	001	Dec 07, 2006	May	CAHN

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

AA	!	COSETTE PHARMS NC	10MG/5ML;6.25MG/5ML	A200386	001	Jun 29, 2012	May	CAHN

COLCHICINE

CAPSULE;ORAL

COLCHICINE

AB		MICRO LABS	0.6MG	A212880	001	Feb 17, 2026	Feb	NEWA

TABLET;ORAL

COLCHICINE

AB		MACLEODS PHARMS	0.6MG	A210633	001	Feb 13, 2026	Feb	NEWA

COLCHICINE; PROBENECID

TABLET;ORAL

PROBENECID AND COLCHICINE

AB		INGENUS PHARMS LLC	0.5MG;500MG	A040618	001	May 13, 2008	May	CAHN

COLESTIPOL HYDROCHLORIDE

GRANULE;ORAL

COLESTID

	+	PFIZER	5GM/SCOOPFUL	N017563	003	Sep 22, 1995	May	CTEC
	+!		5GM/PACKET	N017563	004	Sep 22, 1995	May	CTEC

COLESTIPOL HYDROCHLORIDE

@		IMPAX LABS	5GM/SCOOPFUL	A077277	001	May 02, 2006	May	DISC
@			5GM/PACKET	A077277	002	May 02, 2006	May	DISC

COLISTIMETHATE SODIUM

INJECTABLE;INJECTION

COLISTIMETHATE SODIUM

AP	!	XELLIA PHARMS APS	EQ 150MG BASE/VIAL	A205356	001	May 29, 2015	May	CHRS

COLY-MYCIN M

@ +		PH HEALTH	EQ 150MG BASE/VIAL	N050108	002			DISC

CONIVAPTAN HYDROCHLORIDE

INJECTABLE;INTRAVENOUS

VAPRISOL

>A>		@	APOTEX	20MG/4ML (5MG/ML)	N021697	001	Dec 29, 2005	Jul CAHN
>D>		@	CUMBERLAND	20MG/4ML (5MG/ML)	N021697	001	Dec 29, 2005	Jul CAHN

VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

>A>		+!	APOTEX	20MG/100ML (0.2MG/ML)	N021697	002	Oct 08, 2008	Jul CAHN
>D>		+!	CUMBERLAND	20MG/100ML (0.2MG/ML)	N021697	002	Oct 08, 2008	Jul CAHN

COPPER HISTIDINATE

POWDER;SUBCUTANEOUS

ZYCUBO

		+!	SENTYNL THERAPS INC	2.9MG/VIAL	N211241	001	Jan 12, 2026	Jan NEWA

CROTAMITON

CREAM;TOPICAL

EURAX

		+!	JOURNEY	10%	N006927	001		Apr CMFD

LOTION;TOPICAL

CROTAN

		!	LEGACY	10%	A087204	001		Jun CAHN
			LEGACY PHARMA	10%	A087204	001		Apr CTEC
		!		10%	A087204	001		Apr CHRS

EURAX

		@ +	JOURNEY	10%	N009112	003		Apr DISC

CUPRIC CHLORIDE

INJECTABLE;INJECTION

CUPRIC CHLORIDE

		@	AMNEAL	EQ 0.4MG COPPER/ML	A217287	001	Jan 26, 2026	Mar DISC
	AP			EQ 0.4MG COPPER/ML	A217287	001	Jan 26, 2026	Jan NEWA
	AP		STIRA	EQ 0.4MG COPPER/ML	A217626	001	Apr 30, 2024	Apr CAHN

CYANOCOBALAMIN

INJECTABLE;INJECTION

CYANOCOBALAMIN

	AP		ASPIRO	1MG/ML	A219820	001	Jul 08, 2026	Jun NEWA

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET;ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

	AB		AIPING PHARM INC	7.5MG	A072854	003	May 13, 2026	May NEWA

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

PENTOLAIR

	AT		BAUSCH AND LOMB INC	1%	A040075	001	Apr 29, 1994	May CAHN

CYCLOPHOSPHAMIDE

INJECTABLE;INJECTION

CYCLOPHOSPHAMIDE

		@	HAINAN POLY	500MG/VIAL	A218632	001	Dec 26, 2024	Jan DISC
		@		1GM/VIAL	A218632	002	Dec 26, 2024	Jan DISC
		@		2GM/VIAL	A218632	003	Dec 26, 2024	Jan DISC

CYCLOSPORINE

CAPSULE;ORAL

CYCLOSPORINE

>A>	AB1		ONESOURCE	25MG	A216046	001	Aug 02, 2022	Jul CAHN
>A>	AB1			50MG	A216046	002	Aug 02, 2022	Jul CAHN
>A>	AB1			100MG	A216046	003	Aug 02, 2022	Jul CAHN
>D>	AB1		ONESOURCE SPECIALTY	25MG	A216046	001	Aug 02, 2022	Jul CAHN
>D>	AB1			50MG	A216046	002	Aug 02, 2022	Jul CAHN
>D>	AB1			100MG	A216046	003	Aug 02, 2022	Jul CAHN

EMULSION;OPHTHALMIC

CYCLOSPORINE

	AB		JIANGSU ANBISON	0.05%	A219288	001	Jun 01, 2026	May NEWA
	AB		TWI PHARMS	0.05%	A209064	001	Jan 21, 2026	Jan NEWA

INJECTABLE;INJECTION
CYCLOSPORINE

@	PADAGIS US	50MG/ML	A065151	001	Oct 07, 2003		Mar DISC

CYPROHEPTADINE HYDROCHLORIDE

SYRUP;ORAL
CYPROHEPTADINE HYDROCHLORIDE

AA	ST JOHN PHARM	2MG/5ML	A209108	001	Oct 16, 2018		Jan CAHN

TABLET;ORAL
CYPROHEPTADINE HYDROCHLORIDE

@	ANVI	4MG	A087129	001			Mar CAHN
AA	INGENUS PHARMS LLC	4MG	A205087	001	Sep 23, 2015		Feb CAHN
@	STRIDES PHARMA INTL	4MG	A087129	001			Jun CAHN

>D> DACOMITINIB

>D> TABLET;ORAL
>D> VIZIMPRO

>D> +	PFIZER	15MG	N211288	001	Sep 27, 2018		Jul DISC
>A> @ +		15MG	N211288	001	Sep 27, 2018		Jul DISC
>D> +		30MG	N211288	002	Sep 27, 2018		Jul DISC
>A> @ +		30MG	N211288	002	Sep 27, 2018		Jul DISC
>D> +!		45MG	N211288	003	Sep 27, 2018		Jul DISC
>A> @ +		45MG	N211288	003	Sep 27, 2018		Jul DISC

DALBAVANCIN HYDROCHLORIDE

POWDER;INTRAVENOUS
DALBAVANCIN HYDROCHLORIDE

AP	BE PHARMS	EQ 500MG BASE/VIAL	A219604	001	Jun 04, 2026		May NEWA
AP	LONG GROVE PHARMS	EQ 500MG BASE/VIAL	A218602	001	Feb 26, 2026		Feb NEWA

DAPAGLIFLOZIN

TABLET;ORAL
DAPAGLIFLOZIN

AB	AIZANT	5MG	A211523	001	Apr 06, 2026		Mar NFTG
AB		10MG	A211523	002	Apr 06, 2026		Mar NFTG
AB	AJANTA PHARMA LTD	5MG	A211482	001	Apr 06, 2026		Mar NFTG
AB		10MG	A211482	002	Apr 06, 2026		Mar NFTG
AB	ALEMBIC	5MG	A211560	001	Apr 06, 2026		Mar NFTG
AB		10MG	A211560	002	Apr 06, 2026		Mar NFTG
AB	ALKEM LABS LTD	5MG	A211545	001	Apr 06, 2026		Mar NFTG
AB		10MG	A211545	002	Apr 06, 2026		Mar NFTG
AB	AUROBINDO PHARMA	5MG	A211468	001	Apr 06, 2026		Mar NFTG
AB		10MG	A211468	002	Apr 06, 2026		Mar NFTG
AB	BIOCON PHARMA	5MG	A211470	001	Apr 06, 2026		Mar NFTG
AB		10MG	A211470	002	Apr 06, 2026		Mar NFTG
AB	CIPLA	5MG	A211535	001	Apr 06, 2026		Mar NFTG
AB		10MG	A211535	002	Apr 06, 2026		Mar NFTG
AB	INVENTIA	5MG	A211156	001	Apr 06, 2026		Mar NFTG
AB		10MG	A211156	002	Apr 06, 2026		Mar NFTG
AB	LUPIN	5MG	A211531	001	Apr 06, 2026		Mar NFTG
AB		10MG	A211531	002	Apr 06, 2026		Mar NFTG
AB	MACLEODS PHARMS	5MG	A211506	001	Apr 06, 2026		Mar NFTG
AB		10MG	A211506	002	Apr 06, 2026		Mar NFTG
AB	MICRO LABS	5MG	A211467	001	Apr 06, 2026		Mar NFTG
AB		10MG	A211467	002	Apr 06, 2026		Mar NFTG
AB	MSN	5MG	A211478	001	Apr 06, 2026		Mar NFTG
AB		10MG	A211478	002	Apr 06, 2026		Mar NFTG
AB	SANDOZ	5MG	A211312	001	Apr 06, 2026		Mar NFTG
AB		10MG	A211312	002	Apr 06, 2026		Mar NFTG
AB	TEVA PHARMS USA	5MG	A211541	001	Apr 06, 2026		Mar NFTG
AB		10MG	A211541	002	Apr 06, 2026		Mar NFTG
AB	ZYDUS PHARMS	5MG	A211582	001	Apr 06, 2026		Mar NFTG
AB		10MG	A211582	002	Apr 06, 2026		Mar NFTG

FARXIGA

AB +	ASTRAZENECA AB	5MG	N202293	001	Jan 08, 2014		Mar CFTG
AB +!		10MG	N202293	002	Jan 08, 2014		Mar CFTG

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE

AB		ALKEM LABS LTD	5MG;500MG	A211563	001	Apr 06, 2026	Mar NFTG
AB			5MG;1GM	A211563	002	Apr 06, 2026	Mar NFTG
AB			10MG;500MG	A211563	003	Apr 06, 2026	Mar NFTG
AB			10MG;1GM	A211563	004	Apr 06, 2026	Mar NFTG
AB		AUROBINDO PHARMA	5MG;500MG	A211489	001	Apr 06, 2026	Mar NFTG
AB			5MG;1GM	A211489	002	Apr 06, 2026	Mar NFTG
AB			10MG;500MG	A211489	003	Apr 06, 2026	Mar NFTG
AB			10MG;1GM	A211489	004	Apr 06, 2026	Mar NFTG
AB		CIPLA	5MG;1GM	A211595	001	Apr 06, 2026	Mar NFTG
AB		CIPLA LTD	5MG;500MG	A211536	001	Apr 06, 2026	Mar NFTG
AB			10MG;500MG	A211536	002	Apr 06, 2026	Mar NFTG
AB			10MG;1GM	A211536	003	Apr 06, 2026	Mar NFTG
AB		LUPIN	5MG;500MG	A211579	001	Apr 06, 2026	Mar NFTG
AB			5MG;1GM	A211579	002	Apr 06, 2026	Mar NFTG
AB			10MG;500MG	A211579	003	Apr 06, 2026	Mar NFTG
AB			10MG;1GM	A211579	004	Apr 06, 2026	Mar NFTG
AB		MACLEODS PHARMS	5MG;500MG	A211559	001	Apr 06, 2026	Mar NFTG
AB			5MG;1GM	A211559	002	Apr 06, 2026	Mar NFTG
AB			10MG;500MG	A211559	003	Apr 06, 2026	Mar NFTG
AB			10MG;1GM	A211559	004	Apr 06, 2026	Mar NFTG
AB		MICRO LABS	5MG;500MG	A211466	001	Apr 06, 2026	Mar NFTG
AB			5MG;1GM	A211466	002	Apr 06, 2026	Mar NFTG
AB			10MG;500MG	A211466	003	Apr 06, 2026	Mar NFTG
AB			10MG;1GM	A211466	004	Apr 06, 2026	Mar NFTG
AB		MSN	5MG;500MG	A211479	001	Apr 06, 2026	Mar NFTG
AB			5MG;1GM	A211479	002	Apr 06, 2026	Mar NFTG
AB			10MG;500MG	A211479	003	Apr 06, 2026	Mar NFTG
AB			10MG;1GM	A211479	004	Apr 06, 2026	Mar NFTG
AB		SUN PHARM	5MG;1GM	A211491	001	Apr 06, 2026	Mar NFTG
AB			10MG;500MG	A211491	002	Apr 06, 2026	Mar NFTG
AB			10MG;1GM	A211491	003	Apr 06, 2026	Mar NFTG
AB		TEVA PHARMS USA INC	2.5MG;1GM	A211583	001	Apr 06, 2026	Mar NFTG
AB			5MG;500MG	A211583	002	Apr 06, 2026	Mar NFTG
AB			5MG;1GM	A211583	003	Apr 06, 2026	Mar NFTG
AB			10MG;500MG	A211583	004	Apr 06, 2026	Mar NFTG
AB			10MG;1GM	A211583	005	Apr 06, 2026	Mar NFTG

XIGDUO XR

AB	+	ASTRAZENECA AB	2.5MG;1GM	N205649	005	Jul 28, 2017	Mar CFTG
AB	+		5MG;500MG	N205649	001	Oct 29, 2014	Mar CFTG
AB	+		5MG;1GM	N205649	002	Oct 29, 2014	Mar CFTG
AB	+		10MG;500MG	N205649	003	Oct 29, 2014	Mar CFTG
AB	+!		10MG;1GM	N205649	004	Oct 29, 2014	Mar CFTG

DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE

TABLET;ORAL

DAPAGLIFLOZIN AND SAXAGLIPTIN HYDROCHLORIDE

AB	!	MSN	10MG;EQ 5MG BASE	A211533	001	Apr 06, 2026	Mar NFTG
AB		TORRENT	10MG;EQ 5MG BASE	A211537	001	Apr 06, 2026	Mar NFTG

DAPSONE

GEL;TOPICAL

DAPSONE

AB		ALEMBIC	5%	A213414	001	Jun 25, 2026	Jun NEWA
	@	CHARTWELL RX	5%	A215087	001	Oct 31, 2023	May CAHN
	@		7.5%	A212657	001	Nov 01, 2023	May CAHN
AB		COSETTE PHARMS NC	5%	A210178	001	Mar 31, 2022	May CAHN

TABLET;ORAL

DAPSONE

AB		MACLEODS PHARMS	25MG	A218335	001	Jul 08, 2026	Jun NEWA
AB			100MG	A218335	002	Jul 08, 2026	Jun NEWA
AB		ZYDUS LIFESCIENCES	25MG	A220103	001	Feb 26, 2026	Feb NEWA
AB			100MG	A220103	002	Feb 26, 2026	Feb NEWA

DAPTOMYCIN

POWDER;INTRAVENOUS

DAPTOMYCIN

	@	HENGRUI PHARMA	500MG/VIAL	A212022	001	Aug 22, 2019	Jan DISC

DASIGLUCAGON HYDROCHLORIDE

SOLUTION;SUBCUTANEOUS

ZEGALOGUE

	@ +	ZEALAND PHARMA	EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	N214231	001	Mar 22, 2021	Feb DISC

ZEGALOGUE (AUTOINJECTOR)

	@ +	ZEALAND PHARMA	EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	N214231	002	Mar 22, 2021	Feb DISC

DECITABINE

INJECTABLE;INTRAVENOUS

DECITABINE

	@	INGENUS PHARMS LLC	50MG/VIAL	A210984	001	Sep 16, 2019	Jun CAHN
	@	NOVAST LABS	50MG/VIAL	A210984	001	Sep 16, 2019	Feb DISC

DEFERIPRONE

TABLET;ORAL

FERRIPROX

	@ +	CHIESI	500MG	N021825	001	Oct 14, 2011	Apr DISC

DEFEROXAMINE MESYLATE

INJECTABLE;INJECTION

DEFEROXAMINE MESYLATE

	@	HIKMA	500MG/VIAL	A078086	001	May 30, 2007	Mar DISC
	@		2GM/VIAL	A078086	002	May 30, 2007	Mar DISC

DEFLAZACORT

SUSPENSION;ORAL

DEFLAZACORT

AB		BIOCON PHARMA	22.75MG/ML	A220709	001	May 28, 2026	Jun CAHN
AB		CARNEGIE	22.75MG/ML	A220709	001	May 28, 2026	May NEWA
AB		SUN PHARM INDS INC	22.75MG/ML	A219930	001	Jan 27, 2026	Jan NEWA

DEHYDRATED ALCOHOL

SOLUTION;INTRA-ARTERIAL

ABLYSINOL

	@ +	BPI LABS	99% (1ML)	N207987	001	Jun 21, 2018	Jan CAIN
AP	+!		99% (5ML)	N207987	002	Jun 21, 2018	Jan CAIN

DEHYDRATED ALCOHOL

AP		ACCORD HLTHCARE	99% (5ML)	A217845	001	Jun 23, 2025	Jan CAIN
AP		BRECKENRIDGE	99% (5ML)	A219444	001	Jun 23, 2025	Jan CAIN
AP		INGENUS PHARMS LLC	99% (5ML)	A219569	001	Jul 09, 2025	Jan CAIN
AP		XGEN PHARMS	99% (5ML)	A219400	001	Jun 23, 2025	Jan CAIN

SOLUTION;INTRAVENOUS

DEHYDRATED ALCOHOL

	+!	BE PHARMS	98% (5ML)	N214988	001	Oct 23, 2025	Jun CAHN
	+!	ROYAL PHARMS	98% (5ML)	N214988	001	Oct 23, 2025	Jan CAIN

DESFLURANE

LIQUID;INHALATION

DESFLURANE

	@	SHANGHAI HENGRUI	100%	A208234	001	Feb 26, 2018	Jun DISC

SUPRANE

	+!	BAXTER HLTHCARE	100%	N020118	001	Sep 18, 1992	Jun CTEC

DESIPRAMINE HYDROCHLORIDE

TABLET;ORAL

DESIPRAMINE HYDROCHLORIDE

	@	HERITAGE	10MG	A207433	001	May 05, 2016	Jan DISC
	@		25MG	A207433	002	May 05, 2016	Jan DISC
	@		50MG	A207433	003	May 05, 2016	Jan DISC
	@		75MG	A207433	004	May 05, 2016	Jan DISC
	@		100MG	A207433	005	May 05, 2016	Jan DISC
	@		150MG	A207433	006	May 05, 2016	Jan DISC
AB		INGENUS PHARMS LLC	10MG	A204963	001	Dec 26, 2017	Feb CAHN
AB			25MG	A204963	002	Dec 26, 2017	Feb CAHN
AB			50MG	A204963	003	Dec 26, 2017	Feb CAHN
AB			75MG	A204963	004	Dec 26, 2017	Feb CAHN
>D> AB			100MG	A204963	005	Dec 26, 2017	Jul CHRS
>A> AB	!		100MG	A204963	005	Dec 26, 2017	Jul CHRS
AB			100MG	A204963	005	Dec 26, 2017	Feb CAHN

TABLET;ORAL
DESIPRAMINE HYDROCHLORIDE

	AB			150MG	A204963	006	Dec 26, 2017	Feb CAHN
>D>		NORPRAMIN						
>D>	AB	+	VALIDUS PHARMS	10MG	N014399	007	Feb 11, 1982	Jul DISC
>A>		@ +		10MG	N014399	007	Feb 11, 1982	Jul DISC
>D>	AB	+		25MG	N014399	001		Jul DISC
>A>		@ +		25MG	N014399	001		Jul DISC
>D>	AB	+		50MG	N014399	003		Jul DISC
>A>		@ +		50MG	N014399	003		Jul DISC
>D>	AB	+		75MG	N014399	004		Jul DISC
>A>		@ +		75MG	N014399	004		Jul DISC
>D>	AB	+!		100MG	N014399	005		Jul DISC
>A>		@ +		100MG	N014399	005		Jul DISC
>D>	AB	+		150MG	N014399	006		Jul DISC
>A>		@ +		150MG	N014399	006		Jul DISC

DESLORATADINE
TABLET;ORAL
DESLORATADINE

	AB		NATCO PHARMA USA	5MG	A078351	001	Feb 10, 2012	May CMFD
		@		5MG	A078351	001	Feb 10, 2012	Mar CAHN

DESMOPRESSIN ACETATE
INJECTABLE;INJECTION
DDAVP

	AP	+!	J MOLNER	0.004MG/ML	N018938	001	Mar 30, 1984	Jun CAHN
		@		0.015MG/ML	N018938	002	Apr 25, 1995	Jun CAHN

DESMOPRESSIN ACETATE

	AP		CAPLIN	0.004MG/ML	A219981	001	Feb 27, 2026	Feb NEWA

SOLUTION;ORAL
DESMODA

		+!	ETON	0.05MG/ML	N219873	001	Feb 25, 2026	Feb NEWA

DESOGESTREL; ETHINYL ESTRADIOL
TABLET;ORAL-28
DESOGESTREL AND ETHINYL ESTRADIOL

	AB		ANNORA PHARMA	0.15MG,N/A;0.02MG,0.01MG	A219670	001	Jul 07, 2026	Jun NEWA
	AB			0.15MG;0.03MG	A219761	001	Mar 18, 2026	Mar NEWA

DESONIDE
AEROSOL, FOAM;TOPICAL
VERDESO

		@ +	GENUS	0.05%	N021978	001	Sep 19, 2006	Apr CAHN

CREAM;TOPICAL
DESONIDE

	AB		COSETTE PHARMS NC	0.05%	A074027	001	Sep 28, 1992	May CAHN

LOTION;TOPICAL
DESONIDE

		@	ENCUBE	0.05%	A207855	001	Sep 28, 2017	May CAHN
		@	VERTICE	0.05%	A207855	001	Sep 28, 2017	Apr CAHN

DESOXIMETASONE
CREAM;TOPICAL
DESOXIMETASONE

		@	COSETTE PHARMS NC	0.25%	A209595	001	Mar 04, 2020	Jun CAHN
	AB		SCIEGEN PHARMS	0.05%	A203787	001	Jan 06, 2017	Apr CMFD
	AB			0.25%	A203234	001	Jun 12, 2015	Apr CMFD

GEL;TOPICAL
DESOXIMETASONE

		@	PADAGIS US	0.05%	A077552	001	Jan 09, 2006	Mar DISC

OINTMENT;TOPICAL
DESOXIMETASONE

		@	COSETTE PHARMS NC	0.25%	A206740	001	Dec 23, 2016	Jun CAHN
		@	ENCUBE	0.25%	A208101	001	Feb 25, 2016	May CAHN

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

DESVENLAFAXINE SUCCINATE

AB		PLATINUM	EQ 50MG BASE	A204805	001	May 07, 2019	Mar CAHN
AB			EQ 100MG BASE	A204805	002	May 07, 2019	Mar CAHN
AB		YICHANG HUMANWELL	EQ 25MG BASE	A220460	001	Mar 10, 2026	Feb NEWA
AB			EQ 50MG BASE	A220460	002	Mar 10, 2026	Feb NEWA
AB			EQ 100MG BASE	A220460	003	Mar 10, 2026	Feb NEWA

DEXAMETHASONE

CONCENTRATE;ORAL

DEXAMETHASONE INTENSOL

	+!	HIKMA	1MG/ML	A088252	001	Sep 01, 1983	Jan CRLD

>D> SUSPENSION;INTRAOCULAR

>D> DEXYCU KIT

>D>	+!	EYEPOINT PHARMS	9%	N208912	001	Feb 09, 2018	Jul DISC
>A>	@ +		9%	N208912	001	Feb 09, 2018	Jul DISC

TABLET;ORAL

DEXAMETHASONE

		PANGEA	0.25MG	A088149	001	Apr 28, 1983	Mar CMFD

DEXAMETHASONE SODIUM PHOSPHATE

SOLUTION/DROPS;OPHTHALMIC, OTIC

DEXAMETHASONE SODIUM PHOSPHATE

	!	BAUSCH AND LOMB INC	EQ 0.1% PHOSPHATE	A040069	001	Jul 26, 1996	May CAHN
	@	CAPLIN	EQ 0.1% PHOSPHATE	A088771	001	Jan 16, 1985	Jan CAHN

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

AT		BAUSCH AND LOMB INC	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A064063	001	Jul 25, 1994	May CAHN
	@	PADAGIS US	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062938	001	Jul 31, 1989	Mar DISC

SUSPENSION/DROPS;OPHTHALMIC

DEXASPORIN

AT		BAUSCH AND LOMB INC	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A064135	001	Sep 13, 1995	May CAHN

DEXAMETHASONE; TOBRAMYCIN

SUSPENSION/DROPS;OPHTHALMIC

TOBRAMYCIN AND DEXAMETHASONE

AB		BAUSCH AND LOMB INC	0.1%;0.3%	A064134	001	Oct 27, 1999	May CAHN

DEXMEDETOMIDINE HYDROCHLORIDE

FILM;BUCCAL, SUBLINGUAL

IGALMI

	+	BIOXCEL	EQ 0.18MG BASE	N215390	002	Apr 05, 2022	Jan CHRS

INJECTABLE;INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

AP		BAXTER HLTHCARE CORP	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A208103	001	Apr 15, 2026	Apr NEWA
	@	CAPLIN	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A091465	001	Jun 14, 2016	Apr DISC
AP			EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A091465	001	Jun 14, 2016	Jan CAHN
AP		DR REDDYS	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A220315	001	Feb 25, 2026	Feb NEWA
AP			EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A220315	002	Feb 25, 2026	Feb NEWA
	@	HENGRUI PHARMA	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A209065	001	Sep 19, 2017	Jun DISC
	@	KNACK	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A218675	001	Mar 09, 2026	May DISC
AP			EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A218675	001	Mar 09, 2026	Feb NEWA

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

	@	AUROLIFE PHARMA LLC	5MG	A202580	002	Aug 25, 2015	Mar CMS1
	@		10MG	A202580	003	Aug 25, 2015	Mar CMS1
	@		15MG	A202580	004	Aug 25, 2015	Mar CMS1

CAPSULE, EXTENDED RELEASE;ORAL
DEXMETHYLPHENIDATE HYDROCHLORIDE

		@		20MG	A202580	005	Dec 21, 2015	Mar CMS1
		@		25MG	A202580	006	May 04, 2021	Mar CMS1
		@		35MG	A202580	007	May 04, 2021	Mar CMS1
		@		40MG	A202580	008	Aug 25, 2015	Mar CMS1
	AB		PLATINUM	5MG	A078992	001	Nov 23, 2021	Apr CAHN
	AB			10MG	A078992	002	Nov 23, 2021	Apr CAHN
	AB			15MG	A078992	003	Nov 18, 2013	Apr CAHN
	AB			30MG	A078992	004	Nov 18, 2013	Apr CAHN
	AB			20MG	A078992	005	Nov 23, 2021	Apr CAHN
	AB			40MG	A078992	006	Nov 23, 2021	Apr CAHN

DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE

CAPSULE;ORAL
AZSTARYS

		+	COMMAVE SUB	EQ 5.2MG BASE;EQ 26.1MG BASE	N212994	001	May 07, 2021	May CAHN
		+		EQ 7.8MG BASE;EQ 39.2MG BASE	N212994	002	May 07, 2021	May CAHN
		+!		EQ 10.4MG BASE;EQ 52.3MG BASE	N212994	003	May 07, 2021	May CAHN

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL
DEXTROAMPHETAMINE SULFATE

		@	QUAGEN	5MG	A206735	001	Jan 27, 2016	Apr CAHN
		@		10MG	A206735	002	Jan 27, 2016	Apr CAHN
		@		15MG	A206735	003	Jan 27, 2016	Apr CAHN
		@	STRIDES PHARMA INTL	5MG	A205673	001	Oct 31, 2017	Jan DISC
		@		10MG	A205673	002	Oct 31, 2017	Jan DISC
		@		15MG	A205673	003	Oct 31, 2017	Jan DISC

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL
PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

	AA		COSETTE PHARMS NC	15MG/5ML;6.25MG/5ML	A091687	001	Jun 28, 2012	May CAHN
	AA		HETERO LABS LTD III	15MG/5ML;6.25MG/5ML	A218264	001	Mar 12, 2026	Mar NEWA
	AA		RUBICON RESEARCH	15MG/5ML;6.25MG/5ML	A220869	001	Jun 23, 2026	Jun NEWA

DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE

CAPSULE;ORAL
DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE

	AB		SUN PHARM	20MG;10MG	A204196	001	Jun 03, 2026	May NEWA

NUEDEXTA

	AB	+!	OTSUKA AMERICA PHARM	20MG;10MG	N021879	001	Oct 29, 2010	May CAHN

DIAZEPAM

INJECTABLE;INJECTION
DIAZEPAM

>A>	AP		BAXTER HLTHCARE CORP	10MG/2ML (5MG/ML)	A219882	001	Jul 28, 2026	Jul NEWA
>A>		!		20MG/4ML (5MG/ML)	A219882	002	Jul 28, 2026	Jul NFTG
>A>	AP		LUPIN	10MG/2ML (5MG/ML)	A220365	001	Jul 27, 2026	Jul NEWA

TABLET;ORAL
DIAZEPAM

		@	STRIDES PHARMA INTL	2MG	A077749	001	Mar 31, 2006	Jan DISC
		@		5MG	A077749	002	Mar 31, 2006	Jan DISC
		@		10MG	A077749	003	Mar 31, 2006	Jan DISC

DICLOFENAC POTASSIUM

CAPSULE;ORAL
DICLOFENAC POTASSIUM

>A>	AB		ONESOURCE	25MG	A210078	001	Dec 03, 2019	Jul CAHN
>D>	AB		ONESOURCE SPECIALTY	25MG	A210078	001	Dec 03, 2019	Jul CAHN

ZIPSOR

	AB	+!	ASSERTIO SPECLTY	25MG	N022202	001	Jun 16, 2009	Feb CAHN
	AB	+!	COSETTE	25MG	N022202	001	Jun 16, 2009	Jun CAHN

FOR SOLUTION;ORAL
CAMBIA

	AB	+!	ASSERTIO SPECLTY	50MG	N022165	001	Jun 17, 2009	Feb CAHN
	AB	+!	COSETTE	50MG	N022165	001	Jun 17, 2009	Jun CAHN

TABLET;ORAL
DICLOFENAC POTASSIUM

	AB		INGENUS PHARMS LLC	50MG	A215585	001	Oct 08, 2021	Feb CAHN
	AB		RISING	50MG	A075463	001	Jul 26, 1999	Jun CAHN

DICLOFENAC SODIUM

GEL;TOPICAL

DICLOFENAC SODIUM

	AB		ALEMBIC	3%	A212351	001	Jul 27, 2022	Jun CTEC
		@	AMNEAL	3%	A200936	001	Oct 28, 2013	Mar DISC

SOLARAZE

>A>		@ +	FOUGERA	3%	N021005	001	Oct 16, 2000	Jul CAHN
>D>		@ +	FOUGERA PHARMS	3%	N021005	001	Oct 16, 2000	Jul CAHN

TABLET, EXTENDED RELEASE;ORAL

DICLOFENAC SODIUM

>D>		@	AUROBINDO PHARMA USA	100MG	A076152	001	Dec 13, 2001	Jul CMFD
>A>	AB			100MG	A076152	001	Dec 13, 2001	Jul CMFD
	AB		INGENUS PHARMS LLC	100MG	A216275	001	Sep 23, 2022	Feb CAHN

DICYCLOMINE HYDROCHLORIDE

CAPSULE;ORAL

DICYCLOMINE HYDROCHLORIDE

>A>	AB		RUBICON RESEARCH	10MG	A216515	001	Jul 17, 2026	Jul NEWA

DIFAMILAST

OINTMENT;TOPICAL

ADQUEY

		+!	ACROTECH BIOPHARMA	1%	N219474	001	Feb 12, 2026	Feb NEWA

DIFLUPREDNATE

EMULSION;OPHTHALMIC

DIFLUPREDNATE

	AB		ALEMBIC	0.05%	A213774	001	Jan 26, 2026	Jan NEWA

DIGOXIN

INJECTABLE;INJECTION

LANOXIN

>D>	AP	+!	AZURITY	0.25MG/ML	N009330	002		Jul CAHN
>A>	AP	+!		0.25MG/ML	N009330	002		Jul CAHN
	AP	+!		0.25MG/ML	N009330	002		Mar CAHN

LANOXIN PEDIATRIC

>D>		+!	AZURITY	0.1MG/ML	N009330	004		Jul CAHN
>A>		+!		0.1MG/ML	N009330	004		Jul CAHN
		+!		0.1MG/ML	N009330	004		Mar CAHN

TABLET;ORAL

DIGOXIN

		@	SUN PHARM INDS INC	0.125MG	A076363	001	Jan 31, 2003	May DISC
		@		0.25MG	A076363	002	Jan 31, 2003	May DISC

DIHYDROERGOTAMINE MESYLATE

INJECTABLE;INJECTION

DIHYDROERGOTAMINE MESYLATE

		@	PADAGIS US	1MG/ML	A040475	001	Apr 28, 2003	Mar DISC

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

CARDIZEM CD

>D>	AB3	+!	BAUSCH	360MG	N020062	005	Aug 24, 1999	Jul CHRS
>A>	AB3	+		360MG	N020062	005	Aug 24, 1999	Jul CHRS

DILTIAZEM HYDROCHLORIDE

	AB3		MACLEODS PHARMS	120MG	A218744	001	Feb 27, 2026	Feb NEWA
	AB3			180MG	A218744	002	Feb 27, 2026	Feb NEWA
	AB3			240MG	A218744	003	Feb 27, 2026	Feb NEWA
	AB3			300MG	A218744	004	Feb 27, 2026	Feb NEWA
	AB3			360MG	A218744	005	Feb 27, 2026	Feb NEWA
>D>	AB3		NOVAST LABS	360MG	A208783	005	Jun 14, 2019	Jul CHRS
>A>	AB3	!		360MG	A208783	005	Jun 14, 2019	Jul CHRS

TABLET;ORAL

DILTIAZEM HYDROCHLORIDE

	AB		ZYDUS LIFESCIENCES	30MG	A219253	001	Aug 08, 2025	May CMFD
		@		30MG	A219253	001	Aug 08, 2025	Jan DISC
	AB			60MG	A219253	002	Aug 08, 2025	May CMFD
		@		60MG	A219253	002	Aug 08, 2025	Jan DISC
	AB			90MG	A219253	003	Aug 08, 2025	May CMFD
		@		90MG	A219253	003	Aug 08, 2025	Jan DISC
	AB			120MG	A219253	004	Aug 08, 2025	May CMFD

TABLET;ORAL
DILTIAZEM HYDROCHLORIDE

	@		120MG	A219253	004	Aug 08, 2025	Jan DISC

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE;ORAL
DIMETHYL FUMARATE

	@	MYLAN	120MG	A210531	001	Aug 17, 2020	Mar DISC
	@		240MG	A210531	002	Aug 17, 2020	Mar DISC

DIMETHYL SULFOXIDE

SOLUTION;INTRAVESICAL
DIMETHYL SULFOXIDE

>A> AT		RENOVA PHARMS	50%	A220173	001	Jul 07, 2026	Jul CAHN
>D> AT		STIRA	50%	A220173	001	Jul 07, 2026	Jul CAHN
AT			50%	A220173	001	Jul 07, 2026	Jun NEWA

RIMSO-50

AT	+!	MYLAN INSTITUTIONAL	50%	N017788	001		Jun CTEC

DIPHENHYDRAMINE HYDROCHLORIDE

ELIXIR;ORAL
DIPHENHYDRAMINE HYDROCHLORIDE

AA		ANNORA PHARMA	12.5MG/5ML	A219470	001	Jun 17, 2026	Jun NEWA
AA	+!	PHARM ASSOC	12.5MG/5ML	A087513	001	Feb 10, 1982	Jun CTEC

DISULFIRAM

TABLET;ORAL
DISULFIRAM

	@	NATCO PHARMA USA	250MG	A203916	001	Mar 04, 2015	Mar CAHN
	@		500MG	A203916	002	Mar 04, 2015	Mar CAHN

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE;ORAL
DIVALPROEX SODIUM

	@	LUPIN	EQ 125MG VALPROIC ACID	A078790	001	Jul 29, 2008	May DISC
	@		EQ 250MG VALPROIC ACID	A078790	002	Jul 29, 2008	May DISC
	@		EQ 500MG VALPROIC ACID	A078790	003	Jul 29, 2008	May DISC

TABLET, EXTENDED RELEASE;ORAL
DIVALPROEX SODIUM

	@	COSETTE PHARMS NC	EQ 500MG VALPROIC ACID	A078700	001	Aug 03, 2009	Jun CAHN

DOBUTAMINE HYDROCHLORIDE

INJECTABLE;INJECTION
DOBUTAMINE HYDROCHLORIDE

>A> AP		HAINAN POLY	EQ 12.5MG BASE/ML	A216131	001	Dec 21, 2022	Jul CAHN
>D> AP		SLATE RUN PHARMA	EQ 12.5MG BASE/ML	A216131	001	Dec 21, 2022	Jul CAHN

DOCETAXEL

INJECTABLE;INJECTION
DOCETAXEL

>D> AP		GUANGDONG SUNHO	20MG/ML (20MG/ML)	A213768	001	May 13, 2025	Jul DISC
>A>	@		20MG/ML (20MG/ML)	A213768	001	May 13, 2025	Jul DISC
>D> AP			80MG/4ML (20MG/ML)	A213768	002	May 13, 2025	Jul DISC
>A>	@		80MG/4ML (20MG/ML)	A213768	002	May 13, 2025	Jul DISC
	@	INGENUS PHARMS LLC	20MG/2ML (10MG/ML)	A207563	001	Aug 31, 2017	Feb CAHN
	@		80MG/8ML (10MG/ML)	A207563	002	Aug 31, 2017	Feb DISC
AP			80MG/8ML (10MG/ML)	A207563	002	Aug 31, 2017	Feb CAHN
	@		160MG/16ML (10MG/ML)	A207563	003	Aug 31, 2017	Feb DISC
AP			160MG/16ML (10MG/ML)	A207563	003	Aug 31, 2017	Feb CAHN

SOLUTION;INTRAVENOUS
BEIZRAY

>A>	+!	ZHUHAI	20MG/ML (20MG/ML)	N218711	002	Dec 10, 2025	Jul NEWA

DOFETILIDE

CAPSULE;ORAL
DOFETILIDE

	@	APPCO	0.125MG	A215323	001	Apr 14, 2022	Jun CAHN
	@		0.25MG	A215323	002	Apr 14, 2022	Jun CAHN
	@		0.5MG	A215323	003	Apr 14, 2022	Jun CAHN
	@	INGENUS PHARMS LLC	0.125MG	A212410	001	Dec 27, 2019	Feb CAHN
	@		0.25MG	A212410	002	Dec 27, 2019	Feb CAHN
	@		0.5MG	A212410	003	Dec 27, 2019	Feb CAHN

CAPSULE;ORAL
DOFETILIDE

>A>	AB		INNOGENIX INC	0.125MG	A212496	001	Jul 29, 2026	Jul NEWA
>A>	AB			0.25MG	A212496	002	Jul 29, 2026	Jul NEWA
>A>	AB			0.5MG	A212496	003	Jul 29, 2026	Jul NEWA
		@	STRIDES PHARMA INTL	0.125MG	A208519	001	Oct 09, 2018	Jan DISC
		@		0.25MG	A208519	002	Oct 09, 2018	Jan DISC
		@		0.5MG	A208519	003	Oct 09, 2018	Jan DISC

DONEPEZIL HYDROCHLORIDE

TABLET;ORAL
DONEPEZIL HYDROCHLORIDE

		@	LUPIN	23MG	A202782	001	Oct 30, 2015	Feb DISC
		@	STRIDES PHARMA	5MG	A078662	001	May 31, 2011	Jun DISC
		@		10MG	A078662	002	May 31, 2011	Jun DISC

DORAVIRINE; ISLATRAVIR

TABLET;ORAL
IDVYNSO

		+!	MSD	100MG;0.25MG	N216964	001	Apr 20, 2026	Apr NEWA

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

	AT2		ALEMBIC THERAP	EQ 2% BASE;EQ 0.5% BASE	A216308	001	Feb 18, 2025	May CAHN

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL
DOXEPIN HYDROCHLORIDE

>D>	AB	!	PH HEALTH	EQ 150MG BASE	A071422	006	Nov 09, 1987	Jul DISC
>A>		@		EQ 150MG BASE	A071422	006	Nov 09, 1987	Jul DISC
	AB		UNIQUE	EQ 10MG BASE	A217975	001	Aug 21, 2023	Mar CAHN
	AB			EQ 25MG BASE	A217975	002	Aug 21, 2023	Mar CAHN
	AB			EQ 50MG BASE	A217975	003	Aug 21, 2023	Mar CAHN
	AB			EQ 75MG BASE	A217975	004	Aug 21, 2023	Mar CAHN
	AB			EQ 100MG BASE	A217975	005	Aug 21, 2023	Mar CAHN
>D>	AB		VELZEN PHARMA PVT	EQ 150MG BASE	A211618	001	Mar 01, 2021	Jul CHRS
>A>	AB	!		EQ 150MG BASE	A211618	001	Mar 01, 2021	Jul CHRS

CREAM;TOPICAL
DOXEPIN HYDROCHLORIDE

	AB		SUN PHARMA CANADA	5%	A213919	001	Apr 28, 2026	Apr NEWA

DOXERCALCIFEROL

INJECTABLE;INJECTION
DOXERCALCIFEROL

		@	CAPLIN	4MCG/2ML (2MCG/ML)	A200926	001	Feb 04, 2014	Apr DISC
	AP			4MCG/2ML (2MCG/ML)	A200926	001	Feb 04, 2014	Jan CAHN
		@		2MCG/ML (2MCG/ML)	A200926	002	Sep 04, 2014	Apr DISC
				2MCG/ML (2MCG/ML)	A200926	002	Sep 04, 2014	Apr NEWA
		@	EUGIA PHARMA	4MCG/2ML (2MCG/ML)	A213717	002	Jan 24, 2022	Mar DISC
		@	HIKMA	4MCG/2ML (2MCG/ML)	A091101	001	Aug 30, 2013	Mar DISC

DOXORUBICIN HYDROCHLORIDE

INJECTABLE, LIPOSOMAL;INJECTION
DOXORUBICIN HYDROCHLORIDE

	AB		QILU PHARM HAINAN	20MG/10ML (2MG/ML)	A219881	001	Feb 03, 2026	Jan NEWA
	AB			50MG/25ML (2MG/ML)	A219881	002	Feb 03, 2026	Jan NEWA

DOXYCYCLINE

CAPSULE;ORAL
DOXYCYCLINE

	AB		AIPING PHARM INC	40MG	A219978	001	Oct 01, 2025	Jan CAHN
		@	COSETTE PHARMS NC	EQ 50MG BASE	A204446	001	May 28, 2015	Jun CAHN
		@		EQ 75MG BASE	A204446	002	May 28, 2015	Jun CAHN
		@		EQ 100MG BASE	A204446	003	May 28, 2015	Jun CAHN

DOXYCYCLINE HYCLATE

INJECTABLE;INJECTION
DOXYCYCLINE HYCLATE

		@	AVET LIFESCIENCES	EQ 100MG BASE/VIAL	A203276	001	Feb 19, 2026	Feb DISC
	AP			EQ 100MG BASE/VIAL	A203276	001	Feb 19, 2026	Feb NEWA
>A>	AP		HAINAN POLY	EQ 100MG BASE/VIAL	A217685	001	Jun 21, 2024	Jul CAHN

		INJECTABLE;INJECTION						
		DOXYCYCLINE HYCLATE						
>A>	AP		EQ 200MG BASE/VIAL	A217685	002	Jun 21, 2024	Jul	CAHN
	AP	PHARMOBEDIENT	EQ 100MG BASE/VIAL	A217078	001	Feb 21, 2025	Jun	CAHN
>D>	AP	SLATE RUN PHARMA	EQ 100MG BASE/VIAL	A217685	001	Jun 21, 2024	Jul	CAHN
>D>	AP		EQ 200MG BASE/VIAL	A217685	002	Jun 21, 2024	Jul	CAHN
		TABLET;ORAL						
		DOXYCYCLINE HYCLATE						
	@	APOTEX	EQ 75MG BASE	A209243	001	Apr 15, 2019	Jan	DISC
	@		EQ 150MG BASE	A209243	002	Apr 15, 2019	Jan	DISC
>A>	@	ARTHUR GRP	EQ 100MG BASE	A212487	001	Mar 30, 2022	Jul	CAHN
>D>	@	PRAXGEN	EQ 100MG BASE	A212487	001	Mar 30, 2022	Jul	CAHN
		TABLET, DELAYED RELEASE;ORAL						
		DORYX						
	@ +	MAYNE PHARMA	EQ 80MG BASE	N050795	004	Apr 11, 2013	Apr	DISC
	@ +		EQ 200MG BASE	N050795	005	Apr 11, 2013	Apr	DISC
		DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE						
		TABLET, DELAYED RELEASE;ORAL						
		DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE						
	@	PHARMOBEDIENT	10MG;10MG	A207825	001	Jul 06, 2020	Jun	DISC
		DRONABINOL						
		CAPSULE;ORAL						
		DRONABINOL						
	@	RHODES	2.5MG	A078292	001	Jun 27, 2008	May	CAHN
	@		5MG	A078292	002	Jun 27, 2008	May	CAHN
	@		10MG	A078292	003	Jun 27, 2008	May	CAHN
		SOLUTION;ORAL						
		SYNDROS						
	@ +	WELLHOUSE PHARMA	5MG/ML	N205525	001	Mar 23, 2017	Jan	CAHN
		DRONEDARONE HYDROCHLORIDE						
		TABLET;ORAL						
		DRONEDARONE HYDROCHLORIDE						
	@	LUPIN	EQ 400MG BASE	A205904	001	Jan 31, 2024	Mar	DISC
		MULTAQ						
	+!	SANOFI AVENTIS US	EQ 400MG BASE	N022425	001	Jul 01, 2009	Mar	CTEC
		DULOXETINE HYDROCHLORIDE						
		CAPSULE, DELAYED REL PELLETS;ORAL						
		DULOXETINE HYDROCHLORIDE						
	+!	ALMATICA	EQ 80MG BASE	N219131	001	Feb 27, 2026	Feb	NEWA
	+		EQ 90MG BASE	N219131	002	Feb 27, 2026	Feb	NEWA
	+		EQ 120MG BASE	N219131	003	Feb 27, 2026	Feb	NEWA
		DUTASTERIDE						
		CAPSULE;ORAL						
		DUTASTERIDE						
>A>	AB	ONESOURCE	0.5MG	A204262	001	Nov 20, 2015	Jul	CAHN
>D>	AB	ONESOURCE SPECIALTY	0.5MG	A204262	001	Nov 20, 2015	Jul	CAHN
		ECONAZOLE NITRATE						
		CREAM;TOPICAL						
		ECONAZOLE NITRATE						
	AB	AUROBINDO PHARMA USA	1%	A210364	001	Apr 18, 2018	Mar	CMFD
	AB	ENCUBE	1%	A076574	001	Dec 17, 2004	Jun	CMFD
		EDARAVONE						
		SOLUTION;INTRAVENOUS						
		EDARAVONE						
	@	DR REDDYS	60MG/100ML (0.6MG/ML)	A215917	001	May 06, 2024	Apr	DISC
	@	GLAND	60MG/100ML (0.6MG/ML)	A216199	002	May 06, 2024	Apr	DISC
	@	PHARMOBEDIENT	30MG/100ML (0.3MG/ML)	A217565	001	Oct 31, 2024	Jun	DISC
	@		60MG/100ML (0.6MG/ML)	A217565	002	Oct 31, 2024	Jun	DISC
	!		60MG/100ML (0.6MG/ML)	A217565	002	Oct 31, 2024	Apr	CTEC
>A>	AP	ZYDUS PHARMS	30MG/100ML (0.3MG/ML)	A218349	001	Jul 22, 2026	Jul	NEWA
		RADICAVA						
	@ +	SHIONOGI	30MG/100ML (0.3MG/ML)	N209176	001	May 05, 2017	Apr	CAHN
	@ +		60MG/100ML (0.6MG/ML)	N209176	002	Nov 15, 2018	Apr	DISC
	AP +		60MG/100ML (0.6MG/ML)	N209176	002	Nov 15, 2018	Apr	CAHN

		SUSPENSION;ORAL						
		RADICAVA ORS						
		+! SHIONOGI	105MG/5ML	N215446	001	May 12, 2022	Apr	CAHN
		EFAVIRENZ						
		TABLET;ORAL						
		EFAVIRENZ						
>D>	AB	PHARMOBEDIENT	600MG	A204869	001	Mar 12, 2018	Jul	DISC
>A>		@	600MG	A204869	001	Mar 12, 2018	Jul	DISC
		EFINACONAZOLE						
		SOLUTION;TOPICAL						
		EFINACONAZOLE						
	AB	ALEMBIC	10%	A212027	001	Feb 23, 2026	Feb	NEWA
	AB	NIVAGEN PHARMS INC	10%	A211969	001	Jun 21, 2021	Mar	CAHN
		ELETRIPTAN HYDROBROMIDE						
		TABLET;ORAL						
		ELETRIPTAN HYDROBROMIDE						
		@ CARLSBAD	EQ 20MG BASE	A209680	001	Jul 13, 2020	Feb	CAHN
		@	EQ 40MG BASE	A209680	002	Jul 13, 2020	Feb	CAHN
		ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR						
		GRANULE;ORAL						
		TRIKAFTA (COPACKAGED)						
		+ VERTEX PHARMS INC	80MG, 60MG, 40MG;59.5MG	N217660	001	Apr 26, 2023	Apr	CDFR
		+!	100MG, 75MG, 50MG;75MG	N217660	002	Apr 26, 2023	Apr	CDFR
		ELIGLUSTAT TARTRATE						
		CAPSULE;ORAL						
		ELIGLUSTAT TARTRATE						
		@ CIPLA	EQ 84MG BASE	A212369	001	Dec 10, 2024	Feb	DISC
		ELTROMBOPAG OLAMINE						
		TABLET;ORAL						
		ELTROMBOPAG OLAMINE						
	AB	ACTAVIS LABS FL	EQ 50MG ACID	A208815	001	Jun 17, 2026	Jun	NEWA
	AB	AIZANT	EQ 12.5MG ACID	A220660	001	Apr 28, 2026	Apr	NEWA
	AB		EQ 25MG ACID	A220660	002	Apr 28, 2026	Apr	NEWA
	AB		EQ 50MG ACID	A220660	003	Apr 28, 2026	Apr	NEWA
	AB		EQ 75MG ACID	A220660	004	Apr 28, 2026	Apr	NEWA
	AB	AMNEAL	EQ 12.5MG ACID	A212884	001	Jan 14, 2026	Jan	NEWA
	AB		EQ 25MG ACID	A212884	003	Jan 14, 2026	Jan	NEWA
	AB		EQ 50MG ACID	A212884	002	Jan 14, 2026	Jan	NEWA
	AB		EQ 75MG ACID	A212884	004	Jan 14, 2026	Jan	NEWA
	AB	BIOCON PHARMA	EQ 12.5MG ACID	A220660	001	Apr 28, 2026	May	CAHN
	AB		EQ 25MG ACID	A220660	002	Apr 28, 2026	May	CAHN
	AB		EQ 50MG ACID	A220660	003	Apr 28, 2026	May	CAHN
	AB		EQ 75MG ACID	A220660	004	Apr 28, 2026	May	CAHN
	AB	DR REDDYS	EQ 12.5MG ACID	A219121	001	Mar 16, 2026	Mar	NEWA
	AB		EQ 25MG ACID	A219121	002	Mar 16, 2026	Mar	NEWA
	AB		EQ 50MG ACID	A219121	003	Mar 16, 2026	Mar	NEWA
	AB		EQ 75MG ACID	A219121	004	Mar 16, 2026	Mar	NEWA
	AB	HIKMA	EQ 12.5MG ACID	A220033	001	Apr 08, 2026	Apr	CAHN
	AB		EQ 25MG ACID	A220033	002	Apr 08, 2026	Apr	CAHN
	AB		EQ 50MG ACID	A220033	003	Apr 08, 2026	Apr	CAHN
	AB		EQ 75MG ACID	A220033	004	Apr 08, 2026	Apr	CAHN
	AB	MSN	EQ 12.5MG ACID	A220250	001	Jan 14, 2026	Jan	NEWA
	AB		EQ 25MG ACID	A220250	002	Jan 14, 2026	Jan	NEWA
	AB		EQ 50MG ACID	A220250	003	Jan 14, 2026	Jan	NEWA
	AB		EQ 75MG ACID	A220250	004	Jan 14, 2026	Jan	NEWA
	AB	SOMERSET THERAPS LLC	EQ 12.5MG ACID	A219638	001	Jan 14, 2026	Jan	NEWA
	AB		EQ 25MG ACID	A219638	002	Jan 14, 2026	Jan	NEWA
	AB		EQ 50MG ACID	A219638	003	Jan 14, 2026	Jan	NEWA
	AB		EQ 75MG ACID	A219638	004	Jan 14, 2026	Jan	NEWA
>A>	AB	TEVA PHARMS USA	EQ 12.5MG ACID	A209938	001	Jul 13, 2026	Jul	NEWA
>A>	AB		EQ 25MG ACID	A209938	002	Jul 13, 2026	Jul	NEWA
>A>	AB		EQ 75MG ACID	A209938	003	Jul 13, 2026	Jul	NEWA
	AB	ZENARA	EQ 12.5MG ACID	A220033	001	Apr 08, 2026	Mar	NEWA
	AB		EQ 25MG ACID	A220033	002	Apr 08, 2026	Mar	NEWA
	AB		EQ 50MG ACID	A220033	003	Apr 08, 2026	Mar	NEWA
	AB		EQ 75MG ACID	A220033	004	Apr 08, 2026	Mar	NEWA
	AB	ZYDUS PHARMS	EQ 12.5MG ACID	A216281	001	Jan 14, 2026	Jan	NEWA

TABLET;ORAL
ELTROMBOPAG OLAMINE

AB		EQ 25MG ACID	A216281	002	Jan 14, 2026	Jan	NEWA
AB		EQ 50MG ACID	A216281	003	Jan 14, 2026	Jan	NEWA
AB		EQ 75MG ACID	A216281	004	Jan 14, 2026	Jan	NEWA

ELUXADOLINE

TABLET;ORAL
ELUXADOLINE

	@ AUROBINDO PHARMA	75MG	A213511	001	Jun 02, 2026	Jun	DISC
AB		75MG	A213511	001	Jun 02, 2026	May	NEWA
	@	100MG	A213511	002	Jun 02, 2026	Jun	DISC
AB		100MG	A213511	002	Jun 02, 2026	May	NEWA

VIBERZI

	+ ABBVIE	75MG	N206940	001	May 27, 2015	Jun	CTEC
AB	+	75MG	N206940	001	May 27, 2015	May	CTEC
AB	+	75MG	N206940	001	May 27, 2015	May	CTEC
	+!	100MG	N206940	002	May 27, 2015	Jun	CTEC
AB	+!	100MG	N206940	002	May 27, 2015	May	CTEC
AB	+!	100MG	N206940	002	May 27, 2015	May	CTEC

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL
>D> EMTRICITABINE, RILPIVIRINE, AND TENOFOVIR ALAFENAMIDE

>D> AB	APOTEX	200MG;EQ 25MG BASE;EQ 25MG BASE	A214095	001	Jan 30, 2026	Jul	DISC
>A>	@	200MG;EQ 25MG BASE;EQ 25MG BASE	A214095	001	Jan 30, 2026	Jul	DISC
AB		200MG;EQ 25MG BASE;EQ 25MG BASE	A214095	001	Jan 30, 2026	Jan	NFTG

ODEFSEY

>D> AB	+! GILEAD SCIENCES INC	200MG;EQ 25MG BASE;EQ 25MG BASE	N208351	001	Mar 01, 2016	Jul	CTEC
>A>	+!	200MG;EQ 25MG BASE;EQ 25MG BASE	N208351	001	Mar 01, 2016	Jul	CTEC
AB	+!	200MG;EQ 25MG BASE;EQ 25MG BASE	N208351	001	Mar 01, 2016	Jan	CFTG

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL
EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE

AB	LAURUS	200MG;EQ 25MG BASE;300MG	A220232	001	Mar 04, 2026	Feb	NEWA

EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL
EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE

	@ LUPIN	200MG;EQ 25MG BASE	A213926	001	Dec 13, 2024	Mar	DISC
AB	MACLEODS PHARMS	200MG;EQ 25MG BASE	A214216	001	Apr 07, 2026	Mar	NEWA

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

	@ PHARMOBEDIENT	200MG;300MG	A206436	001	Apr 09, 2018	Jun	DISC

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

	@ COSETTE PHARMS NC	5MG;12.5MG	A075727	001	Sep 18, 2001	Jun	CAHN
	@	10MG;25MG	A075727	002	Sep 18, 2001	Jun	CAHN

>A> ENLICITIDE DECANOATE

>A> TABLET;ORAL
>A> LIPFENDRA

>A>	+! MSD	EQ 20MG BASE	N220848	001	Jul 15, 2026	Jul	NEWA

ENSIFENTRINE

SUSPENSION;INHALATION
OHTUVAYRE

	+! MSD	3MG/2.5ML	N217389	001	Jun 26, 2024	Apr	CAHN

ENSITRELVIR

TABLET;ORAL

XOCOVA

	+!	SHIONOGI	125MG	N220442	001	May 29, 2026	May NEWA

ENTECAVIR

TABLET;ORAL

ENTECAVIR

	@	PHARMADAX	0.5MG	A212106	001	Aug 10, 2020	Mar CAHN
	@		1MG	A212106	002	Aug 10, 2020	Mar CAHN

ENZALUTAMIDE

TABLET;ORAL

ENZALUTAMIDE

AB		SANDOZ	40MG	A216068	001	Apr 20, 2026	Apr NFTG
AB			80MG	A216068	002	Apr 20, 2026	Apr NFTG

XTANDI

AB	+	ASTELLAS	40MG	N213674	001	Aug 04, 2020	Apr CFTG
AB	+!		80MG	N213674	002	Aug 04, 2020	Apr CFTG

EPHEDRINE SULFATE

SOLUTION;INTRAVENOUS

EPHEDRINE SULFATE

AP		BAXTER HLTHCARE CORP	50MG/ML (50MG/ML)	A216740	001	Jul 08, 2026	Jun NEWA
	@	CIVICA	50MG/ML (50MG/ML)	A215593	001	Dec 23, 2025	Jun DISC
AP2		FRESENIUS KABI USA	50MG/10ML (5MG/ML)	A219991	001	Mar 19, 2026	Mar NEWA

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

EPINASTINE HYDROCHLORIDE

	@	APOTEX	0.05%	A090919	001	Oct 31, 2011	Apr DISC
	!	SOMERSET THERAPS LLC	0.05%	A090951	001	Oct 31, 2011	Apr CTEC

EPINEPHRINE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

EPINEPHRINE

	+!	BAXTER HLTHCARE CORP	1MG/ML (1MG/ML)	N220626	001	Mar 30, 2026	Mar NEWA
	+!		30MG/30ML (1MG/ML)	N220626	002	Mar 30, 2026	Mar NEWA
AP	+!	BPI LABS	1MG/ML (1MG/ML)	N205029	005	Mar 04, 2024	May CFTG
>A> AP		DEVA HLDING	1MG/ML (1MG/ML)	A217426	001	Jul 31, 2026	Jul NEWA
AP		HIKMA	1MG/ML (1MG/ML)	A220562	001	May 29, 2026	May NFTG

SOLUTION;INTRAVENOUS

EPINEPHRINE

	@ +	HOSPIRA	1MG/10ML (0.1MG/ML)	N209359	001	Nov 05, 2019	Jun DISC

EPINEPHRINE BITARTRATE

SOLUTION;INTRAVENOUS

EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

	+!	BAXTER HLTHCARE CORP	EQ 4MG BASE/250ML (EQ 16MCG BASE/ML)	N218475	002	Mar 16, 2026	Mar NEWA
	@ +		EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	N218475	001	Feb 28, 2025	Jun DISC

EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDE

SOLUTION;INJECTION

FLAVALTA

	+!	DEPROCO	EQ 0.017MG BASE/1.7ML (EQ 0.01MG BASE/ML);34MG/1.7ML (20MG/ML)	N216564	001	Mar 19, 2026	Mar NEWA

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

	@ +	WEST-WARD PHARMS INT	0.01MG/ML;1%	A080406	001		Apr CRLD

EPLERENONE

TABLET;ORAL

EPLERENONE

	@	INNOGENIX	25MG	A203896	001	Feb 02, 2017	May CAHN
	@		50MG	A203896	002	Feb 02, 2017	May CAHN

EPLONTERSEN SODIUM

SOLUTION;SUBCUTANEOUS

WAINUA

		+!	ASTRAZENECA AB	EQ 45MG BASE/0.8ML (EQ 45MG BASE/0.8ML)	N217388	002	Apr 15, 2026	Apr NEWA

EPOPROSTENOL SODIUM

INJECTABLE;INJECTION

EPOPROSTENOL SODIUM

		@	MEITHEAL	EQ 0.5MG BASE/VIAL	A078396	001	Apr 23, 2008	Jun DISC
		@		EQ 1.5MG BASE/VIAL	A078396	002	Apr 23, 2008	Jun DISC

EPTIFIBATIDE

INJECTABLE;INJECTION

EPTIFIBATIDE

>A>	AP		HAINAN POLY	2MG/ML	A209864	001	Jan 25, 2019	Jul CAHN
>A>	AP			75MG/100ML	A209864	002	Jan 25, 2019	Jul CAHN
>D>	AP		SLATE RUN PHARMA	2MG/ML	A209864	001	Jan 25, 2019	Jul CAHN
>D>	AP			75MG/100ML	A209864	002	Jan 25, 2019	Jul CAHN

ERGOCALCIFEROL

CAPSULE;ORAL

ERGOCALCIFEROL

>A>	AA	!	ONESOURCE	50,000 IU	A090455	001	Aug 03, 2010	Jul CAHN
>D>	AA	!	ONESOURCE SPECIALTY	50,000 IU	A090455	001	Aug 03, 2010	Jul CAHN

ERGOTAMINE TARTRATE

TABLET;SUBLINGUAL

ERGOMAR

>D>		!	PANGEA	2MG	A087693	001	Feb 24, 1983	Jul CRLD
>A>		+!		2MG	A087693	001	Feb 24, 1983	Jul CRLD

ERIBULIN MESYLATE

SOLUTION;INTRAVENOUS

ERIBULIN MESYLATE

	AP		FORMOSA LABS	1MG/2ML (0.5MG/ML)	A219054	001	Mar 16, 2026	Mar NEWA
	AP		NATCO	1MG/2ML (0.5MG/ML)	A217085	001	Jun 01, 2026	May NEWA
	AP		XGEN PHARMS	1MG/2ML (0.5MG/ML)	A219054	001	Mar 16, 2026	Mar CAHN

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS;ORAL

ERYTHROMYCIN

	AB		CARNEGIE	250MG	A062746	001	Dec 22, 1986	Feb CAHN

OINTMENT;OPHTHALMIC

ERYTHROMYCIN

	AT	!	BAUSCH AND LOMB INC	0.5%	A064067	001	Jul 29, 1994	May CAHN

ILOTYCIN

>D>		@	DISTA	0.5%	N050368	001		Jul CRLD
>A>		@ +		0.5%	N050368	001		Jul CRLD

SOLUTION;TOPICAL

ERYTHROMYCIN

		@	ENCUBE	2%	A208100	001	Nov 20, 2017	May CAHN

TABLET;ORAL

ERYTHROMYCIN

	AB		CARNEGIE	250MG	A061621	001		Feb CAHN
	AB			500MG	A061621	002		Feb CAHN

TABLET, DELAYED RELEASE;ORAL

ERY-TAB

	AB		CARNEGIE	250MG	A062298	001		Feb CAHN
	AB			333MG	A062298	003	Mar 29, 1982	Feb CAHN
	AB	!		500MG	A062298	002		Feb CAHN

ERYTHROMYCIN ESTOLATE

SUSPENSION;ORAL

ERYTHROMYCIN ESTOLATE

		@	COSETTE PHARMS NC	EQ 125MG BASE/5ML	A062169	001	Oct 17, 1990	Jun CAHN
		@		EQ 250MG BASE/5ML	A062169	002	Oct 17, 1990	Jun CAHN

ERYTHROMYCIN ETHYLSUCCINATE

TABLET;ORAL

E.E.S. 400

	@	CARNEGIE	EQ 400MG BASE	A061905	001			Feb CAHN
BX	!		EQ 400MG BASE	A061905	002	Aug 12, 1982		Feb CAHN

ERYTHROMYCIN ETHYLSUCCINATE

BX	!	CARNEGIE	EQ 400MG BASE	A061904	001			Feb CAHN

ESCITALOPRAM OXALATE

TABLET;ORAL

ESCITALOPRAM OXALATE

AB		MICRO LABS	EQ 5MG BASE	A091655	001	Apr 22, 2026		Apr NEWA
AB			EQ 10MG BASE	A091655	002	Apr 22, 2026		Apr NEWA
AB			EQ 20MG BASE	A091655	003	Apr 22, 2026		Apr NEWA

ESLICARBAZEPINE ACETATE

TABLET;ORAL

ESLICARBAZEPINE ACETATE

>A> AB		AUROBINDO PHARMA	200MG	A216481	001	Aug 05, 2026		Jul NEWA
>A> AB			400MG	A216481	002	Aug 05, 2026		Jul NEWA
>A> AB			600MG	A216481	003	Aug 05, 2026		Jul NEWA
>A> AB			800MG	A216481	004	Aug 05, 2026		Jul NEWA

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL

ESOMEPRAZOLE MAGNESIUM

	@	CISEN	EQ 20MG BASE	A213158	001	Sep 22, 2020		May DISC
	@		EQ 40MG BASE	A213158	002	Sep 22, 2020		May DISC

ESOMEPRAZOLE SODIUM

INJECTABLE;INTRAVENOUS

ESOMEPRAZOLE SODIUM

>A> AP	!	HAINAN POLY	EQ 40MG BASE/VIAL	A215732	001	Feb 10, 2022		Jul CAHN
>D> AP	!	SLATE RUN PHARMA	EQ 40MG BASE/VIAL	A215732	001	Feb 10, 2022		Jul CAHN

ESTRADIOL

CREAM;VAGINAL

ESTRACE

AB	+!	ABBVIE	0.01%	A086069	001	Jan 31, 1984		Mar CAHN

GEL;TRANSDERMAL

ESTRADIOL

AB		SOLARIS PHARMA CORP	0.1% (0.25GM/PACKET)	A217863	001	Jul 12, 2024		Feb CAHN
AB			0.1% (0.5GM/PACKET)	A217863	002	Jul 12, 2024		Feb CAHN
AB			0.1% (0.75GM/PACKET)	A217863	003	Jul 12, 2024		Feb CAHN
AB			0.1% (1GM/PACKET)	A217863	004	Jul 12, 2024		Feb CAHN
AB			0.1% (1.25GM/PACKET)	A217863	005	Jul 12, 2024		Feb CAHN
AB		XIROMED	0.1% (0.25GM/PACKET)	A211783	001	Aug 10, 2022		Jan CAHN
AB			0.1% (0.5GM/PACKET)	A211783	002	Aug 10, 2022		Jan CAHN
AB			0.1% (1GM/PACKET)	A211783	003	Aug 10, 2022		Jan CAHN

GEL, METERED;TRANSDERMAL

ESTRADIOL

AB		ENCUBE	0.06% (1.25GM/ACTIVATION)	A218214	001	May 11, 2026		May NEWA
AB		LONG GROVE PHARMS	0.06% (1.25GM/ACTIVATION)	A215096	001	Feb 02, 2026		Jan NEWA
	@	PADAGIS US	0.06% (1.25GM/ACTIVATION)	A215096	001	Feb 02, 2026		Jun DISC
AB			0.06% (1.25GM/ACTIVATION)	A215096	001	Feb 02, 2026		May CAHN

ESTRADIOL ACETATE

INSERT, EXTENDED RELEASE;VAGINAL

FEMRING

	+	MILLICENT MFG PR	EQ 0.05MG BASE/24HR	N021367	001	Mar 20, 2003		Jan CAHN
	+!		EQ 0.1MG BASE/24HR	N021367	002	Mar 20, 2003		Jan CAHN

ESTRADIOL; NORETHINDRONE ACETATE

FILM, EXTENDED RELEASE;TRANSDERMAL

COMBIPATCH

	+!	NOVEN PHARMS INC	0.05MG/24HR;0.14MG/24HR	N020870	001	Aug 07, 1998		Mar CHRS

ESZOPICLONE

TABLET;ORAL

ESZOPICLONE

	@	LUPIN LTD	1MG	A091124	001	Sep 13, 2011	Apr	DISC
	@		2MG	A091124	002	Sep 13, 2011	Apr	DISC
	@		3MG	A091124	003	Sep 13, 2011	Apr	DISC

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET;ORAL-28

ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL

AB	!	XIROMED	0.05MG;1MG	A204704	001	Feb 09, 2016	Apr	CHRS

KELNOR 1/50

	@	WATSON LABS	0.05MG;1MG	A072723	001	Dec 30, 1991	Apr	DISC

ETHINYL ESTRADIOL; LEVONORGESTREL

SYSTEM;TRANSDERMAL

TWIRLA

	+!	AGILE	0.01MG/24HR;0.04MG/24HR	N204017	001	Feb 14, 2020	Jun	CPOT

TABLET;ORAL

QUARTETTE

AB	+!	TEVA BRANDED PHARM	0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A	N204061	001	Mar 28, 2013	Mar	CAHN

TABLET;ORAL-28

MYZILRA

	@	PH HEALTH	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A077502	001	Nov 23, 2011	Apr	DISC

ETHINYL ESTRADIOL; NORELGESTROMIN

SYSTEM;TRANSDERMAL

GWYN LO

>A>	+!	VIATRIS SPECIALTY	0.02MG/24HR;0.22MG/24HR	N219990	001	Jul 28, 2026	Jul	NEWA

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-28

GILDAGIA

	@	PH HEALTH	0.035MG;0.4MG	A078376	001	Nov 06, 2012	Apr	DISC

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL

GILDESS 24 FE

	@	PH HEALTH	0.02MG;1MG	A090293	001	Dec 01, 2014	Apr	DISC

LO JUNEL FE

AB		TEVA PHARMS INC	0.01MG,0.01MG;1MG,N/A	A219324	001	Jun 22, 2026	Jun	NEWA

LO LOESTRIN FE

AB	+!	APIL	0.01MG,0.01MG;1MG,N/A	N022501	001	Oct 21, 2010	Jun	CTEC

TABLET, ORALLY DISINTEGRATING;ORAL

FEMLYV

	+!	MILLICENT MFG PR	0.02MG;1MG	N218718	001	Jul 22, 2024	Jun	CAHN

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-28

PREVIFEM

	@	PH HEALTH	0.035MG;0.25MG	A076334	001	Jan 09, 2004	Apr	DISC

ETHOSUXIMIDE

CAPSULE;ORAL

ETHOSUXIMIDE

	@	HERITAGE PHARMS INC	250MG	A200892	001	Sep 25, 2012	Apr	DISC
>A>	AB	ONESOURCE	250MG	A211928	001	Feb 19, 2019	Jul	CAHN
>D>	AB	ONESOURCE SPECIALTY	250MG	A211928	001	Feb 19, 2019	Jul	CAHN

ETODOLAC

TABLET;ORAL

ETODOLAC

>A>	AB	AUROBINDO PHARMA LTD	400MG	A214872	001	Jul 15, 2026	Jul	NEWA
>A>	AB		500MG	A214872	002	Jul 15, 2026	Jul	NEWA
	@	SENORES PHARMS	400MG	A074839	001	Jul 11, 1997	Jan	CAHN

ETOPOSIDE

CAPSULE;ORAL

ETOPOSIDE

AB		!	MYLAN	50MG	A075635	001	Sep 19, 2001	Jan CTEC

VEPESID

AB		+	ONESOURCE SPECIALTY	50MG	N019557	001	Dec 30, 1986	Jan CMFD

INJECTABLE;INJECTION

ETOPOSIDE

		@	NATCO PHARMA USA	20MG/ML	A203507	001	Nov 20, 2017	Mar CAHN
		@		20MG/ML	A204927	001	Oct 31, 2017	Mar CAHN

INJECTABLE;INTRAVENOUS

AVOPEF

		+!	AVYXA HOLDINGS	100MG/5ML (20MG/ML)	N220200	001	Feb 13, 2026	Feb NEWA

SOLUTION;INTRAVENOUS

AVOPEF

		+!	AVYXA HOLDINGS	100MG/5ML (20MG/ML)	N220200	001	Feb 13, 2026	Mar CDFR
		+!		500MG/25ML (20MG/ML)	N220200	002	Jun 24, 2026	Jun NEWA

EVEROLIMUS

TABLET;ORAL

EVEROLIMUS

AB		!	ALKEM LABS LTD	1MG	A214138	004	Nov 26, 2021	May CHRS
AB			APOTEX	2.5MG	A218488	001	May 12, 2026	May NEWA
AB				5MG	A218488	002	May 12, 2026	May NEWA
AB				7.5MG	A218488	003	May 12, 2026	May NEWA
AB				10MG	A218488	004	May 12, 2026	May NEWA
AB			EUGIA PHARMA	0.25MG	A219533	001	Feb 25, 2026	Feb NEWA
AB				0.5MG	A219533	002	Feb 25, 2026	Feb NEWA
AB				0.75MG	A219533	003	Feb 25, 2026	Feb NEWA
AB				1MG	A219533	004	Feb 25, 2026	Feb NEWA
AB			I3 PHARMS	0.25MG	A219464	001	Jun 30, 2026	Jun NEWA
AB				0.5MG	A219464	002	Jun 30, 2026	Jun NEWA
AB				0.75MG	A219464	003	Jun 30, 2026	Jun NEWA
AB				1MG	A219464	004	Jun 30, 2026	Jun NEWA
		@	PH HEALTH	2.5MG	A207934	001	Dec 09, 2019	Jan DISC
		@		5MG	A207934	002	Dec 09, 2019	Jan DISC
		@		7.5MG	A207934	003	Dec 09, 2019	Jan DISC
		@		10MG	A207934	004	Dec 09, 2020	Jan DISC

ZORTRESS

AB		+	NOVARTIS	1MG	N021560	004	Aug 10, 2018	May CHRS

TABLET, FOR SUSPENSION;ORAL

EVEROLIMUS

AB			BIOCON PHARMA	2MG	A217216	001	Jan 09, 2026	Jan NEWA
AB				3MG	A217216	002	Jan 09, 2026	Jan NEWA
AB				5MG	A217216	003	Jan 09, 2026	Jan NEWA

EXEMESTANE

TABLET;ORAL

EXEMESTANE

>D>		@	ALVOGEN	25MG	A200898	001	Jul 28, 2014	Jul CAHN
>A>		@	EIRGEN	25MG	A200898	001	Jul 28, 2014	Jul CAHN

EZETIMIBE; SIMVASTATIN

TABLET;ORAL

EZETIMIBE AND SIMVASTATIN

		@	WATSON LABS INC	10MG;10MG	A202968	001	Apr 26, 2017	Feb DISC
		@		10MG;20MG	A202968	002	Apr 26, 2017	Feb DISC
		@		10MG;40MG	A202968	003	Apr 26, 2017	Feb DISC
		@		10MG;80MG	A202968	004	Apr 26, 2017	Feb DISC

FAMCICLOVIR

TABLET;ORAL

FAMCICLOVIR

>D>	AB		APOTEX	125MG	A091480	001	Jul 22, 2011	Jul DISC
>A>		@		125MG	A091480	001	Jul 22, 2011	Jul DISC
>D>	AB			250MG	A091480	002	Jul 22, 2011	Jul DISC
>A>		@		250MG	A091480	002	Jul 22, 2011	Jul DISC
>D>	AB			500MG	A091480	003	Jul 22, 2011	Jul DISC
>A>		@		500MG	A091480	003	Jul 22, 2011	Jul DISC

FAMOTIDINE

FOR SUSPENSION;ORAL

FAMOTIDINE

AB		CARNEGIE	40MG/5ML	A217137	001	Jul 07, 2023	Feb CAHN
AB		CONTRACT PHARMACAL	40MG/5ML	A219603	001	Mar 09, 2026	Feb NEWA

INJECTABLE;INJECTION

FAMOTIDINE

AP		LUPIN	10MG/ML	A217432	001	May 12, 2026	May NEWA

>D> SOLUTION;INTRAVENOUS

>D> FAMOTIDINE

>D>	+!	SAGENT	20MG/5ML (4MG/ML)	N219935	001	Jul 16, 2025	Jul DISC
>A>	@ +		20MG/5ML (4MG/ML)	N219935	001	Jul 16, 2025	Jul DISC
>D>	+!		40MG/10ML (4MG/ML)	N219935	002	Jul 16, 2025	Jul DISC
>A>	@ +		40MG/10ML (4MG/ML)	N219935	002	Jul 16, 2025	Jul DISC
>D>	+!		200MG/50ML (4MG/ML)	N219935	003	Jul 16, 2025	Jul DISC
>A>	@ +		200MG/50ML (4MG/ML)	N219935	003	Jul 16, 2025	Jul DISC

TABLET;ORAL

FAMOTIDINE

AB		VKT PHARMA	20MG	A215630	001	Jan 07, 2022	Jan CAHN
AB			40MG	A215630	002	Jan 07, 2022	Jan CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

PEPCID RPD

@ +		MERCK	20MG	N020752	001	May 28, 1998	Jun CRLD
@ +			40MG	N020752	002	May 28, 1998	Jun CRLD

FAMOTIDINE; IBUPROFEN

TABLET;ORAL

IBUPROFEN AND FAMOTIDINE

AB		ZYDUS LIFESCIENCES	26.6MG;800MG	A218684	001	Feb 20, 2025	Feb CAHN

FENOFIBRATE

CAPSULE;ORAL

FENOFIBRATE (MICRONIZED)

@		INGENUS PHARMS LLC	67MG	A207564	001	Apr 19, 2019	May CAHN
@			134MG	A207564	002	Apr 19, 2019	May CAHN
@			200MG	A207564	003	Apr 19, 2019	May CAHN

LIPOFEN

@ +		CIPHER PHARMS INC	100MG	N021612	002	Jan 11, 2006	Jan CRLD

TABLET;ORAL

FENOFIBRATE

AB		MACLEODS PHARMS	54MG	A210379	001	Jan 21, 2026	Jan NEWA
AB			160MG	A210379	002	Jan 21, 2026	Jan NEWA

TRIGLIDE

@		JAGOTEC	50MG	N021350	001	May 07, 2005	Jan CAHN
@ +			160MG	N021350	002	May 07, 2005	Jan CAHN

FENOFIBRIC ACID

TABLET;ORAL

FIBRICOR

@ +		ROSEMONT	35MG	N022418	001	Aug 14, 2009	Mar CAHN
@ +			105MG	N022418	002	Aug 14, 2009	Mar CAHN

FENOPROFEN CALCIUM

CAPSULE;ORAL

FENOPROFEN CALCIUM

>D>	@	MISEMER	EQ 300MG BASE	A215548	002	May 16, 2023	Jul CMFD
>A> AB			EQ 300MG BASE	A215548	002	May 16, 2023	Jul CMFD
>D>		RISING	EQ 300MG BASE	A214475	003	Jul 26, 2024	Jul CTEC
>A> AB			EQ 300MG BASE	A214475	003	Jul 26, 2024	Jul CTEC

FERRIC CARBOXYMALTOSE

SOLUTION;INTRAVENOUS

FERRIC CARBOXYMALTOSE

AP		MYLAN	100MG IRON/2ML (50MG IRON/ML)	A217769	001	Jun 25, 2026	Jun NFTG
AP			1GM IRON/20ML (50MG IRON/ML)	A217076	001	Jun 25, 2026	Jun NFTG
AP		MYLAN LABS LTD	750MG IRON/15ML (50MG IRON/ML)	A212572	001	Jun 25, 2026	Jun NFTG

INJECTAFER

AP	+!	AM REGENT	750MG IRON/15ML (50MG IRON/ML)	N203565	001	Jul 25, 2013	Jun CFTG
AP	+!		100MG IRON/2ML (50MG IRON/ML)	N203565	004	Feb 04, 2022	Jun CFTG
AP	+!		1GM IRON/20ML (50MG IRON/ML)	N203565	003	Apr 28, 2021	Jun CFTG

FERRIC CITRATE

TABLET;ORAL

AURYXIA

	AB	+!	KERYX BIOPHARMS	EQ 210MG IRON	N205874	001	Sep 05, 2014	Feb CFTG

FERRIC CITRATE

	AB		TEVA PHARMS USA	EQ 210MG IRON	A212563	001	Mar 11, 2026	Feb NFTG

FERUMOXYTOL

SOLUTION;INTRAVENOUS

FERABRIGHT

>D>		+!	AZURITY	EQ 300MG IRON/10ML (EQ 30MG IRON/ML)	N219868	001	Oct 16, 2025	Jul CAHN
>A>		+!		EQ 300MG IRON/10ML (EQ 30MG IRON/ML)	N219868	001	Oct 16, 2025	Jul CAHN
		+!		EQ 300MG IRON/10ML (EQ 30MG IRON/ML)	N219868	001	Oct 16, 2025	Apr CAHN
>D>		+!		EQ 510MG IRON/17ML (EQ 30MG IRON/ML)	N219868	002	Oct 16, 2025	Jul CAHN
>A>		+!		EQ 510MG IRON/17ML (EQ 30MG IRON/ML)	N219868	002	Oct 16, 2025	Jul CAHN
		+!		EQ 510MG IRON/17ML (EQ 30MG IRON/ML)	N219868	002	Oct 16, 2025	Apr CAHN

FERAHEME

>D>	AB	+!	AZURITY	EQ 510MG IRON/17ML (EQ 30MG IRON/ML)	N022180	001	Jun 30, 2009	Jul CAHN
>A>	AB	+!		EQ 510MG IRON/17ML (EQ 30MG IRON/ML)	N022180	001	Jun 30, 2009	Jul CAHN
	AB	+!		EQ 510MG IRON/17ML (EQ 30MG IRON/ML)	N022180	001	Jun 30, 2009	Apr CAHN

FEXOFENADINE HYDROCHLORIDE

TABLET;ORAL

FEXOFENADINE HYDROCHLORIDE

	@		DR REDDYS LABS LTD	30MG	A076502	001	Apr 11, 2006	Mar DISC
	@			60MG	A076502	002	Apr 11, 2006	Mar DISC
	@			180MG	A076502	003	Apr 11, 2006	Mar DISC
	@		RISING	60MG	A077081	003	Apr 11, 2008	Mar DISC
	@			180MG	A077081	001	Apr 16, 2007	Mar DISC
	@		TEVA	30MG	A076447	001	Sep 01, 2005	Mar DISC
	@			60MG	A076447	002	Sep 01, 2005	Mar DISC
	@			180MG	A076447	003	Sep 01, 2005	Mar DISC

FIDAXOMICIN

TABLET;ORAL

FIDAXOMICIN

	AB		APOTEX	200MG	A219559	001	Feb 02, 2026	Jan NEWA
>A>	AB		SANDOZ	200MG	A220465	001	Aug 13, 2026	Jul NEWA
	AB		TORRENT	200MG	A220374	001	Jan 27, 2026	Jan NEWA

FINAFLOXACIN

SUSPENSION/DROPS;OTIC

XTORO

		+!	FONSECA BIOSCIENCES	0.3%	N206307	001	Dec 17, 2014	Apr CMFD

FINERENONE

TABLET;ORAL

KERENDIA

		+	BAYER HLTHCARE	20MG	N215341	002	Jul 09, 2021	May CHRS
		+!		40MG	N215341	003	Jul 11, 2025	May CHRS

FINGOLIMOD HYDROCHLORIDE

CAPSULE;ORAL

FINGOLIMOD HYDROCHLORIDE

	AB		ALEMBIC	EQ 0.5MG BASE	A207974	001	Apr 24, 2026	Apr NEWA

FLECAINIDE ACETATE

TABLET;ORAL

FLECAINIDE ACETATE

	AB		OMSAV PHARMA	50MG	A218093	001	Apr 22, 2026	Apr NEWA
	AB			100MG	A218093	002	Apr 22, 2026	Apr NEWA
	AB			150MG	A218093	003	Apr 22, 2026	Apr NEWA

FLORBETABEN F-18

SOLUTION;INTRAVENOUS

NEURACEQ

		+!	LANTHEUS	1.4-135mCi/ML	N204677	001	Mar 19, 2014	Mar CAHN

FLUCONAZOLE

TABLET;ORAL

FLUCONAZOLE

AB			UNIQUE	50MG	A076957	001	Sep 28, 2005	Mar CAHN
AB				100MG	A076957	002	Sep 28, 2005	Mar CAHN
AB				150MG	A076957	004	Feb 27, 2017	Mar CAHN
AB				200MG	A076957	003	Sep 28, 2005	Mar CAHN

FLUDARABINE PHOSPHATE

INJECTABLE;INJECTION

FLUDARABINE PHOSPHATE

	@	+	CAPLIN ONE LABS	50MG/2ML (25MG/ML)	N022137	001	Sep 21, 2007	Jan CAHN
>A>		!	HISUN PHARM HANGZHOU	50MG/2ML (25MG/ML)	A220196	001	Jul 23, 2026	Jul NEWA

FLUDEOXYGLUCOSE F-18

INJECTABLE;INTRAVENOUS

FLUDEOXYGLUCOSE F18

	@		NUKEMED	4-500mCi/ML	A203911	001	Apr 22, 2015	Apr DISC
	@		PHARMALOGIC	20-300mCi/ML	A204264	001	Dec 18, 2014	Jun DISC

FLUDROCORTISONE ACETATE

TABLET;ORAL

FLUDROCORTISONE ACETATE

AB			HIBROW HLTHCARE	0.1MG	A220308	001	Feb 10, 2026	Jan NEWA

FLUMAZENIL

INJECTABLE;INJECTION

FLUMAZENIL

	@		HIKMA	0.5MG/5ML (0.1MG/ML)	A076787	002	Oct 12, 2004	Mar DISC
	@			1MG/10ML (0.1MG/ML)	A076787	001	Oct 12, 2004	Mar DISC

FLUOCINOLONE ACETONIDE

CREAM;TOPICAL

FLUOCINOLONE ACETONIDE

AT			COSETTE PHARMS NC	0.01%	A089526	001	Jul 26, 1988	May CAHN
	@			0.025%	A089525	001	Jul 26, 1988	Jun CAHN
	@			0.025%	A089525	001	Jul 26, 1988	May CAHN
AT				0.025%	A210747	001	Nov 05, 2018	May CAHN

SYNALAR

AT		+!	EUROFARMA	0.01%	N012787	004		Feb CAHN
AT		+!		0.025%	N012787	002		Feb CAHN
AT		+!		0.025%	N012787	005		Feb CAHN

SYNALAR-HP

	@		EUROFARMA	0.2%	N016161	002		Feb CAHN

IMPLANT;INTRAVITREAL

RETISERT

	@	+	BAUSCH AND LOMB	0.59MG	N021737	001	Apr 08, 2005	Jun DISC

OINTMENT;TOPICAL

FLUOCINOLONE ACETONIDE

AT			COSETTE PHARMS NC	0.025%	A089524	001	Jul 26, 1988	May CAHN

SYNALAR

AT		+!	EUROFARMA	0.025%	N013960	001		Feb CAHN

SOLUTION;TOPICAL

FLUOCINOLONE ACETONIDE

	@		COSETTE PHARMS NC	0.01%	A207441	001	Sep 28, 2016	Jun CAHN

SYNALAR

AT		+!	EUROFARMA	0.01%	N015296	001		Feb CAHN

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE

CREAM;TOPICAL

NEO-SYNALAR

		!	EUROFARMA	0.025%;EQ 3.5MG BASE/GM	A060700	001		Feb CAHN

FLUOCINONIDE

CREAM;TOPICAL

FLUOCINONIDE

AB1		COSETTE PHARMS NC	0.05%	A073085	001	Feb 14, 1992	May CAHN
	@	ENCUBE	0.1%	A211758	001	Apr 03, 2019	May CAHN

FLUOCINONIDE EMULSIFIED BASE

AB2		COSETTE PHARMS NC	0.05%	A074204	001	Jun 13, 1995	May CAHN

GEL;TOPICAL

FLUOCINONIDE

	@	COSETTE PHARMS NC	0.05%	A072537	001	Feb 07, 1989	Jun CAHN

SOLUTION;TOPICAL

FLUOCINONIDE

	@	COSETTE PHARMS NC	0.05%	A071535	001	Dec 02, 1988	Jun CAHN
AT		SCIEGEN PHARMS	0.05%	A207554	001	Mar 18, 2019	May CMFD

FLUORESCEIN SODIUM

INJECTABLE;INTRAVENOUS

FLUORESCEIN SODIUM

AP		BPI LABS	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A220046	001	Apr 30, 2026	Apr NEWA
	@	NEXUS	EQ 500MG BASE/2ML (EQ 250MG BASE/ML)	A215709	002	Sep 25, 2023	May DISC
			EQ 500MG BASE/2ML (EQ 250MG BASE/ML)	A215709	002	Sep 25, 2023	Apr CHRS
AP		ZYDUS LIFESCIENCES	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A218651	001	Jun 01, 2026	May NEWA
	!		EQ 500MG BASE/2ML (EQ 250MG BASE/ML)	A218651	002	Jun 01, 2026	May NEWA

FLUOROMETHOLONE

SUSPENSION/DROPS;OPHTHALMIC

FLUOROMETHOLONE

AB		DIFGEN PHARMS	0.1%	A218819	001	Feb 12, 2026	Jan NEWA
AB		SANDOZ	0.1%	A218819	001	Feb 12, 2026	May CAHN

FLUOROURACIL

INJECTABLE;INJECTION

FLUOROURACIL

	@	INGENUS PHARMS LLC	500MG/10ML (50MG/ML)	A209219	001	Dec 12, 2019	May CAHN
	@		1GM/20ML (50MG/ML)	A209219	002	Dec 12, 2019	May CAHN
	@		2.5GM/50ML (50MG/ML)	A209271	002	Dec 11, 2019	May CAHN
	@		5GM/100ML (50MG/ML)	A209271	001	Dec 11, 2019	May CAHN

SOLUTION;INTRAVENOUS

FAVLYXA

	+!	AVYXA HOLDINGS	250MG/10ML (25MG/ML)	N220201	001	Feb 20, 2026	Feb NEWA
>A>	+!		2.5GM/100ML (25MG/ML)	N220201	002	Jul 06, 2026	Jul NEWA

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL

FLUOXETINE HYDROCHLORIDE

AB	!	AUROBINDO PHARMA	EQ 40MG BASE	A078619	003	Jan 31, 2008	May CHRS
AB1		SENORES PHARMS	EQ 10MG BASE	A075049	001	Aug 02, 2001	Feb CAHN
AB1			EQ 20MG BASE	A075049	002	Jan 29, 2002	Feb CAHN
AB			EQ 40MG BASE	A075049	003	Jan 29, 2002	Feb CAHN
	@	STRIDES PHARMA INTL	EQ 10MG BASE	A076922	001	Dec 16, 2004	Jan DISC
	@		EQ 20MG BASE	A076922	002	Dec 16, 2004	Jan DISC
	@		EQ 40MG BASE	A076922	003	Dec 16, 2004	Jan DISC

PROZAC

	@ +	ELI LILLY AND CO	EQ 10MG BASE	N018936	006	Dec 23, 1992	May DISC
	@ +		EQ 20MG BASE	N018936	001	Dec 29, 1987	May DISC
	@ +		EQ 40MG BASE	N018936	003	Jun 15, 1999	May DISC

SOLUTION;ORAL

FLUOXETINE HYDROCHLORIDE

AA	!	AUROBINDO PHARMA	EQ 20MG BASE/5ML	A079209	001	Mar 20, 2009	Apr CHRS
	@	PHARM ASSOC	EQ 20MG BASE/5ML	A076015	001	Jan 30, 2002	Apr DISC

TABLET;ORAL

FLUOXETINE HYDROCHLORIDE

	@	LUPIN	EQ 60MG BASE	A211632	001	Feb 08, 2019	Mar DISC

FLUPHENAZINE HYDROCHLORIDE

TABLET;ORAL

FLUPHENAZINE HYDROCHLORIDE

	@		BRECKENRIDGE	1MG	A216891	001	Nov 15, 2022	Feb DISC
	@			2.5MG	A216891	002	Nov 15, 2022	Feb DISC
	@			5MG	A216891	003	Nov 15, 2022	Feb DISC
	@			10MG	A216891	004	Nov 15, 2022	Feb DISC
AB			ZAMEER PHARMS	1MG	A215141	001	Oct 20, 2021	Jan CAHN
AB				2.5MG	A215141	002	Oct 20, 2021	Jan CAHN
AB				5MG	A215141	003	Oct 20, 2021	Jan CAHN
AB				10MG	A215141	004	Oct 20, 2021	Jan CAHN

FLURAZEPAM HYDROCHLORIDE

CAPSULE;ORAL

FLURAZEPAM HYDROCHLORIDE

	@		HIKMA INTL PHARMS	15MG	A071108	002	Dec 08, 1986	Feb CMS1

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE

POWDER;INHALATION

BREO ELLIPTA

	+!		GLAXO GRP LTD	0.05MG/INH;EQ 0.025MG BASE/INH	N204275	003	May 12, 2023	Jan CHRS

FLUTICASONE PROPIONATE

AEROSOL, METERED;INHALATION

FLOVENT HFA

AB		+!	GLAXO GRP LTD	0.044MG/INH	N021433	003	May 14, 2004	Feb CFTG

FLUTICASONE PROPIONATE

AB			GLENMARK SPECLT	0.044MG/INH	A219602	001	Mar 03, 2026	Feb NFTG

CREAM;TOPICAL

FLUTICASONE PROPIONATE

AB			COSETTE PHARMS NC	0.05%	A077055	001	Jun 30, 2006	May CAHN

OINTMENT;TOPICAL

CUTIVATE

>A>	@	+	FOUGERA	0.005%	N019957	001	Dec 14, 1990	Jul CAHN
>D>	@	+	FOUGERA PHARMS	0.005%	N019957	001	Dec 14, 1990	Jul CAHN

FLUTICASONE PROPIONATE

AB			COSETTE PHARMS NC	0.005%	A077168	001	Mar 03, 2006	May CAHN

SPRAY, METERED;NASAL

XHANCE

	+!		PARATEK PHARMS	0.093MG/SPRAY	N209022	001	Sep 18, 2017	May CPOT

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

POWDER;INHALATION

AIRDUO RESPICLICK

	+!		TEVA PHARM	0.055MG/INH;EQ 0.014MG BASE/INH	N208799	001	Jan 27, 2017	Jan CHRS
	+!			0.113MG/INH;EQ 0.014MG BASE/INH	N208799	002	Jan 27, 2017	Jan CHRS

FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE

>A>	AB		CIPLA	0.1MG/INH;EQ 0.05MG BASE/INH	A213087	001	Jul 27, 2026	Jul NEWA
>A>	AB			0.25MG/INH;EQ 0.05MG BASE/INH	A213087	002	Jul 27, 2026	Jul NEWA
>A>	AB			0.5MG/INH;EQ 0.05MG BASE/INH	A213087	003	Jul 27, 2026	Jul NEWA
	AB		RESPIRENT PHARMS	0.1MG/INH;EQ 0.05MG BASE/INH	A214464	001	Jan 12, 2026	Jun CMFD
	@			0.1MG/INH;EQ 0.05MG BASE/INH	A214464	001	Jan 12, 2026	Mar DISC
	AB			0.1MG/INH;EQ 0.05MG BASE/INH	A214464	001	Jan 12, 2026	Jan NEWA
	AB			0.25MG/INH;EQ 0.05MG BASE/INH	A214464	002	Jan 12, 2026	Jun CMFD
	@			0.25MG/INH;EQ 0.05MG BASE/INH	A214464	002	Jan 12, 2026	Mar DISC
	AB			0.25MG/INH;EQ 0.05MG BASE/INH	A214464	002	Jan 12, 2026	Jan NEWA

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE;ORAL

FLUVOXAMINE MALEATE

	AB		APPCO	100MG	A220328	001	Apr 30, 2026	Apr NEWA
	AB			150MG	A220328	002	Apr 30, 2026	Apr NEWA
	AB		MICRO LABS	100MG	A220768	001	Jun 23, 2026	Jun NEWA
	AB			150MG	A220768	002	Jun 23, 2026	Jun NEWA
>A>	AB		ZYDUS PHARMS	100MG	A220447	001	Jul 21, 2026	Jul NEWA
>A>	AB			150MG	A220447	002	Jul 21, 2026	Jul NEWA

FOLIC ACID

SOLUTION;ORAL

QUIOFIC

	+!	CMP DEV LLC	0.2MG/ML	N216395	001	Jan 26, 2026	Jan	NEWA
	+!	SOLUBIOMIX	0.2MG/ML	N216395	001	Jan 26, 2026	Mar	CAHN

TABLET;ORAL

FOLIC ACID

AA	+	WATSON LABS	1MG	A080680	001		Feb	CHRS

FONDAPARINUX SODIUM

SOLUTION;SUBCUTANEOUS

ARIXTRA

AP	+!	MYLAN IRELAND LTD	2.5MG/0.5ML (2.5MG/0.5ML)	N021345	001	Dec 07, 2001	Mar	CPOT
AP	+!		2.5MG/0.5ML	N021345	001	Dec 07, 2001	Jan	CDFR
AP	+!		5MG/0.4ML (5MG/0.4ML)	N021345	002	May 28, 2004	Mar	CPOT
AP	+!		5MG/0.4ML	N021345	002	May 28, 2004	Jan	CDFR
AP	+!		7.5MG/0.6ML (7.5MG/0.6ML)	N021345	003	May 28, 2004	Mar	CPOT
AP	+!		7.5MG/0.6ML	N021345	003	May 28, 2004	Jan	CDFR
AP	+!		10MG/0.8ML (10MG/0.8ML)	N021345	004	May 28, 2004	Mar	CPOT
AP	+!		10MG/0.8ML	N021345	004	May 28, 2004	Jan	CDFR

FONDAPARINUX SODIUM

	@	BRIGHTGENE	2.5MG/0.5ML (2.5MG/0.5ML)	A218312	001	Dec 18, 2024	Mar	CPOT
	@		2.5MG/0.5ML	A218312	001	Dec 18, 2024	Jan	CDFR
AP		DR REDDYS LABS LTD	2.5MG/0.5ML (2.5MG/0.5ML)	A091316	001	Jul 11, 2011	Mar	CPOT
AP			2.5MG/0.5ML	A091316	001	Jul 11, 2011	Jan	CDFR
AP			5MG/0.4ML (5MG/0.4ML)	A091316	002	Jul 11, 2011	Mar	CPOT
AP			5MG/0.4ML	A091316	002	Jul 11, 2011	Jan	CDFR
AP			7.5MG/0.6ML (7.5MG/0.6ML)	A091316	003	Jul 11, 2011	Mar	CPOT
AP			7.5MG/0.6ML	A091316	003	Jul 11, 2011	Jan	CDFR
AP			10MG/0.8ML (10MG/0.8ML)	A091316	004	Jul 11, 2011	Mar	CPOT
AP			10MG/0.8ML	A091316	004	Jul 11, 2011	Jan	CDFR
AP		EUGIA PHARMA	2.5MG/0.5ML (2.5MG/0.5ML)	A206918	001	Dec 26, 2017	Mar	CPOT
AP			2.5MG/0.5ML	A206918	001	Dec 26, 2017	Jan	CDFR
AP			5MG/0.4ML (5MG/0.4ML)	A206918	002	Dec 26, 2017	Mar	CPOT
AP			5MG/0.4ML	A206918	002	Dec 26, 2017	Jan	CDFR
AP			7.5MG/0.6ML (7.5MG/0.6ML)	A206918	003	Dec 26, 2017	Mar	CPOT
AP			7.5MG/0.6ML	A206918	003	Dec 26, 2017	Jan	CDFR
AP			10MG/0.8ML (10MG/0.8ML)	A206918	004	Dec 26, 2017	Mar	CPOT
AP			10MG/0.8ML	A206918	004	Dec 26, 2017	Jan	CDFR
	@	HANGZHOU ZHONGMEI	2.5MG/0.5ML (2.5MG/0.5ML)	A216493	001	Aug 19, 2024	Mar	CPOT
	@		2.5MG/0.5ML	A216493	001	Aug 19, 2024	Jan	CDFR
	@		5MG/0.4ML (5MG/0.4ML)	A216493	002	Aug 19, 2024	Mar	CPOT
	@		5MG/0.4ML	A216493	002	Aug 19, 2024	Jan	CDFR
	@		7.5MG/0.6ML (7.5MG/0.6ML)	A216493	003	Aug 19, 2024	Mar	CPOT
	@		7.5MG/0.6ML	A216493	003	Aug 19, 2024	Jan	CDFR
	@		10MG/0.8ML (10MG/0.8ML)	A216493	004	Aug 19, 2024	Mar	CPOT
	@		10MG/0.8ML	A216493	004	Aug 19, 2024	Jan	CDFR
	@	HENGRUI PHARMA	2.5MG/0.5ML (2.5MG/0.5ML)	A206812	001	May 15, 2018	Jun	DISC
AP			2.5MG/0.5ML (2.5MG/0.5ML)	A206812	001	May 15, 2018	Mar	CPOT
AP			2.5MG/0.5ML	A206812	001	May 15, 2018	Jan	CDFR
	@		5MG/0.4ML (5MG/0.4ML)	A206812	002	May 15, 2018	Jun	DISC
AP			5MG/0.4ML (5MG/0.4ML)	A206812	002	May 15, 2018	Mar	CPOT
AP			5MG/0.4ML	A206812	002	May 15, 2018	Jan	CDFR
	@		7.5MG/0.6ML (7.5MG/0.6ML)	A206812	003	May 15, 2018	Jun	DISC
AP			7.5MG/0.6ML (7.5MG/0.6ML)	A206812	003	May 15, 2018	Mar	CPOT
AP			7.5MG/0.6ML	A206812	003	May 15, 2018	Jan	CDFR
	@		10MG/0.8ML (10MG/0.8ML)	A206812	004	May 15, 2018	Jun	DISC
AP			10MG/0.8ML (10MG/0.8ML)	A206812	004	May 15, 2018	Mar	CPOT
AP			10MG/0.8ML	A206812	004	May 15, 2018	Jan	CDFR
AP		SCINOPHARM TAIWAN	2.5MG/0.5ML (2.5MG/0.5ML)	A208615	001	Nov 14, 2018	Mar	CPOT
AP			2.5MG/0.5ML	A208615	001	Nov 14, 2018	Jan	CDFR
AP			5MG/0.4ML (5MG/0.4ML)	A208615	002	Nov 14, 2018	Mar	CPOT
AP			5MG/0.4ML	A208615	002	Nov 14, 2018	Jan	CDFR
AP			7.5MG/0.6ML (7.5MG/0.6ML)	A208615	003	Nov 14, 2018	Mar	CPOT
AP			7.5MG/0.6ML	A208615	003	Nov 14, 2018	Jan	CDFR
AP			10MG/0.8ML (10MG/0.8ML)	A208615	004	Nov 14, 2018	Mar	CPOT
AP			10MG/0.8ML	A208615	004	Nov 14, 2018	Jan	CDFR

FOSAPREPITANT DIMEGLUMINE

POWDER;INTRAVENOUS

FOSAPREPITANT DIMEGLUMINE

	@	BAXTER HLTHCARE CORP	EQ 150MG BASE/VIAL	A211860	001	Sep 05, 2019	May	DISC
	@	CAPLIN	EQ 150MG BASE/VIAL	A203939	001	Dec 08, 2020	Jan	CAHN
>A>	@	CHARTWELL RX	EQ 150MG BASE/VIAL	A212957	002	Aug 20, 2020	Jul	CAHN
>D>	@	NAVINTA LLC	EQ 150MG BASE/VIAL	A212957	002	Aug 20, 2020	Jul	CAHN

NAVITRUX

	+!	AVYXA HOLDINGS	EQ 150MG BASE/VIAL	N220436	001	Jun 24, 2026	Jun	NEWA

FOSCARNET SODIUM

SOLUTION;INTRAVENOUS

FOSCARNET SODIUM

AP		CAPLIN	6GM/250ML (24MG/ML)	A220068	001	May 13, 2026	May	NEWA

FOSFOMYCIN TROMETHAMINE

FOR SOLUTION;ORAL

FOSFOMYCIN TROMETHAMINE

AA		AUCTA	EQ 3GM BASE/PACKET	A217772	001	Apr 09, 2026	Mar	NEWA
>A> AA		NOVITIUM PHARMA	EQ 3GM BASE/PACKET	A210426	001	Aug 12, 2026	Jul	NEWA

FOSTAMATINIB DISODIUM

TABLET;ORAL

FOSTAMATINIB DISODIUM

AB		ANNORA PHARMA	EQ 100MG BASE	A217329	001	Jun 17, 2026	Jun	NFTG
AB			EQ 150MG BASE	A217329	002	Jun 17, 2026	Jun	NFTG

TAVALISSE

AB	+	RIGEL PHARMS	EQ 100MG BASE	N209299	001	Apr 17, 2018	Jun	CFTG
AB	+!		EQ 150MG BASE	N209299	002	Apr 17, 2018	Jun	CFTG

FROVATRIPTAN SUCCINATE

TABLET;ORAL

FROVA

	@ +	ENDO OPERATIONS	EQ 2.5MG BASE	N021006	001	Nov 08, 2001	Feb	DISC

FROVATRIPTAN SUCCINATE

AB	!	RENATA	EQ 2.5MG BASE	A213891	001	Apr 06, 2022	Feb	CHRS

FULVESTRANT

SOLUTION;INTRAMUSCULAR

CLIGAVYX

	!	AVYXA HOLDINGS	250MG/5ML (50MG/ML)	N210063	001	Aug 19, 2019	Jun	CMFD
	@		250MG/5ML (50MG/ML)	N210063	001	Aug 19, 2019	Apr	CTNA

FULVESTRANT

	@	EUGIA PHARMA	250MG/5ML (50MG/ML)	A215169	001	Jun 30, 2023	Mar	DISC

FUROSEMIDE

INJECTABLE;INJECTION

FUROSEMIDE

>D> AP		AMNEAL PHARMS CO	10MG/ML	A207552	001	Jul 20, 2016	Jul	DISC
>A>	@		10MG/ML	A207552	001	Jul 20, 2016	Jul	DISC
AP		MICRO LABS	10MG/ML	A218188	001	Jan 08, 2026	Jan	NEWA

SOLUTION;SUBCUTANEOUS

FUROSCIX

>D>	+!	SCPHARMACEUTICALS	80MG/10ML (8MG/ML)	N209988	001	Oct 07, 2022	Jul	CAHN
>A>	+!		80MG/10ML (8MG/ML)	N209988	001	Oct 07, 2022	Jul	CAHN

>A> FUROSCIX READYFLOW (AUTOINJECTOR)

>A>	+!	SCPHARMACEUTICALS	80MG/ML (80MG/ML)	N209988	002	Jul 23, 2026	Jul	NEWA

FUTIBATINIB

TABLET;ORAL

LYTGOBI

	@ +	TAIHO ONCOLOGY	16MG	N214801	002	Jul 28, 2025	May	DISC

GABAPENTIN

CAPSULE;ORAL

GABAPENTIN

>D>	@	ALLIED	100MG	A090158	001	Feb 14, 2011	Jul	CAHN
	@		100MG	A090158	001	Feb 14, 2011	Jun	CAHN
>D>	@		300MG	A090158	002	Feb 14, 2011	Jul	CAHN
	@		300MG	A090158	002	Feb 14, 2011	Jun	CAHN
>D>	@		400MG	A090158	003	Feb 14, 2011	Jul	CAHN

CAPSULE;ORAL
GABAPENTIN

	@		400MG	A090158	003	Feb 14, 2011	Jun	CAHN
	AB	PRINSTON INC	100MG	A219814	001	Mar 06, 2026	Feb	NEWA
	AB		300MG	A219814	002	Mar 06, 2026	Feb	NEWA
	AB		400MG	A219814	003	Mar 06, 2026	Feb	NEWA
>A>	@	SENORES PHARMS	100MG	A090158	001	Feb 14, 2011	Jul	CAHN
	AB		200MG	A219319	004	May 14, 2026	May	NEWA
>A>	@		300MG	A090158	002	Feb 14, 2011	Jul	CAHN
>A>	@		400MG	A090158	003	Feb 14, 2011	Jul	CAHN

RELGAABI

	AB	SCIEGEN PHARMS	100MG	A204989	001	Feb 18, 2016	Mar	CTNA
	AB		200MG	A204989	004	Mar 06, 2026	May	CFTG
			200MG	A204989	004	Mar 06, 2026	Mar	CTNA
			200MG	A204989	004	Mar 06, 2026	Feb	NEWA
	AB		300MG	A204989	002	Feb 18, 2016	Mar	CTNA
	AB		400MG	A204989	003	Feb 18, 2016	Mar	CTNA

TABLET;ORAL
GABAPENTIN

	AB2	ACTAVIS ELIZABETH	300MG	A203611	001	Jun 23, 2026	Jun	NEWA
	AB2		600MG	A203611	002	Jun 23, 2026	Jun	NEWA
	AB2	EPIC PHARMA LLC	300MG	A216252	001	Feb 26, 2024	May	CAHN
	AB2		600MG	A216252	002	Feb 26, 2024	May	CAHN

GADOBUTROL

SOLUTION;INTRAVENOUS
GADOBUTROL

	@	HENGRUI PHARMA	1.20944GM/2ML (604.72MG/ML)	A216081	003	Nov 17, 2022	Jun	DISC
	@		4.5354GM/7.5ML (604.72MG/ML)	A216081	004	Nov 17, 2022	Jun	DISC
	@		6.0472GM/10ML (604.72MG/ML)	A216081	005	Nov 17, 2022	Jun	DISC
	@		9.0708GM/15ML (604.72MG/ML)	A216081	006	Nov 17, 2022	Jun	DISC
	AP	VIWIT PHARM	4.5354GM/7.5ML (604.72MG/ML)	A219287	001	Jun 11, 2026	Jun	NEWA
	AP		6.0472GM/10ML (604.72MG/ML)	A219287	002	Jun 11, 2026	Jun	NEWA
	AP		9.0708GM/15ML (604.72MG/ML)	A219287	003	Jun 11, 2026	Jun	NEWA
	AP	ZENARA	1.20944GM/2ML (604.72MG/ML)	A219146	001	Jun 08, 2026	May	NEWA
	AP		4.5354GM/7.5ML (604.72MG/ML)	A219146	002	Jun 08, 2026	May	NEWA
	AP		6.0472GM/10ML (604.72MG/ML)	A219146	003	Jun 08, 2026	May	NEWA
	AP		9.0708GM/15ML (604.72MG/ML)	A219146	004	Jun 08, 2026	May	NEWA
	AP		18.1416GM/30ML (604.72MG/ML)	A219146	005	Jun 08, 2026	May	NEWA
	AP		39.3068GM/65ML (604.72MG/ML)	A219146	006	Jun 08, 2026	May	NEWA

PIXXOSCAN

	AP	GE HLTHCARE	1.20944GM/2ML (604.72MG/ML)	A215957	001	Jun 29, 2026	Jun	NEWA
	AP		4.5354GM/7.5ML (604.72MG/ML)	A215957	002	Jun 29, 2026	Jun	NEWA
	AP		6.0472GM/10ML (604.72MG/ML)	A215957	003	Jun 29, 2026	Jun	NEWA
	AP		9.0708GM/15ML (604.72MG/ML)	A215957	004	Jun 29, 2026	Jun	NEWA

GADOQUATRANE

SOLUTION;INTRAVENOUS
AMBELVIST

	+!	BAYER HEALTHCARE	0.5158GM/2ML (257.9MG/ML)	N219627	001	Jun 12, 2026	Jun	NEWA
	+!		1.93425GM/7.5ML (257.9MG/ML)	N219627	002	Jun 12, 2026	Jun	NEWA
	+!		2.579GM/10ML (257.9MG/ML)	N219627	003	Jun 12, 2026	Jun	NEWA
	+!		3.8685GM/15ML (257.9MG/ML)	N219627	004	Jun 12, 2026	Jun	NEWA
	+!		7.737GM/30ML (257.9MG/ML)	N219627	005	Jun 12, 2026	Jun	NEWA
	+!		16.7635GM/65ML (257.9MG/ML)	N219627	006	Jun 12, 2026	Jun	NEWA

GADOTERATE MEGLUMINE

SOLUTION;INTRAVENOUS
GADOTERATE MEGLUMINE

>A>	AP	VIWIT PHARM	3.769GM/10ML (376.9MG/ML)	A219286	001	Aug 10, 2026	Jul	NEWA
>A>	AP		5.6535GM/15ML (376.9MG/ML)	A219286	002	Aug 10, 2026	Jul	NEWA
>A>	AP		7.538GM/20ML (376.9MG/ML)	A219286	003	Aug 10, 2026	Jul	NEWA

GALANTAMINE HYDROBROMIDE

TABLET;ORAL
GALANTAMINE HYDROBROMIDE

	AB	SENORES PHARMS	EQ 4MG BASE	A077593	001	Sep 11, 2008	Jan	CAHN
	AB		EQ 8MG BASE	A077593	002	Sep 11, 2008	Jan	CAHN
	AB		EQ 12MG BASE	A077593	003	Sep 11, 2008	Jan	CAHN

GALLIUM DOTATATE GA-68

POWDER;INTRAVENOUS

NETSPOT

	+!	NOVARTIS	2.1-5.5mCi/ML	N208547	001	Jun 01, 2016	Jun CAHN

GALLIUM GA-68 GOZETOTIDE

SOLUTION;INTRAVENOUS

GALLIUM GA 68 GOZETOTIDE

AP		RADIOMEDIX	0.5-5mCi/ML	A216410	001	Jun 08, 2026	May NEWA
AP	+!	UNIV OF CA SAN FRAN	0.5-5mCi/mL	N212643	001	Dec 01, 2020	May CFTG

GALLIUM GA-68 GOZETOTIDE

AP		IONETIX	0.5-5mCi/mL	A219189	001	May 14, 2026	May NFTG

GANAXOLONE

SUSPENSION;ORAL

ZTALMY

	+!	IMMEDICA PHARMA	50MG/ML	N215904	001	Jun 01, 2022	Mar CAHN

GANCICLOVIR SODIUM

INJECTABLE;INJECTION

GANCICLOVIR SODIUM

>A> AP		HAINAN POLY	EQ 500MG BASE/VIAL	A204204	001	Nov 08, 2018	Jul CAHN
>D> AP		SLATE RUN PHARMA	EQ 500MG BASE/VIAL	A204204	001	Nov 08, 2018	Jul CAHN

GANIRELIX ACETATE

INJECTABLE;INJECTION

GANIRELIX ACETATE

	@	TRIS PHARMA INC	250MCG/0.5ML	A219454	001	Jun 27, 2025	Mar DISC

>A> GEDATOLISIB

>A> POWDER;INTRAVENOUS

>A> REVTORPYK

>A>	+!	CELCUITY	180MG/VIAL	N219908	001	Jul 14, 2026	Jul NEWA

GEFITINIB

TABLET;ORAL

GEFITINIB

	@	APOTEX	250MG	A209532	001	Sep 23, 2022	Jan DISC
	@	CIPLA	250MG	A211826	001	May 16, 2025	Apr DISC

GEMCITABINE HYDROCHLORIDE

INJECTABLE;INJECTION

GEMCITABINE HYDROCHLORIDE

	@	INGENUS PHARMS LLC	200MG/5.26ML (38MG/ML)	A210383	001	Feb 14, 2019	May CAHN
	@		1GM/26.3ML (38MG/ML)	A210383	002	Feb 14, 2019	May CAHN
	@		2GM/52.6ML (38MG/ML)	A210383	003	Feb 14, 2019	May CAHN
	@	NOVAST LABS	200MG/5.26ML (38MG/ML)	A210383	001	Feb 14, 2019	Feb DISC
	@		1GM/26.3ML (38MG/ML)	A210383	002	Feb 14, 2019	Feb DISC
	@		2GM/52.6ML (38MG/ML)	A210383	003	Feb 14, 2019	Feb DISC

SOLUTION;INTRAVENOUS

GEMCITABINE HYDROCHLORIDE

	@ +	ACCORD HLTHCARE	1GM/10ML (100MG/ML)	N209604	002	Aug 03, 2017	May DISC
	@ +		1.5GM/15ML (100MG/ML)	N209604	003	Aug 03, 2017	May DISC
	@ +		2GM/20ML (100MG/ML)	N209604	004	Aug 03, 2017	May DISC
	@ +		200MG/2ML (100MG/ML)	N209604	001	Aug 03, 2017	May DISC

GENTAMICIN SULFATE

CREAM;TOPICAL

GENTAMICIN SULFATE

AT		COSETTE PHARMS NC	EQ 0.1% BASE	A064056	001	Apr 29, 1994	May CAHN

OINTMENT;TOPICAL

GENTAMICIN SULFATE

AT		COSETTE PHARMS NC	EQ 0.1% BASE	A064054	001	Apr 29, 1994	May CAHN

SOLUTION/DROPS;OPHTHALMIC

GENTAMICIN SULFATE

AT		BAUSCH AND LOMB INC	EQ 0.3% BASE	A064048	001	May 11, 1994	May CAHN
	@	PADAGIS US	EQ 0.3% BASE	A065121	001	Jan 30, 2004	Mar DISC

GLATIRAMER ACETATE

INJECTABLE;SUBCUTANEOUS

GLATIRAMER ACETATE

	AP		HYBIO	20MG/ML	A213382	001	Feb 11, 2026	Jan NEWA
	AP			40MG/ML	A214022	001	Feb 11, 2026	Jan NEWA
	AP		SYNTHON BV	20MG/ML	A203857	001	Sep 25, 2024	Jun CAHN
	AP			40MG/ML	A206873	001	Sep 25, 2024	Jun CAHN

GLECAPREVIR; PIBRENTASVIR

PELLETS;ORAL

MAVYRET

		+!	ABBVIE	50MG/PACKET;20MG/PACKET	N215110	001	Jun 10, 2021	Mar CPOT

GLIPIZIDE

TABLET;ORAL

GLIPIZIDE

>D>		@	AIPING PHARM INC	5MG	A074305	001	Apr 07, 1995	Jul CMFD
>A>	AB			5MG	A074305	001	Apr 07, 1995	Jul CMFD
>D>		@		10MG	A074305	002	Apr 07, 1995	Jul CMFD
>A>	AB			10MG	A074305	002	Apr 07, 1995	Jul CMFD
	AB		GRAVITI PHARMS	5MG	A219159	001	Mar 04, 2026	Feb NEWA
	AB			10MG	A219159	002	Mar 04, 2026	Feb NEWA
		!	RUBICON RESEARCH	15MG	A214874	004	Feb 04, 2026	Jan NFTG

GLUCAGON

SOLUTION;INTRAVENOUS

GVOKE VIALDX

		@ +	XERIS	1MG/0.2ML (1MG/0.2ML)	N212097	006	Mar 14, 2025	May DISC

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

GLYBURIDE AND METFORMIN HYDROCHLORIDE

	AB		IMPAX	1.25MG;250MG	A076345	001	Feb 18, 2004	Mar CAHN
	AB			2.5MG;500MG	A076345	002	Feb 18, 2004	Mar CAHN
	AB			5MG;500MG	A076345	003	Feb 18, 2004	Mar CAHN

GLYCEROL PHENYLBUTYRATE

LIQUID;ORAL

GLYCEROL PHENYLBUTYRATE

	AA		AUROBINDO PHARMA	1.1GM/ML	A220313	001	Apr 15, 2026	Apr NEWA
>A>	AA		ESJAY PHARMA	1.1GM/ML	A220579	001	Jul 28, 2026	Jul NEWA
	AA		LUPIN	1.1GM/ML	A207694	001	Apr 30, 2026	Apr NEWA
	AA		MSN	1.1GM/ML	A219540	001	Apr 15, 2026	Apr NEWA
	AA		NAVINTA LLC	1.1GM/ML	A220568	001	Apr 23, 2026	Apr NEWA
	AA		TEVA PHARMS INC	1.1GM/ML	A218738	001	Apr 15, 2026	Apr NEWA

GLYCOPYRROLATE

INJECTABLE;INJECTION

GLYCOPYRROLATE

	AP		NIVAGEN PHARMS INC	0.2MG/ML	A212591	001	Oct 13, 2021	Apr CAHN

SOLUTION;ORAL

GLYCOPYRROLATE

	AA		QUAGEN	1MG/5ML	A216910	001	May 18, 2026	May NEWA

GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS

PREVDUO

		@ +	AZURITY	0.6MG/3ML (0.2MG/ML);3MG/3ML (1MG/ML)	N216903	001	Feb 23, 2023	Jun DISC

GLYCOPYRRONIUM TOSYLATE

CLOTH;TOPICAL

GLYCOPYRRONIUM TOSYLATE

		@	PADAGIS US	EQ 2.4% BASE	A214448	001	Apr 03, 2026	Apr DISC
	AB			EQ 2.4% BASE	A214448	001	Apr 03, 2026	Mar NFTG

QBREXZA

		+!	JOURNEY	EQ 2.4% BASE	N210361	001	Jun 28, 2018	Apr CTEC
	AB	+!		EQ 2.4% BASE	N210361	001	Jun 28, 2018	Mar CFTG

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS;OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

AT		!	BAUSCH AND LOMB INC	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	A064047	001	Jan 31, 1996	May CAHN

NEOSPORIN

		@	MONARCH PHARMS	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	A060582	001		Jan DISC

GRANISETRON

FILM, EXTENDED RELEASE;TRANSDERMAL

SANCUSO

>A>		+!	APOTEX	3.1MG/24HR	N022198	001	Sep 12, 2008	Jul CAHN
>D>		+!	CUMBERLAND	3.1MG/24HR	N022198	001	Sep 12, 2008	Jul CAHN

GRISEOFULVIN, MICROSIZE

SUSPENSION;ORAL

GRISEOFULVIN

	AB		COSETTE PHARMS NC	125MG/5ML	A065438	001	Oct 08, 2010	May CAHN

GUANFACINE HYDROCHLORIDE

TABLET;ORAL

GUANFACINE HYDROCHLORIDE

	AB		ASCENT PHARMS INC	EQ 1MG BASE	A220675	001	Mar 24, 2026	Mar NEWA
	AB			EQ 2MG BASE	A220675	002	Mar 24, 2026	Mar NEWA
	AB		RUBICON RESEARCH	EQ 1MG BASE	A216762	001	Oct 17, 2023	Mar CTEC
	AB			EQ 2MG BASE	A216762	002	Oct 17, 2023	Mar CTEC

HALOBETASOL PROPIONATE

AEROSOL, FOAM;TOPICAL

HALOBETASOL PROPIONATE

		!	PADAGIS ISRAEL	0.05%	A215266	001	Aug 11, 2023	Feb CTEC
	AB	!		0.05%	A215266	001	Aug 11, 2023	Feb CHRS

LEXETTE

		@ +	MAYNE PHARMA	0.05%	N210566	001	May 24, 2018	Feb DISC

CREAM;TOPICAL

HALOBETASOL PROPIONATE

	AB	!	COSETTE PHARMS NC	0.05%	A078162	001	Apr 24, 2007	May CAHN

OINTMENT;TOPICAL

HALOBETASOL PROPIONATE

	AB		COSETTE PHARMS NC	0.05%	A077109	001	Jun 14, 2005	May CAHN
		@		0.05%	A077721	001	Sep 07, 2006	Jun CAHN
	AB		ENCUBE	0.05%	A209978	001	Mar 20, 2018	Jun CMFD

HALOPERIDOL

TABLET;ORAL

HALOPERIDOL

	AB		AIPING PHARM INC	0.5MG	A071130	004	Apr 08, 2026	Mar NEWA
	AB			1MG	A071130	005	Apr 08, 2026	Mar NEWA
	AB			20MG	A071130	006	Apr 08, 2026	Mar NEWA
	AB		ALEMBIC	1MG	A214470	001	Jun 04, 2026	May NEWA
	AB			2MG	A214470	002	Jun 04, 2026	May NEWA
	AB			5MG	A214470	003	Jun 04, 2026	May NEWA
	AB			10MG	A214470	004	Jun 04, 2026	May NEWA
	AB			20MG	A214470	005	Jun 04, 2026	May NEWA
>D>	AB	!	MYLAN	2MG	A070278	001	Jun 10, 1986	Jul CHRS
>A>	AB			2MG	A070278	001	Jun 10, 1986	Jul CHRS
		@		20MG	A070278	003	Jul 16, 2009	Apr DISC
>D>	AB		ZYDUS PHARMS USA	2MG	A077580	006	Jan 17, 2023	Jul CHRS
>A>	AB	!		2MG	A077580	006	Jan 17, 2023	Jul CHRS

HEPARIN SODIUM

INJECTABLE;INJECTION

HEPARIN SODIUM PRESERVATIVE FREE

		+!	PFIZER	1,000 UNITS/ML	N201370	004	Jul 21, 2011	Feb CMFD

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP;ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

>A>		@	APOZEAL PHARMS	1.5MG/5ML;5MG/5ML	A204765	001	Mar 06, 2017	Jul CAHN
		@	PADAGIS US	1.5MG/5ML;5MG/5ML	A205731	001	Feb 15, 2017	Mar DISC
		@	PHARMOBEDIENT	1.5MG/5ML;5MG/5ML	A088008	001	Mar 03, 1983	Jun DISC
>D>		@	SCIEGEN PHARMS	1.5MG/5ML;5MG/5ML	A204765	001	Mar 06, 2017	Jul CAHN

HYDRALAZINE HYDROCHLORIDE

TABLET;ORAL

HYDRALAZINE HYDROCHLORIDE

		@	HERITAGE	10MG	A086242	001	Feb 04, 2010	Mar DISC
		@		25MG	A086242	003		Mar DISC
		@		50MG	A086242	002		Mar DISC
		@		100MG	A086242	004	Feb 04, 2010	Mar DISC
		@	STRIDES PHARMA INTL	10MG	A087836	001	Oct 05, 1982	Jan DISC
		@		25MG	A086961	002		Jan DISC
		@		50MG	A086962	001		Jan DISC
		@		100MG	A088391	001	Sep 27, 1983	Jan DISC

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE;ORAL

HYDRA-ZIDE

		@	STRIDES PHARMA INTL	25MG;25MG	A088957	001	Oct 21, 1985	Jan DISC
		@		50MG;50MG	A088946	001	Oct 21, 1985	Jan DISC

HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE

TABLET;ORAL

ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE

AB			INGENUS PHARMS LLC	37.5MG;20MG	A215586	001	Apr 06, 2022	Feb CAHN

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET;ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

		@	CHARTWELL RX	12.5MG;150MG	A201524	001	Feb 27, 2013	Apr CAHN
		@		12.5MG;300MG	A201524	002	Feb 27, 2013	Apr CAHN
		@	HIKMA	12.5MG;150MG	A090351	001	Oct 15, 2012	Jun DISC
		@		12.5MG;300MG	A090351	002	Oct 15, 2012	Jun DISC
		@		25MG;300MG	A090351	003	Jun 08, 2017	Jun DISC

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET;ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB			HETERO LABS LTD V	12.5MG;50MG	A219869	001	May 27, 2026	May NEWA
AB				12.5MG;100MG	A219869	002	May 27, 2026	May NEWA
AB				25MG;100MG	A219869	003	May 27, 2026	May NEWA

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET;ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

		@	STRIDES PHARMA INTL	15MG;250MG	A070614	002	Feb 02, 1987	Jan CMS1
		@		25MG;250MG	A070614	003	Feb 02, 1987	Jan CMS1
		@		30MG;500MG	A070614	004	Feb 02, 1987	Jan CMS1

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET;ORAL

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

AB			ALEMBIC	25MG;100MG	A202870	002	Nov 06, 2013	Feb CHRS
AB		!	MYLAN	50MG;100MG	A076792	003	Aug 20, 2004	Feb CHRS

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

AB			MICRO LABS	12.5MG;20MG	A206371	001	Apr 13, 2026	Apr NEWA
AB				12.5MG;40MG	A206371	002	Apr 13, 2026	Apr NEWA
AB				25MG;40MG	A206371	003	Apr 13, 2026	Apr NEWA
AB			SCIEGEN PHARMS	12.5MG;20MG	A208465	001	Mar 31, 2026	Mar NEWA
AB				12.5MG;40MG	A208465	002	Mar 31, 2026	Mar NEWA
AB				25MG;40MG	A208465	003	Mar 31, 2026	Mar NEWA

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET;ORAL

TELMISARTAN AND HYDROCHLOROTHIAZIDE

		@	LUPIN	12.5MG;40MG	A091351	001	Aug 07, 2014	Jun DISC
		@		12.5MG;80MG	A091351	002	Aug 07, 2014	Jun DISC
		@		25MG;80MG	A091351	003	Aug 07, 2014	Jun DISC

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

		@	LUPIN LTD	12.5MG;80MG	A078946	003	Mar 21, 2013	May DISC
		@		12.5MG;160MG	A078946	004	Mar 21, 2013	May DISC
		@		12.5MG;320MG	A078946	001	Mar 21, 2013	May DISC
		@		25MG;160MG	A078946	005	Mar 21, 2013	May DISC
		@		25MG;320MG	A078946	002	Mar 21, 2013	May DISC
	AB		SCIEGEN PHARMS	12.5MG;80MG	A204687	001	Apr 23, 2026	Apr NEWA
	AB			12.5MG;160MG	A204687	002	Apr 23, 2026	Apr NEWA
	AB			12.5MG;320MG	A204687	003	Apr 23, 2026	Apr NEWA
	AB			25MG;160MG	A204687	004	Apr 23, 2026	Apr NEWA
	AB			25MG;320MG	A204687	005	Apr 23, 2026	Apr NEWA

HYDROCODONE BITARTRATE

TABLET, EXTENDED RELEASE;ORAL

HYSINGLA ER

	AB	+!	KNOA PHARMA	20MG	N206627	001	Nov 20, 2014	May CAHN
	AB	+		30MG	N206627	002	Nov 20, 2014	May CAHN
	AB	+		40MG	N206627	003	Nov 20, 2014	May CAHN
	AB	+		60MG	N206627	004	Nov 20, 2014	May CAHN
	AB	+		80MG	N206627	005	Nov 20, 2014	May CAHN
	AB	+		100MG	N206627	006	Nov 20, 2014	May CAHN
	@	+		120MG	N206627	007	Nov 20, 2014	May CAHN

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET;ORAL

REPREXAIN

			AMNEAL PHARMS NY	10MG;200MG	A076642	004	Oct 19, 2007	May CMFD

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

>A>		@	APOZEAL PHARMS	5MG/5ML;60MG/5ML	A206661	001	Jan 23, 2019	Jul CAHN
>D>		@	SCIEGEN PHARMS	5MG/5ML;60MG/5ML	A206661	001	Jan 23, 2019	Jul CAHN

HYDROCORTISONE

CREAM;TOPICAL

HYDROCORTISONE

		@	ACTAVIS MID ATLANTIC	2.5%	A089682	001	Mar 10, 1988	Jun DISC
>D>		@	ENCUBE	2.5%	A203810	001	Jul 23, 2018	Jul CMFD
>A>	AT			2.5%	A203810	001	Jul 23, 2018	Jul CMFD

LOTION;TOPICAL

ALA-SCALP

		+	LEGACY	2%	A083231	001		Jun CAHN

HYDROCORTISONE

>A>	AT		RISING	2.5%	A218298	001	Jul 16, 2026	Jul NEWA

STIE-CORT

>D>		!	PADAGIS US	2.5%	A089074	001	Nov 26, 1985	Jul CTEC
>A>	AT	!		2.5%	A089074	001	Nov 26, 1985	Jul CTEC

TABLET;ORAL

HYDROCORTISONE

	AB		APPCO	5MG	A220329	001	Feb 25, 2026	Feb NEWA
	AB			10MG	A220329	002	Feb 25, 2026	Feb NEWA
	AB			20MG	A220329	003	Feb 25, 2026	Feb NEWA

HYDROCORTISONE ACETATE

CREAM;TOPICAL

MICORT-HC

		@	LEGACY	2%	A040398	001	Mar 29, 2002	Jun CAHN
				2.5%	A040396	001	Feb 27, 2001	Jun CAHN

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

CREAM;TOPICAL

PRAMOSONE

		LEGACY	0.5%;1%	A083778	001		Jun CAHN
			1%;1%	A085368	001		Jun CAHN

LOTION;TOPICAL

PRAMOSONE

		LEGACY	1%;1%	A085980	001		Jun CAHN
			2.5%;1%	A085979	001		Jun CAHN

HYDROCORTISONE BUTYRATE

OINTMENT;TOPICAL

HYDROCORTISONE BUTYRATE

	!	TARO	0.1%	A076842	001	Dec 27, 2004	Feb CTEC
AB	!		0.1%	A076842	001	Dec 27, 2004	Feb CHRS

LOCOID

	@ +	PRECISION DERMAT	0.1%	N018652	001	Oct 29, 1982	Feb DISC

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE;INJECTION

HYDROCORTISONE SODIUM SUCCINATE

AP		APOTEX	EQ 100MG BASE/VIAL	A219856	001	Feb 05, 2026	Jan NEWA
AP		ZYDUS PHARMS	EQ 100MG BASE/VIAL	A217191	001	May 07, 2026	Apr NEWA

HYDROCORTISONE VALERATE

CREAM;TOPICAL

HYDROCORTISONE VALERATE

	@	COSETTE PHARMS NC	0.2%	A074489	001	Aug 12, 1998	Jun CAHN
AB			0.2%	A213724	001	Feb 11, 2021	May CAHN
	@	PADAGIS ISRAEL	0.2%	A075666	001	May 24, 2000	Mar DISC

OINTMENT;TOPICAL

HYDROCORTISONE VALERATE

AB		COSETTE PHARMS NC	0.2%	A211764	001	Mar 04, 2020	May CAHN

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS;OTIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

AT	!	BAUSCH AND LOMB INC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A064053	001	Dec 29, 1995	May CAHN

SUSPENSION/DROPS;OTIC

OTICAIR

AT		BAUSCH AND LOMB INC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A064065	001	Aug 28, 1996	May CAHN

HYDROCORTISONE; UREA

CREAM;TOPICAL

ALPHADERM

	@ +	BIOGLAN	1%;10%	A086008	001		May CRLD

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE;INJECTION

DILAUDID-HP

AP	+!	FRESENIUS KABI USA	10MG/ML	N019034	001	Jan 11, 1984	Apr CMFD

HYDROXYCHLOROQUINE SULFATE

TABLET;ORAL

HYDROXYCHLOROQUINE SULFATE

AB		SENORES PHARMS	200MG	A212902	001	May 14, 2020	Jan CAHN

HYDROXYUREA

CAPSULE;ORAL

DROXIA

>D>	@ +	WAYLIS THERAP	200MG	N016295	002	Feb 25, 1998	Jul CMFD
>A>	+		200MG	N016295	002	Feb 25, 1998	Jul CMFD
>D>	@ +		300MG	N016295	003	Feb 25, 1998	Jul CMFD
>A>	+		300MG	N016295	003	Feb 25, 1998	Jul CMFD
>D>	@ +		400MG	N016295	004	Feb 25, 1998	Jul CMFD
>A>	+		400MG	N016295	004	Feb 25, 1998	Jul CMFD

HYDROXYZINE HYDROCHLORIDE

SYRUP;ORAL

HYDROXYZINE HYDROCHLORIDE

	AA		SAPTALIS PHARMS	10MG/5ML	A220271	001	Jun 11, 2026	May NEWA

TABLET;ORAL

HYDROXYZINE HYDROCHLORIDE

		@	AMNEAL PHARM	10MG	A040808	001	Sep 24, 2008	Apr DISC
		@		25MG	A040808	002	Sep 24, 2008	Apr DISC
		@		50MG	A040808	003	Sep 24, 2008	Apr DISC

IBANDRONATE SODIUM

INJECTABLE;INTRAVENOUS

IBANDRONATE SODIUM

		@	CHEMI SPA	EQ 3MG BASE/3ML	A202235	001	Sep 02, 2014	May DISC
		@	PHARMOBEDIENT	EQ 3MG BASE/3ML	A202671	001	Sep 02, 2014	Jun DISC

IBUPROFEN

SOLUTION;INTRAVENOUS

CALDOLOR

>A>		@	APOTEX	400MG/4ML (100MG/ML)	N022348	001	Jun 11, 2009	Jul CAHN
>A>		+!		800MG/8ML (100MG/ML)	N022348	002	Jun 11, 2009	Jul CAHN
>A>		+!		800MG/200ML (4MG/ML)	N022348	003	Jan 25, 2019	Jul CAHN
>D>		@	CUMBERLAND PHARMS	400MG/4ML (100MG/ML)	N022348	001	Jun 11, 2009	Jul CAHN
>D>		+!		800MG/8ML (100MG/ML)	N022348	002	Jun 11, 2009	Jul CAHN
>D>		+!		800MG/200ML (4MG/ML)	N022348	003	Jan 25, 2019	Jul CAHN

TABLET;ORAL

IBUPROFEN

>A>		@	ALLIED	400MG	A070045	001	Sep 24, 1985	Jul CAHN
>A>		@		600MG	A070057	001	Sep 24, 1985	Jul CAHN
>A>		@		800MG	A071999	001	Dec 03, 1987	Jul CAHN
>D>		@	PHARMOBEDIENT	400MG	A070045	001	Sep 24, 1985	Jul CAHN
>D>		@		600MG	A070057	001	Sep 24, 1985	Jul CAHN
>D>		@		800MG	A071999	001	Dec 03, 1987	Jul CAHN
>A>		@	SENORES PHARMS	400MG	A070045	001	Sep 24, 1985	Jul CAHN
>A>		@		600MG	A070057	001	Sep 24, 1985	Jul CAHN
>A>		@		800MG	A071999	001	Dec 03, 1987	Jul CAHN

ICOSAPENT ETHYL

CAPSULE;ORAL

ICOSAPENT ETHYL

	AB		AUROBINDO PHARMA LTD	1GM	A218949	001	Jun 24, 2026	Jun NEWA
>A>	AB		ONESOURCE	500MG	A217844	001	Sep 22, 2023	Jul CAHN
>A>	AB			1GM	A217844	002	Sep 22, 2023	Jul CAHN
>D>	AB		ONESOURCE SPECIALTY	500MG	A217844	001	Sep 22, 2023	Jul CAHN
>D>	AB			1GM	A217844	002	Sep 22, 2023	Jul CAHN
	AB		TORRENT	1GM	A218994	001	Dec 20, 2024	Apr CAHN

ICOTROKINRA HYDROCHLORIDE

TABLET;ORAL

ICOTYDE

		+!	JANSSEN BIOTECH	EQ 200MG BASE	N220149	001	Mar 17, 2026	Mar NEWA

IDELALISIB

TABLET;ORAL

IDELALISIB

	AB		NATCO	100MG	A216921	001	Feb 17, 2026	Feb NFTG
	AB			150MG	A216921	002	Feb 17, 2026	Feb NFTG

ZYDELIG

	AB	+	GILEAD SCIENCES INC	100MG	N205858	001	Jul 23, 2014	Feb CFTG
	AB	+!		150MG	N205858	002	Jul 23, 2014	Feb CFTG

ILOPROST

SOLUTION;INHALATION

>A>		ILOPROST						
>A>		!	BELOTECA	10MCG/ML (10MCG/ML)	A214997	001	Jul 10, 2026	Jul NFTG
>A>		!		20MCG/ML (20MCG/ML)	A214997	002	Jul 10, 2026	Jul NFTG

IMATINIB MESYLATE

TABLET;ORAL

GLEEVEC

AB		+!	NOVARTIS	EQ 100MG BASE	N021588	001	Apr 18, 2003	Mar CHRS
AB		+		EQ 400MG BASE	N021588	002	Apr 18, 2003	Mar CHRS

IMATINIB MESYLATE

	@		SUN PHARM	EQ 100MG BASE	A078340	001	Dec 03, 2015	Feb DISC
	@			EQ 400MG BASE	A078340	002	Dec 03, 2015	Feb DISC

IMIQUIMOD

CREAM;TOPICAL

IMIQUIMOD

	@		COSETTE PHARMS NC	5%	A200481	001	Apr 18, 2011	Jun CAHN

INDIUM IN-111 PENTETREOTIDE KIT

INJECTABLE;INJECTION

INDIUM IN-111 PENTETREOTIDE KIT

	@		SUN PHARM INDS INC	3mCi/ML	A212785	001	Jul 01, 2024	Apr DISC

OCTREOSCAN

		+!	CURIUM	3mCi/ML	N020314	001	Jun 02, 1994	Apr CTEC

INDOCYANINE GREEN

INJECTABLE;INJECTION

IC-GREEN

		!	RENEW PHARMS	10MG/VIAL	N011525	003		May CMFD

INDOCYANINE GREEN

>A>	AP		ZYDUS LIFESCIENCES	25MG/VIAL	A219139	001	Aug 03, 2026	Jul NEWA

SOLUTION;INTRAVENOUS, INTERSTITIAL

>A> ZYOGREEN

>A>		+!	PROVEPHARM SAS	25MG/10ML (2.5MG/ML)	N218579	001	Jul 10, 2026	Jul NEWA

INDOMETHACIN

SUPPOSITORY;RECTAL

INDOCIN

	@	+	COSETTE	50MG	N017814	001	Aug 13, 1984	Jun CAHN

SUSPENSION;ORAL

INDOCIN

AB		+!	COSETTE	25MG/5ML	N018332	001	Oct 10, 1985	Jun CAHN

IOHEXOL

SOLUTION;INJECTION, ORAL

IOHEXOL

AP			AMNEAL	75.5%	A217737	002	Jun 25, 2026	Jun NFTG

OMNIPAQUE 350

AP		+!	GE HEALTHCARE	75.5%	N018956	004	Dec 26, 1985	Jun CFTG

IOMEPROL

SOLUTION;INTRA-ARTERIAL

IOMERVU

		+!	BRACCO	35GM IODINE/100ML (350MG IODINE/ML)	N216016	007	Nov 27, 2024	Feb CMFD
		+!		40GM IODINE/100ML (400MG IODINE/ML)	N216016	011	Nov 27, 2024	Feb CMFD
		+!		70GM IODINE/200ML (350MG IODINE/ML)	N216016	009	Nov 27, 2024	Feb CMFD
		+!		80GM IODINE/200ML (400MG IODINE/ML)	N216016	013	Nov 27, 2024	Feb CMFD

SOLUTION;INTRAVENOUS

IOMERVU

		+!	BRACCO	35GM IODINE/100ML (350MG IODINE/ML)	N216017	007	Nov 27, 2024	Feb CMFD
		+!		40GM IODINE/100ML (400MG IODINE/ML)	N216017	011	Nov 27, 2024	Feb CMFD
		+!		70GM IODINE/200ML (350MG IODINE/ML)	N216017	009	Nov 27, 2024	Feb CMFD
		+!		80GM IODINE/200ML (400MG IODINE/ML)	N216017	013	Nov 27, 2024	Feb CMFD

IPRATROPIUM BROMIDE

AEROSOL, METERED;INHALATION

ATROVENT HFA

AB	+!	BOEHRINGER INGELHEIM	0.021MG/INH	N021527	001	Nov 27, 2004	Feb	CFTG

IPRATROPIUM BROMIDE

AB		ARMSTRONG PHARMS	0.021MG/INH	A217953	001	Feb 23, 2026	Feb	NFTG

IRINOTECAN HYDROCHLORIDE

INJECTABLE;INJECTION

IRINOTECAN HYDROCHLORIDE

AP		INGENUS PHARMS LLC	40MG/2ML (20MG/ML)	A206935	001	May 26, 2017	May	CAHN
AP			100MG/5ML (20MG/ML)	A206935	002	May 26, 2017	May	CAHN

ISONIAZID

TABLET;ORAL

ISONIAZID

>A>	@	HIKMA INTL PHARMS	300MG	A080212	002		Jul	CMS1

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE;INJECTION

ISOPROTERENOL HYDROCHLORIDE

AP		ASPIRO	0.2MG/ML	A220299	001	May 18, 2026	May	NEWA
AP		J MOLNER	0.2MG/ML	A211237	001	May 19, 2021	Jun	CAHN

ISOSORBIDE DINITRATE

TABLET;ORAL

ISOSORBIDE DINITRATE

AB		RUBICON RESEARCH	5MG	A215723	001	Jul 08, 2022	May	CAHN
AB			10MG	A215723	002	Jul 08, 2022	May	CAHN
AB			20MG	A215723	003	Jul 08, 2022	May	CAHN
AB			30MG	A215723	004	Jul 08, 2022	May	CAHN
AB			40MG	A215723	005	Jul 08, 2022	May	CAHN

ISOSORBIDE MONONITRATE

TABLET;ORAL

ISOSORBIDE MONONITRATE

AB		ANI PHARMS	10MG	A075147	002	Mar 27, 2026	Apr	NEWA
AB			20MG	A075147	001	Nov 27, 1998	Mar	CMFD

ISOSULFAN BLUE

SOLUTION;SUBCUTANEOUS

ISOSULFAN BLUE

AP		EUGIA PHARMA	50MG/5ML (10MG/ML)	A206831	001	Feb 02, 2016	May	CMFD
	!	MYLAN INSTITUTIONAL	10MG/ML (10MG/ML)	A090874	002	Jan 28, 2026	Jan	NFTG
	!		30MG/3ML (10MG/ML)	A090874	003	Jan 28, 2026	Jan	NFTG
AP		SABA ILAY SANAYI	50MG/5ML (10MG/ML)	A210714	001	Jan 16, 2019	Jun	CMFD
AP		SOMERSET THERAPS LLC	50MG/5ML (10MG/ML)	A210558	001	Jul 12, 2019	May	CMFD

ISOTRETINOIN

CAPSULE;ORAL

ISOTRETINOIN

	@	AMNEAL PHARMS NY	10MG	A216097	001	Oct 07, 2025	Mar	DISC
	@		20MG	A216097	002	Oct 07, 2025	Mar	DISC
	@		25MG	A216097	003	Oct 07, 2025	Mar	DISC
	@		30MG	A216097	004	Oct 07, 2025	Mar	DISC
	@		35MG	A216097	005	Oct 07, 2025	Mar	DISC
	@		40MG	A216097	006	Oct 07, 2025	Mar	DISC

IVABRADINE

SOLUTION;ORAL

CORLANOR

	@ +	AMGEN INC	5MG/5ML (1MG/ML)	N209964	001	Apr 22, 2019	Mar	DISC

IVABRADINE HYDROCHLORIDE

TABLET;ORAL

CORLANOR

	@ +	AMGEN INC	EQ 5MG BASE	N206143	001	Apr 15, 2015	Jan	DISC
	@ +		EQ 7.5MG BASE	N206143	002	Apr 15, 2015	Jan	DISC

IVABRADINE HYDROCHLORIDE

AB	!	INGENUS PHARMS LLC	EQ 7.5MG BASE	A214051	002	Dec 30, 2021	Jan	CHRS

IVERMECTIN

TABLET;ORAL

IVERMECTIN

	AB		AJANTA PHARMA LTD	3MG	A218509	001	Apr 07, 2026	Mar NEWA
	AB		E5 PHARMA	3MG	A216808	001	Mar 09, 2026	Feb NEWA
	AB		ZYDUS LIFESCIENCES	3MG	A216863	001	Feb 26, 2026	Feb NEWA

KETAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

KETAMINE HYDROCHLORIDE

		@	CAPLIN	EQ 10MG BASE/ML	A217858	001	Aug 07, 2025	Apr DISC

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

KETAMINE HYDROCHLORIDE

>A>		!	BAXTER HLTHCARE CORP	EQ 50MG BASE/5ML (EQ 10MG BASE/ML)	A219684	002	Aug 11, 2026	Jul NFTG
		@		EQ 100MG BASE/10ML (EQ 10MG BASE/ML)	A219684	001	Sep 17, 2025	May DISC

KETOCONAZOLE

CREAM;TOPICAL

KETOCONAZOLE

		@	PADAGIS US	2%	A215185	001	Nov 17, 2021	Jan DISC

SHAMPOO;TOPICAL

KETOCONAZOLE

	AB		COSETTE PHARMS NC	2%	A076942	001	Apr 11, 2005	May CAHN

KETOROLAC TROMETHAMINE

SOLUTION/DROPS;OPHTHALMIC

ACULAR LS

		+	ABBVIE	0.4%	N021528	001	May 30, 2003	Apr CTEC

KETOROLAC TROMETHAMINE

		@	APOTEX	0.4%	A077308	001	Nov 05, 2009	Apr DISC

SPRAY, METERED;NASAL

SPRIX

		+!	COSETTE	15.75MG/SPRAY	N022382	001	May 14, 2010	Jun CAHN

L-GLUTAMINE

FOR SOLUTION;ORAL

L-GLUTAMINE

	AA		ANNORA PHARMA	5GM/PACKET	A219722	001	May 26, 2026	May NEWA
	AA		RENOVA PHARMS	5GM/PACKET	A219750	001	May 14, 2026	May CAHN
	AA		STIRA	5GM/PACKET	A219750	001	May 14, 2026	May NEWA

LABETALOL HYDROCHLORIDE

TABLET;ORAL

LABETALOL HYDROCHLORIDE

>D>	AB		ANDAS 5 HOLDING	100MG	A075215	001	Jul 29, 1999	Jul CAHN
>D>	AB			200MG	A075215	002	Jul 29, 1999	Jul CAHN
>D>	AB			300MG	A075215	003	Jul 29, 1999	Jul CAHN
	AB		APPCO	400MG	A209603	004	Oct 18, 2024	Mar CTEC
	AB		HERITAGE PHARMA	400MG	A074787	004	Mar 26, 2026	Mar NEWA
>A>	AB		INNOGENIX	100MG	A075215	001	Jul 29, 1999	Jul CAHN
>A>	AB			200MG	A075215	002	Jul 29, 1999	Jul CAHN
>A>	AB			300MG	A075215	003	Jul 29, 1999	Jul CAHN
>D>	AB		PH HEALTH	100MG	A200908	001	Jul 10, 2012	Jul DISC
>A>		@		100MG	A200908	001	Jul 10, 2012	Jul DISC
>D>	AB	!		200MG	A200908	002	Jul 10, 2012	Jul DISC
>A>		@		200MG	A200908	002	Jul 10, 2012	Jul DISC
>D>	AB			300MG	A200908	003	Jul 10, 2012	Jul DISC
>A>		@		300MG	A200908	003	Jul 10, 2012	Jul DISC
>D>	AB		ZYDUS PHARMS	200MG	A207743	002	Sep 19, 2017	Jul CHRS
>A>	AB	!		200MG	A207743	002	Sep 19, 2017	Jul CHRS

LACOSAMIDE

SOLUTION;INTRAVENOUS

LACOSAMIDE

	AP		ANTHEA PHARMA	200MG/20ML (10MG/ML)	A220268	001	Jan 21, 2026	Jan NEWA
	AP		GLENMARK PHARMS	200MG/20ML (10MG/ML)	A220268	001	Jan 21, 2026	Mar CAHN

SOLUTION;ORAL

LACOSAMIDE

		@	APOTEX	10MG/ML	A206355	001	Sep 26, 2022	Feb DISC

SOLUTION;ORAL
LACOSAMIDE

	AA		INDOCO	10MG/ML	A220386	001	Jan 29, 2026	Jan NEWA
	AA		PROD DEVELOPMENT	10MG/ML	A217596	001	Jun 15, 2026	Jun NEWA
	AA		REGCON HOLDINGS	10MG/ML	A220386	001	Jan 29, 2026	Jan CAHN
>D>	AA		STERANCO HLTHCARE	10MG/ML	A220366	001	May 21, 2026	Jul DISC
>A>		@		10MG/ML	A220366	001	May 21, 2026	Jul DISC
	AA			10MG/ML	A220366	001	May 21, 2026	May NEWA

LACTULOSE
FOR SOLUTION;ORAL
LACTULOSE

>A>	AA	!	APOTEX	10GM/PACKET	A074712	001	Dec 10, 1997	Jul CAHN
>A>	AA	!		20GM/PACKET	A074712	002	Dec 10, 1997	Jul CAHN
>D>	AA	!	CUMBERLAND PHARMS	10GM/PACKET	A074712	001	Dec 10, 1997	Jul CAHN
>D>	AA	!		20GM/PACKET	A074712	002	Dec 10, 1997	Jul CAHN

SOLUTION;ORAL, RECTAL
LACTULOSE

>A>	AA		APOZEAL PHARMS	10GM/15ML	A203762	001	Mar 27, 2015	Jul CAHN
>D>	AA		SCIEGEN PHARMS	10GM/15ML	A203762	001	Mar 27, 2015	Jul CAHN

LAMIVUDINE
TABLET;ORAL
LAMIVUDINE

		@	LUPIN	150MG	A205217	001	Dec 18, 2014	Jan DISC
		@		300MG	A205217	002	Dec 18, 2014	Jan DISC

LAMIVUDINE; ZIDOVUDINE
TABLET;ORAL
LAMIVUDINE AND ZIDOVUDINE

>D>	AB		PHARMOBEDIENT	150MG;300MG	A079128	001	May 13, 2015	Jul DISC
>A>		@		150MG;300MG	A079128	001	May 13, 2015	Jul DISC

LAMOTRIGINE
TABLET;ORAL
LAMICTAL

	AB	+	GLAXOSMITHKLINE LLC	25MG	N020241	005	Dec 27, 1994	Jun CHRS

LAMOTRIGINE

	AB	!	ALEMBIC PHARMS LTD	25MG	A090607	001	Jan 13, 2011	Jun CHRS
		@	LUPIN LTD	25MG	A078691	001	Jun 01, 2010	Apr DISC
		@		100MG	A078691	002	Jun 01, 2010	Apr DISC
		@		150MG	A078691	003	Jun 01, 2010	Apr DISC
		@		200MG	A078691	004	Jun 01, 2010	Apr DISC

TABLET, EXTENDED RELEASE;ORAL
LAMOTRIGINE

		@	PH HEALTH	25MG	A201791	001	Jan 18, 2013	Apr DISC
		@		50MG	A201791	002	Jan 18, 2013	Apr DISC
		@		100MG	A201791	003	Jan 18, 2013	Apr DISC
		@		200MG	A201791	004	Jan 18, 2013	Apr DISC
		@		250MG	A201791	005	Jan 18, 2013	Apr DISC
		@		300MG	A201791	006	Jan 18, 2013	Apr DISC

TABLET, ORALLY DISINTEGRATING;ORAL
LAMOTRIGINE

	AB		ALEMBIC	25MG	A217278	001	Feb 25, 2026	Feb NEWA
	AB			50MG	A217278	002	Feb 25, 2026	Feb NEWA
	AB			100MG	A217278	003	Feb 25, 2026	Feb NEWA
	AB			200MG	A217278	004	Feb 25, 2026	Feb NEWA
	AB		J MOLNER	25MG	A214124	001	Feb 03, 2022	Jun CAHN
	AB			50MG	A214124	002	Feb 03, 2022	Jun CAHN
	AB			100MG	A214124	003	Feb 03, 2022	Jun CAHN
	AB			200MG	A214124	004	Feb 03, 2022	Jun CAHN
	AB		TORRENT	25MG	A217100	001	Jan 08, 2026	Jan NEWA
	AB			50MG	A217100	002	Jan 08, 2026	Jan NEWA
	AB			100MG	A217100	003	Jan 08, 2026	Jan NEWA
	AB			200MG	A217100	004	Jan 08, 2026	Jan NEWA

LASMIDITAN SUCCINATE
TABLET;ORAL
REYVOW

		@ +	ELI LILLY AND CO	EQ 50MG BASE	N211280	001	Jan 31, 2020	Jun DISC
		@ +		EQ 100MG BASE	N211280	002	Jan 31, 2020	Jun DISC

LATANOPROST

SOLUTION/DROPS;OPHTHALMIC

LATANOPROST

>D>	AT		AMRING PHARMS	0.005%	A200925	001	Mar 22, 2011	Jul	CAHN
		@	CARNEGIE	0.005%	A202077	001	Feb 11, 2013	Feb	CAHN
>A>	AT		J MOLNER	0.005%	A200925	001	Mar 22, 2011	Jul	CAHN
		@	MANKIND PHARMA	0.005%	A220360	001	Dec 17, 2025	Jun	DISC

LEDIPASVIR; SOFOSBUVIR

PELLETS;ORAL

HARVONI

>D>		+	GILEAD SCIENCES INC	33.75MG;150MG/PACKET	N212477	001	Aug 28, 2019	Jul	CPOT
>A>		+		33.75MG/PACKET;150MG/PACKET	N212477	001	Aug 28, 2019	Jul	CPOT
>D>		+!		45MG;200MG/PACKET	N212477	002	Aug 28, 2019	Jul	CPOT
>A>		+!		45MG/PACKET;200MG/PACKET	N212477	002	Aug 28, 2019	Jul	CPOT

LEFLUNOMIDE

TABLET;ORAL

ARAVA

		@ +	SANOFI AVENTIS US	100MG	N020905	003	Sep 10, 1998	Jun	DISC

LENALIDOMIDE

CAPSULE;ORAL

LENALIDOMIDE

	AB		ALVOGEN	2.5MG	A210480	005	Mar 06, 2023	Jan	CAHN
	AB			5MG	A210480	001	Aug 31, 2022	Jan	CAHN
	AB			10MG	A210480	002	Aug 31, 2022	Jan	CAHN
	AB			15MG	A210480	003	Aug 31, 2022	Jan	CAHN
	AB			20MG	A210480	006	Mar 06, 2023	Jan	CAHN
	AB			25MG	A210480	004	Aug 31, 2022	Jan	CAHN
	AB		CIPLA	5MG	A213165	001	Feb 02, 2026	Jan	NEWA
	AB			10MG	A213165	002	Feb 02, 2026	Jan	NEWA
	AB			15MG	A213165	003	Feb 02, 2026	Jan	NEWA
	AB			20MG	A213165	004	Feb 02, 2026	Jan	NEWA
	AB			25MG	A213165	005	Feb 02, 2026	Jan	NEWA
		@	TORRENT	2.5MG	A213405	005	Feb 10, 2026	Mar	DISC
	AB			2.5MG	A213405	005	Feb 10, 2026	Jan	NEWA
		@		5MG	A213405	006	Feb 10, 2026	Mar	DISC
	AB			5MG	A213405	006	Feb 10, 2026	Jan	NEWA
		@		15MG	A213405	004	Nov 04, 2025	Mar	DISC

LEUCOVORIN CALCIUM

FOR SOLUTION;ORAL

LEUCOVORIN CALCIUM

>D>		@	HOSPIRA	EQ 60MG BASE/VIAL	N008107	003	Jan 30, 1987	Jul	CRLD
>A>		@ +		EQ 60MG BASE/VIAL	N008107	003	Jan 30, 1987	Jul	CRLD

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

LEUCOVORIN CALCIUM

		@	INGENUS PHARMS LLC	EQ 500MG BASE/50ML (EQ 10MG BASE/ML)	A210917	001	Nov 23, 2018	Feb	CAHN

VYKOURA

		+!	AVYXA HOLDINGS	EQ 50MG BASE/5ML (EQ 10MG BASE/ML)	N220406	001	Feb 03, 2026	Feb	NEWA
		+!		EQ 350MG BASE/35ML (EQ 10MG BASE/ML)	N220406	002	Feb 03, 2026	Feb	NEWA
		+!		EQ 500MG BASE/50ML (EQ 10MG BASE/ML)	N220406	003	Feb 03, 2026	Feb	NEWA

TABLET;ORAL

LEUCOVORIN CALCIUM

	AB		HIKMA	EQ 25MG BASE	A072736	001	Feb 22, 1993	May	CHRS
	AB		INGENUS PHARMS LLC	EQ 5MG BASE	A211132	001	Jul 30, 2020	Apr	CAHN
	AB			EQ 10MG BASE	A211132	002	Jul 30, 2020	Apr	CAHN
	AB			EQ 15MG BASE	A211132	003	Jul 30, 2020	Apr	CAHN
	AB	!		EQ 25MG BASE	A211132	004	Jul 30, 2020	May	CHRS
	AB			EQ 25MG BASE	A211132	004	Jul 30, 2020	Apr	CAHN

LEUPROLIDE ACETATE

SOLUTION;SUBCUTANEOUS

LEUPROLIDE ACETATE

	AP		SOMERSET THERAPS LLC	14MG/2.8ML (1MG/0.2ML)	A213829	001	Aug 13, 2021	Feb	CAHN

LEUPROLIDE MESYLATE

EMULSION;SUBCUTANEOUS

CAMCEVI ETM

	+!	ACCORD	EQ 21MG BASE	N219745	001	Aug 25, 2025	Jan	CAHN

LEVALBUTEROL HYDROCHLORIDE

SOLUTION;INHALATION

LEVALBUTEROL HYDROCHLORIDE

AN		NEPHRON	EQ 0.021% BASE	A215217	001	May 26, 2026	May	NEWA
AN			EQ 0.042% BASE	A215217	002	May 26, 2026	May	NEWA

LEVETIRACETAM

INJECTABLE;INTRAVENOUS

LEVETIRACETAM

>A> AP		BAXTER HLTHCARE CORP	500MG/5ML (100MG/ML)	A208458	001	Aug 06, 2026	Jul	NEWA
	@	KNACK	500MG/5ML (100MG/ML)	A215465	001	Dec 02, 2025	May	DISC

LEVETIRACETAM IN SODIUM CHLORIDE

AP		MYLAN LABS LTD	500MG/100ML (5MG/ML)	A218364	001	May 08, 2026	May	NEWA
AP			1GM/100ML (10MG/ML)	A218364	002	May 08, 2026	May	NEWA
AP			1.5GM/100ML (15MG/ML)	A218364	003	May 08, 2026	May	NEWA

SOLUTION;ORAL

LEVETIRACETAM

AA		ANDA REPOSITORY	100MG/ML	A218080	001	Nov 21, 2025	Mar	CAHN
	@	STRIDES PHARMA	100MG/ML	A078582	001	Jan 15, 2009	Jun	DISC

TABLET;ORAL

LEVETIRACETAM

>A> AB		NOVAX	250MG	A078869	001	Mar 13, 2009	Jul	CAHN
>A> AB			500MG	A078869	002	Mar 13, 2009	Jul	CAHN
>A> AB			750MG	A078869	003	Mar 13, 2009	Jul	CAHN
>A> AB			1GM	A078869	004	Mar 13, 2009	Jul	CAHN
AB		SENORES PHARMS	250MG	A076920	001	Jan 15, 2009	Jan	CAHN
AB			500MG	A076920	002	Jan 15, 2009	Jan	CAHN
AB			750MG	A076920	003	Jan 15, 2009	Jan	CAHN
AB			1GM	A078904	001	Jan 15, 2009	Jan	CAHN
>D> AB		VIWIT PHARM	250MG	A078869	001	Mar 13, 2009	Jul	CAHN
>D> AB			500MG	A078869	002	Mar 13, 2009	Jul	CAHN
>D> AB			750MG	A078869	003	Mar 13, 2009	Jul	CAHN
>D> AB			1GM	A078869	004	Mar 13, 2009	Jul	CAHN

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

LEVOBUNOLOL HYDROCHLORIDE

AT		BAUSCH AND LOMB INC	0.5%	A074326	001	Mar 04, 1994	May	CAHN

LEVOCARNITINE

INJECTABLE;INJECTION

LEVOCARNITINE

AP		BAXTER HLTHCARE CORP	200MG/ML	A217896	001	Jul 02, 2026	Jun	NEWA

LEVOFLOXACIN

TABLET;ORAL

LEVOFLOXACIN

	@	LUPIN	250MG	A078424	001	Jun 20, 2011	May	DISC
	@		500MG	A078424	002	Jun 20, 2011	May	DISC
	@		750MG	A078424	003	Jun 20, 2011	May	DISC

LEVOLEUCOVORIN CALCIUM

SOLUTION;INTRAVENOUS

LEVOLEUCOVORIN CALCIUM

	@	AMNEAL	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A207548	001	Sep 08, 2017	Mar	DISC
	@	INGENUS PHARMS LLC	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A210623	001	May 03, 2018	May	CAHN
	@		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A210623	002	May 03, 2018	May	CAHN

LEVOTHYROXINE SODIUM

POWDER;INTRAVENOUS

LEVOTHYROXINE SODIUM

>D>	AP		PIRAMAL CRITICAL	100MCG/VIAL	A206163	001	Jun 29, 2016	Jul DISC
>A>		@		100MCG/VIAL	A206163	001	Jun 29, 2016	Jul DISC
>D>	AP			500MCG/VIAL	A206163	002	Jun 29, 2016	Jul DISC
>A>		@		500MCG/VIAL	A206163	002	Jun 29, 2016	Jul DISC

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

EUTHYROX

	@		EMD SERONO INC	0.025MG	N021292	001	May 31, 2002	Apr DISC
	@			0.05MG	N021292	002	May 31, 2002	Apr DISC
	@			0.075MG	N021292	003	May 31, 2002	Apr DISC
	@			0.088MG	N021292	004	May 31, 2002	Apr DISC
	@			0.1MG	N021292	005	May 31, 2002	Apr DISC
	@			0.112MG	N021292	006	May 31, 2002	Apr DISC
	@			0.125MG	N021292	007	May 31, 2002	Apr DISC
	@			0.137MG	N021292	008	May 31, 2002	Apr DISC
	@			0.15MG	N021292	009	May 31, 2002	Apr DISC
	@			0.175MG	N021292	010	May 31, 2002	Apr DISC
	@			0.2MG	N021292	011	May 31, 2002	Apr DISC

LEVOTHYROXINE SODIUM

	AB2		ALEMBIC	0.025MG	A216370	001	May 20, 2026	May NEWA
	AB2			0.05MG	A216370	002	May 20, 2026	May NEWA
	AB2			0.075MG	A216370	003	May 20, 2026	May NEWA
	AB2			0.088MG	A216370	004	May 20, 2026	May NEWA
	AB2			0.1MG	A216370	005	May 20, 2026	May NEWA
	AB2			0.112MG	A216370	006	May 20, 2026	May NEWA
	AB2			0.125MG	A216370	007	May 20, 2026	May NEWA
	AB2			0.137MG	A216370	008	May 20, 2026	May NEWA
	AB2			0.15MG	A216370	009	May 20, 2026	May NEWA
	AB2			0.175MG	A216370	010	May 20, 2026	May NEWA
	AB2			0.2MG	A216370	011	May 20, 2026	May NEWA
	AB2			0.3MG	A216370	012	May 20, 2026	May NEWA

LIDOCAINE

OINTMENT;TOPICAL

LIDOCAINE

	AT		ALEMBIC	5%	A211469	001	Nov 23, 2018	May CTEC
		@	COSETTE PHARMS NC	5%	A211019	001	Dec 12, 2018	Jun CAHN
	AT		ENCUBE	5%	A205318	001	Feb 01, 2016	Jun CMFD

PATCH;TOPICAL

LIDOCAINE

	AB		USPHARMA	5%	A207059	001	Feb 09, 2026	Mar CMFD
		@		5%	A207059	001	Feb 09, 2026	Feb DISC
	AB			5%	A207059	001	Feb 09, 2026	Jan NEWA

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE

	AP		ANTHEA PHARMA	2%	A219535	002	Feb 06, 2026	Jan NEWA
	AP		VIWIT PHARM	1%	A220071	001	Mar 19, 2026	Mar NEWA
	AP			2%	A220071	002	Mar 19, 2026	Mar NEWA

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE

		@	CHARTWELL RX	2%	A090665	001	Sep 27, 2010	May CAHN

JELLY;TOPICAL

LIDOCAINE HYDROCHLORIDE

		@	COSETTE PHARMS NC	2%	A081318	001	Apr 29, 1993	Jun CAHN

SOLUTION;ORAL

LIDOCAINE HYDROCHLORIDE

	AT		QUAGEN	2%	A218676	001	Mar 20, 2026	Mar NEWA

>D> SYSTEM;INTRADERMAL

>D> ZINGO

>D>			POWDER PHARMS	0.5MG	N022114	001	Aug 16, 2007	Jul DISC
>A>		@		0.5MG	N022114	001	Aug 16, 2007	Jul DISC

LINAGLIPTIN

TABLET;ORAL

LINAGLIPTIN

	AB		TEVA PHARMS USA	5MG	A208433	001	May 27, 2026	May NEWA

LINCOMYCIN HYDROCHLORIDE

INJECTABLE;INJECTION

LINCOMYCIN HYDROCHLORIDE

>A>		@	HAINAN POLY	EQ 300MG BASE/ML	A216662	001	Dec 21, 2022	Jul CAHN
>D>		@	SLATE RUN PHARMA	EQ 300MG BASE/ML	A216662	001	Dec 21, 2022	Jul CAHN

LINERIXIBAT

TABLET;ORAL

LYNAVOY

		+!	GLAXOSMITHKLINE	40MG	N220295	001	Mar 17, 2026	Mar NEWA
		+!	INTERCEPT	40MG	N220295	001	Mar 17, 2026	May CAHN

LIRAGLUTIDE

SOLUTION;SUBCUTANEOUS

LIRAGLUTIDE

	AP1		BIOCON PHARMA	18MG/3ML (6MG/ML)	A215245	001	Mar 11, 2026	Feb NEWA
	AP2			18MG/3ML (6MG/ML)	A217063	001	Feb 24, 2026	Feb NEWA
	AP1		FRESENIUS KABI USA	18MG/3ML (6MG/ML)	A212552	001	Mar 30, 2026	Mar NEWA
	AP1		MYLAN INSTITUTIONAL	18MG/3ML (6MG/ML)	A213155	001	Jun 15, 2026	Jun NEWA
	AP2		ORBICULAR	18MG/3ML (6MG/ML)	A217234	001	Feb 24, 2026	Feb NEWA
	AP1			18MG/3ML (6MG/ML)	A217590	001	Jan 14, 2026	Jan NEWA
	AP1		SANDOZ	18MG/3ML (6MG/ML)	A212972	001	Jul 01, 2026	Jun NEWA

LITHIUM CARBONATE

TABLET;ORAL

LITHIUM CARBONATE

>D>	AB	+!	HIKMA	300MG	N018558	001	Jan 29, 1982	Jul CTEC
>A>		+!		300MG	N018558	001	Jan 29, 1982	Jul CTEC
>D>	AB		SUN PHARM INDS INC	300MG	A091027	001	Jun 24, 2010	Jul DISC
>A>		@		300MG	A091027	001	Jun 24, 2010	Jul DISC

LITHIUM CITRATE

SYRUP;ORAL

LITHIUM CITRATE

	AA		PAI HOLDINGS PHARM	EQ 300MG CARBONATE/5ML	A070755	001	May 21, 1986	Mar CMFD

LOMITAPIDE MESYLATE

CAPSULE;ORAL

JUXTAPID

		+	CHIESI	EQ 2MG BASE	N203858	007	Feb 25, 2026	Feb NEWA
		+!		EQ 30MG BASE	N203858	004	Apr 23, 2015	Mar CHRS

LOTEPREDNOL ETABONATE

GEL;OPHTHALMIC

LOTEPREDNOL ETABONATE

>D>	AB		SUN PHARM	0.5%	A215384	001	Aug 09, 2023	Jul DISC
>A>		@		0.5%	A215384	001	Aug 09, 2023	Jul DISC

LOVASTATIN

TABLET, EXTENDED RELEASE;ORAL

ALTOPREV

>D>		@	AZURITY	10MG	N021316	001	Jun 26, 2002	Jul CAHN
>A>		@		10MG	N021316	001	Jun 26, 2002	Jul CAHN
		@		10MG	N021316	001	Jun 26, 2002	Mar CAHN
>D>		@ +		20MG	N021316	002	Jun 26, 2002	Jul CAHN
>A>		@ +		20MG	N021316	002	Jun 26, 2002	Jul CAHN
		@ +		20MG	N021316	002	Jun 26, 2002	Mar CAHN
>D>		@ +		40MG	N021316	003	Jun 26, 2002	Jul CAHN
>A>		@ +		40MG	N021316	003	Jun 26, 2002	Jul CAHN
		@ +		40MG	N021316	003	Jun 26, 2002	Mar CAHN
>D>		@ +		60MG	N021316	004	Jun 26, 2002	Jul CAHN
>A>		@ +		60MG	N021316	004	Jun 26, 2002	Jul CAHN
		@ +		60MG	N021316	004	Jun 26, 2002	Mar CAHN

LUBIPROSTONE

CAPSULE;ORAL

LUBIPROSTONE

AB		AMNEAL	8MCG	A209450	001	Nov 30, 2021	Jan CMFD
AB			24MCG	A209450	002	Nov 30, 2021	Jan CMFD

MACIMORELIN ACETATE

FOR SOLUTION;ORAL

MACRILEN

@	+	AETERNA ZENTARIS	EQ 60MG BASE/POUCH	N205598	001	Dec 20, 2017	Jan CAHN

MACITENTAN

TABLET;ORAL

MACITENTAN

AB		AMNEAL	10MG	A211000	001	Jun 08, 2026	May NEWA
AB		APOTEX	10MG	A211195	001	Jan 09, 2024	Mar CMFD
AB		MYLAN	10MG	A211161	001	Dec 03, 2025	May CMFD
AB		SEASONS BIOTECH	10MG	A211026	001	Dec 03, 2025	Apr CMFD
AB		TEVA PHARMS USA INC	10MG	A211187	001	Jun 08, 2026	May NEWA
AB		TORRENT	10MG	A211107	001	Aug 05, 2024	Apr CMFD
AB		ZYDUS LIFESCIENCES	10MG	A211224	001	Apr 06, 2021	Apr CMFD

MAFENIDE ACETATE

FOR SOLUTION;TOPICAL

MAFENIDE ACETATE

@		INGENUS PHARMS LLC	5%	A206716	001	Jul 31, 2017	Feb CAHN

MAGNESIUM SULFATE

INJECTABLE;INJECTION

MAGNESIUM SULFATE

!		BAXTER HLTHCARE CORP	3GM/100ML (30MG/ML)	A211966	004	Jan 08, 2026	Jan NFTG

MAGNESIUM SULFATE IN PLASTIC CONTAINER

@		MYLAN LABS LTD	2GM/50ML (40MG/ML)	A209911	001	Sep 14, 2018	Mar DISC

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

>A>	AP		SQUARE PHARMS PLC	1GM/2ML (500MG/ML)	A217461	001	Jul 09, 2026	Jul NEWA
>A>	AP			5GM/10ML (500MG/ML)	A217461	002	Jul 09, 2026	Jul NEWA
>A>	AP			10GM/20ML (500MG/ML)	A217461	003	Jul 09, 2026	Jul NEWA
>A>	AP			25GM/50ML (500MG/ML)	A217461	004	Jul 09, 2026	Jul NEWA

MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE

TABLET;ORAL

SODIUM SULFATE, MAGNESIUM SULFATE AND POTASSIUM CHLORIDE

AB		LUPIN	0.225GM;0.188GM;1.479GM	A216095	001	May 28, 2026	May NFTG

SUTAB

AB	+!	AZURITY	0.225GM;0.188GM;1.479GM	N213135	001	Nov 10, 2020	May CFTG

MARAVIROC

TABLET;ORAL

MARAVIROC

@		RHODES PHARMS	150MG	A216143	001	Nov 04, 2025	Apr DISC
@			300MG	A216143	002	Nov 04, 2025	Apr DISC

MECLIZINE HYDROCHLORIDE

TABLET;ORAL

MECLIZINE HYDROCHLORIDE

AA		HERITAGE	50MG	A205136	003	Feb 22, 2019	Jun CMFD
AA		SENORES PHARMS	12.5MG	A087128	002		Feb CAHN
AA			25MG	A087128	001		Feb CAHN

MELOXICAM

TABLET;ORAL

MELOXICAM

>D>		@	YABAO PHARM	7.5MG	A077933	001	Jul 19, 2006	Jul CAHN
>D>		@		15MG	A077933	002	Jul 19, 2006	Jul CAHN
>A>		@	ZENNOVA	7.5MG	A077933	001	Jul 19, 2006	Jul CAHN
>A>		@		15MG	A077933	002	Jul 19, 2006	Jul CAHN

MELPHALAN HYDROCHLORIDE

INJECTABLE;INJECTION

MELPHALAN HYDROCHLORIDE

		@	INGENUS PHARMS LLC	EQ 50MG BASE/VIAL	A210947	001	Feb 18, 2020	May	CAHN

MEMANTINE HYDROCHLORIDE

SOLUTION;ORAL

MEMANTINE HYDROCHLORIDE

>A>		@	APOZEAL PHARMS	2MG/ML	A205446	001	Dec 07, 2015	Jul	CAHN
	AA		MEDLEY PHARMS	2MG/ML	A210319	001	Aug 31, 2020	Mar	CAHN
>D>		@	SCIEGEN PHARMS	2MG/ML	A205446	001	Dec 07, 2015	Jul	CAHN

TABLET;ORAL

MEMANTINE HYDROCHLORIDE

	AB	!	DR REDDYS LABS LTD	10MG	A090048	002	Apr 14, 2010	Mar	CHRS
	AB		RENATA	5MG	A209527	001	May 07, 2018	Feb	CAHN
	AB			10MG	A209527	002	May 07, 2018	Feb	CAHN
		@	STRIDES PHARMA	5MG	A202350	001	May 23, 2017	Jun	DISC
		@		10MG	A202350	002	May 23, 2017	Jun	DISC

NAMENDA

		@ +	ABBVIE	5MG	N021487	001	Oct 16, 2003	Mar	DISC
		@ +		10MG	N021487	002	Oct 16, 2003	Mar	DISC

MEPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

POLOCAINE

		!	FRESENIUS KABI USA	1%	A089407	001	Dec 01, 1986	Jan	CHRS
		!		2%	A089410	001	Dec 01, 1986	Jan	CHRS

POLOCAINE-MPF

		!	FRESENIUS KABI USA	1%	A089406	001	Dec 01, 1986	Jan	CHRS
		!		1.5%	A089408	001	Dec 01, 1986	Jan	CHRS
		!		2%	A089409	001	Dec 01, 1986	Jan	CHRS

MERCAPTOPURINE

TABLET;ORAL

MERCAPTOPURINE

		@	MYLAN	50MG	A040594	001	Jul 01, 2005	Jun	DISC

MEROPENEM

POWDER;INTRAVENOUS

MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER

		+!	B BRAUN MEDICAL	500MG/VIAL	N202106	001	Apr 30, 2015	Jun	CHRS
		+		500MG/VIAL	N202106	001	Apr 30, 2015	Jun	CRLD
		+!		1GM/VIAL	N202106	002	Apr 30, 2015	Jun	CHRS
		+		1GM/VIAL	N202106	002	Apr 30, 2015	Jun	CRLD

MESALAMINE

CAPSULE, EXTENDED RELEASE;ORAL

MESALAMINE

>D>	AB		DIFGEN PHARMS	250MG	A219997	001	Mar 10, 2026	Jul	CAHN
	AB			250MG	A219997	001	Mar 10, 2026	Feb	NFTG
>D>	AB			500MG	A219997	002	Mar 10, 2026	Jul	CAHN
	AB			500MG	A219997	002	Mar 10, 2026	Feb	NEWA
>A>	AB		SANDOZ	250MG	A219997	001	Mar 10, 2026	Jul	CAHN
>A>	AB			500MG	A219997	002	Mar 10, 2026	Jul	CAHN

PENTASA

	AB	+	TAKEDA PHARMS USA	250MG	N020049	001	May 10, 1993	Feb	CFTG

ENEMA;RECTAL

MESALAMINE

	AB		KLM LABS PVT	4GM/60ML	A220016	001	Mar 31, 2026	Mar	NEWA

SUPPOSITORY;RECTAL

MESALAMINE

	AB		J MOLNER	1GM	A208362	001	Jun 21, 2019	Jun	CAHN

MESNA

INJECTABLE;INTRAVENOUS

MESNA

	AP		EUGIA PHARMA	100MG/ML	A220518	001	Jan 27, 2026	Jan	NEWA

TABLET;ORAL

MESNA

	AB		INGENUS PHARMS LLC	400MG	A218871	001	Jan 13, 2025	Feb	CAHN

METAPROTERENOL SULFATE

SYRUP;ORAL

METAPROTERENOL SULFATE

	@	COSETTE PHARMS NC	10MG/5ML	A072761	001	Feb 27, 1992	Jun	CAHN

METAXALONE

TABLET;ORAL

METAXALONE

	@	INGENUS PHARMS LLC	800MG	A213836	001	Oct 21, 2020	Feb	CAHN

METFORMIN HYDROCHLORIDE

TABLET;ORAL

METFORMIN HYDROCHLORIDE

AB		CHARTWELL	625MG	A075972	005	Jan 24, 2002	Jan	CTEC
AB			750MG	A075972	004	Jan 24, 2002	Jan	CTEC
AB		SCIEGEN PHARMS	625MG	A203769	004	Feb 09, 2026	Jan	NEWA
AB			750MG	A203769	005	Feb 09, 2026	Jan	NEWA

TABLET, EXTENDED RELEASE;ORAL

METFORMIN HYDROCHLORIDE

	@	ALLIED	500MG	A215629	001	Jun 20, 2023	Apr	CAHN
	@		1GM	A215629	002	Jun 20, 2023	Apr	CAHN
	@	AMNEAL PHARMS NY	500MG	A078596	001	Jan 03, 2008	Mar	DISC
	@		750MG	A078596	002	Jan 03, 2008	Mar	DISC
	@	APOTEX	500MG	A213356	001	Dec 13, 2021	Feb	DISC
	@		1GM	A213356	002	Dec 13, 2021	Feb	DISC
AB1		PLATINUM	500MG	A202306	001	Feb 23, 2017	Apr	CAHN
AB			750MG	A202306	002	Feb 23, 2017	Apr	CAHN
	@	RK PHARMA	500MG	A215629	001	Jun 20, 2023	Jan	DISC
	@		1GM	A215629	002	Jun 20, 2023	Jan	DISC
	@	SENORES PHARMS	500MG	A215629	001	Jun 20, 2023	Apr	CAHN
	@		1GM	A215629	002	Jun 20, 2023	Apr	CAHN

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

TABLET;ORAL

SITAGLIPTIN AND METFORMIN HYDROCHLORIDE

AB		APOTEX	500MG;EQ 50MG BASE	A202426	001	Apr 30, 2026	Apr	NEWA
AB			1GM;EQ 50MG BASE	A202426	002	Apr 30, 2026	Apr	NEWA

TABLET, EXTENDED RELEASE;ORAL

JANUMET XR

AB	+	MSD SUB MERCK	500MG;EQ 50MG BASE	N202270	001	Feb 02, 2012	May	CTEC
AB	+		1GM;EQ 50MG BASE	N202270	002	Feb 02, 2012	May	CTEC
AB	+!		1GM;EQ 100MG BASE	N202270	003	Feb 02, 2012	May	CTEC

SITAGLIPTIN AND METFORMIN HYDROCHLORIDE

AB		PH HEALTH	500MG;EQ 50MG BASE	A204144	001	Jun 04, 2025	May	CMFD
AB			1GM;EQ 50MG BASE	A204144	002	Jun 04, 2025	May	CMFD
AB			1GM;EQ 100MG BASE	A204144	003	Jun 04, 2025	May	CMFD

METHADONE HYDROCHLORIDE

SOLUTION;ORAL

METHADONE HYDROCHLORIDE

AA		VISTAPHARM LLC	5MG/5ML	A090707	001	Jun 30, 2010	Feb	CMFD

METHAZOLAMIDE

TABLET;ORAL

METHAZOLAMIDE

AB		AJANTA PHARMA LTD	25MG	A217408	001	Feb 09, 2026	Jan	NEWA
AB			50MG	A217408	002	Feb 09, 2026	Jan	NEWA
	@	POM PHARMA	25MG	A040102	001	Aug 28, 1996	Apr	CAHN
	@		50MG	A040102	002	Aug 28, 1996	Apr	CAHN

METHENAMINE HIPPURATE

TABLET;ORAL

METHENAMINE HIPPURATE

AB		INGENUS PHARMS LLC	1GM	A210068	001	Nov 27, 2020	Feb	CAHN

METHOCARBAMOL

SOLUTION;IM-IV

METHOCARBAMOL

>A> AP		HAINAN POLY	1GM/10ML (100MG/ML)	A208116	001	Jan 19, 2017	Jul	CAHN
>D> AP		SLATE RUN PHARMA	1GM/10ML (100MG/ML)	A208116	001	Jan 19, 2017	Jul	CAHN

		SUSPENSION;ORAL						
		ATMEKSI						
		+! ROSEMONT PHARMS	750MG/5ML	N219843	001	Jul 30, 2025	May	CAHN
		TABLET;ORAL						
		METHOCARBAMOL						
	AA	DBL PHARMS	500MG	A203550	001	Feb 08, 2017	Mar	CAHN
	AA		750MG	A203550	002	Feb 08, 2017	Mar	CAHN
		@ HIKMA INTL PHARMS	500MG	A085123	002		Jun	CMS1
	AA	HLTHCARE	500MG	A203550	001	Feb 08, 2017	Feb	CAHN
	AA		750MG	A203550	002	Feb 08, 2017	Feb	CAHN
		METHOTREXATE						
		SOLUTION;SUBCUTANEOUS						
		OTREXUP						
		@ + COSETTE	7.5MG/0.4ML (7.5MG/0.4ML)	N204824	005	Nov 07, 2014	Jun	CAHN
		@ +	10MG/0.4ML (10MG/0.4ML)	N204824	001	Oct 11, 2013	Jun	CAHN
		@ +	12.5MG/0.4ML (12.5MG/0.4ML)	N204824	006	Mar 24, 2016	Jun	CAHN
		@ +	15MG/0.4ML (15MG/0.4ML)	N204824	002	Oct 11, 2013	Jun	CAHN
		@ +	17.5MG/0.4ML (17.5MG/0.4ML)	N204824	007	Mar 24, 2016	Jun	CAHN
		@ +	20MG/0.4ML (20MG/0.4ML)	N204824	003	Oct 11, 2013	Jun	CAHN
		@ +	22.5MG/0.4ML (22.5MG/0.4ML)	N204824	008	Mar 24, 2016	Jun	CAHN
		@ +	25MG/0.4ML (25MG/0.4ML)	N204824	004	Oct 11, 2013	Jun	CAHN
		OTREXUP PFS						
		@ + COSETTE	10MG/0.4ML (10MG/0.4ML)	N204824	009	May 31, 2017	Jun	CAHN
		@ +	15MG/0.6ML (15MG/0.6ML)	N204824	010	May 31, 2017	Jun	CAHN
		@ +	17.5MG/0.7ML (17.5MG/0.7ML)	N204824	011	May 31, 2017	Jun	CAHN
		@ +	20MG/0.8ML (20MG/0.8ML)	N204824	012	May 31, 2017	Jun	CAHN
		@ +	22.5MG/0.9ML (22.5MG/0.9ML)	N204824	013	May 31, 2017	Jun	CAHN
		@ +	25MG/ML (25MG/ML)	N204824	014	May 31, 2017	Jun	CAHN
		METHOTREXATE SODIUM						
		INJECTABLE;INJECTION						
		METHOTREXATE SODIUM						
	AP	ALEMBIC	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A220225	001	Apr 15, 2026	Apr	NEWA
	AP		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A220225	002	Apr 15, 2026	Apr	NEWA
	AP	HETERO LABS LTD VI	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A219865	001	Apr 30, 2026	Apr	NEWA
	AP	! HIKMA	EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A089342	001	Sep 16, 1986	Apr	CTEC
		METHOTREXATE SODIUM PRESERVATIVE FREE						
		@ CAPLIN ONE LABS	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A090039	001	Mar 31, 2009	Mar	DISC
	AP		EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A090039	001	Mar 31, 2009	Jan	CAHN
		@	EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A090039	002	Mar 31, 2009	Mar	DISC
	AP		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A090039	002	Mar 31, 2009	Jan	CAHN
		@	EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A090029	001	Mar 31, 2009	Mar	DISC
	AP		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A090029	001	Mar 31, 2009	Jan	CAHN
	AP	EUGIA PHARMA SPECLTS	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A201529	001	Mar 29, 2012	Apr	CMFD
	AP		EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A201529	002	Mar 29, 2012	Apr	CMFD
	AP		EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A201529	003	Mar 29, 2012	Apr	CMFD
	AP		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A201529	004	Mar 29, 2012	Apr	CMFD
		TABLET;ORAL						
		METHOTREXATE SODIUM						
		@ DAITO	EQ 2.5MG BASE	A213362	001	Aug 07, 2023	Mar	DISC
		METHOXSALEN						
		CAPSULE;ORAL						
		METHOXSALEN						
>A>	AB	ONESOURCE	10MG	A202687	001	Jun 05, 2014	Jul	CAHN
>D>	AB	ONESOURCE SPECIALTY	10MG	A202687	001	Jun 05, 2014	Jul	CAHN

METHSCOPOLAMINE BROMIDE

TABLET;ORAL

PAMINE

>A>		@	FOUGERA	2.5MG	N008848	001		Jul CAHN
>D>		@	FOUGERA PHARMS	2.5MG	N008848	001		Jul CAHN

PAMINE FORTE

>A>		@	FOUGERA	5MG	N008848	002	Mar 25, 2003	Jul CAHN
>D>		@	FOUGERA PHARMS	5MG	N008848	002	Mar 25, 2003	Jul CAHN

METHYLDOPA

TABLET;ORAL

METHYLDOPA

		@	QUAGEN	125MG	A070535	001	Jan 02, 1987	Apr CAHN
		@		250MG	A070536	001	Jan 02, 1987	Apr CAHN
		@		500MG	A070537	001	Jan 02, 1987	Apr CAHN

METHYLENE BLUE

SOLUTION;INTRAVENOUS

METHYLENE BLUE

		!	ZYDUS LIFESCIENCES	5MG/ML (5MG/ML)	A215636	003	Feb 02, 2026	Jan NFTG
		!		100MG/10ML (10MG/ML)	A215636	004	Mar 31, 2026	Mar NFTG

METHYLPHENIDATE

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL

COTEMPLA XR-ODT

AB		+	NEOS THERAPS INC	8.6MG	N205489	001	Jun 19, 2017	May CTEC
AB		+		17.3MG	N205489	002	Jun 19, 2017	May CTEC
AB		+!		25.9MG	N205489	003	Jun 19, 2017	May CTEC

METHYLPHENIDATE

AB			ACTAVIS ELIZABETH	8.6MG	A210924	001	Jun 19, 2020	May CMFD
AB				17.3MG	A210924	002	Jun 19, 2020	May CMFD
AB				25.9MG	A210924	003	Jun 19, 2020	May CMFD

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

ADHANSIA XR

		@ +	KNOA PHARMA	25MG	N212038	001	Feb 27, 2019	May CAHN
		@ +		35MG	N212038	002	Feb 27, 2019	May CAHN
		@ +		45MG	N212038	003	Feb 27, 2019	May CAHN
		@ +		55MG	N212038	004	Feb 27, 2019	May CAHN
		@ +		70MG	N212038	005	Feb 27, 2019	May CAHN
		@ +		85MG	N212038	006	Feb 27, 2019	May CAHN

METADATE CD

AB2		+	LANNETT	10MG	N021259	003	May 27, 2003	Jun CAHN
AB2		+		20MG	N021259	001	Apr 03, 2001	Jun CAHN
AB2		+		30MG	N021259	002	Jun 19, 2003	Jun CAHN
AB2		+		40MG	N021259	004	Feb 19, 2006	Jun CAHN
AB2		+		50MG	N021259	005	Feb 19, 2006	Jun CAHN
AB2		+!		60MG	N021259	006	Feb 19, 2006	Jun CAHN

METHYLPHENIDATE HYDROCHLORIDE

AB1			DR REDDYS LABS SA	60MG	A078458	004	Jun 23, 2016	Feb CHRS
AB1		!	GRANULES	60MG	A211796	005	May 23, 2019	Feb CHRS

TABLET, CHEWABLE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

		@	QUAGEN	2.5MG	A204954	001	Jan 26, 2017	Apr CAHN
		@		5MG	A204954	002	Jan 26, 2017	Apr CAHN
		@		10MG	A204954	003	Jan 26, 2017	Apr CAHN

TABLET, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

		@	SPECGX LLC	27MG	A202608	001	Dec 28, 2012	Jun DISC
		@		36MG	A202608	002	Dec 28, 2012	Jun DISC
		@		54MG	A202608	003	Dec 28, 2012	Jun DISC
>D>	AB		SUN PHARM INDS INC	18MG	A205135	001	Aug 19, 2020	Jul DISC
>A>		@		18MG	A205135	001	Aug 19, 2020	Jul DISC
>D>	AB			27MG	A205135	002	Aug 19, 2020	Jul DISC
>A>		@		27MG	A205135	002	Aug 19, 2020	Jul DISC
>D>	AB			36MG	A205135	003	Aug 19, 2020	Jul DISC
>A>		@		36MG	A205135	003	Aug 19, 2020	Jul DISC
>D>	AB			54MG	A205135	004	Aug 19, 2020	Jul DISC
>A>		@		54MG	A205135	004	Aug 19, 2020	Jul DISC

METHYLPREDNISOLONE

TABLET;ORAL

METHYLPREDNISOLONE

@		INGENUS PHARMS LLC	4MG	A210985	001	Jan 09, 2019	Feb CAHN

METHYLPREDNISOLONE ACETATE

INJECTABLE;INJECTION

METHYLPREDNISOLONE ACETATE

AB		CAPLIN	40MG/ML	A220556	001	Jan 26, 2026	Jan NEWA
AB			80MG/ML	A220556	002	Jan 26, 2026	Jan NEWA

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE;INJECTION

METOCLOPRAMIDE HYDROCHLORIDE

AP		FRESENIUS KABI USA	EQ 5MG BASE/ML	A091392	001	Apr 19, 2013	Jun CMFD

SOLUTION;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

AA	!	PAI HOLDINGS	EQ 5MG BASE/5ML	A072744	001	May 28, 1991	May CAHN

SPRAY, METERED;NASAL

GIMOTI

	+!	QOL MEDCL	EQ 15MG BASE/SPRAY	N209388	001	Jun 19, 2020	Feb CAHN

TABLET;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

@		STRIDES PHARMA INTL	EQ 10MG BASE	A070581	001	Oct 17, 1985	Jan DISC

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

METOPROLOL SUCCINATE

@		MYLAN PHARMS INC	EQ 25MG TARTRATE	A202033	001	Dec 15, 2011	Jun DISC
@			EQ 50MG TARTRATE	A202033	002	Dec 15, 2011	Jun DISC
@			EQ 100MG TARTRATE	A202033	003	Dec 15, 2011	May DISC
@			EQ 200MG TARTRATE	A202033	004	Dec 15, 2011	Mar DISC
AB		ZHEJIANG JUTAI PHARM	EQ 25MG TARTRATE	A214110	004	May 15, 2026	May NEWA

METRONIDAZOLE

CREAM;TOPICAL

METRONIDAZOLE

AB		COSETTE PHARMS NC	0.75%	A077549	001	Dec 19, 2007	May CAHN

GEL;TOPICAL

METRONIDAZOLE

AB	!	COSETTE PHARMS NC	0.75%	A078178	001	Jan 19, 2011	May CAHN
AB			1%	A216692	001	Jan 23, 2023	May CAHN
AB		ZYDUS LIFESCIENCES	0.75%	A220095	001	Feb 13, 2026	Feb NEWA

GEL;VAGINAL

METRONIDAZOLE

AB		COSETTE PHARMS NC	0.75%	A216323	001	Jul 12, 2023	May CAHN

NUVESSA

	+!	ALEMBIC THERAP	1.3%	N205223	001	Mar 24, 2014	May CAHN

INJECTABLE;INJECTION

METRO I.V. IN PLASTIC CONTAINER

@ +		B BRAUN	500MG/100ML	N018900	001	Sep 29, 1983	Jan DISC

METRONIDAZOLE IN PLASTIC CONTAINER

AP	!	INFORLIFE	500MG/100ML	A206191	001	Feb 25, 2019	Jan CHRS

MEXILETINE HYDROCHLORIDE

CAPSULE;ORAL

MEXILETINE HYDROCHLORIDE

AB		INGENUS PHARMS LLC	150MG	A214352	001	Jan 25, 2021	Feb CAHN
AB			200MG	A214352	002	Jan 25, 2021	Feb CAHN
AB			250MG	A214352	003	Jan 25, 2021	Feb CAHN
AB		MACLEODS PHARMS	150MG	A219987	001	Mar 23, 2026	Mar NEWA
AB			200MG	A219987	002	Mar 23, 2026	Mar NEWA
AB			250MG	A219987	003	Mar 23, 2026	Mar NEWA

MICAFUNGIN SODIUM

INJECTABLE;INTRAVENOUS

MICAFUNGIN SODIUM

AP		ASPIRO	EQ 50MG BASE/VIAL	A220296	001	Mar 17, 2026	Mar NEWA
AP			EQ 100MG BASE/VIAL	A220296	002	Mar 17, 2026	Mar NEWA
AP		HISUN PHARM HANGZHOU	EQ 50MG BASE/VIAL	A219712	001	Jan 21, 2026	Jan NEWA

INJECTABLE;INTRAVENOUS
MICAFUNGIN SODIUM

AP			EQ 100MG BASE/VIAL	A219712	002	Jan 21, 2026	Jan NEWA
AP		YICHANG HUMANWELL	EQ 50MG BASE/VIAL	A219518	001	Feb 24, 2026	Feb NEWA
AP			EQ 100MG BASE/VIAL	A219518	002	Feb 24, 2026	Feb NEWA

MIDODRINE HYDROCHLORIDE

TABLET;ORAL
MIDODRINE HYDROCHLORIDE

	@	IMPAX PHARMS	2.5MG	A076449	001	May 27, 2004	Apr DISC
	@		5MG	A076449	002	May 27, 2004	Apr DISC
	@		10MG	A076449	003	Dec 16, 2005	Apr DISC
AB		UNIQUE	2.5MG	A207613	001	Nov 02, 2018	Mar CAHN
AB			5MG	A207613	002	Nov 02, 2018	Mar CAHN
AB			10MG	A207613	003	Nov 02, 2018	Mar CAHN

MIGLITOL

TABLET;ORAL
MIGLITOL

	!	ORIENT PHARMA	25MG	A203965	001	Feb 24, 2015	Mar CAHN
			50MG	A203965	002	Feb 24, 2015	Mar CAHN
			100MG	A203965	003	Feb 24, 2015	Mar CAHN

MILNACIPRAN HYDROCHLORIDE

TABLET;ORAL
MILNACIPRAN HYDROCHLORIDE

AB		AMNEAL PHARMS	12.5MG	A205081	001	Apr 22, 2016	Jan CMFD
AB			25MG	A205081	002	Apr 22, 2016	Jan CMFD
AB			50MG	A205081	003	Apr 22, 2016	Jan CMFD
AB			100MG	A205081	004	Apr 22, 2016	Jan CMFD
AB		BRECKENRIDGE	12.5MG	A205071	001	Jan 27, 2016	Jan CMFD
AB			25MG	A205071	002	Jan 27, 2016	Jan CMFD
AB			50MG	A205071	003	Jan 27, 2016	Jan CMFD
AB			100MG	A205071	004	Jan 27, 2016	Jan CMFD
AB		HETERO LABS LTD V	12.5MG	A205147	001	Oct 03, 2024	Feb CMFD
AB			25MG	A205147	002	Oct 03, 2024	Feb CMFD
AB			50MG	A205147	003	Oct 03, 2024	Feb CMFD
AB			100MG	A205147	004	Oct 03, 2024	Feb CMFD

SAVELLA

AB	+	ABBVIE	12.5MG	N022256	001	Jan 14, 2009	Jan CTEC
AB	+		25MG	N022256	002	Jan 14, 2009	Jan CTEC
AB	+!		50MG	N022256	003	Jan 14, 2009	Jan CTEC
AB	+		100MG	N022256	004	Jan 14, 2009	Jan CTEC

MILRINONE LACTATE

INJECTABLE;INJECTION
MILRINONE LACTATE

	@	HIKMA	EQ 1MG BASE/ML	A075530	001	May 28, 2002	Mar DISC

MILSAPERIDONE

TABLET;ORAL
BYSANTI

	+!	VANDA PHARMS INC	1MG	N220358	001	Feb 20, 2026	Feb NEWA
	+		2MG	N220358	002	Feb 20, 2026	Feb NEWA
	+		4MG	N220358	003	Feb 20, 2026	Feb NEWA
	+		6MG	N220358	004	Feb 20, 2026	Feb NEWA
	+		8MG	N220358	005	Feb 20, 2026	Feb NEWA
	+		10MG	N220358	006	Feb 20, 2026	Feb NEWA
	+		12MG	N220358	007	Feb 20, 2026	Feb NEWA

MINOCYCLINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
MINOCYCLINE HYDROCHLORIDE

AB		LUPIN	EQ 45MG BASE	A091424	001	Nov 30, 2011	Apr CAHN
AB			EQ 55MG BASE	A091424	002	Nov 30, 2011	Apr CAHN
AB			EQ 90MG BASE	A091424	003	Nov 30, 2011	Apr CAHN
AB			EQ 135MG BASE	A091424	004	Nov 30, 2011	Apr CAHN

MIRABEGRON

FOR SUSPENSION, EXTENDED RELEASE;ORAL

MIRABEGRON

AB			ALKEM LABS LTD	8MG/ML	A219323	001	Jan 20, 2026	Jan NFTG

MYRBETRIQ GRANULES

AB		+!	APGDI	8MG/ML	N213801	001	Mar 25, 2021	Jan CFTG

TABLET, EXTENDED RELEASE;ORAL

MIRABEGRON

AB			DEVA HOLDING AS	25MG	A219941	001	May 01, 2026	Apr NEWA
AB				50MG	A219941	002	May 01, 2026	Apr NEWA

MIRDAMETINIB

TABLET, FOR SUSPENSION;ORAL

GOMEKLI

>A>		+	SPRINGWORKS	3MG	N219379	002	Jul 28, 2026	Jul NEWA
>A>		+		4MG	N219379	003	Jul 28, 2026	Jul NEWA

MIRTAZAPINE

TABLET;ORAL

MIRTAZAPINE

>D>		@	ALLIED	15MG	A076176	001	Jun 19, 2003	Jul CAHN
		@		15MG	A076176	001	Jun 19, 2003	Jun CAHN
>D>		@		30MG	A076176	002	Jun 19, 2003	Jul CAHN
		@		30MG	A076176	002	Jun 19, 2003	Jun CAHN
>D>		@		45MG	A076176	003	Jun 19, 2003	Jul CAHN
		@		45MG	A076176	003	Jun 19, 2003	Jun CAHN
AB			MICRO LABS	7.5MG	A220104	001	May 19, 2026	May NEWA
AB				15MG	A220104	002	May 19, 2026	May NEWA
AB				30MG	A220104	003	May 19, 2026	May NEWA
AB				45MG	A220104	004	May 19, 2026	May NEWA
AB			NOVITIUM PHARMA	7.5MG	A219919	001	Feb 02, 2026	Jan NEWA
AB				15MG	A219919	002	Feb 02, 2026	Jan NEWA
AB				30MG	A219919	003	Feb 02, 2026	Jan NEWA
AB				45MG	A219919	004	Feb 02, 2026	Jan NEWA
>A>		@	SENORES PHARMS	15MG	A076176	001	Jun 19, 2003	Jul CAHN
>A>		@		30MG	A076176	002	Jun 19, 2003	Jul CAHN
>A>		@		45MG	A076176	003	Jun 19, 2003	Jul CAHN

MITAPIVAT SULFATE

TABLET;ORAL

AQVESME

		+!	AGIOS PHARMS INC	EQ 100MG BASE	N216196	004	Dec 23, 2025	Jan NEWA

MOMETASONE FUROATE

CREAM;TOPICAL

MOMETASONE FUROATE

AB		!	COSETTE PHARMS NC	0.1%	A077447	001	May 22, 2006	May CAHN

IMPLANT;IMPLANTATION

SINUVA

		+!	INTERSECT ENT INC	1.35MG	N209310	001	Dec 08, 2017	Mar CHRS

LOTION;TOPICAL

MOMETASONE FUROATE

		@	COSETTE PHARMS NC	0.1%	A077678	001	Nov 21, 2007	Jun CAHN

OINTMENT;TOPICAL

MOMETASONE FUROATE

AB			COSETTE PHARMS NC	0.1%	A077401	001	Jun 20, 2006	May CAHN
AB			ENCUBE	0.1%	A076481	001	Nov 14, 2003	Apr CMFD

MONTELUKAST SODIUM

GRANULE;ORAL

MONTELUKAST SODIUM

AB		!	AJANTA PHARMA LTD	EQ 4MG BASE/PACKET	A203438	001	Jul 31, 2015	May CHRS

SINGULAIR

		@ +	ORGANON	EQ 4MG BASE/PACKET	N021409	001	Jul 26, 2002	May DISC

TABLET, CHEWABLE;ORAL

MONTELUKAST SODIUM

		@	AMNEAL PHARMS	EQ 4MG BASE	A205107	001	Sep 04, 2020	Mar DISC
		@		EQ 5MG BASE	A205107	002	Sep 04, 2020	Mar DISC
AB			SENORES PHARMS	EQ 4MG BASE	A201581	001	Aug 06, 2012	Jan CAHN
AB				EQ 5MG BASE	A201581	002	Aug 06, 2012	Jan CAHN

TABLET, CHEWABLE;ORAL
SINGULAIR
@ + ORGANON EQ 4MG BASE N020830 002 Mar 03, 2000 Jun DISC

MORPHINE SULFATE
SOLUTION;ORAL
MORPHINE SULFATE
@ PADAGIS US 100MG/5ML A201574 001 Aug 06, 2012 Mar DISC
AA QUAGEN 10MG/5ML A213892 001 Jul 07, 2026 Jun NEWA
AA 20MG/5ML A213892 002 Jul 07, 2026 Jun NEWA
AA 100MG/5ML A213892 003 Jul 07, 2026 Jun NEWA
@ TRIS PHARMA INC 10MG/5ML A203518 001 May 12, 2015 Mar DISC
TABLET, EXTENDED RELEASE;ORAL
MORPHINE SULFATE
@ STRIDES PHARMA INTL 15MG A075295 001 Oct 28, 1998 Jan DISC
@ 30MG A075295 002 Oct 28, 1998 Jan DISC
@ 60MG A075295 003 Oct 28, 1998 Jan DISC
@ 100MG A075295 004 Sep 15, 2000 Jan DISC
@ 200MG A075295 005 Sep 15, 2000 Jan DISC
MS CONTIN
AB + KNOA PHARMA 15MG N019516 003 Sep 12, 1989 May CAHN
AB + 30MG N019516 001 May 29, 1987 May CAHN
AB + 60MG N019516 002 Apr 08, 1988 May CAHN
AB +! 100MG N019516 004 Jan 16, 1990 May CAHN
AB + 200MG N019516 005 Nov 08, 1993 May CAHN

MOXIFLOXACIN HYDROCHLORIDE
SOLUTION/DROPS;OPHTHALMIC
MOXIFLOXACIN HYDROCHLORIDE
@ FDC LTD EQ 0.5% BASE A219475 001 Aug 04, 2025 Feb DISC
TABLET;ORAL
MOXIFLOXACIN HYDROCHLORIDE
AB MACLEODS PHARMS EQ 400MG BASE A209143 001 Mar 02, 2026 Feb NEWA
@ TORRENT EQ 400MG BASE A200160 001 Apr 03, 2014 Apr DISC

MUPIROCIN
OINTMENT;TOPICAL
CENTANY
@ PADAGIS US 2% N050788 001 Dec 04, 2002 Mar DISC

MUPIROCIN CALCIUM
CREAM;TOPICAL
MUPIROCIN
>D> BX ALEMBIC EQ 2% BASE A213053 001 Nov 16, 2021 Jul CTEC
>A> AB EQ 2% BASE A213053 001 Nov 16, 2021 Jul CTEC

MYCOPHENOLATE MOFETIL
CAPSULE;ORAL
MYCOPHENOLATE MOFETIL
@ HIKMA 250MG A065410 001 Jul 29, 2008 Jun DISC
@ MYLAN 250MG A065520 001 May 04, 2009 May DISC
FOR SUSPENSION;ORAL
MYCOPHENOLATE MOFETIL
AB CONCORD BIOTECH LTD 200MG/ML A218566 001 Jun 01, 2026 May NEWA
>D> AB LANNETT CO INC 200MG/ML A214525 001 Jul 29, 2021 Jul CAHN
>A> AB QUAGEN 200MG/ML A214525 001 Jul 29, 2021 Jul CAHN
TABLET;ORAL
MYCOPHENOLATE MOFETIL
@ HIKMA 500MG A065413 001 Jul 29, 2008 Jun DISC
@ MYLAN 500MG A065521 001 May 04, 2009 Jun DISC

MYCOPHENOLATE SODIUM
TABLET, DELAYED RELEASE;ORAL
MYCOPHENOLATE SODIUM
@ RK PHARMA EQ 180MG BASE A091248 002 Jan 08, 2014 Jan DISC
@ EQ 360MG BASE A091248 001 Jan 08, 2014 Jan DISC
@ TWI PHARMS EQ 180MG BASE A214289 001 Nov 03, 2021 Mar DISC
@ EQ 360MG BASE A214289 002 Nov 03, 2021 Mar DISC

NABUMETONE

TABLET;ORAL

NABUMETONE

	!	LGM PHARMA	1GM	A203166	003	Aug 30, 2019	Jan	CHRS
	@	SENORES PHARMS	500MG	A090427	001	Dec 30, 2011	Jun	CAHN
	@		750MG	A090427	002	Dec 30, 2011	Jun	CAHN

NADOLOL

TABLET;ORAL

NADOLOL

	@	INGENUS PHARMS LLC	20MG	A210786	001	Jun 01, 2018	May	CAHN
	@		40MG	A210786	002	Jun 01, 2018	May	CAHN
	@		80MG	A210786	003	Jun 01, 2018	May	CAHN

NAFCILLIN SODIUM

INJECTABLE;INJECTION

NALLPEN IN PLASTIC CONTAINER

>D>	+!	BAXTER HLTHCARE	EQ 20MG BASE/ML	N050655	001	Oct 31, 1989	Jul	DISC
>A>	@ +		EQ 20MG BASE/ML	N050655	001	Oct 31, 1989	Jul	DISC

NAFTIFINE HYDROCHLORIDE

CREAM;TOPICAL

NAFTIFINE HYDROCHLORIDE

	@	AMNEAL	2%	A206960	001	Apr 10, 2017	Feb	DISC

NAFTIN

	@ +	LEGACY	1%	N019599	001	Feb 29, 1988	Jun	CAHN
AB	+!		2%	N019599	002	Jan 13, 2012	Jun	CAHN

GEL;TOPICAL

NAFTIFINE HYDROCHLORIDE

	@	AMNEAL	1%	A206165	001	Mar 20, 2019	Mar	DISC

NAFTIN

	@ +	LEGACY	1%	N019356	001	Jun 18, 1990	Jun	CAHN
AB	+!		2%	N204286	001	Jun 27, 2013	Jun	CAHN
	@ +	LEGACY PHARMA	1%	N019356	001	Jun 18, 1990	Jun	DISC
	+!		1%	N019356	001	Jun 18, 1990	Mar	CTEC

NALMEFENE HYDROCHLORIDE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

NALMEFENE HYDROCHLORIDE

AP	!	KNOA PHARMA	EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	A212955	001	Feb 08, 2022	May	CAHN

SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

ZURNAI (AUTOINJECTOR)

	+!	KNOA PHARMA	EQ 1.5MG BASE/0.5ML (EQ 1.5MG BASE/0.5ML)	N218590	001	Aug 07, 2024	May	CAHN

NALOXONE HYDROCHLORIDE

SPRAY;NASAL

REZENOPY

	+!	SCIENTURE	10MG/SPRAY	N215487	001	Apr 19, 2024	Jan	CMFD

NAPROXEN

SUSPENSION;ORAL

NAPROXEN

	@	AUROBINDO PHARMA	25MG/ML	A216504	001	Oct 03, 2025	Mar	DISC

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET;ORAL

TREXIMET

>A>	@ +	AZURITY	60MG;EQ 10MG BASE	N021926	002	May 14, 2015	Jul	CAHN
>A> AB	+!		500MG;EQ 85MG BASE	N021926	001	Apr 15, 2008	Jul	CAHN
>D>	@ +	CURRAX	60MG;EQ 10MG BASE	N021926	002	May 14, 2015	Jul	CAHN
>D> AB	+!		500MG;EQ 85MG BASE	N021926	001	Apr 15, 2008	Jul	CAHN

NARATRIPTAN HYDROCHLORIDE

TABLET;ORAL

NARATRIPTAN

	@	PADAGIS US	EQ 1MG BASE	A091326	001	Jul 08, 2010	Mar	DISC
	@		EQ 2.5MG BASE	A091326	002	Jul 08, 2010	Mar	DISC

NAVEPEGRITIDE

POWDER;SUBCUTANEOUS

YUVIWEL

	+!	ASCENDIS	1.3MG/VIAL	N219164	001	Feb 27, 2026	Feb	NEWA
	+!		2.8MG/VIAL	N219164	002	Feb 27, 2026	Feb	NEWA
	+!		5.5MG/VIAL	N219164	003	Feb 27, 2026	Feb	NEWA

NEBIVOLOL HYDROCHLORIDE

TABLET;ORAL

NEBIVOLOL HYDROCHLORIDE

	@	TORRENT	EQ 2.5MG BASE	A203966	001	Mar 02, 2018	Mar	DISC
	@		EQ 5MG BASE	A203966	002	Mar 02, 2018	Mar	DISC
	@		EQ 10MG BASE	A203966	003	Mar 02, 2018	Mar	DISC
	@		EQ 20MG BASE	A203966	004	Mar 02, 2018	Mar	DISC

NEOMYCIN SULFATE

TABLET;ORAL

NEOMYCIN SULFATE

AA		SOLARIS PHARMA CORP	500MG	A065220	001	Jul 28, 2006	Apr	CAHN

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION;IRRIGATION

NEOMYCIN AND POLYMYXIN B SULFATE

	@	WATSON LABS	EQ 40MG BASE/ML;200,000 UNITS/ML	A062664	001	Apr 08, 1986	Jan	DISC
	!	XGEN PHARMS	EQ 40MG BASE/ML;200,000 UNITS/ML	A065106	001	Jan 31, 2006	Jan	CTEC
AT	!		EQ 40MG BASE/ML;200,000 UNITS/ML	A065106	001	Jan 31, 2006	Jan	CHRS
	!		EQ 40MG BASE/ML;200,000 UNITS/ML	A065108	001	Jan 31, 2006	Jan	CTEC
AT	!		EQ 40MG BASE/ML;200,000 UNITS/ML	A065108	001	Jan 31, 2006	Jan	CHRS

NEOSPORIN G.U. IRRIGANT

	@	MONARCH PHARMS	EQ 40MG BASE/ML;200,000 UNITS/ML	A060707	001		Jan	DISC

NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS

BLOXIVERZ

	@ +	EXELA PHARMA	5MG/5ML (1MG/ML)	N204078	003	Oct 27, 2023	Jun	DISC

NEOSTIGMINE METHYLSULFATE

>D> AP		AMRING PHARMS	5MG/10ML (0.5MG/ML)	A210989	001	Aug 22, 2018	Jul	CAHN
>D> AP			10MG/10ML (1MG/ML)	A210989	002	Aug 22, 2018	Jul	CAHN
	@	HIKMA	3MG/3ML (1MG/ML)	A216206	001	Jul 13, 2022	Mar	DISC
>A> AP		J MOLNER	5MG/10ML (0.5MG/ML)	A210989	001	Aug 22, 2018	Jul	CAHN
>A> AP			10MG/10ML (1MG/ML)	A210989	002	Aug 22, 2018	Jul	CAHN
AP		NIVAGEN PHARMS INC	5MG/10ML (0.5MG/ML)	A212627	001	Nov 03, 2022	Mar	CAHN
AP			10MG/10ML (1MG/ML)	A212627	002	Nov 03, 2022	Mar	CAHN

NIACIN

TABLET, EXTENDED RELEASE;ORAL

NIACIN

>D> AB		LANNETT CO INC	500MG	A203899	001	Jun 16, 2017	Jul	CAHN
>D> AB			1GM	A203899	002	Jun 16, 2017	Jul	CAHN
>A> AB		QUAGEN	500MG	A203899	001	Jun 16, 2017	Jul	CAHN
>A> AB			1GM	A203899	002	Jun 16, 2017	Jul	CAHN

NICARDIPINE HYDROCHLORIDE

CAPSULE;ORAL

NICARDIPINE HYDROCHLORIDE

>A>	@	CHARTWELL RX	20MG	A218638	001	Jun 25, 2025	Jul	CAHN
>A>	@		30MG	A218638	002	Jun 25, 2025	Jul	CAHN
>D>	@	NAVINTA LLC	20MG	A218638	001	Jun 25, 2025	Jul	CAHN
	@		20MG	A218638	001	Jun 25, 2025	Mar	DISC
>D>	@		30MG	A218638	002	Jun 25, 2025	Jul	CAHN
	@		30MG	A218638	002	Jun 25, 2025	Mar	DISC
AB		SENORES PHARMS	20MG	A215377	001	Jul 17, 2023	Jan	CAHN
AB			30MG	A215377	002	Jul 17, 2023	Jan	CAHN

INJECTABLE;INJECTION

CARDENE

AP	+	CHIESI	25MG/10ML (2.5MG/ML)	N019734	001	Jan 30, 1992	Jan	CMFD

INJECTABLE;INJECTION
NICARDIPINE HYDROCHLORIDE

	AP		SOMERSET THERAPS LLC	25MG/10ML (2.5MG/ML)	A090664	001	Nov 17, 2009	Jan CAHN

INJECTABLE;INTRAVENOUS
NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE

>A>	AP		FRESENIUS KABI USA	20MG/200ML (0.1MG/ML)	A219334	001	Aug 04, 2026	Jul NEWA
>A>	AP			40MG/200ML (0.2MG/ML)	A219334	002	Aug 04, 2026	Jul NEWA

NIFEDIPINE

CAPSULE;ORAL
NIFEDIPINE

	AB	!	HERITAGE PHARMA	10MG	A202644	001	Apr 25, 2013	Mar CHRS

PROCARDIA

		@ +	PFIZER	10MG	N018482	001		Mar DISC

TABLET, EXTENDED RELEASE;ORAL
NIFEDIPINE

	AB2	!	NOVAST LABS	90MG	A210614	003	Mar 12, 2019	Apr CHRS
		@	PHARMADAX	30MG	A216019	001	Nov 18, 2022	Mar CAHN
		@		60MG	A216019	002	Nov 18, 2022	Mar CAHN

PROCARDIA XL

		@ +	PFIZER	90MG	N019684	003	Sep 06, 1989	Apr DISC

NILOTINIB

TABLET, ORALLY DISINTEGRATING;ORAL
CAVHANZA

		+	FLEX PHARMA	60MG	N217379	001	May 29, 2026	May NEWA
		+!		80MG	N217379	002	May 29, 2026	May NEWA

NILOTINIB HYDROCHLORIDE

CAPSULE;ORAL
NILOTINIB HYDROCHLORIDE

	AB		TEVA PHARMS INC	EQ 50MG BASE	A219134	001	Jun 26, 2026	Jun NEWA
	AB			EQ 150MG BASE	A219134	002	Jun 26, 2026	Jun NEWA
	AB			EQ 200MG BASE	A219134	003	Jun 26, 2026	Jun NEWA

NILUTAMIDE

TABLET;ORAL
NILANDRON

		@ +	ADVANZ PHARMA	150MG	N020169	002	Apr 30, 1999	Apr DISC

NILUTAMIDE

		!	ANI PHARMS	150MG	A207631	001	Jul 15, 2016	Apr CTEC
	AB	!		150MG	A207631	001	Jul 15, 2016	Apr CHRS

NINTEDANIB ESYLATE

CAPSULE;ORAL
NINTEDANIB ESYLATE

	AB		APOTEX	EQ 100MG BASE	A219227	001	Apr 02, 2026	Mar NFTG
	AB			EQ 150MG BASE	A219227	002	Apr 02, 2026	Mar NFTG
	AB		CIPLA	EQ 100MG BASE	A212609	001	Apr 02, 2026	Mar NFTG
	AB			EQ 150MG BASE	A212609	002	Apr 02, 2026	Mar NFTG
	AB		DEXCEL	EQ 100MG BASE	A219819	001	Apr 02, 2026	Mar NFTG
	AB			EQ 150MG BASE	A219819	002	Apr 02, 2026	Mar NFTG
	AB		DR REDDYS	EQ 100MG BASE	A219283	001	Apr 02, 2026	Mar NFTG
	AB			EQ 150MG BASE	A219283	002	Apr 02, 2026	Mar NFTG
>A>	AB		GLENMARK PHARMS LTD	EQ 100MG BASE	A212555	001	Jul 09, 2026	Jul NEWA
>A>	AB			EQ 150MG BASE	A212555	002	Jul 09, 2026	Jul NEWA
	AB		HUMANWELL PURACAP	EQ 100MG BASE	A218472	001	Jul 09, 2026	Jun NEWA
	AB			EQ 150MG BASE	A218472	002	Jul 09, 2026	Jun NEWA
>A>	AB		MACLEODS PHARMS	EQ 100MG BASE	A219926	001	Aug 03, 2026	Jul NEWA
>A>	AB			EQ 150MG BASE	A219926	002	Aug 03, 2026	Jul NEWA
	AB		SANDOZ	EQ 100MG BASE	A216915	001	Apr 02, 2026	Mar NFTG
	AB			EQ 150MG BASE	A216915	002	Apr 02, 2026	Mar NFTG

OFEV

	AB	+	BOEHRINGER INGELHEIM	EQ 100MG BASE	N205832	001	Oct 15, 2014	Mar CFTG
	AB	+!		EQ 150MG BASE	N205832	002	Oct 15, 2014	Mar CFTG

NIROGACESTAT HYDROBROMIDE

TABLET;ORAL
OGSIVEO

		@ +	SPRINGWORKS	EQ 50MG BASE	N217677	001	Nov 27, 2023	Mar DISC

NISOLDIPINE

TABLET, EXTENDED RELEASE;ORAL

NISOLDIPINE

AB		AMTA	8.5MG	A216606	001	Apr 10, 2023	Apr	CMFD
	!		17MG	A216606	002	Dec 12, 2025	Jun	CTEC
AB	!		17MG	A216606	002	Dec 12, 2025	Jun	CHRS
	@	MYLAN	8.5MG	A091001	001	Jan 26, 2011	Apr	DISC
	@		17MG	A091001	002	Jan 26, 2011	Apr	DISC
	@		20MG	A079051	001	Jul 25, 2008	Apr	DISC
	@		25.5MG	A091001	003	Jan 26, 2011	Apr	DISC
	@		30MG	A079051	002	Jul 25, 2008	Apr	DISC
	@		34MG	A091001	004	Jan 26, 2011	Feb	DISC
	@		40MG	A079051	003	Jul 25, 2008	Apr	DISC

SULAR

AB	+!	AZURITY	8.5MG	N020356	008	Jan 02, 2008	Jun	CAHN
	+!		8.5MG	N020356	008	Jan 02, 2008	Apr	CTEC
AB	+!		8.5MG	N020356	008	Jan 02, 2008	Apr	CTEC
AB	+!		8.5MG	N020356	008	Jan 02, 2008	Feb	CAHN
	@ +		10MG	N020356	001	Feb 02, 1995	Jun	CAHN
	@ +		10MG	N020356	001	Feb 02, 1995	Feb	CAHN
	@ +		17MG	N020356	007	Jan 02, 2008	Jun	CAHN
	@ +		17MG	N020356	007	Jan 02, 2008	Jun	DISC
AB	+!		17MG	N020356	007	Jan 02, 2008	Feb	CAHN
AB	+!		17MG	N020356	007	Jan 02, 2008	Feb	CAHN
AB	+!		17MG	N020356	007	Jan 02, 2008	Feb	CAHN
AB	+!		17MG	N020356	007	Jan 02, 2008	Feb	CAHN
	@ +		20MG	N020356	002	Feb 02, 1995	Jun	CAHN
	@ +		20MG	N020356	002	Feb 02, 1995	Feb	CAHN
	@ +		25.5MG	N020356	006	Jan 02, 2008	Jun	CAHN
	@ +		25.5MG	N020356	006	Jan 02, 2008	Feb	CAHN
	@ +		30MG	N020356	003	Feb 02, 1995	Jun	CAHN
	@ +		30MG	N020356	003	Feb 02, 1995	Feb	CAHN
	@ +		34MG	N020356	005	Jan 02, 2008	Jun	CAHN
	@ +		34MG	N020356	005	Jan 02, 2008	Jun	DISC
	+!		34MG	N020356	005	Jan 02, 2008	Feb	CAHN
	@ +		40MG	N020356	004	Feb 02, 1995	Jun	CAHN
	@ +		40MG	N020356	004	Feb 02, 1995	Feb	CAHN
	+!	COVIS	34MG	N020356	005	Jan 02, 2008	Feb	CTEC

NITRIC OXIDE

GAS;INHALATION

NOXIVENT

	@	VERO BIOTECH INC	100PPM	A207141	001	Oct 02, 2018	Mar	CAHN
AA			800PPM	A207141	002	Oct 02, 2018	Mar	CAHN

NITROFURANTOIN

SUSPENSION;ORAL

NITROFURANTOIN

	@	AMNEAL PHARMS	25MG/5ML	A201679	001	May 11, 2011	Apr	DISC

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN

	@	POM PHARMA	25MG	A074336	001	Jan 25, 1995	Apr	CAHN
	@		50MG	A074336	002	Jan 25, 1995	Apr	CAHN
	@		100MG	A074336	003	Jan 25, 1995	Apr	CAHN

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

AB		CREEKWOOD PHARMS	75MG;25MG	A220269	001	Apr 07, 2026	Mar	NEWA

NITROGLYCERIN

FILM, EXTENDED RELEASE;TRANSDERMAL

NITRO-DUR

	+	USPHARMA	0.1MG/HR	N020145	001	Apr 04, 1995	Jan	CHRS
	+		0.2MG/HR	N020145	002	Apr 04, 1995	Jan	CHRS
	+		0.3MG/HR	N020145	003	Apr 04, 1995	Jan	CHRS
	+		0.6MG/HR	N020145	005	Apr 04, 1995	Jan	CHRS
	+		0.8MG/HR	N020145	006	Apr 04, 1995	Jan	CHRS

		FILM, EXTENDED RELEASE;TRANSDERMAL							
		NITROGLYCERIN							
	AB2		MYLAN TECHNOLOGIES	0.1MG/HR	A074559	004	Feb 06, 1998	Jan	CHRS
	AB2			0.2MG/HR	A074559	003	Aug 30, 1996	Jan	CHRS
	AB2			0.6MG/HR	A074559	001	Aug 30, 1996	Jan	CHRS
		OINTMENT;INTRA-ANAL							
		NITROGLYCERIN							
	AB	!	COSETTE	0.4%	A216103	001	Feb 16, 2024	Mar	CHRS
	AB	!	COSETTE PHARMS NC	0.4%	A216103	001	Feb 16, 2024	May	CAHN
	AB		PADAGIS ISRAEL	0.4%	A214565	001	Jul 06, 2026	Jun	NEWA
		RECTIV							
		@ +	ABBVIE	0.4%	N021359	001	Jun 21, 2011	Mar	DISC
		NOREPINEPHRINE BITARTRATE							
		INJECTABLE;INJECTION							
		NOREPINEPHRINE BITARTRATE							
>D>	AP		AMNEAL	EQ 1MG BASE/ML	A210839	001	Dec 17, 2018	Jul	DISC
>A>		@		EQ 1MG BASE/ML	A210839	001	Dec 17, 2018	Jul	DISC
	AP		NEPHRON	EQ 1MG BASE/ML	A216272	001	Jun 11, 2026	May	NEWA
		SOLUTION;INTRAVENOUS							
		NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE							
		+!	BAXTER HLTHCARE CORP	EQ 4MG BASE/250ML (EQ 16MCG BASE/ML)	N214313	004	Feb 06, 2026	Feb	NEWA
		+!		EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	N214313	005	Feb 06, 2026	Feb	NEWA
		+!		EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	N214313	006	Feb 06, 2026	Feb	NEWA
		NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE							
	AP	+!	BAXTER HLTHCARE CORP	EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	N214313	003	Nov 21, 2023	Mar	CFTG
	AP		SAGENT	EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	A220483	001	Mar 26, 2026	Mar	NFTG
		NORETHINDRONE ACETATE							
		TABLET;ORAL							
		NORETHINDRONE ACETATE							
	AB		INGENUS PHARMS LLC	5MG	A206490	001	Nov 05, 2018	Feb	CAHN
		NUSINERSEN SODIUM							
		SOLUTION;INTRATHECAL							
		SPINRAZA							
		+!	BIOGEN	EQ 12MG BASE/5ML (EQ 2.4MG BASE/ML)	N209531	001	Dec 23, 2016	May	CAHN
		+!		EQ 28MG BASE/5ML (EQ 5.6MG BASE/ML)	N209531	002	Mar 27, 2026	May	CAHN
		+!		EQ 50MG BASE/5ML (EQ 10MG BASE/ML)	N209531	003	Mar 27, 2026	May	CAHN
		+!	BIOGEN IDEC	EQ 28MG BASE/5ML (EQ 5.6MG BASE/ML)	N209531	002	Mar 27, 2026	Apr	NEWA
		+!		EQ 50MG BASE/5ML (EQ 10MG BASE/ML)	N209531	003	Mar 27, 2026	Apr	NEWA
		NYSTATIN							
		CREAM;TOPICAL							
		NYSTATIN							
	AT		COSETTE PHARMS NC	100,000 UNITS/GM	A061966	001		May	CAHN
		SUSPENSION;ORAL							
		NILSTAT							
	AA	+	CHARTWELL MOLECULES	100,000 UNITS/ML	N050299	001		Mar	CMFD
		NYSTATIN							
		@	COSETTE PHARMS NC	100,000 UNITS/ML	A062776	001	Dec 17, 1987	Jun	CAHN
	AA		SCIEGEN PHARMS	100,000 UNITS/ML	A062832	001	Dec 27, 1991	Jan	CAHN
>D>	AA		STERANCO HLTHCARE	100,000 UNITS/ML	A220367	001	Feb 05, 2026	Jul	DISC
>A>		@		100,000 UNITS/ML	A220367	001	Feb 05, 2026	Jul	DISC
	AA			100,000 UNITS/ML	A220367	001	Feb 05, 2026	Jan	NEWA
		NYSTATIN; TRIAMCINOLONE ACETONIDE							
		CREAM;TOPICAL							
		MYKACET							
		@	COSETTE PHARMS NC	100,000 UNITS/GM;0.1%	A062367	001	May 28, 1985	Jun	CAHN
		OINTMENT;TOPICAL							
		MYKACET							
		@	COSETTE PHARMS NC	100,000 UNITS/GM;0.1%	A062733	001	Mar 06, 1987	Jun	CAHN

OFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

OFLOXACIN

AT		MICRO LABS	0.3%	A218557	001	Apr 08, 2026	Mar	NEWA

SOLUTION/DROPS;OTIC

OFLOXACIN

AT	!	BAUSCH AND LOMB INC	0.3%	A076128	001	Mar 17, 2008	May	CAHN

OLANZAPINE

POWDER;INTRAMUSCULAR

OLANZAPINE

AP		AM REGENT	10MG/VIAL	A201741	001	Mar 20, 2012	Jan	CDFR
AP		ANTHEA PHARMA	10MG/VIAL	A220323	001	Mar 05, 2026	Feb	NEWA
AP		ASPIRO	10MG/VIAL	A217466	001	Mar 22, 2023	Jan	CDFR
AP		EUGIA PHARMA	10MG/VIAL	A210968	001	Oct 22, 2020	Jan	CDFR
AP		OMNIVIUM PHARMS	10MG/VIAL	A219048	001	Jan 23, 2026	Jan	NEWA
AP		QILU	10MG/VIAL	A218116	001	May 16, 2025	Jan	CDFR
AP		SANDOZ INC	10MG/VIAL	A201588	001	Oct 24, 2011	Jan	CDFR
AP		UBI	10MG/VIAL	A211072	001	Jun 11, 2025	Jan	CDFR

ZYPREXA

AP	+!	CHEPLAPHARM	10MG/VIAL	N021253	001	Mar 29, 2004	Jan	CDFR

TABLET;ORAL

OLANZAPINE

AB		SUNSHINE	2.5MG	A206238	001	Nov 19, 2018	Feb	CMFD
AB			5MG	A206238	002	Nov 19, 2018	Feb	CMFD
AB			7.5MG	A206238	003	Nov 19, 2018	Feb	CMFD
AB			10MG	A206238	004	Nov 19, 2018	Feb	CMFD
AB			15MG	A206238	005	Nov 19, 2018	Feb	CMFD
AB			20MG	A206238	006	Nov 19, 2018	Feb	CMFD
AB		TORRENT PHARMS LTD	2.5MG	A091434	001	Apr 23, 2012	Jan	CMFD
AB			5MG	A091434	002	Apr 23, 2012	Jan	CMFD
AB			7.5MG	A091434	003	Apr 23, 2012	Jan	CMFD
AB			10MG	A091434	004	Apr 23, 2012	Jan	CMFD
AB			15MG	A091434	005	Apr 23, 2012	Jan	CMFD
AB			20MG	A091434	006	Apr 23, 2012	Jan	CMFD

OLEZARSEN SODIUM

SOLUTION;SUBCUTANEOUS

TRYNGOLZA (AUTOINJECTOR)

>A>	+!	IONIS PHARMS INC	EQ 50MG BASE/0.8ML (EQ 50MG BASE/0.8ML)	N218614	002	Jun 24, 2026	Jul	NEWA

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL

OMEGA-3-ACID ETHYL ESTERS

	@	AMNEAL PHARMS	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A204940	001	Nov 27, 2015	Apr	DISC
	@	APOTEX	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A090973	001	Sep 30, 2014	Apr	DISC
>A>	@	ONESOURCE	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A091018	001	Jun 24, 2014	Jul	CAHN
>A> AB			1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A203893	001	Sep 19, 2017	Jul	CAHN
>D>	@	ONESOURCE SPECIALTY	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A091018	001	Jun 24, 2014	Jul	CAHN
>D> AB			1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A203893	001	Sep 19, 2017	Jul	CAHN

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

OMEPRAZOLE

>D>	@	ALLIED	10MG	A205070	001	Jun 29, 2018	Jul	CAHN
	@		10MG	A205070	001	Jun 29, 2018	Jun	CAHN
>D>	@		20MG	A205070	002	Jun 29, 2018	Jul	CAHN
	@		20MG	A205070	002	Jun 29, 2018	Jun	CAHN
>D>	@		40MG	A205070	003	Jun 29, 2018	Jul	CAHN
	@		40MG	A205070	003	Jun 29, 2018	Jun	CAHN
AB	!	GLENMARK PHARMS LTD	20MG	A091672	002	Oct 31, 2014	Apr	CHRS

CAPSULE, DELAYED REL PELLETS;ORAL
OMEPRAZOLE

	AB	!		40MG	A091672	003	Oct 31, 2014	Apr CHRS
	AB		SANDOZ	20MG	A075757	002	Jan 28, 2003	Apr CHRS
	AB			40MG	A076515	001	Jan 21, 2009	Apr CHRS
>A>		@	SENORES PHARMS	10MG	A205070	001	Jun 29, 2018	Jul CAHN
>A>		@		20MG	A205070	002	Jun 29, 2018	Jul CAHN
>A>		@		40MG	A205070	003	Jun 29, 2018	Jul CAHN

OMEPRAZOLE MAGNESIUM

FOR SUSPENSION, DELAYED RELEASE;ORAL
PRILOSEC

>D>		+	AZURITY	EQ 2.5MG BASE/PACKET	N022056	001	Mar 20, 2008	Jul CAHN
>A>		+		EQ 2.5MG BASE/PACKET	N022056	001	Mar 20, 2008	Jul CAHN
		+		EQ 2.5MG BASE/PACKET	N022056	001	Mar 20, 2008	Feb CAHN
>D>		+!		EQ 10MG BASE/PACKET	N022056	002	Mar 20, 2008	Jul CAHN
>A>		+!		EQ 10MG BASE/PACKET	N022056	002	Mar 20, 2008	Jul CAHN
		+!		EQ 10MG BASE/PACKET	N022056	002	Mar 20, 2008	Feb CAHN

ONDANSETRON HYDROCHLORIDE

SOLUTION;ORAL
ONDANSETRON HYDROCHLORIDE

	AA		PHARM ASSOC	EQ 4MG BASE/5ML	A078127	001	Jun 25, 2007	Feb CMFD

ORFORGLIPRON CALCIUM

TABLET;ORAL
FOUNDAYO

		+	ELI LILLY AND CO	EQ 0.8MG BASE	N220934	001	Apr 01, 2026	Apr NEWA
		+		EQ 2.5MG BASE	N220934	002	Apr 01, 2026	Apr NEWA
		+		EQ 5.5MG BASE	N220934	003	Apr 01, 2026	Apr NEWA
		+		EQ 9MG BASE	N220934	004	Apr 01, 2026	Apr NEWA
		+		EQ 14.5MG BASE	N220934	005	Apr 01, 2026	Apr NEWA
		+!		EQ 17.2MG BASE	N220934	006	Apr 01, 2026	Apr NEWA

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL
OSELTAMIVIR PHOSPHATE

		@	CEDIPROF INC	EQ 30MG BASE	A217451	001	Dec 03, 2024	Apr DISC
		@		EQ 45MG BASE	A217451	002	Dec 03, 2024	Apr DISC
		@		EQ 75MG BASE	A217451	003	Dec 03, 2024	Apr DISC
		@	UPSHER SMITH LABS	EQ 30MG BASE	A213437	001	Jan 22, 2026	Apr DISC
	AB			EQ 30MG BASE	A213437	001	Jan 22, 2026	Jan NEWA
		@		EQ 45MG BASE	A213437	002	Jan 22, 2026	Apr DISC
	AB			EQ 45MG BASE	A213437	002	Jan 22, 2026	Jan NEWA
		@		EQ 75MG BASE	A213437	003	Jan 22, 2026	Apr DISC
	AB			EQ 75MG BASE	A213437	003	Jan 22, 2026	Jan NEWA

FOR SUSPENSION;ORAL
OSELTAMIVIR PHOSPHATE

	AB		ALEMBIC	EQ 6MG BASE/ML	A218307	001	Jun 25, 2026	Jun NEWA
		@	AMNEAL PHARMS NY	EQ 6MG BASE/ML	A210186	001	Feb 27, 2018	May DISC

OSILODROSTAT PHOSPHATE

TABLET;ORAL
ISTURISA

		+!	RECORDATI RARE	EQ 5MG BASE	N212801	002	Mar 06, 2020	Jun CHRS

OXACILLIN SODIUM

INJECTABLE;INJECTION
BACTOCILL IN PLASTIC CONTAINER

>D>		+!	BAXTER HLTHCARE	EQ 20MG BASE/ML	N050640	001	Oct 26, 1989	Jul DISC
>A>		@ +		EQ 20MG BASE/ML	N050640	001	Oct 26, 1989	Jul DISC

OXALIPLATIN

INJECTABLE;INTRAVENOUS
OXALIPLATIN

		@	ACTAVIS	50MG/10ML (5MG/ML)	A204880	001	Mar 05, 2018	Apr DISC
		@		100MG/20ML (5MG/ML)	A204880	002	Mar 05, 2018	Apr DISC
		@	HENGRUI PHARMA	50MG/10ML (5MG/ML)	A203869	001	Jun 18, 2014	Apr DISC
		@		100MG/20ML (5MG/ML)	A203869	002	Jun 18, 2014	Apr DISC
		@	INGENUS PHARMS LLC	50MG/10ML (5MG/ML)	A207562	001	Oct 16, 2018	May CAHN
		@		100MG/20ML (5MG/ML)	A207562	002	Oct 16, 2018	May CAHN
		@	NOVAST LABS	100MG/20ML (5MG/ML)	A207562	002	Oct 16, 2018	Apr DISC

INJECTABLE;INTRAVENOUS
OXALIPLATIN

AP			SHANDONG	50MG/10ML (5MG/ML)	A219765	001	Jan 15, 2026	Jan NEWA
AP				100MG/20ML (5MG/ML)	A219765	002	Jan 15, 2026	Jan NEWA
	@	+	TEVA PHARMS	50MG/10ML (5MG/ML)	N022160	001	Aug 07, 2009	Apr DISC
	@	+		100MG/20ML (5MG/ML)	N022160	002	Aug 07, 2009	Apr DISC

OXAPROZIN
TABLET;ORAL
DAYPRO

	@	+	PFIZER	600MG	N018841	004	Oct 29, 1992	Jun DISC

OXAPROZIN

AB		!	DR REDDYS LABS LTD	600MG	A075855	001	Jan 31, 2001	Jun CHRS

OXCARBAZEPINE
SUSPENSION;ORAL
OXCARBAZEPINE

AB			MSN	300MG/5ML	A209020	001	May 29, 2026	May NEWA
>D> AB			STERANCO HLTHCARE	300MG/5ML	A220281	001	Mar 09, 2026	Jul DISC
>A>	@			300MG/5ML	A220281	001	Mar 09, 2026	Jul DISC
AB				300MG/5ML	A220281	001	Mar 09, 2026	Feb NEWA

TABLET;ORAL
OXCARBAZEPINE

AB			EPIC PHARMA LLC	150MG	A219556	001	Mar 02, 2026	Feb NEWA
AB				300MG	A219556	002	Mar 02, 2026	Feb NEWA
AB				600MG	A219556	003	Mar 02, 2026	Feb NEWA
AB			UMEDICA LABS PVT	150MG	A218341	001	Apr 29, 2026	Apr NEWA
AB				300MG	A218341	002	Apr 29, 2026	Apr NEWA
AB				600MG	A218341	003	Apr 29, 2026	Apr NEWA

OXICONAZOLE NITRATE
LOTION;TOPICAL
OXISTAT

	@	+	ANI PHARMS	EQ 1% BASE	N020209	001	Sep 30, 1992	Apr DISC

OXYBUTYNIN CHLORIDE
TABLET;ORAL
OXYBUTYNIN CHLORIDE

AB			AVET LIFESCIENCES	5MG	A211682	001	May 10, 2019	May CMFD
AB			HERITAGE PHARMA AVET	5MG	A211682	001	May 10, 2019	Jun CAHN
AB		!	NOVITIUM PHARMA	5MG	A209823	001	Oct 23, 2017	Jan CHRS
AB		!	RISING	2.5MG	A209025	002	Feb 07, 2023	Feb CTEC
AB			STRIDES PHARMA INTL	2.5MG	A075079	002	Mar 10, 2026	Feb NEWA
AB				5MG	A075079	001	Oct 31, 1997	Jan CHRS
>A> AB			TP ANDA HOLDINGS	2.5MG	A210125	002	Jul 21, 2026	Jul NEWA

TABLET, EXTENDED RELEASE;ORAL
OXYBUTYNIN CHLORIDE

AB			ACCORD HLTHCARE	15MG	A207138	003	Feb 29, 2016	Jan CHRS
AB		!	ZYDUS PHARMS	15MG	A202332	003	Jun 26, 2017	Jan CHRS

OXYCODONE HYDROCHLORIDE
TABLET, EXTENDED RELEASE;ORAL
OXYCONTIN

		+	KNOA PHARMA	10MG	N022272	001	Apr 05, 2010	May CAHN
		+		15MG	N022272	002	Apr 05, 2010	May CAHN
		+		20MG	N022272	003	Apr 05, 2010	May CAHN
		+		30MG	N022272	004	Apr 05, 2010	May CAHN
		+!		40MG	N022272	005	Apr 05, 2010	May CAHN
		+		60MG	N022272	006	Apr 05, 2010	May CAHN
		+		80MG	N022272	007	Apr 05, 2010	May CAHN

OXYMETAZOLINE HYDROCHLORIDE
CREAM;TOPICAL
OXYMETAZOLINE HYDROCHLORIDE

AB			SUN PHARMA CANADA	1%	A213584	001	Oct 04, 2021	May CMFD

RHOFADE

AB		+!	MAYNE PHARMA	1%	N208552	001	Jan 18, 2017	May CTEC

OZENOXACIN

CREAM;TOPICAL

XEPI

	@ +	LNHC	1%	N208945	001	Dec 11, 2017	Jan CAHN

PACLITAXEL

INJECTABLE;INJECTION

PACLITAXEL

	@	NATCO PHARMA USA	6MG/ML	A091540	001	Sep 29, 2011	Mar CAHN

PALIPERIDONE

TABLET, EXTENDED RELEASE;ORAL

PALIPERIDONE

AB		AJANTA PHARMA LTD	3MG	A218514	002	Jun 26, 2024	Mar CMFD
AB			6MG	A218514	003	Jun 26, 2024	Mar CMFD
AB			9MG	A218514	004	Jun 26, 2024	Mar CMFD
	@	APOTEX	3MG	A203279	001	Jan 26, 2026	Apr DISC
AB			3MG	A203279	001	Jan 26, 2026	Jan NEWA
	@		6MG	A203279	002	Jan 26, 2026	Apr DISC
AB			6MG	A203279	002	Jan 26, 2026	Jan NEWA
	@		9MG	A203279	003	Jan 26, 2026	Apr DISC
AB			9MG	A203279	003	Jan 26, 2026	Jan NEWA
AB		I3 PHARMS	1.5MG	A205402	001	May 07, 2026	May NEWA
AB			3MG	A205402	002	May 07, 2026	May NEWA
AB			6MG	A205402	003	May 07, 2026	May NEWA
AB			9MG	A205402	004	May 07, 2026	May NEWA
	@	RK PHARMA	1.5MG	A203802	001	Sep 24, 2015	Jan DISC
	@		3MG	A203802	002	Sep 24, 2015	Jan DISC
	@		6MG	A203802	003	Sep 24, 2015	Jan DISC
	@		9MG	A203802	004	Sep 24, 2015	Jan DISC

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

INVEGA HAFYERA

	+!	JANSSEN PHARMS	1.092GM/3.5ML (312MG/ML)	N207946	005	Aug 30, 2021	Jan CHRS
	+!		1.560GM/5ML (312MG/ML)	N207946	006	Aug 30, 2021	Jan CHRS

INVEGA SUSTENNA

	+!	JANSSEN PHARMS	39MG/0.25ML (39MG/0.25ML)	N022264	001	Jul 31, 2009	Mar CHRS
	+!		78MG/0.5ML (78MG/0.5ML)	N022264	002	Jul 31, 2009	Mar CHRS
	+!		117MG/0.75ML (117MG/0.75ML)	N022264	003	Jul 31, 2009	Mar CHRS
	+!		234MG/1.5ML (156MG/ML)	N022264	005	Jul 31, 2009	Mar CHRS

PALONOSETRON HYDROCHLORIDE

INJECTABLE;INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

	@	BAXTER HLTHCARE CORP	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A206916	001	Nov 12, 2021	Jun DISC
	@	INGENUS PHARMS LLC	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A208789	001	May 22, 2020	May CAHN

PALOPEGTERIPARATIDE

SOLUTION;SUBCUTANEOUS

YORVIPATH

	+!	ASCENDIS PHARMA BONE	EQ 0.294MG TERIPARATIDE/0.98ML (EQ 0.294MG TERIPARATIDE/0.98ML)	N216490	002	Aug 09, 2024	May CHRS
	+!		EQ 0.42MG TERIPARATIDE/1.4ML (EQ 0.3MG TERIPARATIDE/ML)	N216490	003	Aug 09, 2024	May CHRS

PANTOPRAZOLE SODIUM

INJECTABLE;INTRAVENOUS

PANTOPRAZOLE SODIUM

	@	PHARMOBEDIENT	EQ 40MG BASE/VIAL	A208580	001	May 04, 2018	Jan CAHN
AP		SHUANGCHENG	EQ 40MG BASE/VIAL	A219973	001	Apr 22, 2026	Apr NEWA

PARICALCITOL

CAPSULE;ORAL

ZEMPLAR

	@ +	ABBVIE	2MCG	N021606	002	May 26, 2005	Apr DISC

SOLUTION;INTRAVENOUS

PARICALCITOL

	@	CAPLIN	0.002MG/ML (0.002MG/ML)	A204910	001	Aug 17, 2016	Apr DISC

SOLUTION;INTRAVENOUS
PARICALCITOL

	@		0.005MG/ML (0.005MG/ML)	A204910	002	Aug 17, 2016	Apr DISC
	@		0.01MG/2ML (0.005MG/ML)	A204910	003	Aug 17, 2016	Apr DISC
	@	EUGIA PHARMA	0.002MG/ML (0.002MG/ML)	A205982	001	Oct 09, 2018	Jan DISC
	@		0.005MG/ML (0.005MG/ML)	A205982	002	Oct 09, 2018	Jan DISC
	@		0.01MG/2ML (0.005MG/ML)	A205982	003	Oct 09, 2018	Jan DISC

PAROXETINE HYDROCHLORIDE
SUSPENSION;ORAL
PAROXETINE HYDROCHLORIDE

AB		ANNORA PHARMA	EQ 10MG BASE/5ML	A219954	001	Mar 05, 2026	Feb NEWA
AB	!	NOVITIUM PHARMA	EQ 10MG BASE/5ML	A215003	001	Sep 03, 2021	Feb CTEC

TABLET, EXTENDED RELEASE;ORAL
PAROXETINE HYDROCHLORIDE

AB		ALEMBIC	EQ 12.5MG BASE	A217280	003	Mar 26, 2026	Mar NEWA
	@	LUPIN	EQ 12.5MG BASE	A204134	001	Jan 20, 2017	Jun DISC
	@		EQ 25MG BASE	A204134	002	Jan 20, 2017	Jun DISC
	@		EQ 37.5MG BASE	A204134	003	Jan 20, 2017	Jun DISC

PAROXETINE MESYLATE
CAPSULE;ORAL
BRISDELLE

AB	+!	LEGACY	EQ 7.5MG BASE	N204516	001	Jun 28, 2013	Jun CAHN

PEMETREXED DISODIUM
POWDER;INTRAVENOUS
PEMETREXED DISODIUM

>D> AP		APOTEX	EQ 1GM BASE/VIAL	A209085	001	May 25, 2022	Jul DISC
>A>	@		EQ 1GM BASE/VIAL	A209085	001	May 25, 2022	Jul DISC

PENTAMIDINE ISETHIONATE
FOR SOLUTION;INHALATION
PENTAMIDINE ISETHIONATE

AN		PAI HOLDINGS	300MG/VIAL	A206667	001	Apr 24, 2019	Apr CAHN

INJECTABLE;INJECTION
PENTAMIDINE ISETHIONATE

AP		PAI HOLDINGS	300MG/VIAL	A206666	001	Sep 28, 2017	Apr CAHN
	@	PHARMOBEDIENT	300MG/VIAL	A206982	001	Mar 17, 2022	Apr DISC

PERAMPANEL
SUSPENSION;ORAL
PERAMPANEL

AB		TARO	0.5MG/ML	A219052	001	Jun 15, 2026	Jun NEWA

PERMETHRIN
CREAM;TOPICAL
PERMETHRIN

AB		DR REDDYS LABS EU	5%	A209732	001	Aug 01, 2023	Jun CMFD

PHENTERMINE HYDROCHLORIDE
TABLET;ORAL
PHENTERMINE HYDROCHLORIDE

	@	INGENUS PHARMS LLC	37.5MG	A091451	001	Sep 21, 2012	Feb CAHN

PHENYLEPHRINE HYDROCHLORIDE
SOLUTION;INTRAVENOUS
PHENYLEPHRINE HYDROCHLORIDE

AP1		BAXTER HLTHCARE CORP	10MG/ML (10MG/ML)	A217032	001	Apr 03, 2026	Mar NEWA
AP1			50MG/5ML (10MG/ML)	A217032	002	Apr 03, 2026	Mar NEWA
AP1			100MG/10ML (10MG/ML)	A217032	003	Apr 03, 2026	Mar NEWA
AP1		HAINAN POLY	10MG/ML (10MG/ML)	A218412	001	Mar 14, 2024	Jan CMFD
AP1			50MG/5ML (10MG/ML)	A218412	002	Mar 14, 2024	Jan CMFD
AP1			100MG/10ML (10MG/ML)	A218412	003	Mar 14, 2024	Jan CMFD

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE
SYRUP;ORAL
PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE

AA	!	PAI HOLDINGS	5MG/5ML;6.25MG/5ML	A040654	001	Dec 07, 2006	May CAHN

PHENYTOIN SODIUM

CAPSULE;ORAL

EXTENDED PHENYTOIN SODIUM

>D>	AB		MANKIND PHARMA	100MG EXTENDED	A219773	001	Jan 02, 2026	Jul DISC
>A>		@		100MG EXTENDED	A219773	001	Jan 02, 2026	Jul DISC

PHYTONADIONE

INJECTABLE;INJECTION

PHYTONADIONE

	AB1		ALEMBIC	1MG/0.5ML	A216444	001	Sep 08, 2025	Mar CTEC
	AB1		AMNEAL	1MG/0.5ML	A216601	001	Nov 04, 2025	Mar CTEC
	AB1			10MG/ML	A217734	001	Jun 01, 2026	May NEWA
	AB2		BAXTER HLTHCARE CORP	1MG/0.5ML	A216852	001	Feb 26, 2026	Mar CTEC
	AB			1MG/0.5ML	A216852	001	Feb 26, 2026	Feb NEWA
	AB2	!	CIPLA	1MG/0.5ML	A214596	001	Apr 22, 2022	Mar CTEC
	AB1			1MG/0.5ML	A214966	001	Jan 03, 2025	Mar CTEC
	AB1		DR REDDYS	1MG/0.5ML	A215820	001	May 15, 2026	May NEWA
	AB1	+!	INTL MEDICATION	1MG/0.5ML	A083722	001		Mar CTEC
	AB1		ORBICULAR	1MG/0.5ML	A216298	001	Mar 13, 2026	Mar CTEC
	AB			1MG/0.5ML	A216298	001	Mar 13, 2026	Mar NEWA
	AB1		SUNNY	10MG/ML	A215090	001	Jan 09, 2026	Jan NEWA

TABLET;ORAL

PHYTONADIONE

>A>	AB		NOVAX	5MG	A220454	001	Feb 26, 2026	Jul CAHN
>D>	AB		SINOTHERAPEUTICS INC	5MG	A220454	001	Feb 26, 2026	Jul CAHN
	AB			5MG	A220454	001	Feb 26, 2026	Feb NEWA

PIFLUFOLASTAT F-18

SOLUTION;INTRAVENOUS

PYLARIFY TRUVU

		+!	APHELION	1mCi/mL-120mCi/mL	N220089	001	Mar 06, 2026	Mar NEWA

PILOCARPINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

PILOCARPINE HYDROCHLORIDE

		!	AMNEAL	1.25%	A217733	001	Apr 28, 2025	Apr CTEC
	AB	!		1.25%	A217733	001	Apr 28, 2025	Apr CHRS
		@	FDC LTD	1%	A217052	001	Oct 02, 2025	May DISC
		@		2%	A217052	002	Oct 02, 2025	May DISC
		@		4%	A217052	003	Oct 02, 2025	May DISC

VUITY

		@ +	ABBVIE	1.25%	N214028	001	Oct 28, 2021	Apr DISC

TABLET;ORAL

PILOCARPINE HYDROCHLORIDE

>D>	AB		AUROBINDO PHARMA USA	5MG	A212377	001	Aug 13, 2019	Jul CAHN
	AB			5MG	A212377	001	Aug 13, 2019	Jan CAHN
>D>	AB			7.5MG	A212377	002	Aug 13, 2019	Jul CAHN
	AB			7.5MG	A212377	002	Aug 13, 2019	Jan CAHN
		@	PADAGIS US	5MG	A076746	001	Nov 16, 2004	Mar DISC
>A>	AB		QUAGEN	5MG	A212377	001	Aug 13, 2019	Jul CAHN
>A>	AB			7.5MG	A212377	002	Aug 13, 2019	Jul CAHN

PIMOZIDE

TABLET;ORAL

PIMOZIDE

	AB		NOVITIUM PHARMA	1MG	A219897	001	Apr 13, 2026	Apr NEWA
	AB			2MG	A219897	002	Apr 13, 2026	Apr NEWA
	AB		PH HEALTH	1MG	A204521	001	Sep 28, 2015	Apr CTEC
	AB	!		2MG	A204521	002	Sep 28, 2015	Apr CTEC

PINDOLOL

TABLET;ORAL

PINDOLOL

		@	COSETTE PHARMS NC	5MG	A073661	001	Oct 31, 1993	Jun CAHN
		@		5MG	A073687	001	Feb 26, 1993	Jun CAHN
		@		5MG	A074123	001	Apr 17, 1997	Jun CAHN
		@		10MG	A073661	002	Oct 31, 1993	Jun CAHN
		@		10MG	A073687	002	Feb 26, 1993	Jun CAHN
		@		10MG	A074123	002	Apr 17, 1997	Jun CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION

PIPERACILLIN AND TAZOBACTAM

		@	SANDOZ	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065363	001	Oct 21, 2010	Apr DISC
		@		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065363	002	Oct 21, 2010	Apr DISC
		@		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A065363	003	Oct 21, 2010	Apr DISC

PIRFENIDONE

CAPSULE;ORAL

ESBRIET

AB		+!	LEGACY	267MG	N022535	001	Oct 15, 2014	Jun CAHN

PIRFENIDONE

AB			AUROBINDO PHARMA	267MG	A212597	001	Apr 20, 2026	Apr NEWA

TABLET;ORAL

ESBRIET

AB		+	LEGACY	267MG	N208780	001	Jan 11, 2017	Jun CAHN
	@	+		534MG	N208780	002	Jan 11, 2017	Jun CAHN
AB		+!		801MG	N208780	003	Jan 11, 2017	Jun CAHN

PIROXICAM

CAPSULE;ORAL

PIROXICAM

		@	UNICHEM	10MG	A208340	001	Apr 13, 2017	May DISC
		@		20MG	A208340	002	Apr 13, 2017	May DISC

PITOLISANT HYDROCHLORIDE

TABLET;ORAL

>A>			PITOLISANT HYDROCHLORIDE					
>A>	AB		NOVITIUM PHARMA	EQ 4.45MG BASE	A218495	001	Jul 21, 2026	Jul NFTG
>A>	AB			EQ 17.8MG BASE	A218495	002	Jul 21, 2026	Jul NFTG

WAKIX

>D>		+	HARMONY	EQ 4.45MG BASE	N211150	001	Aug 14, 2019	Jul CFTG
>A>	AB	+		EQ 4.45MG BASE	N211150	001	Aug 14, 2019	Jul CFTG
>D>		+!		EQ 17.8MG BASE	N211150	002	Aug 14, 2019	Jul CFTG
>A>	AB	+!		EQ 17.8MG BASE	N211150	002	Aug 14, 2019	Jul CFTG

PIVMECILLINAM HYDROCHLORIDE

TABLET;ORAL

PIVYA

		+!	ALEMBIC THERAP	EQ 185MG BASE	N216483	001	Apr 24, 2024	Jan CAHN

PLAZOMICIN SULFATE

SOLUTION;INTRAVENOUS

ZEMDRI

	@	+	CIPLA USA	EQ 500MG BASE/10ML (EQ 50MG BASE/ML)	N210303	001	Jun 25, 2018	May DISC

PLERIXAFOR

SOLUTION;SUBCUTANEOUS

PLERIXAFOR

		@	TEVA PHARMS USA INC	24MG/1.2ML (20MG/ML)	A205197	001	Jul 24, 2023	Mar DISC

PODOFILOX

GEL;TOPICAL

CONDYLOX

	@	+	ALLERGAN	0.5%	N020529	001	Mar 13, 1997	Jan DISC

PODOFILOX

		!	PADAGIS US	0.5%	A211871	001	Nov 22, 2023	Jan CHRS
				0.5%	A211871	001	Nov 22, 2023	Jan CTEC

SOLUTION;TOPICAL

CONDYLOX

	@	+	TEVA BRANDED PHARM	0.5%	N019795	001	Dec 13, 1990	Apr DISC
AT		+!		0.5%	N019795	001	Dec 13, 1990	Feb CAHN

PODOFILOX

		!	PADAGIS US	0.5%	A075600	001	Jan 29, 2002	Apr CTEC
AT		!		0.5%	A075600	001	Jan 29, 2002	Apr CHRS

POLIDOCANOL

SOLUTION;INTRAVENOUS

VARITHENA

@ +	BOSTON SCITFC	77.5MG/7.75ML (10MG/ML)	N205098	002	Dec 21, 2017	May	CAHN
+!		180MG/18ML (10MG/ML)	N205098	001	Nov 25, 2013	May	CAHN

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION;ORAL

TRILYTE

AA	AUROBINDO PHARMA USA	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT	A076491	001	Feb 05, 2004	Apr	CMFD

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION;ORAL

COLYTE

@ +	QUAGEN	120GM/PACKET;1.49GM/PACKET;3.36GM/PACKET;2.92GM/PACKET;11.36GM/PACKET	N018983	005	Oct 26, 1984	Apr	CRLD
@ +		227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	N018983	004	Oct 26, 1984	Apr	CRLD
@ +		227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	010	Jan 31, 1989	Apr	CRLD
@ +		240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	007	Jun 12, 1987	Apr	CRLD
@ +		360GM/PACKET;4.47GM/PACKET;10.08GM/PACKET;8.76GM/PACKET;34.08GM/PACKET	N018983	006	Oct 26, 1984	Apr	CRLD
@ +	STRIDES PHARMA INTL	120GM/PACKET;1.49GM/PACKET;3.36GM/PACKET;2.92GM/PACKET;11.36GM/PACKET	N018983	005	Oct 26, 1984	Apr	CAHN
@ +		227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	N018983	004	Oct 26, 1984	Apr	CAHN
@ +		227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	010	Jan 31, 1989	Apr	CAHN
@ +		240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	007	Jun 12, 1987	Apr	CAHN
@ +		360GM/PACKET;4.47GM/PACKET;10.08GM/PACKET;8.76GM/PACKET;34.08GM/PACKET	N018983	006	Oct 26, 1984	Apr	CAHN

COLYTE WITH FLAVOR PACKS

@ +	QUAGEN	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	012	Oct 08, 1998	Apr	CRLD
@ +	STRIDES PHARMA INTL	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	012	Oct 08, 1998	Apr	CAHN

COLYTE-FLAVORED

@ +	QUAGEN	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	008	Nov 14, 1991	Apr	CRLD
@ +		240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	009	Nov 14, 1991	Apr	CRLD
@ +	STRIDES PHARMA INTL	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	008	Nov 14, 1991	Apr	CAHN
@ +		240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	009	Nov 14, 1991	Apr	CAHN

PEG 3350 AND ELECTROLYTES

!	NOVEL LABS INC	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	A090186	001	Jun 01, 2009	Apr	CHRS

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS;OPHTHALMIC

TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT	BAUSCH AND LOMB INC	10,000 UNITS/ML;EQ 1MG BASE/ML	A064120	001	Feb 14, 1997	May	CAHN

POMALIDOMIDE

CAPSULE;ORAL

POMALIDOMIDE

AB	APOTEX	1MG	A210164	001	Jun 11, 2024	Jan	CMFD
AB		2MG	A210164	002	Jun 11, 2024	Jan	CMFD
AB		3MG	A210164	003	Jun 11, 2024	Jan	CMFD
AB		4MG	A210164	004	Jun 11, 2024	Jan	CMFD
AB	BRECKENRIDGE	1MG	A210111	001	Oct 30, 2020	Jan	CMFD
AB		2MG	A210111	002	Oct 30, 2020	Jan	CMFD
AB		3MG	A210111	003	Oct 30, 2020	Jan	CMFD
AB		4MG	A210111	004	Oct 30, 2020	Jan	CMFD

	CAPSULE;ORAL						
	POMALIDOMIDE						
AB	EUGIA PHARMA	1MG	A210249	001	Oct 30, 2020	Jan	CMFD
AB		2MG	A210249	002	Oct 30, 2020	Jan	CMFD
AB		3MG	A210249	003	Oct 30, 2020	Jan	CMFD
AB		4MG	A210249	004	Oct 30, 2020	Jan	CMFD
AB	HETERO LABS LTD V	1MG	A210236	001	Sep 26, 2024	Jan	CMFD
AB		2MG	A210236	002	Sep 26, 2024	Jan	CMFD
AB		3MG	A210236	003	Sep 26, 2024	Jan	CMFD
AB		4MG	A210236	004	Sep 26, 2024	Jan	CMFD
AB	TEVA PHARMS USA	1MG	A209956	001	May 04, 2022	Jan	CMFD
AB		2MG	A209956	002	May 04, 2022	Jan	CMFD
AB		3MG	A209956	003	May 04, 2022	Jan	CMFD
AB		4MG	A209956	004	May 04, 2022	Jan	CMFD
	POMALYST						
AB	+ BRISTOL	1MG	N204026	001	Feb 08, 2013	Jan	CTEC
AB	+	2MG	N204026	002	Feb 08, 2013	Jan	CTEC
AB	+	3MG	N204026	003	Feb 08, 2013	Jan	CTEC
AB	+!	4MG	N204026	004	Feb 08, 2013	Jan	CTEC
	PONATINIB HYDROCHLORIDE						
	TABLET;ORAL						
	ICLUSIG						
	+! TAKEDA PHARMS USA	EQ 10MG BASE	N203469	004	Dec 18, 2020	Jan	CHRS
	+	EQ 45MG BASE	N203469	002	Dec 14, 2012	Jan	CHRS
	POSACONAZOLE						
	SOLUTION;INTRAVENOUS						
	NOXAFIL						
	@ + MERCK SHARP DOHME	300MG/16.7ML (18MG/ML)	N205596	001	Mar 13, 2014	Jan	DISC
	POSACONAZOLE						
AP	! GLAND	300MG/16.7ML (18MG/ML)	A217553	001	Dec 26, 2023	Jan	CHRS
	TABLET, DELAYED RELEASE;ORAL						
	POSACONAZOLE						
AB	APOTEX	100MG	A213331	001	Jun 29, 2026	Jun	NEWA
AB	WELDING	100MG	A216326	001	Jun 20, 2023	Apr	CAHN
	POTASSIUM ACETATE						
	INJECTABLE;INJECTION						
	POTASSIUM ACETATE						
	@ EXELA PHARMA	2MEQ/ML	A206203	001	Dec 29, 2015	Jan	DISC
	POTASSIUM CHLORIDE						
	CAPSULE, EXTENDED RELEASE;ORAL						
	POTASSIUM CHLORIDE						
	@ PADAGIS US	8MEQ	A200185	001	May 18, 2011	Mar	DISC
	@	10MEQ	A200185	002	May 18, 2011	Mar	DISC
	FOR SOLUTION;ORAL						
	POKONZA						
	+ GENUS	15MEQ	N208019	004	Nov 12, 2025	Apr	NEWA
	POTASSIUM CHLORIDE						
	@ + GENUS	40MEQ	N208019	003	Aug 25, 2023	Jun	DISC
	INJECTABLE;INJECTION						
	POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER						
	@ + BAXTER HLTHCARE	2.24GM/100ML	N019904	003	Dec 26, 1989	Mar	DISC
	SOLUTION;ORAL						
	POTASSIUM CHLORIDE						
	@ APOTEX	20MEQ/15ML	A211067	001	Aug 08, 2018	May	DISC
	@	40MEQ/15ML	A211067	002	Aug 08, 2018	May	DISC
	@ STRIDES PHARMA	20MEQ/15ML	A211665	002	Jan 16, 2024	Jun	DISC
	POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC						
	SOLUTION;INTRAVENOUS						
	POTASSIUM PHOSPHATES						
AP	CAPLIN	1.18GM/5ML (236MG/ML);1.12GM/5ML	A220373	001	Mar 12, 2026	Mar	NEWA
AP		3.54GM/15ML (236MG/ML);3.36GM/15ML	A220373	002	Mar 12, 2026	Mar	NEWA
AP		11.8GM/50ML (236MG/ML);11.2GM/50ML	A220373	003	Mar 12, 2026	Mar	NEWA

PRALIDOXIME CHLORIDE

INJECTABLE;INJECTION

PROTOPAM CHLORIDE

	@	BAXTER HLTHCARE CORP	300MG/ML	N018799	001	Dec 13, 1982	Jun CTNA

PRASUGREL HYDROCHLORIDE

TABLET;ORAL

PRASUGREL

	@	SENORES PHARMS	EQ 5MG BASE	A205926	001	Jul 07, 2020	Jan CAHN
	@		EQ 10MG BASE	A205926	002	Jul 07, 2020	Jan CAHN

PRAVASTATIN SODIUM

TABLET;ORAL

PRAVASTATIN SODIUM

AB		SENORES PHARMS	10MG	A077491	002	Oct 23, 2006	Feb CAHN
AB			20MG	A077491	003	Oct 23, 2006	Feb CAHN
>A>			30MG	A077491	005	Aug 06, 2026	Jul NEWA
AB			40MG	A077491	004	Oct 23, 2006	Feb CAHN
>A>			60MG	A077491	006	Aug 06, 2026	Jul NFTG
AB			80MG	A077491	001	Feb 11, 2008	Feb CAHN

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION;ORAL

PEDIAPRED

AA	+!	PAI HOLDINGS	EQ 5MG BASE/5ML	N019157	001	May 28, 1986	Apr CAHN

SOLUTION/DROPS;OPHTHALMIC

PREDNISOLONE SODIUM PHOSPHATE

	!	BAUSCH AND LOMB INC	EQ 0.9% PHOSPHATE	A040070	001	Jul 29, 1994	May CAHN

PREDNISONE

TABLET, DELAYED RELEASE;ORAL

PREDNISONE

		DR REDDYS	1MG	A219477	001	Oct 01, 2025	Jun CHRS
	!		5MG	A218035	001	Jun 26, 2026	Jun NEWA

PREGABALIN

CAPSULE;ORAL

PREGABALIN

AB		FOURRTS LABS	25MG	A218529	001	Feb 24, 2026	Feb NEWA
AB			50MG	A218529	002	Feb 24, 2026	Feb NEWA
AB			75MG	A218529	003	Feb 24, 2026	Feb NEWA
AB			100MG	A218529	004	Feb 24, 2026	Feb NEWA
AB			150MG	A218529	005	Feb 24, 2026	Feb NEWA
AB			200MG	A218529	006	Feb 24, 2026	Feb NEWA
AB			225MG	A218529	007	Feb 24, 2026	Feb NEWA
AB			300MG	A218529	008	Feb 24, 2026	Feb NEWA
AB		RENATA	50MG	A210585	001	Dec 26, 2019	Feb CAHN
AB			75MG	A210585	002	Dec 26, 2019	Feb CAHN
AB			100MG	A210585	003	Dec 26, 2019	Feb CAHN
AB			150MG	A210585	004	Dec 26, 2019	Feb CAHN
AB			200MG	A210585	005	Dec 26, 2019	Feb CAHN
AB			300MG	A210585	006	Dec 26, 2019	Feb CAHN
	@	STRIDES PHARMA	25MG	A215755	001	Apr 26, 2023	Jun DISC
	@		50MG	A215755	002	Apr 26, 2023	Jun DISC
	@		75MG	A215755	003	Apr 26, 2023	Jun DISC
	@		100MG	A215755	004	Apr 26, 2023	Jun DISC
	@		150MG	A215755	005	Apr 26, 2023	Jun DISC
	@		200MG	A215755	006	Apr 26, 2023	Jun DISC
	@		225MG	A215755	007	Apr 26, 2023	Jun DISC
	@		300MG	A215755	008	Apr 26, 2023	Jun DISC
AB		UNICHEM	25MG	A219593	001	Apr 30, 2026	Apr NEWA
AB			50MG	A219593	002	Apr 30, 2026	Apr NEWA
AB			75MG	A219593	003	Apr 30, 2026	Apr NEWA
AB			100MG	A219593	004	Apr 30, 2026	Apr NEWA
AB			150MG	A219593	005	Apr 30, 2026	Apr NEWA
AB			200MG	A219593	006	Apr 30, 2026	Apr NEWA
AB			225MG	A219593	007	Apr 30, 2026	Apr NEWA
AB			300MG	A219593	008	Apr 30, 2026	Apr NEWA

SOLUTION;ORAL

PREGABALIN

AA		PATRIN	20MG/ML	A212604	001	Feb 18, 2022	Mar CAHN

TABLET, EXTENDED RELEASE;ORAL
PREGABALIN

AB		AIPING PHARM INC	165MG	A217857	002	Jun 24, 2026	Jun NEWA

PRIMAQUINE PHOSPHATE

TABLET;ORAL
PRIMAQUINE PHOSPHATE

AB		INGENUS PHARMS LLC	EQ 15MG BASE	A206043	001	Jun 23, 2016	Feb CAHN

PRIMIDONE

TABLET;ORAL
PRIMIDONE

AB		CARNEGIE	50MG	A218366	001	Jan 23, 2024	Feb CAHN
AB			250MG	A218366	002	Jan 23, 2024	Feb CAHN

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE;INJECTION
PROCAINAMIDE HYDROCHLORIDE

AP	!	GLAND	100MG/ML	A218135	001	Jul 22, 2024	Jan CHRS
AP	!		500MG/ML	A218135	002	Jul 22, 2024	Jan CHRS
AP		HOSPIRA	100MG/ML	A089069	001	Feb 12, 1986	Jan CHRS
	@		500MG/ML	A089070	001	Feb 12, 1986	Jan DISC

PROCHLORPERAZINE

SUPPOSITORY;RECTAL
PROCHLORPERAZINE

AB	!	COSETTE PHARMS NC	25MG	A040058	001	Nov 24, 1993	May CAHN

PROCHLORPERAZINE EDISYLATE

INJECTABLE;INJECTION
PROCHLORPERAZINE EDISYLATE

	@	AMNEAL	EQ 5MG BASE/ML	A214192	001	Nov 28, 2022	Feb DISC

PROGESTERONE

GEL;VAGINAL
CRINONE

	@ +	ABBVIE	4%	N020701	001	Jul 31, 1997	Apr DISC

INJECTABLE;INJECTION
PROGESTERONE

>D>	@	ACCORD HLTHCARE	50MG/ML	A217707	001	Nov 21, 2023	Jul CMFD
>A> AO			50MG/ML	A217707	001	Nov 21, 2023	Jul CMFD

INSERT;VAGINAL
PROGESTERONE

AB		GLENMARK PHARMS	100MG	A216363	001	Apr 08, 2026	Apr CAHN
AB		GLENMARK PHARMS LTD	100MG	A216363	001	Apr 08, 2026	Mar NEWA

PROMETHAZINE HYDROCHLORIDE

SUPPOSITORY;RECTAL
PHENERGAN

	@ +	PHARMOBEDIENT	12.5MG	N010926	002		May CAHN
	@ +		25MG	N010926	001		May CAHN

PROMETHAZINE HYDROCHLORIDE

AB		COSETTE PHARMS NC	12.5MG	A040428	002	Mar 31, 2003	May CAHN
AB	!		25MG	A040428	001	Feb 05, 2002	May CAHN

PROMETHEGAN

	!	COSETTE PHARMS NC	50MG	A087165	001	Aug 14, 1987	May CAHN

SYRUP;ORAL
PROMETHAZINE HYDROCHLORIDE

AA		COSETTE PHARMS NC	6.25MG/5ML	A091675	001	Jun 28, 2012	May CAHN

PROPAFENONE HYDROCHLORIDE

TABLET;ORAL
PROPAFENONE HYDROCHLORIDE

>D> AB		WATSON LABS	150MG	A075203	001	Oct 24, 2000	Jul DISC
>A>	@		150MG	A075203	001	Oct 24, 2000	Jul DISC
>D> AB			225MG	A075203	002	Oct 24, 2000	Jul DISC
>A>	@		225MG	A075203	002	Oct 24, 2000	Jul DISC

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

PROPARACAINE HYDROCHLORIDE

AT	!	BAUSCH AND LOMB INC	0.5%	A040074	001	Sep 29, 1995	May	CAHN

PROPOFOL

INJECTABLE;INJECTION

PROPOFOL

>A> AB		ANTHEA PHARMA	10MG/ML	A220857	001	Jul 14, 2026	Jul	NEWA
AB		EMERGE BIOSCIENCE	10MG/ML	A217945	001	Dec 02, 2025	May	CAHN

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

PROPRANOLOL HYDROCHLORIDE

	@	CHARTWELL RX	60MG	A078022	001	Feb 15, 2007	May	CAHN
	@		80MG	A078022	002	Feb 15, 2007	May	CAHN
	@		120MG	A078022	003	Feb 15, 2007	May	CAHN
	@		160MG	A078022	004	Feb 15, 2007	May	CAHN
AB		IPCA LABS LTD	60MG	A203103	001	May 01, 2026	Apr	NEWA
AB			80MG	A203103	002	May 01, 2026	Apr	NEWA
AB			120MG	A203103	003	May 01, 2026	Apr	NEWA
AB			160MG	A203103	004	May 01, 2026	Apr	NEWA
AB		MICRO LABS	60MG	A217238	001	Jun 24, 2026	Jun	NEWA
AB			80MG	A217238	002	Jun 24, 2026	Jun	NEWA
AB			120MG	A217238	003	Jun 24, 2026	Jun	NEWA
AB			160MG	A217238	004	Jun 24, 2026	Jun	NEWA

INJECTABLE;INJECTION

PROPRANOLOL HYDROCHLORIDE

	@	ALLIED	1MG/ML	A076400	001	Feb 26, 2003	Apr	CAHN

SOLUTION;ORAL

HEMANGEOL

	+!	ETON	4.28MG/ML	N205410	001	Mar 14, 2014	Mar	CAHN

PROPRANOLOL HYDROCHLORIDE

AA	!	HIKMA	20MG/5ML	A070690	002	May 15, 1987	May	CTEC
	!		20MG/5ML	A070690	002	May 15, 1987	Feb	CMS1
AA		PAI HOLDINGS	20MG/5ML	A219165	001	Jun 10, 2026	May	NEWA

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE

AB		MANKIND PHARMA	10MG	A216663	001	Jan 27, 2026	Jan	NEWA
AB			20MG	A216663	002	Jan 27, 2026	Jan	NEWA
AB			40MG	A216663	003	Jan 27, 2026	Jan	NEWA
AB			60MG	A216663	004	Jan 27, 2026	Jan	NEWA
AB			80MG	A216663	005	Jan 27, 2026	Jan	NEWA

PRUCALOPRIDE SUCCINATE

TABLET;ORAL

PRUCALOPRIDE SUCCINATE

AB		AJANTA PHARMA LTD	EQ 1MG BASE	A219220	001	Jan 16, 2026	Jan	NEWA
AB			EQ 2MG BASE	A219220	002	Jan 16, 2026	Jan	NEWA
>A> AB		ALEMBIC	EQ 1MG BASE	A219234	001	Jul 27, 2026	Jul	NEWA
>A> AB			EQ 2MG BASE	A219234	002	Jul 27, 2026	Jul	NEWA
AB		MICRO LABS	EQ 1MG BASE	A219180	001	Jun 29, 2026	Jun	NEWA
AB			EQ 2MG BASE	A219180	002	Jun 29, 2026	Jun	NEWA
AB		TEVA PHARMS INC	EQ 1MG BASE	A219071	001	Feb 05, 2026	Jan	NEWA
AB			EQ 2MG BASE	A219071	002	Feb 05, 2026	Jan	NEWA

PYRIDOSTIGMINE BROMIDE

TABLET, EXTENDED RELEASE;ORAL

PYRIDOSTIGMINE BROMIDE

	@	IMPAX LABS INC	180MG	A203184	001	Sep 15, 2015	Jan	DISC

QUETIAPINE FUMARATE

TABLET;ORAL

QUETIAPINE FUMARATE

	@	SUN PHARM	EQ 25MG BASE	A201190	001	Mar 27, 2012	Apr	DISC
	@		EQ 400MG BASE	A201190	006	Mar 27, 2012	Apr	DISC

TABLET, EXTENDED RELEASE;ORAL

QUETIAPINE FUMARATE

AB		PLATINUM	EQ 50MG BASE	A202939	001	May 09, 2017	Apr	CAHN
AB			EQ 150MG BASE	A202939	002	May 09, 2017	Apr	CAHN
AB			EQ 200MG BASE	A202939	003	May 09, 2017	Apr	CAHN

TABLET, EXTENDED RELEASE;ORAL
QUETIAPINE FUMARATE

	AB			EQ 300MG BASE	A202939	004	May 09, 2017	Apr CAHN
	AB			EQ 400MG BASE	A202939	005	May 09, 2017	Apr CAHN

QUINIDINE SULFATE

TABLET, EXTENDED RELEASE;ORAL
QUINIDINE SULFATE

		@	COSETTE PHARMS NC	300MG	A040045	001	Jun 30, 1994	Jun CAHN

QUININE SULFATE

CAPSULE;ORAL
QUININE SULFATE

	AB	!	INGENUS PHARMS LLC	324MG	A204372	001	Jul 22, 2015	May CAHN

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE;ORAL
RABEPRAZOLE SODIUM

>D>	AB		AUROBINDO PHARMA USA	20MG	A205761	001	Feb 17, 2017	Jul CAHN
	AB			20MG	A205761	001	Feb 17, 2017	Jan CAHN
>A>	AB		QUAGEN	20MG	A205761	001	Feb 17, 2017	Jul CAHN

RAMELTEON

TABLET;ORAL
RAMELTEON

	AB		AUROBINDO PHARMA LTD	8MG	A215972	001	Jul 10, 2023	Feb CTEC
	AB		HIBROW HLTHCARE	8MG	A215485	001	Jun 04, 2026	May NEWA
	AB		XIROMED	8MG	A216209	001	Nov 25, 2022	Mar CTEC

RAMIPRIL

CAPSULE;ORAL
RAMIPRIL

	AB		SENORES PHARMS	1.25MG	A078191	001	Jun 18, 2008	Jan CAHN
	AB			2.5MG	A078191	002	Jun 18, 2008	Jan CAHN
	AB			5MG	A078191	003	Jun 18, 2008	Jan CAHN
	AB			10MG	A078191	004	Jun 18, 2008	Jan CAHN

SOLUTION;ORAL
VOSTALLY

		@ +	ROSEMONT PHARMS	1MG/ML	N219757	001	Jul 23, 2025	Apr DISC
		+!		1MG/ML	N219757	001	Jul 23, 2025	Feb CAHN

RANITIDINE HYDROCHLORIDE

CAPSULE;ORAL
RANITIDINE HYDROCHLORIDE

		@	RISING	EQ 150MG BASE	A075564	001	Oct 27, 2000	Mar CAHN
		@		EQ 300MG BASE	A075564	002	Oct 27, 2000	Mar CAHN

RANOLAZINE

GRANULE, EXTENDED RELEASE;ORAL
ASPRUZYO SPRINKLE

		@ +	SPIL	500MG	N216018	001	Feb 28, 2022	Apr CDFR
		@ +		1GM	N216018	002	Feb 28, 2022	Apr CDFR

TABLET, EXTENDED RELEASE;ORAL
RANOLAZINE

		@	ACTAVIS ELIZABETH	500MG	A208862	001	May 28, 2019	Jun DISC
		@		1GM	A208862	002	May 28, 2019	Jun DISC
	AB		PIRAMAL	500MG	A213085	001	Jul 25, 2023	Feb CMFD
	AB			1GM	A213085	002	Jul 25, 2023	Feb CMFD
>A>	AB		UMEDICA	500MG	A214551	001	Aug 05, 2026	Jul NEWA
>A>	AB			1GM	A214551	002	Aug 05, 2026	Jul NEWA

REGADENOSON

SOLUTION;INTRAVENOUS
REGADENOSON

		@	GE HEALTHCARE	0.4MG/5ML (0.08MG/ML)	A215955	001	Aug 05, 2024	Feb DISC
>D>	AP		MYLAN	0.4MG/5ML (0.08MG/ML)	A213856	001	Apr 04, 2023	Jul DISC
>A>		@		0.4MG/5ML (0.08MG/ML)	A213856	001	Apr 04, 2023	Jul DISC

RELACORILANT

CAPSULE;ORAL

LIFYORLI (COPACKAGED)

		+!	CORCEPT THERAP	100MG;25MG	N220641	001	Mar 25, 2026	Mar NEWA

REPAGLINIDE

TABLET;ORAL

REPAGLINIDE

		@	PADAGIS US	0.5MG	A201189	001	Jul 17, 2013	Mar DISC
		@		1MG	A201189	002	Jan 22, 2014	Mar DISC
		@		2MG	A201189	003	Jan 22, 2014	Mar DISC

RIBAVIRIN

FOR SOLUTION;INHALATION

RIBAVIRIN

>A>		@	CHARTWELL RX	6GM/VIAL	A207366	001	Oct 06, 2016	Jul CAHN
>D>		@	NAVINTA LLC	6GM/VIAL	A207366	001	Oct 06, 2016	Jul CAHN
		@		6GM/VIAL	A207366	001	Oct 06, 2016	Mar DISC

RIFABUTIN

CAPSULE;ORAL

RIFABUTIN

	AB		I3 PHARMS	150MG	A212430	001	Mar 19, 2026	Mar NEWA

RIFAMPIN

CAPSULE;ORAL

RIFAMPIN

	AB		NOVITIUM PHARMA	150MG	A219918	001	Jun 29, 2026	Jun NEWA
	AB			300MG	A219918	002	Jun 29, 2026	Jun NEWA

RIFAPENTINE

TABLET;ORAL

PRIFTIN

	AB	+!	SANOFI AVENTIS US	150MG	N021024	001	Jun 22, 1998	Jun CFTG

RIFAPENTINE

	AB		MACLEODS PHARMS	150MG	A217042	001	Jun 23, 2026	Jun NFTG

RIFAXIMIN

TABLET;ORAL

RIFAXIMIN

	AB		ACTAVIS LABS FL INC	550MG	A208959	001	Mar 19, 2026	Mar NFTG

XIFAXAN

	AB	+!	SALIX PHARMS	550MG	N021361	002	Mar 24, 2010	Mar CFTG

RILPIVIRINE HYDROCHLORIDE

TABLET;ORAL

EDURANT

	AB	+!	JANSSEN PRODS	EQ 25MG BASE	N202022	001	May 20, 2011	Jan CFTG

RILPIVIRINE HYDROCHLORIDE

>A>	AB		LAURUS	EQ 25MG BASE	A219788	001	Jul 10, 2026	Jul NEWA
	AB		SOMERSET THERAPS LLC	EQ 25MG BASE	A218798	001	Jan 29, 2026	Jan NFTG

RILUZOLE

TABLET;ORAL

RILUTEK

>D>		@ +	AZURITY	50MG	N020599	001	Dec 12, 1995	Jul CAHN
>A>		@ +		50MG	N020599	001	Dec 12, 1995	Jul CAHN
		@ +		50MG	N020599	001	Dec 12, 1995	Mar CAHN

RISPERIDONE

FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

RYKINDO

		@ +	SHANDONG LUYE	37.5MG	N212849	003	Jan 13, 2023	Jun DISC
		@ +		50MG	N212849	004	Jan 13, 2023	Jun DISC

FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

PERSERIS KIT

		@ +	INDIVIOR	90MG	N210655	001	Jul 27, 2018	Jun DISC
		@ +		120MG	N210655	002	Jul 27, 2018	Jun DISC

	POWDER;INTRAMUSCULAR						
	RISPERDAL CONSTA						
AB	+! JANSSEN PHARMS	12.5MG/VIAL	N021346	004	Apr 12, 2007	Jan	CHRS
AB	+	12.5MG/VIAL	N021346	004	Apr 12, 2007	Jan	CDFR
AB	+!	25MG/VIAL	N021346	001	Oct 29, 2003	Jan	CDFR
AB	+!	37.5MG/VIAL	N021346	002	Oct 29, 2003	Jan	CHRS
AB	+	37.5MG/VIAL	N021346	002	Oct 29, 2003	Jan	CDFR
AB	+!	50MG/VIAL	N021346	003	Oct 29, 2003	Jan	CHRS
AB	+	50MG/VIAL	N021346	003	Oct 29, 2003	Jan	CDFR
	RISPERIDONE						
AB	AMNEAL	12.5MG/VIAL	A218586	001	Sep 02, 2025	Jan	CDFR
AB		25MG/VIAL	A218586	002	Sep 02, 2025	Jan	CDFR
AB		37.5MG/VIAL	A218586	003	Sep 02, 2025	Jan	CDFR
AB		50MG/VIAL	A218586	004	Sep 02, 2025	Jan	CDFR
AB	NANOMI	25MG/VIAL	A211220	001	Sep 02, 2025	Jan	CDFR
AB		37.5MG/VIAL	A211220	002	Sep 02, 2025	Jan	CDFR
AB		50MG/VIAL	A211220	003	Sep 02, 2025	Jan	CDFR
AB	TEVA PHARMS USA INC	12.5MG/VIAL	A214068	001	Dec 05, 2023	Jan	CDFR
AB		25MG/VIAL	A214068	002	Dec 05, 2023	Jan	CDFR
AB		37.5MG/VIAL	A214068	003	Dec 05, 2023	Jan	CDFR
AB		50MG/VIAL	A214068	004	Dec 05, 2023	Jan	CDFR
	TABLET;ORAL						
	RISPERIDONE						
	@ NATCO PHARMA USA	0.25MG	A076288	001	Sep 15, 2008	Mar	CAHN
	@	0.5MG	A076288	002	Sep 15, 2008	Mar	CAHN
	@	1MG	A076288	003	Sep 15, 2008	Mar	CAHN
	@	2MG	A076288	004	Sep 15, 2008	Mar	CAHN
	@	3MG	A076288	005	Sep 15, 2008	Mar	CAHN
	@	4MG	A076288	006	Sep 15, 2008	Mar	CAHN
	TABLET, ORALLY DISINTEGRATING;ORAL						
	RISPERIDONE						
	@ NATCO PHARMA USA	0.25MG	A091537	006	Feb 12, 2013	Mar	CAHN
	@	0.5MG	A091537	001	Mar 30, 2011	Mar	CAHN
	@	1MG	A091537	002	Mar 30, 2011	Mar	CAHN
	@	2MG	A091537	003	Mar 30, 2011	Mar	CAHN
	@	3MG	A091537	004	Mar 30, 2011	Mar	CAHN
	@	4MG	A091537	005	Mar 30, 2011	Mar	CAHN
	RITONAVIR						
	TABLET;ORAL						
	NORVIR						
AB	+ ABBVIE	100MG	N022417	001	Feb 10, 2010	Jan	CHRS
	RITONAVIR						
	@ AMNEAL	100MG	A208890	001	Sep 17, 2018	Mar	DISC
AB	! AUROBINDO PHARMA LTD	100MG	A206614	001	Sep 17, 2018	Jan	CHRS
	RIVAROXABAN						
	FOR SUSPENSION;ORAL						
	RIVAROXABAN						
AB	APOTEX	1MG/ML	A218427	001	Mar 02, 2026	Feb	NEWA
	TABLET;ORAL						
	RIVAROXABAN						
	@ APOTEX	10MG	A208579	001	Nov 14, 2025	Apr	DISC
	@	15MG	A208579	002	Nov 14, 2025	Apr	DISC
	@	20MG	A208579	003	Nov 14, 2025	Apr	DISC
BX	BIOCON PHARMA	2.5MG	A218107	001	May 14, 2025	Feb	CTEC
BX		10MG	A218107	002	May 14, 2025	Feb	CTEC
BX		15MG	A218107	003	May 14, 2025	Feb	CTEC
BX		20MG	A218107	004	May 14, 2025	Feb	CTEC
AB	INVAGEN PHARMS	2.5MG	A218768	001	Feb 20, 2026	Feb	NEWA
AB	MANKIND PHARMA	2.5MG	A220874	001	Jul 01, 2026	Jun	NEWA
AB		10MG	A220874	002	Jul 01, 2026	Jun	NEWA
AB		15MG	A220874	003	Jul 01, 2026	Jun	NEWA
AB		20MG	A220874	004	Jul 01, 2026	Jun	NEWA
AB	MICRO LABS	2.5MG	A208334	001	Jun 30, 2026	Jun	NEWA
AB		10MG	A208334	002	Jun 30, 2026	Jun	NEWA
AB		15MG	A208334	003	Jun 30, 2026	Jun	NEWA
AB		20MG	A208334	004	Jun 30, 2026	Jun	NEWA

>D>		RIZATRIPTAN BENZOATE						
>D>		FILM;ORAL						
>D>		RIZAFILM						
>D>		+! GENSCO	EQ 5MG BASE	N205394	002	Feb 26, 2026	Jul DISC	
>A>		@ +	EQ 5MG BASE	N205394	002	Feb 26, 2026	Jul DISC	
		+!	EQ 5MG BASE	N205394	002	Feb 26, 2026	Feb NEWA	
		TABLET;ORAL						
		RIZATRIPTAN BENZOATE						
		@ PHARMOBEDIENT	EQ 5MG BASE	A201993	001	Dec 31, 2012	Feb DISC	
		@	EQ 10MG BASE	A201993	002	Dec 31, 2012	Feb DISC	
		ROCURONIUM BROMIDE						
		INJECTABLE;INJECTION						
		ROCURONIUM BROMIDE						
	AP	ASPIRO	50MG/5ML (10MG/ML)	A220124	001	Mar 04, 2026	Feb NEWA	
	AP		100MG/10ML (10MG/ML)	A220124	002	Mar 04, 2026	Feb NEWA	
		@ KNACK	50MG/5ML (10MG/ML)	A213476	001	Jan 06, 2026	May DISC	
		@	100MG/10ML (10MG/ML)	A213476	002	Jan 06, 2026	May DISC	
		ROFLUMILAST						
		TABLET;ORAL						
		ROFLUMILAST						
		@ PHARMOBEDIENT	500MCG	A208257	001	Jul 13, 2018	Feb DISC	
	AB	SENORES PHARMS	250MCG	A208236	002	Oct 19, 2023	Feb CMFD	
	AB		500MCG	A208236	001	Oct 03, 2018	Feb CMFD	
		ROMIDEPSIN						
		SOLUTION;INTRAVENOUS						
		ROMIDEPSIN						
		! AMNEAL	27.5MG/5.5ML (5MG/ML)	A219099	001	Jun 02, 2026	May NFTG	
		ROPINIROLE HYDROCHLORIDE						
		TABLET;ORAL						
		ROPINIROLE HYDROCHLORIDE						
		@ COSETTE PHARMS NC	EQ 0.25MG BASE	A077460	001	May 05, 2008	Jun CAHN	
		@	EQ 0.5MG BASE	A077460	002	May 05, 2008	Jun CAHN	
		@	EQ 1MG BASE	A077460	003	May 05, 2008	Jun CAHN	
		@	EQ 2MG BASE	A077460	004	May 05, 2008	Jun CAHN	
		@	EQ 3MG BASE	A077460	005	May 05, 2008	Jun CAHN	
		@	EQ 4MG BASE	A077460	006	May 05, 2008	Jun CAHN	
		@	EQ 5MG BASE	A077460	007	May 19, 2008	Jun CAHN	
		ROSUVASTATIN CALCIUM						
		TABLET;ORAL						
		ROSUVASTATIN CALCIUM						
		@ ANVI	EQ 5MG BASE	A079161	001	Jul 19, 2016	Mar CAHN	
		@	EQ 10MG BASE	A079161	002	Jul 19, 2016	Mar CAHN	
		@	EQ 20MG BASE	A079161	003	Jul 19, 2016	Mar CAHN	
		@	EQ 40MG BASE	A079161	004	Jul 19, 2016	Mar CAHN	
		@ STRIDES PHARMA INTL	EQ 5MG BASE	A079161	001	Jul 19, 2016	Jun CAHN	
		@	EQ 10MG BASE	A079161	002	Jul 19, 2016	Jun CAHN	
		@	EQ 20MG BASE	A079161	003	Jul 19, 2016	Jun CAHN	
		@	EQ 40MG BASE	A079161	004	Jul 19, 2016	Jun CAHN	
	AB	SUNSHINE	EQ 5MG BASE	A210667	001	Apr 01, 2020	Jun CMFD	
	AB		EQ 10MG BASE	A210667	002	Apr 01, 2020	Jun CMFD	
	AB		EQ 20MG BASE	A210667	003	Apr 01, 2020	Jun CMFD	
	AB		EQ 40MG BASE	A210667	004	Apr 01, 2020	Jun CMFD	
		RUFINAMIDE						
		TABLET;ORAL						
		RUFINAMIDE						
>D>	AB	ALLIED	200MG	A205095	001	May 16, 2016	Jul CAHN	
	AB		200MG	A205095	001	May 16, 2016	Jun CAHN	
>D>	AB		400MG	A205095	002	May 16, 2016	Jul CAHN	
	AB		400MG	A205095	002	May 16, 2016	Jun CAHN	
>A>	AB	SCIEGEN PHARMS	200MG	A205095	001	May 16, 2016	Jul CAHN	
>A>	AB		400MG	A205095	002	May 16, 2016	Jul CAHN	

RUXOLITINIB PHOSPHATE

TABLET, EXTENDED RELEASE;ORAL

JAKAFI XR

	+	INCYTE CORP	EQ 11MG BASE	N217180	001	May 01, 2026	May NEWA
	+		EQ 22MG BASE	N217180	002	May 01, 2026	May NEWA
	+		EQ 33MG BASE	N217180	003	May 01, 2026	May NEWA
	+		EQ 44MG BASE	N217180	004	May 01, 2026	May NEWA
	+!		EQ 55MG BASE	N217180	005	May 01, 2026	May NEWA

SACUBITRIL; VALSARTAN

TABLET;ORAL

SACUBITRIL AND VALSARTAN

AB	SOMERSET THERAPS LLC	24MG;26MG	A219983	001	Jan 20, 2026	Jan NEWA
AB		49MG;51MG	A219983	002	Jan 20, 2026	Jan NEWA
AB		97MG;103MG	A219983	003	Jan 20, 2026	Jan NEWA
>A> AB	UMEDICA	24MG;26MG	A219946	001	Aug 04, 2026	Jul NEWA
>A> AB		49MG;51MG	A219946	002	Aug 04, 2026	Jul NEWA
>A> AB		97MG;103MG	A219946	003	Aug 04, 2026	Jul NEWA

SAPROPTERIN DIHYDROCHLORIDE

FOR SOLUTION;ORAL

KUVAN

AB	+!	BIOMARIN PHARM	100MG/PACKET	N205065	001	Dec 19, 2013	Jun CDFR
AB	+!		500MG/PACKET	N205065	002	Oct 27, 2015	Jun CDFR

SAPROPTERIN DIHYDROCHLORIDE

AB	ANNORA PHARMA	100MG/PACKET	A215420	001	Aug 18, 2022	Jun CDFR
AB		500MG/PACKET	A215420	002	Aug 18, 2022	Jun CDFR
AB	DR REDDYS	100MG/PACKET	A209452	001	Mar 30, 2021	Jun CDFR
AB		500MG/PACKET	A215798	001	May 13, 2022	Jun CDFR
AB	MICRO LABS	100MG/PACKET	A219511	001	Jan 08, 2026	Jun CDFR
AB		500MG/PACKET	A219511	002	Jan 08, 2026	Jun CDFR
AB	PH HEALTH	100MG/PACKET	A207207	001	Aug 20, 2019	Jun CDFR
AB		500MG/PACKET	A210027	001	Aug 20, 2019	Jun CDFR
AB	TP ANDA HOLDINGS	100MG/PACKET	A216432	001	Sep 03, 2025	Jun CDFR
AB		500MG/PACKET	A216432	002	Sep 03, 2025	Jun CDFR

ZELVYSIA

AB	AUCTA	100MG/PACKET	A218645	001	Apr 29, 2025	Jun CDFR
AB		500MG/PACKET	A218645	002	Apr 29, 2025	Jun CDFR

POWDER;ORAL

KUVAN

AB	+!	BIOMARIN PHARM	500MG/PACKET	N205065	002	Oct 27, 2015	Jan CHRS

SAPROPTERIN DIHYDROCHLORIDE

AB	MICRO LABS	100MG/PACKET	A219511	001	Jan 08, 2026	Jan NEWA
AB		500MG/PACKET	A219511	002	Jan 08, 2026	Jan NEWA

TABLET;ORAL

SAPROPTERIN DIHYDROCHLORIDE

AB	HIKMA	100MG	A218797	001	Jun 11, 2025	Jun CAHN

SELEGILINE HYDROCHLORIDE

TABLET;ORAL

SELEGILINE HYDROCHLORIDE

@	COSETTE PHARMS NC	5MG	A074744	001	Jan 27, 1997	Jun CAHN
@		5MG	A074756	001	Nov 25, 1998	Jun CAHN

SELENIOUS ACID

SOLUTION;INTRAVENOUS

SELENIOUS ACID

@	CIPLA	EQ 12MCG SELENIUM/2ML (EQ 6MCG SELENIUM/ML)	A218661	001	Jul 21, 2025	Jan DISC
@		EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A218661	002	Jul 21, 2025	Jan DISC
AP	KINDOS	EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A219472	001	Feb 03, 2026	Jan NEWA
AP	STIRA	EQ 60MCG SELENIUM/ML (EQ 60MCG SELENIUM/ML)	A218536	001	Dec 31, 2025	Apr CAHN
AP		EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A218536	002	Dec 31, 2025	Apr CAHN
AP	ZYDUS PHARMS	EQ 12MCG SELENIUM/2ML (EQ 6MCG SELENIUM/ML)	A219322	001	Jun 30, 2026	Jun NEWA
AP		EQ 60MCG SELENIUM/ML (EQ 60MCG SELENIUM/ML)	A219322	002	Jun 30, 2026	Jun NEWA
AP		EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A219322	003	Jun 30, 2026	Jun NEWA

SELENIUM SULFIDE

LOTION/SHAMPOO;TOPICAL

SELENIUM SULFIDE

@	COSETTE PHARMS NC	2.5%	A086209	001			Jun CAHN

SELEXIPAG

TABLET;ORAL

SELEXIPAG

AB		RK PHARMA	0.2MG	A214055	001	Apr 16, 2026	Apr NEWA
AB			0.4MG	A214055	002	Apr 16, 2026	Apr NEWA
AB			0.6MG	A214055	003	Apr 16, 2026	Apr NEWA
AB			0.8MG	A214055	004	Apr 16, 2026	Apr NEWA
AB			1MG	A214055	005	Apr 16, 2026	Apr NEWA
AB			1.2MG	A214055	006	Apr 16, 2026	Apr NEWA
AB			1.4MG	A214055	007	Apr 16, 2026	Apr NEWA
AB			1.6MG	A214055	008	Apr 16, 2026	Apr NEWA

UPTRAVI

	+	ACTELION	0.1MG	N207947	010	May 23, 2026	Jun NEWA
	+		0.15MG	N207947	011	May 23, 2026	Jun NEWA
AB	+		1MG	N207947	005	Dec 21, 2015	Apr CTEC
AB	+		1.2MG	N207947	006	Dec 21, 2015	Apr CTEC

SELUMETINIB SULFATE

GRANULE;ORAL

KOSELUGO

	+!	ASTRAZENECA	EQ 5MG BASE	N219943	001	Sep 10, 2025	May CHRS
	+		EQ 7.5MG BASE	N219943	002	Sep 10, 2025	May CHRS

SEMAGLUTIDE

SOLUTION;SUBCUTANEOUS

OZEMPIC

	+!	NOVO	0.25MG/0.5ML (0.25MG/0.5ML)	N209637	005	May 05, 2026	May NEWA
	+!		0.5MG/0.5ML (0.5MG/0.5ML)	N209637	006	May 05, 2026	May NEWA
	+!		1MG/0.5ML (1MG/0.5ML)	N209637	007	May 05, 2026	May NEWA

WEGOVY

	+!	NOVO	0.25MG/0.5ML (0.25MG/0.5ML)	N215256	007	May 05, 2026	May NEWA
	+!		0.5MG/0.5ML (0.5MG/0.5ML)	N215256	008	May 05, 2026	May NEWA
	+!		1MG/0.5ML (1MG/0.5ML)	N215256	009	May 05, 2026	May NEWA
	+!		1.7MG/0.75ML (1.7MG/0.75ML)	N215256	010	May 05, 2026	May NEWA
	+!		2.4MG/0.75ML (2.4MG/0.75ML)	N215256	011	May 05, 2026	May NEWA

WEGOVY FLEXTOUCH

	+!	NOVO	9.6MG/3ML (3.2MG/ML)	N215256	012	Jun 18, 2026	Jun NEWA

WEGOVY HD

	+!	NOVO	7.2MG/0.75ML (7.2MG/0.75ML)	N215256	006	Mar 19, 2026	Mar NEWA

TABLET;ORAL

OZEMPIC

	+!	NOVO	1.5MG	N213051	004	Dec 09, 2024	Mar CTNA
	+!		4MG	N213051	005	Dec 09, 2024	Mar CTNA
	+!		9MG	N213051	006	Dec 09, 2024	Mar CTNA

WEGOVY

	+!	NOVO	1.5MG	N218316	001	Dec 22, 2025	Mar CHRS
	+!		4MG	N218316	002	Dec 22, 2025	Mar CHRS
	+!		9MG	N218316	003	Dec 22, 2025	Mar CHRS

SERTRALINE HYDROCHLORIDE

CAPSULE;ORAL

SERTRALINE HYDROCHLORIDE

AB		AMNEAL	EQ 150MG BASE	A219655	001	Jan 28, 2026	Mar CAHN
AB			EQ 200MG BASE	A219655	002	Jan 28, 2026	Mar CAHN
AB		APPCO	EQ 150MG BASE	A218712	001	Jan 20, 2026	Jan NEWA
AB			EQ 200MG BASE	A218712	002	Jan 20, 2026	Jan NEWA
AB		NOVITIUM PHARMA	EQ 150MG BASE	A219714	001	Jan 20, 2026	Jan NEWA
AB			EQ 200MG BASE	A219714	002	Jan 20, 2026	Jan NEWA
AB		SKG PHARMA	EQ 150MG BASE	A219655	001	Jan 28, 2026	Jan NEWA
AB			EQ 200MG BASE	A219655	002	Jan 28, 2026	Jan NEWA
AB		UMEDICA	EQ 150MG BASE	A218342	001	Jan 20, 2026	Jan NEWA
AB			EQ 200MG BASE	A218342	002	Jan 20, 2026	Jan NEWA
AB		ZYDUS LIFESCIENCES	EQ 150MG BASE	A220275	001	Jan 29, 2026	Jan NEWA
AB			EQ 200MG BASE	A220275	002	Jan 29, 2026	Jan NEWA

TABLET;ORAL
SERTRALINE HYDROCHLORIDE

	@	APPCO	EQ 25MG BASE	A077713	001	Feb 06, 2007	Jan	CAHN
	@		EQ 50MG BASE	A077713	002	Feb 06, 2007	Jan	CAHN
	@		EQ 100MG BASE	A077713	003	Feb 06, 2007	Jan	CAHN
>A>	!	ASCENT PHARMS INC	EQ 75MG BASE	A214790	004	Aug 10, 2026	Jul	NFTG

SEVELAMER CARBONATE

FOR SUSPENSION;ORAL
RENVELA

	@ +	GENZYME	800MG/PACKET	N022318	001	Aug 12, 2009	Jun	DISC
	@ +		2.4GM/PACKET	N022318	002	Feb 18, 2009	Jun	DISC

SEVELAMER CARBONATE

AB	!	STRIDES PHARMA INTL	2.4GM/PACKET	A211917	002	Sep 08, 2023	Jun	CHRS

TABLET;ORAL
RENVELA

	@ +	SANOFI	800MG	N022127	001	Oct 19, 2007	Jun	DISC

SEVELAMER CARBONATE

AB	!	AUROBINDO PHARMA	800MG	A207179	001	Jul 17, 2017	Jun	CHRS

SILDENAFIL CITRATE

FOR SUSPENSION;ORAL
REVATIO

	@ +	VIATRIS	EQ 10MG BASE/ML	N203109	001	Aug 30, 2012	Mar	DISC

SILDENAFIL CITRATE

AB	!	AUROBINDO PHARMA LTD	EQ 10MG BASE/ML	A214773	001	Dec 23, 2022	Mar	CHRS

TABLET;ORAL
SILDENAFIL CITRATE

	@	TEVA PHARMS	EQ 20MG BASE	A078380	001	Jan 07, 2013	Apr	DISC

SIPONIMOD

TABLET;ORAL
MAYZENT

	+	NOVARTIS	EQ 0.25MG BASE	N209884	001	Mar 26, 2019	Mar	CTEC
AB	+		EQ 0.25MG BASE	N209884	001	Mar 26, 2019	Feb	CTEC
	+		EQ 1MG BASE	N209884	003	Aug 24, 2021	Mar	CTEC
AB	+		EQ 1MG BASE	N209884	003	Aug 24, 2021	Feb	CTEC
	+!		EQ 2MG BASE	N209884	002	Mar 26, 2019	Mar	CTEC
AB	+!		EQ 2MG BASE	N209884	002	Mar 26, 2019	Feb	CTEC

SIPONIMOD

	@	AUROBINDO PHARMA LTD	EQ 0.25MG BASE	A218459	001	Mar 06, 2026	Mar	DISC
AB			EQ 0.25MG BASE	A218459	001	Mar 06, 2026	Feb	NEWA
	@		EQ 1MG BASE	A218459	002	Mar 06, 2026	Mar	DISC
AB			EQ 1MG BASE	A218459	002	Mar 06, 2026	Feb	NEWA
	@		EQ 2MG BASE	A218459	003	Mar 06, 2026	Mar	DISC
AB			EQ 2MG BASE	A218459	003	Mar 06, 2026	Feb	NEWA

SIROLIMUS

POWDER;INTRAVENOUS
FYARRO

	+!	AADI	100MG/VIAL	N213312	001	Nov 22, 2021	Apr	CAHN

SITAGLIPTIN PHOSPHATE

TABLET;ORAL
JANUVIA

AB	+	MSD	EQ 25MG BASE	N021995	001	Oct 16, 2006	May	CAHN
AB	+		EQ 50MG BASE	N021995	002	Oct 16, 2006	May	CAHN
AB	+!		EQ 100MG BASE	N021995	003	Oct 16, 2006	May	CAHN

SITAGLIPTIN PHOSPHATE

AB		APOTEX	EQ 25MG BASE	A202425	001	Jan 20, 2026	Jan	NEWA
AB			EQ 50MG BASE	A202425	002	Jan 20, 2026	Jan	NEWA
AB			EQ 100MG BASE	A202425	003	Jan 20, 2026	Jan	NEWA
AB		SANDOZ	EQ 25MG BASE	A202387	001	Jan 14, 2026	Jan	NEWA
AB			EQ 50MG BASE	A202387	002	Jan 14, 2026	Jan	NEWA
AB			EQ 100MG BASE	A202387	003	Jan 14, 2026	Jan	NEWA

SODIUM ACETATE

SOLUTION;INTRAVENOUS

SODIUM ACETATE

AP		AMNEAL	40MEQ/20ML (2MEQ/ML)	A218469	003	Mar 02, 2026	Feb NEWA
AP		EXTROVIS	100MEQ/50ML (2MEQ/ML)	A220274	001	Apr 17, 2026	Apr NEWA
AP			200MEQ/100ML (2MEQ/ML)	A220274	002	Apr 17, 2026	Apr NEWA

SODIUM BICARBONATE

SOLUTION;INTRAVENOUS

SODIUM BICARBONATE

AP		AMNEAL	50MEQ/50ML (1MEQ/ML)	A217523	001	Jan 13, 2026	Jan NEWA
>A>	+!		150MEQ/1000ML (0.15MEQ/ML)	N220790	001	Jul 09, 2026	Jul NEWA
AP		ASPIRO	5MEQ/10ML (0.5MEQ/ML)	A220788	001	Apr 15, 2026	Apr NEWA
AP			10MEQ/10ML (1MEQ/ML)	A220788	002	Apr 15, 2026	Apr NEWA
AP			50MEQ/50ML (1MEQ/ML)	A220788	003	Apr 15, 2026	Apr NEWA
AP		MILLA PHARMS	50MEQ/50ML (1MEQ/ML)	A219089	001	Jul 08, 2026	Jun NEWA

SODIUM FLUORIDE F-18

INJECTABLE;INTRAVENOUS

SODIUM FLUORIDE F-18

@		NUKEMED	10-200mCi/ML	A203912	001	Apr 22, 2015	Apr DISC

SODIUM GLYCEROPHOSPHATE

SOLUTION;INTRAVENOUS

>A>		GLYCOPHOS						
>A>	+!	FRESENIUS KABI USA	4.32GM/20ML (216MG/ML)	N220381	001	Jul 29, 2026	Jul NEWA
>A>	+!		21.6GM/100ML (216MG/ML)	N220381	002	Jul 29, 2026	Jul NEWA

SODIUM NITROPRUSSIDE

INJECTABLE;INJECTION

SODIUM NITROPRUSSIDE

>A>	AP	HAINAN POLY	25MG/ML	A214199	001	Aug 25, 2020	Jul CAHN
>D>	AP	SLATE RUN PHARMA	25MG/ML	A214199	001	Aug 25, 2020	Jul CAHN

SOLUTION;INTRAVENOUS

SODIUM NITROPRUSSIDE

>A>		HAINAN POLY	10MG/50ML (0.2MG/ML)	A215846	001	Aug 26, 2022	Jul CAHN
>A>	AP		20MG/100ML (0.2MG/ML)	A215846	002	Aug 26, 2022	Jul CAHN
>A>	AP		50MG/100ML (0.5MG/ML)	A215846	003	Aug 26, 2022	Jul CAHN
>D>		SLATE RUN PHARMA	10MG/50ML (0.2MG/ML)	A215846	001	Aug 26, 2022	Jul CAHN
>D>	AP		20MG/100ML (0.2MG/ML)	A215846	002	Aug 26, 2022	Jul CAHN
>D>	AP		50MG/100ML (0.5MG/ML)	A215846	003	Aug 26, 2022	Jul CAHN

SODIUM PHENYLBUTYRATE

POWDER;ORAL

BUPHENYL

@ +	HORIZON THERAP US	3GM/TEASPOONFUL	N020573	001	Apr 30, 1996	Jan DISC

SODIUM PHENYLBUTYRATE

	!	PH HEALTH	3GM/TEASPOONFUL	A203918	001	Jun 15, 2016	Jun CTEC
AB	!		3GM/TEASPOONFUL	A203918	001	Jun 15, 2016	Jan CHRS
@		SIGMAPHARM LABS LLC	3GM/TEASPOONFUL	A202819	001	Mar 22, 2013	Jun DISC

TABLET;ORAL

BUPHENYL

@ +	HORIZON THERAP US	500MG	N020572	001	May 13, 1996	Jan DISC

SODIUM PHENYLBUTYRATE

AB		NAVINTA LLC	500MG	A220418	001	Feb 17, 2026	Feb NEWA
AB	!	PH HEALTH	500MG	A204395	001	Apr 15, 2016	Jan CHRS

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

SOLUTION;INTRAVENOUS

SODIUM PHOSPHATES

AP		CAPLIN	1.34GM/5ML;1.38GM/5ML (268MG/ML; 276MG/ML)	A220683	001	Feb 23, 2026	Feb NEWA
AP			4.02GM/15ML;4.14GM/15ML (268MG/ML; 276MG/ML)	A220683	002	Feb 23, 2026	Feb NEWA
AP			13.4GM/50ML;13.8GM/50ML (268MG/ML; 276MG/ML)	A220683	003	Feb 23, 2026	Feb NEWA

SODIUM ZIRCONIUM CYCLOSILICATE

FOR SUSPENSION;ORAL

LOKELMA

>D>		+	ASTRAZENECA	5GM/PACKET	N207078	001	May 18, 2018	Jul	CFTG
>A>	AB	+		5GM/PACKET	N207078	001	May 18, 2018	Jul	CFTG
>D>		+!		10GM/PACKET	N207078	002	May 18, 2018	Jul	CFTG
>A>	AB	+!		10GM/PACKET	N207078	002	May 18, 2018	Jul	CFTG

SODIUM ZIRCONIUM CYCLOSILICATE

>A>	AB		LUPIN	5GM/PACKET	A217549	001	Aug 07, 2026	Jul	NFTG
>A>	AB			10GM/PACKET	A217549	002	Aug 07, 2026	Jul	NFTG

SOFOSBUVIR; VELPATASVIR

PELLETS;ORAL

EPCLUSA

>D>		+	GILEAD SCIENCES INC	150MG;37.5MG/PACKET	N214187	001	Jun 10, 2021	Jul	CPOT
>A>		+		150MG/PACKET;37.5MG/PACKET	N214187	001	Jun 10, 2021	Jul	CPOT
>D>		+!		200MG;50MG/PACKET	N214187	002	Jun 10, 2021	Jul	CPOT
>A>		+!		200MG/PACKET;50MG/PACKET	N214187	002	Jun 10, 2021	Jul	CPOT

SOLIFENACIN SUCCINATE

TABLET;ORAL

SOLIFENACIN SUCCINATE

	AB		SUNSHINE	5MG	A213346	001	Apr 13, 2020	May	CMFD
	AB			10MG	A213346	002	Apr 13, 2020	May	CMFD

SOLRIAMFETOL HYDROCHLORIDE

TABLET;ORAL

SOLRIAMFETOL HYDROCHLORIDE

	AB		ALKEM LABS LTD	EQ 75MG BASE	A218722	001	Jun 17, 2026	Jun	NFTG
	AB			EQ 150MG BASE	A218722	002	Jun 17, 2026	Jun	NFTG
	AB		HIKMA	EQ 75MG BASE	A218016	001	Jun 17, 2026	Jun	NFTG
	AB			EQ 150MG BASE	A218016	002	Jun 17, 2026	Jun	NFTG

SUNOSI

	AB	+	AXSOME MALTA	EQ 75MG BASE	N211230	001	Jun 17, 2019	Jun	CFTG
	AB	+!		EQ 150MG BASE	N211230	002	Jun 17, 2019	Jun	CFTG

SONROTOCLAX

TABLET;ORAL

BEQALZI

		+	BEONE MEDICINES USA	1MG	N220711	001	May 13, 2026	May	NEWA
		+		5MG	N220711	002	May 13, 2026	May	NEWA
		+!		20MG	N220711	003	May 13, 2026	Jun	CHRS
		+		20MG	N220711	003	May 13, 2026	May	NEWA
		+		80MG	N220711	004	May 13, 2026	Jun	CHRS
		+!		80MG	N220711	004	May 13, 2026	May	NEWA

SOTALOL HYDROCHLORIDE

TABLET;ORAL

BETAPACE

	AB	+	LEGACY	80MG	N019865	001	Oct 30, 1992	Jun	CAHN
	AB	+		120MG	N019865	005	Apr 20, 1994	Jun	CAHN
	AB	+!		160MG	N019865	002	Oct 30, 1992	Jun	CAHN
	AB	+		240MG	N019865	003	Oct 30, 1992	Jun	CAHN
		@		320MG	N019865	004	Oct 30, 1992	Jun	CAHN

BETAPACE AF

>A>		@	LEGACY	40MG	N021151	006	Apr 02, 2003	Jul	CAHN
>A>		@		60MG	N021151	007	Apr 02, 2003	Jul	CAHN
>A>	AB	+		80MG	N021151	001	Feb 22, 2000	Jul	CAHN
>A>		@		100MG	N021151	005	Mar 14, 2003	Jul	CAHN
>A>	AB	+		120MG	N021151	002	Feb 22, 2000	Jul	CAHN
>A>	AB	+!		160MG	N021151	003	Feb 22, 2000	Jul	CAHN
>D>		@	LEGACY PHARMA	40MG	N021151	006	Apr 02, 2003	Jul	CAHN
>D>		@		60MG	N021151	007	Apr 02, 2003	Jul	CAHN
>D>	AB	+		80MG	N021151	001	Feb 22, 2000	Jul	CAHN
>D>		@		100MG	N021151	005	Mar 14, 2003	Jul	CAHN
>D>	AB	+		120MG	N021151	002	Feb 22, 2000	Jul	CAHN
>D>	AB	+!		160MG	N021151	003	Feb 22, 2000	Jul	CAHN

SUCCINYLCHOLINE CHLORIDE

INJECTABLE;INJECTION

SUCCINYLCHOLINE CHLORIDE

>D>	AP		AMNEAL	20MG/ML	A211432	001	Nov 16, 2018	Jul	DISC
>A>		@		20MG/ML	A211432	001	Nov 16, 2018	Jul	DISC
	AP		J MOLNER	20MG/ML	A210231	001	Jun 04, 2018	Jun	CAHN
	AP		NIVAGEN PHARMS INC	20MG/ML	A211625	001	May 19, 2020	Apr	CAHN

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

SUCCINYLCHOLINE CHLORIDE

	AP	!	FRESENIUS KABI USA	100MG/5ML (20MG/ML)	A217884	001	Feb 11, 2025	Mar	CHRS
		@ +	HIKMA	100MG/5ML (20MG/ML)	N215143	001	Aug 20, 2021	Mar	DISC

SUCRALFATE

SUSPENSION;ORAL

CARAFATE

		@ +	ABBVIE	1GM/10ML	N019183	001	Dec 16, 1993	Jun	DISC

SUCRALFATE

	AB		CHARTWELL RX	1GM/10ML	A211780	001	Apr 14, 2025	Jun	CAHN
	AB		COSETTE PHARMS NC	1GM/10ML	A217126	001	Nov 13, 2024	May	CAHN
	AB	!	VISTAPHARM LLC	1GM/10ML	A211884	001	Mar 15, 2022	Jun	CHRS

SUFENTANIL CITRATE

INJECTABLE;INJECTION

SUFENTANIL CITRATE

		@	HIKMA	EQ 0.05MG BASE/ML	A074413	001	Dec 15, 1995	Mar	DISC

SUGAMMADEX SODIUM

SOLUTION;INTRAVENOUS

BRIDION

>D>	AP	+	MSD SUB MERCK	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	N022225	002	Dec 15, 2015	Jul	CHRS
>A>	AP	+!		EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	N022225	002	Dec 15, 2015	Jul	CHRS

SUGAMMADEX SODIUM

>A>	AP		DR REDDYS	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A214236	001	Jul 28, 2026	Jul	NEWA
>A>	AP			EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A214236	002	Jul 28, 2026	Jul	NEWA
>A>	AP		FRESENIUS KABI USA	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A219448	001	Jul 28, 2026	Jul	NEWA
>A>	AP		GLAND	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A214364	001	Jul 28, 2026	Jul	NEWA
>A>	AP			EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A214364	002	Jul 28, 2026	Jul	NEWA
>A>	AP		HIKMA	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A218727	001	Jul 28, 2026	Jul	NEWA
>A>	AP			EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A218728	001	Jul 28, 2026	Jul	NEWA
>A>	AP			EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A218728	002	Jul 28, 2026	Jul	NEWA
>A>	AP		LUPIN	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A214338	001	Jul 28, 2026	Jul	NEWA
>A>	AP			EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A214338	002	Jul 28, 2026	Jul	NEWA
>A>	AP		MANKIND PHARMA	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A214230	001	Jul 28, 2026	Jul	NEWA
>A>	AP			EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A214230	002	Jul 28, 2026	Jul	NEWA
>A>	AP		MSN	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A214368	001	Jul 28, 2026	Jul	NEWA
>A>	AP			EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A214368	002	Jul 28, 2026	Jul	NEWA
>A>	AP		MYLAN	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A213915	001	Jul 28, 2026	Jul	NEWA
>A>	AP			EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A213915	002	Jul 28, 2026	Jul	NEWA
>A>	AP		QILU PHARM HAINAN	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A215575	001	Jul 28, 2026	Jul	NEWA
>A>	AP			EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A215575	002	Jul 28, 2026	Jul	NEWA
>A>	AP		SANDOZ	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A214311	001	Jul 28, 2026	Jul	NEWA
>A>	AP			EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A214311	002	Jul 28, 2026	Jul	NEWA
>A>	AP		STERISCIENCE	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A218814	001	Jul 28, 2026	Jul	NEWA

		SOLUTION;INTRAVENOUS							
		SUGAMMADEX SODIUM							
>A>	AP		EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A218814	002	Jul 28, 2026	Jul NEWA		
>A>	AP	SUN PHARM INDS INC	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A214319	001	Jul 28, 2026	Jul NEWA		
>A>	AP		EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A214319	002	Jul 28, 2026	Jul NEWA		
>A>	AP	TAMARANG	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A215260	001	Jul 28, 2026	Jul NEWA		
>A>	AP		EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A215260	002	Jul 28, 2026	Jul NEWA		
>A>	AP	TEVA PHARMS USA INC	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A214126	001	Jul 28, 2026	Jul NEWA		
>A>	AP		EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A214126	002	Jul 28, 2026	Jul NEWA		
>A>	AP	ZENARA	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A214306	001	Jul 28, 2026	Jul NEWA		
>A>	AP		EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A214306	002	Jul 28, 2026	Jul NEWA		
	AP	ZYDUS PHARMS	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A214290	001	Oct 04, 2023	May CMFD		
	AP		EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A214290	002	Oct 04, 2023	May CMFD		
		SULCONAZOLE NITRATE							
		SOLUTION;TOPICAL							
		EXELDERM							
>D>		+! JOURNEY	1%	N018738	001	Aug 30, 1985	Jul DISC		
>A>		@ +	1%	N018738	001	Aug 30, 1985	Jul DISC		
		SULFACETAMIDE SODIUM							
		OINTMENT;OPHTHALMIC							
		SULFACETAMIDE SODIUM							
		@ PADAGIS US	10%	A080029	001		Mar DISC		
		SOLUTION/DROPS;OPHTHALMIC							
		SULFACETAMIDE SODIUM							
	AT	! BAUSCH AND LOMB	10%	A040066	001	Dec 28, 1994	May CAHN		
		SULFANILAMIDE							
		CREAM;VAGINAL							
		SULFANILAMIDE							
		@ COSETTE PHARMS NC	15%	A088718	001	Sep 19, 1985	Jun CAHN		
		SUMATRIPTAN SUCCINATE							
		INJECTABLE;SUBCUTANEOUS							
		SUMATRIPTAN SUCCINATE							
		@ ONESOURCE SPECIALTY	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090314	001	Jun 10, 2010	Jun DISC		
	AP		EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090314	001	Jun 10, 2010	Feb CMFD		
		SUMATRIPTAN SUCCINATE (AUTOINJECTOR)							
	AB	ONESOURCE SPECIALTY	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090314	002	Jan 30, 2026	Jun NEWA		
		POWDER;NASAL							
		ONZETRA XSAIL							
>A>		+! AZURITY	EQ 11MG BASE	N206099	001	Jan 27, 2016	Jul CAHN		
>D>		+! CURRAX	EQ 11MG BASE	N206099	001	Jan 27, 2016	Jul CAHN		
		SUNVOZERTINIB							
		TABLET;ORAL							
		ZEGFROVY							
>A>		+ DIZAL	150MG	N219839	001	Jul 02, 2025	Jul CAHN		
>A>		+!	200MG	N219839	002	Jul 02, 2025	Jul CAHN		
>D>		+ DIZAL JIANGSU	150MG	N219839	001	Jul 02, 2025	Jul CAHN		
>D>		+!	200MG	N219839	002	Jul 02, 2025	Jul CAHN		
		TADALAFIL							
		TABLET;ORAL							
		TADALAFIL							
	AB1	JUBILANT GENERICS	2.5MG	A210329	001	May 15, 2026	May NEWA		
	AB1		5MG	A210329	002	May 15, 2026	May NEWA		
	AB1		10MG	A210329	003	May 15, 2026	May NEWA		
	AB1		20MG	A210329	004	May 15, 2026	May NEWA		
		! TORRENT	40MG	A212062	002	May 20, 2026	May NFTG		

TAFAMIDIS MEGLUMINE

CAPSULE;ORAL

VYNDAQEL

	@ +	FOLDRX PHARMS	20MG	N211996	001	May 03, 2019	Jan DISC

TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL

TAMSULOSIN HYDROCHLORIDE

	@	SANDOZ	0.4MG	A078015	001	Apr 27, 2010	Jun DISC

TAPENTADOL HYDROCHLORIDE

SOLUTION;ORAL

TAPENTADOL HYDROCHLORIDE

		NOVITIUM PHARMA	EQ 20MG BASE/ML	A219119	001	Jan 26, 2026	Jan NFTG

TABLET;ORAL

NUCYNTA

AB	+	COLLEGIUM PHARM INC	EQ 50MG BASE	N022304	001	Nov 20, 2008	Jan CFTG
AB	+		EQ 75MG BASE	N022304	002	Nov 20, 2008	Jan CFTG
AB	+!		EQ 100MG BASE	N022304	003	Nov 20, 2008	Jan CFTG

TAPENTADOL HYDROCHLORIDE

AB		EPIC PHARMA LLC	EQ 50MG BASE	A214378	001	Jan 27, 2026	May CAHN
AB			EQ 75MG BASE	A214378	002	Jan 27, 2026	May CAHN
AB			EQ 100MG BASE	A214378	003	Jan 27, 2026	May CAHN
	@	HIKMA	EQ 50MG BASE	A205057	001	Feb 10, 2026	May DISC
AB			EQ 50MG BASE	A205057	001	Feb 10, 2026	Jan NEWA
	@		EQ 75MG BASE	A205057	002	Feb 10, 2026	May DISC
AB			EQ 75MG BASE	A205057	002	Feb 10, 2026	Jan NEWA
	@		EQ 100MG BASE	A205057	003	Feb 10, 2026	May DISC
AB			EQ 100MG BASE	A205057	003	Feb 10, 2026	Jan NEWA
AB		HUMANWELL	EQ 50MG BASE	A214378	001	Jan 27, 2026	Jan NFTG
AB			EQ 75MG BASE	A214378	002	Jan 27, 2026	Jan NFTG
AB			EQ 100MG BASE	A214378	003	Jan 27, 2026	Jan NFTG

TAVABOROLE

SOLUTION;TOPICAL

TAVABOROLE

	@	CIPLA	5%	A212224	001	Feb 09, 2021	Jan DISC
	@	LUPIN	5%	A212168	001	Feb 08, 2021	Feb DISC
	@	PADAGIS US	5%	A211848	001	Oct 13, 2020	Mar DISC

TAZAROTENE

CREAM;TOPICAL

TAZAROTENE

AB		COSETTE PHARMS NC	0.05%	A208662	002	Mar 10, 2025	May CAHN
AB			0.1%	A208662	001	Dec 22, 2017	May CAHN
AB		SOLARIS PHARMA CORP	0.05%	A214560	001	Nov 24, 2025	Jan CAHN

GEL;TOPICAL

TAZAROTENE

AB		COSETTE PHARMS NC	0.05%	A215433	001	Sep 13, 2022	May CAHN
AB			0.1%	A214136	001	Sep 13, 2022	May CAHN

TAZEMETOSTAT HYDROBROMIDE

TABLET;ORAL

TAZVERIK

	@ +	EPIZYME INC	EQ 200MG BASE	N211723	001	Jan 23, 2020	May DISC

TEBIPENEM PIVOXIL HYDROBROMIDE

TABLET;ORAL

UTEBZI

	+!	GLAXOSMITHKLINE	EQ 300MG BASE	N215960	001	Jun 17, 2026	Jun NEWA

TECHNETIUM TC-99M BICISATE KIT

INJECTABLE;INJECTION

NEUROLITE

	+!	SHINE	N/A	N020256	001	Nov 23, 1994	Feb CAHN

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE;INJECTION

CARDIOLITE

AP		+!	SHINE	N/A	N019785	001	Dec 21, 1990	Feb CAHN

MIRALUMA

		@	SHINE	N/A	N019785	003	May 23, 1997	Feb CAHN

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION;INTRAVENOUS

TECHNELITE

		+!	SHINE	1-20 CI/GENERATOR	N017771	002	Feb 12, 2014	Feb CAHN
		@		0.0083-2.7 CI/GENERATOR	N017771	001		Feb CAHN

TELAVANCIN HYDROCHLORIDE

POWDER;INTRAVENOUS

VIBATIV

>A>		@ +	APOTEX	EQ 250MG BASE/VIAL	N022110	001	Sep 11, 2009	Jul CAHN
>A>		+!		EQ 750MG BASE/VIAL	N022110	002	Sep 11, 2009	Jul CAHN
>D>		@ +	CUMBERLAND	EQ 250MG BASE/VIAL	N022110	001	Sep 11, 2009	Jul CAHN
>D>		+!		EQ 750MG BASE/VIAL	N022110	002	Sep 11, 2009	Jul CAHN

TELMISARTAN

TABLET;ORAL

MICARDIS

>D>	AB	+	BOEHRINGER INGELHEIM	40MG	N020850	001	Nov 10, 1998	Jul DISC
>A>		@ +		40MG	N020850	001	Nov 10, 1998	Jul DISC

TEMAZEPAM

CAPSULE;ORAL

TEMAZEPAM

AB	AMNEAL PHARMS	7.5MG	A203482	001	May 23, 2016	Jan CMFD
AB		15MG	A203482	002	May 23, 2016	Jan CMFD
AB		22.5MG	A203482	003	May 23, 2016	Jan CMFD
AB		30MG	A203482	004	May 23, 2016	Jan CMFD

TERAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

TERAZOSIN HYDROCHLORIDE

AB	SENORES PHARMS	EQ 1MG BASE	A074823	001	Mar 30, 1998	Feb CAHN
AB		EQ 2MG BASE	A074823	002	Mar 30, 1998	Feb CAHN
AB		EQ 5MG BASE	A074823	003	Mar 30, 1998	Feb CAHN
AB		EQ 10MG BASE	A074823	004	Mar 30, 1998	Feb CAHN

TERBINAFINE HYDROCHLORIDE

TABLET;ORAL

TERBINAFINE HYDROCHLORIDE

AB	CIPLA	EQ 250MG BASE	A077137	001	Jul 02, 2007	May CMFD
	@ INVAGEN PHARMS	EQ 250MG BASE	A077533	001	Jul 02, 2007	Jun DISC

TERIFLUNOMIDE

TABLET;ORAL

TERIFLUNOMIDE

AB	CONCORD BIOTECH LTD	7MG	A218663	001	Apr 07, 2025	Feb CMFD
AB		14MG	A218663	002	Apr 07, 2025	Feb CMFD

TESTOSTERONE

SOLUTION, METERED;TRANSDERMAL

TESTOSTERONE

AT	ENCUBE	30MG/1.5ML ACTUATION	A212301	001	Jan 11, 2021	Jun CMFD

TESTOSTERONE CYPIONATE

INJECTABLE;INJECTION

TESTOSTERONE CYPIONATE

	@ CAPLIN ONE LABS	100MG/ML	A040615	001	Aug 10, 2006	Mar DISC
AO		100MG/ML	A040615	001	Aug 10, 2006	Jan CAHN
	@	200MG/ML	A040615	002	Aug 10, 2006	Mar DISC
AO		200MG/ML	A040615	002	Aug 10, 2006	Jan CAHN

THALIDOMIDE

CAPSULE;ORAL

THALIDOMIDE

AB		NATCO	50MG	A213267	002	Apr 24, 2026	Apr NFTG
AB			100MG	A213267	003	Apr 24, 2026	Apr NFTG
AB			200MG	A213267	004	Apr 24, 2026	Apr NFTG

THALOMID

AB	+	BRISTOL-MYERS	50MG	N020785	001	Jul 16, 1998	Apr CFTG
AB	+		100MG	N020785	002	Jan 17, 2003	Apr CFTG
AB	+!		200MG	N020785	003	Jan 17, 2003	Apr CFTG

THEOPHYLLINE

SOLUTION, ELIXIR;ORAL

ELIXOPHYLLIN

	@ +	SOLIS PHARMS	80MG/15ML	A085186	001		Jan DISC

THEOPHYLLINE

	!	PHARM ASSOC	80MG/15ML	A206344	001	Dec 16, 2016	Jan CHRS
			80MG/15ML	A206344	001	Dec 16, 2016	Jan CTEC

THIAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

THIAMINE HYDROCHLORIDE

>A> AP		MANKIND PHARMA	100MG/ML	A220513	001	Jul 31, 2026	Jul NEWA

THIOTEPA

INJECTABLE;INJECTION

THIOTEPA

	@	HENGRUI PHARMA	15MG/VIAL	A209150	001	May 04, 2018	Apr DISC

POWDER;INTRAVENOUS

TEPADINA AND SODIUM CHLORIDE

	+!	ADIENNE SA	400MG	N208264	004	Jan 15, 2026	Jan NEWA

TICAGRELOR

TABLET;ORAL

TICAGRELOR

	@	AMNEAL	60MG	A208531	002	Oct 28, 2025	Mar DISC
AB		MANKIND PHARMA	60MG	A217679	001	Feb 06, 2026	Jan NEWA
AB			90MG	A217679	002	Feb 06, 2026	Jan NEWA
AB		MICRO LABS	60MG	A208539	001	Apr 27, 2026	Apr NEWA
AB			90MG	A208539	002	Apr 27, 2026	Apr NEWA
AB		ZHEJIANG JINGXIN	60MG	A219006	001	Mar 24, 2026	Mar NEWA
AB			90MG	A219006	002	Mar 24, 2026	Mar NEWA

TIGECYCLINE

POWDER;INTRAVENOUS

TIGECYCLINE

	@ +	FRESENIUS KABI USA	50MG/VIAL	N205645	001	Dec 01, 2016	Mar DISC

TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

TIMOLOL MALEATE

AT3		J MOLNER	EQ 0.25% BASE	A212592	001	Dec 13, 2021	Jun CAHN
AT3			EQ 0.5% BASE	A212592	002	Dec 13, 2021	Jun CAHN

TABLET;ORAL

TIMOLOL MALEATE

	@	MYLAN	5MG	A072668	002	Jun 08, 1990	Mar DISC
	@		20MG	A072668	001	Jun 08, 1990	Mar DISC
		RISING	5MG	A207556	001	May 02, 2019	Mar CTEC
	!		20MG	A207556	003	May 02, 2019	Mar CHRS
			20MG	A207556	003	May 02, 2019	Mar CTEC

TINIDAZOLE

TABLET;ORAL

TINIDAZOLE

AB		UNIQUE	250MG	A202489	001	Oct 09, 2013	Mar CAHN
AB			500MG	A202489	002	Oct 09, 2013	Mar CAHN

TIOPRONIN

TABLET;ORAL

TIOCYSTIN

+	CASPER PHARMA LLC	100MG	N212927	001	Jun 02, 2026	Jun	NEWA
+!		200MG	N212927	002	Jun 02, 2026	Jun	NEWA

TABLET, DELAYED RELEASE;ORAL

TIOPRONIN

@	AMNEAL	100MG	A216278	002	Aug 29, 2025	Mar	DISC
@		300MG	A216278	001	Aug 15, 2023	Mar	DISC

TIRZEPATIDE

SOLUTION;SUBCUTANEOUS

MOUNJARO

+!	ELI LILLY AND CO	10MG/2.4ML (4.17MG/ML)	N215866	013	Jan 07, 2026	Jan	NEWA
+!		20MG/2.4ML (8.33MG/ML)	N215866	014	Jan 07, 2026	Jan	NEWA
+!		30MG/2.4ML (12.5MG/ML)	N215866	015	Jan 07, 2026	Jan	NEWA
+!		40MG/2.4ML (16.7MG/ML)	N215866	016	Jan 07, 2026	Jan	NEWA
+!		50MG/2.4ML (20.8MG/ML)	N215866	017	Jan 07, 2026	Jan	NEWA
+!		60MG/2.4ML (25MG/ML)	N215866	018	Jan 07, 2026	Jan	NEWA

MOUNJARO KWIKPEN

+!	ELI LILLY AND CO	10MG/2.4ML (4.17MG/ML)	N215866	019	Jan 20, 2026	Jan	NEWA
+!		20MG/2.4ML (8.33MG/ML)	N215866	020	Jan 20, 2026	Jan	NEWA
+!		30MG/2.4ML (12.5MG/ML)	N215866	021	Jan 20, 2026	Jan	NEWA
+!		40MG/2.4ML (16.7MG/ML)	N215866	022	Jan 20, 2026	Jan	NEWA
+!		50MG/2.4ML (20.8MG/ML)	N215866	023	Jan 20, 2026	Jan	NEWA
+!		60MG/2.4ML (25MG/ML)	N215866	024	Jan 20, 2026	Jan	NEWA

ZEPBOUND

+!	ELI LILLY AND CO	10MG/2.4ML (4.17MG/ML)	N217806	013	Jan 07, 2026	Jan	NEWA
+!		20MG/2.4ML (8.33MG/ML)	N217806	014	Jan 07, 2026	Jan	NEWA
+!		30MG/2.4ML (12.5MG/ML)	N217806	015	Jan 07, 2026	Jan	NEWA
+!		40MG/2.4ML (16.7MG/ML)	N217806	016	Jan 07, 2026	Jan	NEWA
+!		50MG/2.4ML (20.8MG/ML)	N217806	017	Jan 07, 2026	Jan	NEWA
+!		60MG/2.4ML (25MG/ML)	N217806	018	Jan 07, 2026	Jan	NEWA

ZEPBOUND KWIKPEN

+!	ELI LILLY AND CO	10MG/2.4ML (4.17MG/ML)	N217806	019	Jan 20, 2026	Jan	NEWA
+!		20MG/2.4ML (8.33MG/ML)	N217806	020	Jan 20, 2026	Jan	NEWA
+!		30MG/2.4ML (12.5MG/ML)	N217806	021	Jan 20, 2026	Jan	NEWA
+!		40MG/2.4ML (16.7MG/ML)	N217806	022	Jan 20, 2026	Jan	NEWA
+!		50MG/2.4ML (20.8MG/ML)	N217806	023	Jan 20, 2026	Jan	NEWA
+!		60MG/2.4ML (25MG/ML)	N217806	024	Jan 20, 2026	Jan	NEWA

TIZANIDINE HYDROCHLORIDE

CAPSULE;ORAL

TIZANIDINE HYDROCHLORIDE

AB		INGENUS PHARMS LLC	EQ 2MG BASE	A210267	001	Mar 12, 2019	Feb	CAHN
AB			EQ 4MG BASE	A210267	002	Mar 12, 2019	Feb	CAHN
AB			EQ 6MG BASE	A210267	003	Mar 12, 2019	Feb	CAHN
AB		SENORES PHARMS	EQ 4MG BASE	A213365	001	May 13, 2024	Jan	CAHN
AB			EQ 6MG BASE	A213365	002	May 13, 2024	Jan	CAHN

ZANAFLEX

AB	+	LEGACY	EQ 2MG BASE	N021447	001	Aug 29, 2002	Jun	CAHN
AB	+!		EQ 4MG BASE	N021447	002	Aug 29, 2002	Jun	CAHN
AB	+		EQ 6MG BASE	N021447	003	Aug 29, 2002	Jun	CAHN
AB	+!	LEGACY PHARMA USA	EQ 4MG BASE	N021447	002	Aug 29, 2002	Mar	CHRS
AB	+		EQ 6MG BASE	N021447	003	Aug 29, 2002	Mar	CHRS

TABLET;ORAL

ZANAFLEX

@ +	LEGACY	EQ 2MG BASE	N020397	002	Feb 04, 2000	Jun	CAHN
AB	+!		EQ 4MG BASE	N020397	001	Nov 27, 1996	Jun	CAHN

TOBRAMYCIN

SOLUTION;INHALATION

TOBRAMYCIN

>D> AN		TEVA PHARMS USA	300MG/4ML	A210915	001	Jun 26, 2019	Jul	DISC
>A>	@		300MG/4ML	A210915	001	Jun 26, 2019	Jul	DISC

SOLUTION/DROPS;OPHTHALMIC

TOBRAMYCIN

AT		BAUSCH AND LOMB INC	0.3%	A064052	001	Nov 29, 1993	May	CAHN

TOBRAMYCIN SULFATE

INJECTABLE;INJECTION

TOBRAMYCIN SULFATE

AP	EUGIA PHARMA	EQ 1.2GM BASE/VIAL	A217519	001	Jun 21, 2023	Apr	CMFD
>A> AP	HAINAN POLY	EQ 1.2GM BASE/VIAL	A217029	001	Feb 01, 2023	Jul	CAHN
>D> AP	SLATE RUN PHARMA	EQ 1.2GM BASE/VIAL	A217029	001	Feb 01, 2023	Jul	CAHN

TOFACITINIB CITRATE

SOLUTION;ORAL

TOFACITINIB CITRATE

AA	AUSON	EQ 1MG BASE/ML	A219370	001	Jun 09, 2026	May	NEWA
AA	HIKMA	EQ 1MG BASE/ML	A216878	001	Sep 25, 2023	May	CMFD
AA	MSN	EQ 1MG BASE/ML	A217298	001	Jun 03, 2026	May	NEWA
AA	SAPTALIS PHARMS	EQ 1MG BASE/ML	A218900	001	Jun 09, 2026	May	NEWA
AA	SUN PHARM INDS INC	EQ 1MG BASE/ML	A218407	001	Jun 03, 2026	May	NEWA

XELJANZ

AA +!	PFIZER	EQ 1MG BASE/ML	N213082	001	Sep 25, 2020	May	CTEC

TABLET;ORAL

TOFACITINIB CITRATE

AB	AJANTA PHARMA LTD	EQ 10MG BASE	A212943	001	Jun 01, 2021	Apr	CMFD
AB	APOTEX	EQ 5MG BASE	A218096	001	Jun 03, 2026	May	NEWA
AB		EQ 10MG BASE	A218096	002	Jun 03, 2026	May	NEWA
AB	AUROBINDO PHARMA LTD	EQ 5MG BASE	A215356	001	Jun 03, 2026	May	NEWA
AB		EQ 10MG BASE	A215356	002	Jun 03, 2026	May	NEWA
AB	BRECKENRIDGE	EQ 5MG BASE	A209633	001	Jun 03, 2026	May	NEWA
AB		EQ 10MG BASE	A209633	002	Jun 03, 2026	May	NEWA
AB	CONCORD BIOTECH LTD	EQ 5MG BASE	A218821	001	Jun 09, 2026	May	NEWA
AB		EQ 10MG BASE	A218821	002	Jun 09, 2026	May	NEWA
AB	MACLEODS PHARMS	EQ 5MG BASE	A219530	001	Jun 03, 2026	May	NEWA
AB		EQ 10MG BASE	A219530	002	Jun 03, 2026	May	NEWA
AB	MICRO LABS	EQ 5MG BASE	A209738	001	Mar 13, 2023	Apr	CMFD
AB		EQ 10MG BASE	A209738	002	Jun 03, 2026	May	NEWA
AB	MSN	EQ 5MG BASE	A217299	001	Jun 03, 2026	May	NEWA
AB		EQ 10MG BASE	A217299	002	Jun 03, 2026	May	NEWA
AB	SOMERSET THERAPS LLC	EQ 5MG BASE	A220137	001	Jun 03, 2026	May	NEWA
AB		EQ 10MG BASE	A220137	002	Jun 03, 2026	May	NEWA
AB	SPECGX LLC	EQ 5MG BASE	A219395	001	Jun 03, 2026	May	NEWA
AB		EQ 10MG BASE	A219395	002	Jun 03, 2026	May	NEWA
AB	YAOPHARMA CO LTD	EQ 5MG BASE	A215552	001	Jun 09, 2026	May	NEWA
AB		EQ 10MG BASE	A215552	002	Jun 09, 2026	May	NEWA
AB	ZYDUS PHARMS	EQ 5MG BASE	A209829	001	Mar 13, 2023	Apr	CMFD
AB		EQ 10MG BASE	A209829	002	Jun 05, 2026	May	NEWA

XELJANZ

AB +	PF PRISM CV	EQ 5MG BASE	N203214	001	Nov 06, 2012	Apr	CTEC
AB +!		EQ 10MG BASE	N203214	002	May 30, 2018	Apr	CTEC

TABLET, EXTENDED RELEASE;ORAL

TOFACITINIB CITRATE

AB	AJANTA PHARMA LTD	EQ 11MG BASE	A219542	001	Aug 19, 2025	Apr	CMFD
@		EQ 11MG BASE	A219542	001	Aug 19, 2025	Jan	DISC
AB	APOTEX	EQ 11MG BASE	A220458	001	Jun 03, 2026	May	NEWA
AB	AUROBINDO PHARMA LTD	EQ 11MG BASE	A218462	001	Jun 03, 2024	Apr	CMFD
AB	DEXCEL	EQ 11MG BASE	A218668	001	Dec 16, 2024	Apr	CMFD
AB	ORIENT PHARMA	EQ 11MG BASE	A219830	001	Jun 09, 2026	May	NEWA
AB	SCIEGEN PHARMS	EQ 11MG BASE	A220972	001	Jun 25, 2026	Jun	NEWA
AB	ZYDUS PHARMS	EQ 11MG BASE	A214264	001	Aug 19, 2021	Apr	CMFD
AB		EQ 22MG BASE	A214264	002	Aug 19, 2021	Apr	CHRS
AB !		EQ 22MG BASE	A214264	002	Aug 19, 2021	Apr	CMFD

XELJANZ XR

AB +!	PFIZER	EQ 22MG BASE	N208246	002	Dec 12, 2019	Apr	CTEC

TOLCAPONE

TABLET;ORAL

TASMAR

+!	BAUSCH	100MG	N020697	001	Jan 29, 1998	Mar	CTEC

TOLCAPONE

@	INGENUS PHARMS LLC	100MG	A208937	001	Aug 07, 2018	Mar	DISC
AB		100MG	A208937	001	Aug 07, 2018	Feb	CAHN

TOLMETIN SODIUM

TABLET;ORAL

TOLMETIN SODIUM

@		COSETTE PHARMS NC	EQ 600MG BASE	A074399	001	Mar 28, 1996	Jun CAHN
@			EQ 600MG BASE	A074729	001	Feb 27, 1997	Jun CAHN

TOLTERODINE TARTRATE

TABLET;ORAL

TOLTERODINE TARTRATE

AB		UNIQUE	1MG	A204721	001	Jan 24, 2020	Mar CAHN
AB			2MG	A204721	002	Jan 24, 2020	Mar CAHN

TOLVAPTAN

TABLET;ORAL

TOLVAPTAN

AB2		ALKEM LABS LTD	15MG	A220147	001	Apr 21, 2026	Apr NEWA
AB2			30MG	A220147	002	Apr 21, 2026	Apr NEWA
AB			45MG	A220147	003	Apr 21, 2026	Apr NEWA
AB2			60MG	A220147	004	Apr 21, 2026	Apr NEWA
AB			90MG	A220147	005	Apr 21, 2026	Apr NEWA
>A> AB2		TEVA PHARMS INC	15MG	A216933	001	Jul 21, 2026	Jul NEWA
>A> AB2			30MG	A216933	002	Jul 21, 2026	Jul NEWA
>A> AB			45MG	A216933	003	Jul 21, 2026	Jul NEWA
>A> AB2			60MG	A216933	004	Jul 21, 2026	Jul NEWA
>A> AB			90MG	A216933	005	Jul 21, 2026	Jul NEWA

TOPIRAMATE

CAPSULE;ORAL

TOPIRAMATE

AB		SENORES PHARMS	15MG	A218642	001	Oct 10, 2024	Jan CAHN
AB			25MG	A218642	002	Oct 10, 2024	Jan CAHN
AB		STRIDES PHARMA	50MG	A078418	003	Feb 02, 2026	Jan NEWA

CAPSULE, EXTENDED RELEASE;ORAL

TOPIRAMATE

AB1		ASCENT PHARMS INC	25MG	A217443	001	Jan 12, 2026	Jan NEWA
AB1			50MG	A217443	002	Jan 12, 2026	Jan NEWA
AB1			100MG	A217443	003	Jan 12, 2026	Jan NEWA
AB1			200MG	A217443	004	Jan 12, 2026	Jan NEWA
>A> AB1		BIOCON PHARMA	25MG	A220943	001	Jul 22, 2026	Jul NEWA
>A> AB1			50MG	A220943	002	Jul 22, 2026	Jul NEWA
>A> AB1			100MG	A220943	003	Jul 22, 2026	Jul NEWA
>A> AB1			200MG	A220943	004	Jul 22, 2026	Jul NEWA
@		RICONPHARMA LLC	25MG	A220041	001	May 26, 2026	Jun DISC
AB2			25MG	A220041	001	May 26, 2026	May NEWA
@			50MG	A220041	002	May 26, 2026	Jun DISC
AB2			50MG	A220041	002	May 26, 2026	May NEWA
@			100MG	A220041	003	May 26, 2026	Jun DISC
AB2			100MG	A220041	003	May 26, 2026	May NEWA
@			150MG	A220041	004	May 26, 2026	Jun DISC
AB2			150MG	A220041	004	May 26, 2026	May NEWA
@			200MG	A220041	005	May 26, 2026	Jun DISC
AB2			200MG	A220041	005	May 26, 2026	May NEWA

TABLET;ORAL

TOPIRAMATE

@		SENORES PHARMS	25MG	A090353	001	Sep 01, 2010	Jan CAHN
@			50MG	A090353	002	Sep 01, 2010	Jan CAHN
@			100MG	A090353	003	Sep 01, 2010	Jan CAHN
@			200MG	A090353	004	Sep 01, 2010	Jan CAHN

TOPOTECAN HYDROCHLORIDE

INJECTABLE;INJECTION

TOPOTECAN HYDROCHLORIDE

AP		INGENUS PHARMS LLC	EQ 4MG BASE/VIAL	A206962	001	Nov 30, 2016	Feb CAHN

SOLUTION;INTRAVENOUS

TOPOTECAN HYDROCHLORIDE

@		NATCO PHARMA USA	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A206074	001	Nov 24, 2017	Mar CAHN

TORSEMIDE

TABLET;ORAL

TORSEMIDE

AB		MICRO LABS	5MG	A217239	001	May 01, 2026	Apr	NEWA
AB			10MG	A217239	002	May 01, 2026	Apr	NEWA
AB			20MG	A217239	003	May 01, 2026	Apr	NEWA
	@	STRIDES PHARMA INTL	5MG	A076226	001	May 27, 2003	Jun	DISC
	@		5MG	A090613	001	Mar 22, 2011	Jun	DISC
	@		10MG	A076226	002	May 27, 2003	Jun	DISC
	@		10MG	A090613	002	Mar 22, 2011	Jun	DISC
	@		20MG	A076226	003	May 27, 2003	Jun	DISC
	@		20MG	A090613	003	Mar 22, 2011	Jun	DISC
	@		100MG	A076226	004	May 27, 2003	Jun	DISC
	@		100MG	A090613	004	Mar 22, 2011	Jun	DISC

TRABECTEDIN

SOLUTION;INTRAVENOUS

EVDI

	+!	APOTEX	1MG/20ML (0.05MG/ML)	N220837	001	May 01, 2026	May	NEWA

TRAMADOL HYDROCHLORIDE

SOLUTION;ORAL

QDOLO

	@ +	ROSEMONT	5MG/ML	N214044	001	Sep 01, 2020	Mar	CAHN

TRAMADOL HYDROCHLORIDE

	!	NOVITIUM PHARMA	5MG/ML	A219647	001	Jun 26, 2026	Jun	NFTG

TABLET;ORAL

TRAMADOL HYDROCHLORIDE

>A> AB		GRAVITI PHARMS	25MG	A075968	003	Jul 28, 2026	Jul	NEWA
AB		RUBICON	25MG	A208708	003	Nov 27, 2023	Mar	CTEC
AB		RUBICON RESEARCH	25MG	A208708	003	Nov 27, 2023	May	CAHN
AB			50MG	A208708	001	Jun 28, 2019	May	CAHN
			75MG	A208708	004	Apr 04, 2024	May	CAHN
AB	!		100MG	A208708	002	Jun 28, 2019	May	CAHN
AB		STRIDES PHARMA	25MG	A202075	002	Mar 23, 2026	Mar	NEWA

TRANDOLAPRIL

TABLET;ORAL

TRANDOLAPRIL

	@	SENORES PHARMS	1MG	A078493	001	Aug 25, 2008	Jan	CAHN
	@		2MG	A078493	002	Aug 25, 2008	Jan	CAHN
	@		4MG	A078493	003	Aug 25, 2008	Jan	CAHN

TRANEXAMIC ACID

TABLET;ORAL

LYSTEDA

AB	+!	J MOLNER	650MG	N022430	001	Nov 13, 2009	Jun	CAHN

TRANEXAMIC ACID

	@	BIONPHARMA	650MG	A219123	001	Aug 19, 2025	May	DISC
AB		I 3 PHARMS	650MG	A219702	001	Jan 26, 2026	Jan	NEWA

TRETINOIN

CREAM;TOPICAL

RETIN-A

AB1	+!	BAUSCH	0.05%	N017522	001			Jun CAHN
AB	+!		0.1%	N017340	001			Jun CAHN

TRETINOIN

AB1		ALEMBIC	0.05%	A214590	001	Jun 11, 2026	Jun	NEWA
AB1		ENCUBE	0.05%	A217832	001	Mar 25, 2026	Mar	NEWA
AB			0.1%	A217833	001	Feb 10, 2026	Jan	NEWA

GEL;TOPICAL

RETIN-A-MICRO

AB	+!	BAUSCH	0.06%	N020475	004	Oct 23, 2017	Apr	CFTG

TRETINOIN

AB		AMNEAL	0.08%	A217497	001	May 14, 2026	May	NEWA

TRETINOIN MICROSPHERE

AB		ENCUBE	0.06%	A215609	002	Apr 15, 2026	Apr	NFTG

TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

TRIAMCINOLONE ACETONIDE

AT		COSETTE PHARMS NC	0.025%	A089797	001	May 31, 1991	May CAHN
AT			0.1%	A089798	001	May 31, 1991	May CAHN

INJECTABLE;INJECTION

KENALOG-10

AB	+	APOTHECON	10MG/ML	N012041	001		May CHRS
AB	+!		10MG/ML	N012041	001		Jan CHRS

TRIAMCINOLONE ACETONIDE

	@	CAPLIN	10MG/ML	A090166	001	May 27, 2009	Jan CAHN
AB	!	DR REDDYS	10MG/ML	A218773	001	Mar 12, 2025	May CHRS

LOTION;TOPICAL

TRIAMCINOLONE ACETONIDE

AT		COSETTE PHARMS NC	0.1%	A089129	001	Aug 14, 1986	May CAHN
	@	ENCUBE	0.1%	A204606	001	Jul 07, 2016	May CAHN

OINTMENT;TOPICAL

TRIAMCINOLONE ACETONIDE

AT		COSETTE PHARMS NC	0.025%	A089795	001	Dec 23, 1988	May CAHN
AT			0.1%	A089796	001	Dec 23, 1988	May CAHN
	@		0.5%	A208925	001	Oct 06, 2017	Jun CAHN
	@	ENCUBE	0.5%	A208590	001	Mar 03, 2017	May CAHN

PASTE;DENTAL

TRIAMCINOLONE ACETONIDE

AT		COSETTE PHARMS NC	0.1%	A205592	001	Jan 12, 2017	May CAHN

TRIAZOLAM

TABLET;ORAL

TRIAZOLAM

	@	BRECKENRIDGE	0.125MG	A216890	001	Nov 08, 2022	Feb DISC
	@		0.25MG	A216890	002	Nov 08, 2022	Feb DISC
AB		INGENUS PHARMS LLC	0.125MG	A214219	001	Oct 20, 2020	Feb CAHN
AB			0.25MG	A214219	002	Oct 20, 2020	Feb CAHN

TRIENTINE HYDROCHLORIDE

CAPSULE;ORAL

TRIENTINE HYDROCHLORIDE

	@	PH HEALTH	250MG	A210096	001	Sep 25, 2019	Jun DISC
	!	RISING	500MG	A212238	002	Sep 22, 2023	Jan CHRS
	@	WATSON LABS TEVA	250MG	A207567	001	Feb 07, 2018	May DISC

TRIFLUOPERAZINE HYDROCHLORIDE

TABLET;ORAL

TRIFLUOPERAZINE HYDROCHLORIDE

	@	POM PHARMA	EQ 1MG BASE	A040153	001	Oct 25, 1996	Apr CAHN
	@		EQ 2MG BASE	A040153	002	Oct 25, 1996	Apr CAHN
	@		EQ 5MG BASE	A040153	003	Oct 25, 1996	Apr CAHN
	@		EQ 10MG BASE	A040153	004	Oct 25, 1996	Apr CAHN

TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)

CREAM;VAGINAL

GYNE-SULF

	@	COSETTE PHARMS NC	3.7%;2.86%;3.42%	A088607	001	Jun 09, 1986	Jun CAHN

VAGILIA

	@	COSETTE PHARMS NC	3.7%;2.86%;3.42%	A088821	001	Nov 09, 1987	Jun CAHN

TROPICAMIDE

SOLUTION/DROPS;OPHTHALMIC

TROPICAMIDE

AT		BAUSCH AND LOMB	1%	A040064	001	Jul 27, 1994	May CAHN

TROSPIUM CHLORIDE

TABLET;ORAL

TROSPIUM CHLORIDE

AB		ZAMEER PHARMS	20MG	A215781	001	Feb 16, 2022	Jan CAHN

URSODIOL

CAPSULE;ORAL

URSODIOL

>A>	AB		ALLIED	300MG	A214329	001	Jul 28, 2021	Jul CAHN
			LGM PHARMA	200MG	A205789	001	May 08, 2020	Jun CHRS
				400MG	A205789	002	May 08, 2020	Jun CHRS
>D>	AB		RK PHARMA	300MG	A214329	001	Jul 28, 2021	Jul CAHN
			STRIDES PHARMA	150MG	A210344	002	Jan 16, 2026	Jan NFTG

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL

VALACYCLOVIR HYDROCHLORIDE

	AB	!	HETERO LABS LTD V	EQ 1GM BASE	A203047	002	Apr 08, 2015	Feb CHRS

VALTREX

	AB	+	GLAXOSMITHKLINE	EQ 1GM BASE	N020487	002	Jun 23, 1995	Feb CHRS

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION;ORAL

VALGANCICLOVIR HYDROCHLORIDE

	AB		MICRO LABS	50MG/ML	A218838	001	Mar 19, 2026	Mar NEWA

VALSARTAN

SOLUTION;ORAL

PREXXARTAN

>D>		@ +	CARMEL BIOSCIENCES	4MG/ML	N209139	001	Dec 19, 2017	Jul CMFD
>A>	AB	+		4MG/ML	N209139	001	Dec 19, 2017	Jul CMFD

VALSARTAN

	AB		RUBICON RESEARCH	4MG/ML	A216460	001	Jun 05, 2025	May CAHN

TABLET;ORAL

VALSARTAN

>A>	AB		BOSTAL DRUG	40MG	A205357	001	Aug 11, 2026	Jul NEWA
>A>	AB			80MG	A205357	002	Aug 11, 2026	Jul NEWA
>A>	AB			160MG	A205357	003	Aug 11, 2026	Jul NEWA
>A>	AB			320MG	A205357	004	Aug 11, 2026	Jul NEWA
	AB		LAURUS	40MG	A218897	001	Apr 21, 2026	Apr NEWA
	AB			80MG	A218897	002	Apr 21, 2026	Apr NEWA
	AB			160MG	A218897	003	Apr 21, 2026	Apr NEWA
	AB			320MG	A218897	004	Apr 21, 2026	Apr NEWA
		@	LUPIN	40MG	A201677	001	Jan 05, 2015	May DISC
		@		80MG	A201677	002	Jan 05, 2015	May DISC
		@		160MG	A201677	003	Jan 05, 2015	May DISC
		@		320MG	A201677	004	Jan 05, 2015	May DISC
		@	RENATA	40MG	A218169	001	Aug 05, 2024	Feb CAHN
		@		80MG	A218169	002	Aug 05, 2024	Feb CAHN
		@		160MG	A218169	003	Aug 05, 2024	Feb CAHN
		@		320MG	A218169	004	Aug 05, 2024	Feb CAHN

VANCOMYCIN HYDROCHLORIDE

CAPSULE;ORAL

VANCOMYCIN HYDROCHLORIDE

		@	LUPIN	EQ 125MG BASE	A090439	001	Jan 28, 2015	May DISC
		@		EQ 250MG BASE	A090439	002	Jan 28, 2015	May DISC
	AB		PAI HOLDINGS	EQ 125MG BASE	A065478	001	Apr 09, 2012	Mar CMFD
	AB			EQ 250MG BASE	A065478	002	Apr 09, 2012	Mar CMFD

FOR SOLUTION;ORAL

FIRVANQ KIT

	AA	+!	AZURITY	EQ 25MG BASE/ML	N208910	001	Jan 26, 2018	Apr CTEC
	AA	+!		EQ 50MG BASE/ML	N208910	002	Jan 26, 2018	Apr CTEC

VANCOMYCIN HYDROCHLORIDE

	AA		ALKEM LABS LTD	EQ 25MG BASE/ML	A214913	001	Nov 14, 2022	Apr CTEC
	AA			EQ 50MG BASE/ML	A214913	002	Nov 14, 2022	Apr CTEC
>A>	AA		AUROBINDO PHARMA	EQ 25MG BASE/ML	A218130	001	Aug 07, 2026	Jul NEWA
>A>	AA			EQ 50MG BASE/ML	A218130	002	Aug 07, 2026	Jul NEWA

INJECTABLE;INJECTION

VANCOMYCIN HYDROCHLORIDE

	AP		EUROFARMA	EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	Feb CAHN
	AP			EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	Feb CAHN
>A>	AP		HAINAN POLY	EQ 500MG BASE/VIAL	A212332	001	Jun 12, 2019	Jul CAHN
>A>	AP			EQ 1GM BASE/VIAL	A212332	002	Jun 12, 2019	Jul CAHN
>A>	AP			EQ 5GM BASE/VIAL	A215821	001	Nov 18, 2021	Jul CAHN
>A>	AP			EQ 10GM BASE/VIAL	A215821	002	Nov 18, 2021	Jul CAHN

INJECTABLE;INJECTION
VANCOMYCIN HYDROCHLORIDE

>D>	AP		SLATE RUN PHARMA	EQ 500MG BASE/VIAL	A212332	001	Jun 12, 2019	Jul CAHN
>D>	AP			EQ 1GM BASE/VIAL	A212332	002	Jun 12, 2019	Jul CAHN
>D>	AP			EQ 5GM BASE/VIAL	A215821	001	Nov 18, 2021	Jul CAHN
>D>	AP			EQ 10GM BASE/VIAL	A215821	002	Nov 18, 2021	Jul CAHN

POWDER;INTRAVENOUS
VANCOMYCIN HYDROCHLORIDE

		!	SAMSON MEDCL	EQ 100GM BASE	A091532	001	Jan 06, 2016	Jan CHRS
				EQ 100GM BASE	A091532	001	Jan 06, 2016	Jan CTNA

VARENICLINE TARTRATE
TABLET;ORAL
VARENICLINE TARTRATE

		@	PHARMOBEDIENT	EQ 0.5MG BASE	A202019	001	Feb 28, 2024	May DISC
	AB		PIRAMAL	EQ 0.5MG BASE	A217115	001	Jul 23, 2024	Jan CMFD
	AB			EQ 1MG BASE	A217115	002	Jul 23, 2024	Jan CMFD
	AB		SOMERSET THERAPS LLC	EQ 0.5MG BASE	A219382	001	Jul 06, 2026	Jun NEWA
	AB			EQ 1MG BASE	A219382	002	Jul 06, 2026	Jun NEWA
	AB		UMEDICA	EQ 0.5MG BASE	A218985	001	Jan 09, 2026	Jan NEWA
	AB			EQ 1MG BASE	A218985	002	Jan 09, 2026	Jan NEWA

VASOPRESSIN
SOLUTION;INTRAVENOUS
VASOPRESSIN

		@	EAGLE PHARMS	20UNITS/ML (20UNITS/ML)	A211538	001	Dec 15, 2021	Mar DISC
	AP		SANDOZ	20UNITS/ML (20UNITS/ML)	A212068	001	May 06, 2026	Apr NEWA
	AP			200UNITS/10ML (20UNITS/ML)	A212069	001	May 06, 2026	Apr NFTG

VASOPRESSIN IN DEXTROSE 5%

	AP		DR REDDYS	40UNITS/100ML (0.4UNITS/ML)	A213988	002	Jun 03, 2026	May NEWA

VASOSTRICT

	AP	+!	PH HEALTH	200UNITS/10ML (20UNITS/ML)	N204485	002	Dec 17, 2016	Apr CFTG

VECURONIUM BROMIDE
INJECTABLE;INJECTION
VECURONIUM BROMIDE

	AP	!	EUGIA PHARMA	10MG/VIAL	A206670	001	Dec 20, 2018	May CHRS
	AP	!		20MG/VIAL	A206670	002	Dec 20, 2018	May CHRS
	AP		SUN PHARM	10MG/VIAL	A079001	001	Jun 17, 2009	May CHRS
		@		20MG/VIAL	A079001	002	Jun 17, 2009	May DISC

VENETOCLAX
TABLET;ORAL
VENCLEXTA

	AB	+	ABBVIE	10MG	N208573	001	Apr 11, 2016	May CFTG
	AB	+		50MG	N208573	002	Apr 11, 2016	May CFTG
	AB	+!		100MG	N208573	003	Apr 11, 2016	May CFTG

VENETOCLAX

	AB		DR REDDYS	10MG	A214733	001	May 15, 2026	May NFTG
	AB			50MG	A214733	002	May 15, 2026	May NFTG
	AB			100MG	A214733	003	May 15, 2026	May NFTG

VENLAFAXINE HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE;ORAL
VENLAFAXINE HYDROCHLORIDE

>A>	AB		INVENTIA	EQ 37.5MG BASE	A203332	001	Mar 12, 2020	Jul CAHN
>A>	AB			EQ 75MG BASE	A203332	002	Mar 12, 2020	Jul CAHN
>A>				EQ 100MG BASE	A203332	004	Jul 14, 2026	Jul CAHN
>A>	AB			EQ 150MG BASE	A203332	003	Mar 12, 2020	Jul CAHN
>D>	AB		INVENTIA HLTHCARE	EQ 37.5MG BASE	A203332	001	Mar 12, 2020	Jul CAHN
>D>	AB			EQ 75MG BASE	A203332	002	Mar 12, 2020	Jul CAHN
>A>				EQ 100MG BASE	A203332	004	Jul 14, 2026	Jul NFTG
>D>	AB			EQ 150MG BASE	A203332	003	Mar 12, 2020	Jul CAHN
	AB		PLATINUM	EQ 37.5MG BASE	A201272	001	Nov 23, 2018	Apr CAHN
	AB			EQ 75MG BASE	A201272	002	Nov 23, 2018	Apr CAHN
	AB			EQ 150MG BASE	A201272	003	Nov 23, 2018	Apr CAHN

TABLET, EXTENDED RELEASE;ORAL
VENLAFAXINE HYDROCHLORIDE

		@	ADAPTIS	EQ 75MG BASE	A213927	001	Jan 21, 2021	Mar DISC
		@	PHARMADAX	EQ 75MG BASE	A214423	001	Jan 04, 2022	Mar CAHN
		@		EQ 150MG BASE	A214423	002	Jan 04, 2022	Mar CAHN

VEPDEGESTRANT
TABLET;ORAL
VEPPANU

	+	ARVINAS OPERATIONS	100MG	N219835	001	May 01, 2026	May NEWA
	+!		200MG	N219835	002	May 01, 2026	May NEWA
	+	RIGEL PHARMS	100MG	N219835	001	May 01, 2026	Jun CAHN
	+!		200MG	N219835	002	May 01, 2026	Jun CAHN

VERAPAMIL HYDROCHLORIDE
INJECTABLE;INJECTION
VERAPAMIL HYDROCHLORIDE

>A> AP		KNACK	2.5MG/ML	A220076	001	Jul 22, 2026	Jul NEWA

SOLUTION;INTRAVENOUS
VERAPAMIL HYDROCHLORIDE

	@	AMNEAL	5MG/2ML (2.5MG/ML)	A210994	001	Jul 13, 2018	Mar DISC
	@		10MG/4ML (2.5MG/ML)	A210994	002	Jul 13, 2018	Mar DISC
	@	HOSPIRA	5MG/2ML (2.5MG/ML)	A075136	001	Oct 20, 1998	Jun DISC
	@		10MG/4ML (2.5MG/ML)	A075136	001	Oct 20, 1998	Jun CPOT

VIGABATRIN
FOR SOLUTION;ORAL
VIGABATRIN

	@	TEVA PHARMS USA	500MG/PACKET	A209824	001	Apr 23, 2018	Jan DISC

VIGADRONE

>D> AA		AUCTA	500MG/PACKET	A210196	001	Jun 21, 2018	Jul CAHN
>A> AA		BORA	500MG/PACKET	A210196	001	Jun 21, 2018	Jul CAHN

VINORELBINE TARTRATE
INJECTABLE;INJECTION
VINORELBINE TARTRATE

	@	INGENUS PHARMS LLC	EQ 10MG BASE/ML	A208997	001	Aug 05, 2019	May CAHN

VORICONAZOLE
POWDER;INTRAVENOUS
VORICONAZOLE

>A> AP		HAINAN POLY	200MG/VIAL	A211661	001	Nov 30, 2018	Jul CAHN
>D> AP		SLATE RUN PHARMA	200MG/VIAL	A211661	001	Nov 30, 2018	Jul CAHN
AP		ZHEJIANG NOVUS	200MG/VIAL	A220078	001	May 05, 2026	Apr NEWA

XENON XE-133
GAS;INHALATION
XENON XE 133

		SHINE	10mCi/VIAL	N017284	001		Feb CAHN
			20mCi/VIAL	N017284	002		Feb CAHN

ZICONOTIDE ACETATE
INJECTABLE;INTRATHECAL
PRIALT

	+!	ESTEVE	100MCG/1ML (100MCG/ML)	N021060	002	Dec 28, 2004	Apr CAHN
	@		200MCG/2ML (100MCG/ML)	N021060	003	Dec 28, 2004	Apr CAHN
	+!		500MCG/20ML (25MCG/ML)	N021060	001	Dec 28, 2004	Apr CAHN
	+!		500MCG/5ML (100MCG/ML)	N021060	004	Dec 28, 2004	Apr CAHN

>A> ZIDESAMTINIB
>A> TABLET;ORAL
>A> JIDEYTRO

>A>	+	NUVALENT	25MG	N220185	001	Jul 22, 2026	Jul NEWA
>A>	+!		100MG	N220185	002	Jul 22, 2026	Jul NEWA

ZINC CHLORIDE
INJECTABLE;INJECTION
ZINC CHLORIDE

AP		STIRA	EQ 1MG ZINC/ML	A217625	001	Apr 14, 2025	Apr CAHN

ZINC SULFATE
SOLUTION;INTRAVENOUS
ZINC SULFATE

AP		STIRA	EQ 10MG BASE/10ML (EQ 1MG BASE/ML)	A217624	001	Jun 10, 2025	Apr CAHN
AP			EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	A217624	002	Jun 10, 2025	Apr CAHN

SOLUTION;INTRAVENOUS
ZINC SULFATE

AP		EQ 30MG BASE/10ML (EQ 3MG BASE/ML)	A217624	003	Jun 10, 2025	Apr	CAHN

ZOLEDRONIC ACID

INJECTABLE;INTRAVENOUS
ZOLEDRONIC ACID

AP		GLAND	EQ 4MG BASE/100ML	A219984	001	Feb 05, 2026	Jan NEWA
	@	HOSPIRA INC	EQ 5MG BASE/100ML	A202837	001	Apr 05, 2013	Jan DISC
	@	INGENUS PHARMS LLC	EQ 4MG BASE/5ML	A208968	001	Feb 19, 2020	Jun CAHN

ZOLPIDEM TARTRATE

CAPSULE;ORAL
ZOLPIDEM TARTRATE

AB	+!	ALMATICA	7.5MG	N215721	001	May 09, 2023	May CFTG
AB		UMEDICA LABS PVT	7.5MG	A220717	001	May 12, 2026	May NFTG

TABLET;ORAL
ZOLPIDEM TARTRATE

	@	SENORES PHARMS	5MG	A077985	001	Apr 23, 2007	Jan CAHN
	@		10MG	A077985	002	Apr 23, 2007	Jan CAHN
	@	TEVA	5MG	A076410	001	Apr 23, 2007	May DISC
	@		10MG	A076410	002	Apr 23, 2007	May DISC

TABLET, EXTENDED RELEASE;ORAL
ZOLPIDEM TARTRATE

AB		BRECKENRIDGE	6.25MG	A213592	001	Jun 04, 2020	Jan CMFD
AB			12.5MG	A213592	002	Jun 04, 2020	Jan CMFD

ACETAMINOPHEN

SUPPOSITORY;RECTAL

ACEPHEN

@	COSETTE PHARMS NC	120MG	A072218	001	Mar 27, 1992	May	CAHN
@		325MG	A072344	001	Mar 27, 1992	May	CAHN
@		650MG	A072237	001	Mar 27, 1992	May	CAHN

ACETAMINOPHEN; NAPROXEN SODIUM

TABLET;ORAL

TYLENOL WITH NAPROXEN

>A> +!	KENVUE BRANDS	325MG;110MG	N219962	001	Jul 24, 2026	Jul	NEWA

ADAPALENE

GEL;TOPICAL

ADAPALENE

	UNIQUE	0.1%	A219565	001	Jun 30, 2026	Jun	NEWA

ADAPALENE; BENZOYL PEROXIDE

GEL;TOPICAL

DIFFERIN EPIDUO

+!	GALDERMA LABS LP	0.1%;2.5%	N220736	001	May 22, 2026	May	NEWA

ALCOHOL; CHLORHEXIDINE GLUCONATE

SOLUTION;TOPICAL

AVAGARD

+!	SOLVENTUM	61%;1%	N021074	001	Jun 07, 2001	Apr	CAHN

AZELASTINE HYDROCHLORIDE

SPRAY, METERED;NASAL

AZELASTINE HYDROCHLORIDE

@	AMNEAL	0.2055MG/SPRAY	A216576	001	Jun 05, 2024	Feb	DISC

CETIRIZINE HYDROCHLORIDE

CAPSULE;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

>A>	ONESOURCE	10MG	A205291	001	Jul 21, 2017	Jul	CAHN
>D>	ONESOURCE SPECIALTY	10MG	A205291	001	Jul 21, 2017	Jul	CAHN

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

@	AMNEAL PHARMS NY	5MG	A078780	001	Jan 21, 2010	Mar	DISC
@		10MG	A078780	004	Jan 21, 2010	Mar	DISC

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

@	AMNEAL PHARMS NY	5MG	A078780	003	Jan 21, 2010	Mar	DISC
@		10MG	A078780	002	Jan 21, 2010	Mar	DISC

CHLORHEXIDINE GLUCONATE

SOLUTION;TOPICAL

DYNA-HEX 2

+!	XTTRIUM	2%	N019422	001	Dec 17, 1985	Feb	CTNA

DYNA-HEX 4

	XTTRIUM	4%	N019125	001	Dec 24, 1984	Feb	CTNA

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SOLUTION;TOPICAL

SOLUPREP S

+!	SOLVENTUM	2%;70%	N208288	001	Aug 08, 2018	Apr	CAHN

CLOTRIMAZOLE

CREAM;VAGINAL

CLOTRIMAZOLE

!	ENCUBE	1%	A074165	001	Jul 16, 1993	May	CAHN

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

MUCINEX DM

+	RECKITT BENCKISER	30MG;600MG	N021620	002	Apr 29, 2004	Jun	CAHN
+!		60MG;1.2GM	N021620	001	Apr 29, 2004	Jun	CAHN

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN; NAPROXEN SODIUM

TABLET, EXTENDED RELEASE;ORAL

MUCINEX 12HR COLD & FEVER MULTI-SYMPTOM

	+!	RECKITT BENCKISER	30MG;600MG;110MG	N217338	001	Dec 22, 2025	Jun	CAHN

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL

DELSYM

	+!	RECKITT BENCKISER	EQ 30MG HYDROBROMIDE/5ML	N018658	001	Oct 08, 1982	Jun	CAHN

DEXTROMETHORPHAN POLISTIREX

		AUROBINDO PHARMA LTD	EQ 30MG HYDROBROMIDE/5ML	A218417	001	Apr 15, 2026	Apr	NEWA

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE;ORAL

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

>A>		ONESOURCE	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A200888	001	Mar 05, 2012	Jul	CAHN
>D>		ONESOURCE SPECIALTY	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A200888	001	Mar 05, 2012	Jul	CAHN

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET;ORAL

NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE

	@	AMNEAL PHARMS CO	25MG;220MG	A209726	001	Oct 23, 2018	Mar	DISC

DOCOSANOL

CREAM;TOPICAL

DOCOSANOL

>A>		KLM LABS PVT	10%	A220017	001	Jul 31, 2026	Jul	NEWA

ESOMEPRAZOLE MAGNESIUM

TABLET, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

	@	MYLAN	EQ 20MG BASE	A212088	001	Jun 25, 2020	Jun	DISC

FEXOFENADINE HYDROCHLORIDE

TABLET;ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

	@	TEVA	30MG	A076447	004	Apr 13, 2011	Mar	DISC
		TIME CAP LABS	30MG	A079112	002	Feb 08, 2012	Mar	CAHN

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

	@	TEVA	30MG	A076447	005	Apr 13, 2011	Mar	DISC
		TIME CAP LABS	30MG	A079112	001	Feb 08, 2012	Mar	CAHN

FEXOFENADINE HYDROCHLORIDE

>A>		DR REDDYS	60MG	A220413	001	Jul 30, 2026	Jul	NEWA
>A>			180MG	A220413	002	Jul 30, 2026	Jul	NEWA

FEXOFENADINE HYDROCHLORIDE ALLERGY

	@	RISING	60MG	A077081	006	Jul 21, 2011	Mar	DISC
	@		180MG	A077081	008	Jul 21, 2011	Mar	DISC
	@	TEVA	60MG	A076447	006	Apr 13, 2011	Mar	DISC
	@		180MG	A076447	008	Apr 13, 2011	Mar	DISC
		TIME CAP LABS	60MG	A079112	004	Feb 08, 2012	Mar	CAHN
			180MG	A079112	006	Feb 08, 2012	Mar	CAHN

FEXOFENADINE HYDROCHLORIDE HIVES

	@	RISING	60MG	A077081	007	Jul 21, 2011	Mar	DISC
	@		180MG	A077081	009	Jul 21, 2011	Mar	DISC
	@	TEVA	60MG	A076447	007	Apr 13, 2011	Mar	DISC
		TIME CAP LABS	60MG	A079112	003	Feb 08, 2012	Mar	CAHN
			180MG	A079112	005	Feb 08, 2012	Mar	CAHN

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

		AUROBINDO PHARMA LTD	180MG;240MG	A215232	001	Apr 17, 2025	Feb	CMFD

FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

FLUTICASONE PROPIONATE

		GLENMARK PHARMS LTD	0.05MG/SPRAY	A218742	001	Mar 16, 2026	Mar	NEWA
		GLENMARK SPECLT	0.05MG/SPRAY	A218742	001	Mar 16, 2026	Apr	CAHN
		RUBICON RESEARCH	0.05MG/SPRAY	A219060	001	Aug 15, 2025	May	CAHN

GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

MUCINEX

	+	RECKITT BENCKISER	600MG	N021282	001	Jul 12, 2002	Jun CAHN
	+!		1.2GM	N021282	002	Dec 18, 2002	Jun CAHN

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

MUCINEX D

	+	RECKITT BENCKISER	600MG;60MG	N021585	001	Jun 22, 2004	Jun CAHN
	+!		1.2GM;120MG	N021585	002	Jun 22, 2004	Jun CAHN

IBUPROFEN

CAPSULE;ORAL

IBUPROFEN

>A>		ONESOURCE	EQ 200MG FREE ACID AND POTASSIUM SALT	A204469	001	Mar 28, 2018	Jul CAHN
>D>		ONESOURCE SPECIALTY	EQ 200MG FREE ACID AND POTASSIUM SALT	A204469	001	Mar 28, 2018	Jul CAHN

SUSPENSION;ORAL

IBUPROFEN

		RUBICON RESEARCH	100MG/5ML	A220239	001	Mar 05, 2026	Feb NEWA

>A> MOTRIN IB

>A>	+!	KENVUE BRANDS	200MG/10ML	N020516	002	Jul 22, 2026	Jul NEWA

TABLET;ORAL

IBUPROFEN

>A>	@	ALLIED	200MG	A071870	001	May 05, 1988	Jul CAHN
	@	AMNEAL PHARMS	200MG	A079233	001	Mar 18, 2014	Apr DISC
	@	AMNEAL PHARMS NY	200MG	A071333	001	Feb 17, 1987	Mar DISC
	@	PH HEALTH	200MG	A071229	001	Apr 01, 1987	May DISC
>D>	@	PHARMOBEDIENT	200MG	A071870	001	May 05, 1988	Jul CAHN

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET;ORAL

IBUPROHM COLD AND SINUS

>D>		OHM LABS	200MG;30MG	A074567	001	Apr 17, 2001	Jul DISC
>A>	@		200MG;30MG	A074567	001	Apr 17, 2001	Jul DISC

IODINE POVACRYLEX; ISOPROPYL ALCOHOL

SPONGE;TOPICAL

DURAPREP

	+!	SOLVENTUM	EQ 0.7% IODINE;74% (6ML)	N021586	001	Sep 29, 2006	Apr CAHN
	+!		EQ 0.7% IODINE;74% (26ML)	N021586	002	Sep 29, 2006	Apr CAHN

KETOTIFEN FUMARATE

SOLUTION/DROPS;OPHTHALMIC

KETOTIFEN FUMARATE

	@	APOTEX INC	EQ 0.025% BASE	A077354	001	May 09, 2006	Apr DISC

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

LOPERAMIDE HYDROCHLORIDE

>A>		ONESOURCE	2MG	A213070	001	Aug 11, 2021	Jul CAHN
>D>		ONESOURCE SPECIALTY	2MG	A213070	001	Aug 11, 2021	Jul CAHN

LORATADINE

CAPSULE;ORAL

LORATADINE

>A>	@	ONESOURCE	10MG	A211926	001	Jan 15, 2020	Jul CAHN
>D>	@	ONESOURCE SPECIALTY	10MG	A211926	001	Jan 15, 2020	Jul CAHN

TABLET;ORAL

LORATADINE

>A>	@	ALLIED	10MG	A075790	001	Nov 07, 2008	Jul CAHN
>D>	@	PHARMOBEDIENT	10MG	A075790	001	Nov 07, 2008	Jul CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

LORATADINE

		INSTAPILL	5MG	A212795	001	Sep 18, 2020	Feb CAHN
			10MG	A213294	001	Oct 30, 2020	Feb CAHN

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

LORATADINE AND PSEUDOEPHEDRINE SULFATE

>A>		DR REDDYS	5MG;120MG	A220448	001	Aug 06, 2026	Jul NEWA

MENTHOL; METHYL SALICYLATE

PATCH;TOPICAL

SALONPAS

	+!	HISAMITSU PHARM CO	3%;10%	N022029	002	Nov 05, 2012	Mar CHRS

MICONAZOLE NITRATE

CREAM;VAGINAL

MICONAZOLE 7

		ENCUBE	2%	A074164	001	Mar 29, 1996	May CAHN

MICONAZOLE NITRATE

	@	COSETTE PHARMS NC	2%	A074366	001	Feb 22, 1996	Jun CAHN

CREAM, SUPPOSITORY;TOPICAL, VAGINAL

M-ZOLE 3 COMBINATION PACK

		COSETTE PHARMS NC	2%,200MG	A074926	001	Apr 16, 1999	May CAHN

MICONAZOLE 7 COMBINATION PACK

	@	COSETTE PHARMS NC	2%,100MG	A076585	001	Mar 26, 2004	Jun CAHN

SUPPOSITORY;VAGINAL

MICONAZOLE NITRATE

		COSETTE PHARMS NC	100MG	A073507	001	Nov 19, 1993	May CAHN
	@		100MG	A074414	001	Apr 30, 1997	Jun CAHN

MINOXIDIL

SOLUTION;TOPICAL

MINOXIDIL (FOR MEN)

>D>	@	AUROBINDO PHARMA LTD	2%	A074767	001	Feb 28, 1997	Jul CMFD
>A>			2%	A074767	001	Feb 28, 1997	Jul CMFD

MINOXIDIL (FOR WOMEN)

>D>	@	AUROBINDO PHARMA LTD	2%	A074767	002	Nov 25, 1997	Jul CMFD
>A>			2%	A074767	002	Nov 25, 1997	Jul CMFD

NALOXONE HYDROCHLORIDE

SPRAY, METERED;NASAL

REXTOVY

	+!	AMPHASTAR PHARMS INC	4MG/SPRAY	N208969	001	Mar 07, 2023	Jun CMKT

NAPROXEN SODIUM

CAPSULE;ORAL

NAPROXEN SODIUM

>A>	@	ONESOURCE	EQ 200MG BASE	A215472	001	Aug 17, 2022	Jul CAHN
>D>	@	ONESOURCE SPECIALTY	EQ 200MG BASE	A215472	001	Aug 17, 2022	Jul CAHN

NICOTINE POLACRILEX

TROCHE/LOZENGE;ORAL

>A>	HABITROL						
>A>		DR REDDYS LABS SA	EQ 2MG BASE	A215276	001	Jul 17, 2025	Jul CTNA
>A>			EQ 4MG BASE	A215276	002	Jul 17, 2025	Jul CTNA
>D>	NICOTINE POLACRILEX						
>D>		DR REDDYS LABS SA	EQ 2MG BASE	A215276	001	Jul 17, 2025	Jul CTNA
>D>			EQ 4MG BASE	A215276	002	Jul 17, 2025	Jul CTNA

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

	@	FDC LTD	EQ 0.2% BASE	A217051	001	Jul 14, 2025	Feb DISC

PERMETHRIN

LOTION;TOPICAL

PERMETHRIN

	@	PERRIGO NEW YORK	1%	A076090	001	Dec 20, 2001	Feb DISC

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL

POLYETHYLENE GLYCOL 3350

	ALLIED	17GM/SCOOPFUL	A090812	001	Oct 07, 2009		Apr CAHN
>A>	LNK INTL INC	17GM/SCOOPFUL	A217505	001	Jul 29, 2026		Jul NEWA
>A>		17GM/PACKET	A217505	002	Jul 29, 2026		Jul NEWA
	POINTVIEW HLDINGS	17GM/SCOOPFUL	A090812	001	Oct 07, 2009		Jun CAHN

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

@	RISING	EQ 75MG BASE	A075497	001	Jan 14, 2000		Mar CAHN

TRIAMCINOLONE ACETONIDE

SPRAY, METERED;NASAL

TRIAMCINOLONE ACETONIDE

>A>	AUROBINDO PHARMA LTD	0.055MG/SPRAY	A220110	001	Aug 11, 2026		Jul NEWA

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 7 JULY 2026

NO JULY 2026 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO JULY 2026 APPROVALS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ABIRATERONE ACETATE; NIRAPARIB TOSYLATE - AKEEGA						
N 216793 001	11207311	Jul 28, 2037	U-2830		I-980	Dec 12, 2028
	11207311	Jul 28, 2037	U-4368			
	11673877	Mar 27, 2038	DS DP U-2830			
	11673877	Mar 27, 2038	DS DP U-4368			
	11986468	Jul 28, 2037	U-2830			
	11986468	Jul 28, 2037	U-4368			
	11986469	Jul 28, 2037	U-2830			
	11986469	Jul 28, 2037	U-4368			
	11986470	Jul 28, 2037	U-4368			
	11992486	Jul 28, 2037	U-2830			
	11992486	Jul 28, 2037	U-4368			
	12383543	Jul 28, 2037	U-2830			
	12383543	Jul 28, 2037	U-4368			
	8071579	Aug 12, 2027	U-2830			
	8071579	Aug 12, 2027	U-4368			
	8143241	Aug 12, 2027	U-2830			
	8143241	Aug 12, 2027	U-4368			
	8859562	Aug 04, 2031	U-2830			
	8859562	Aug 04, 2031	U-4368			
ABIRATERONE ACETATE; NIRAPARIB TOSYLATE - AKEEGA						
N 216793 002	11207311	Jul 28, 2037	U-2830		I-980	Dec 12, 2028
	11207311	Jul 28, 2037	U-4368			
	11673877	Mar 27, 2038	DS DP U-2830			
	11673877	Mar 27, 2038	DS DP U-4368			
	11986468	Jul 28, 2037	U-2830			
	11986468	Jul 28, 2037	U-4368			
	11986469	Jul 28, 2037	U-2830			
	11986469	Jul 28, 2037	U-4368			
	11986470	Jul 28, 2037	U-4368			
	11992486	Jul 28, 2037	U-2830			
	11992486	Jul 28, 2037	U-4368			
	12383543	Jul 28, 2037	U-2830			
	12383543	Jul 28, 2037	U-4368			
	8071579	Aug 12, 2027	U-2830			
	8071579	Aug 12, 2027	U-4368			
	8143241	Aug 12, 2027	U-2830			
	8143241	Aug 12, 2027	U-4368			
	8859562	Aug 04, 2031	U-2830			
	8859562	Aug 04, 2031	U-4368			
ACALABRUTINIB - CALQUENCE						
N 210259 001	11166951	Aug 11, 2035	U-4426		D-200	Feb 19, 2029
	11166951	Aug 11, 2035	U-4427			
	11166951	Aug 11, 2035	U-4428			
	11166951	Aug 11, 2035	U-4429			
	11166951	Aug 11, 2035	U-4430			
	11166951	Aug 11, 2035	U-4431			
ACALABRUTINIB MALEATE - CALQUENCE						
N 216387 001	11166951	Aug 11, 2035	U-4426		D-200	Feb 19, 2029
	11166951	Aug 11, 2035	U-4427			
	11166951	Aug 11, 2035	U-4428			
	11166951	Aug 11, 2035	U-4429			
	11166951	Aug 11, 2035	U-4430			
	11166951	Aug 11, 2035	U-4431			
ACECLIDINE HYDROCHLORIDE - VIZZ						
N 218585 001	12533347	Oct 08, 2039	U-3741			
>A>	12653779	Jun 18, 2035	U-3741			
ACORAMIDIS HYDROCHLORIDE - ATTRUBY						
N 216540 001	12539290	Aug 16, 2039	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ADAGRASIB - KRAZATI								
N 216340	001	>A>	12653789	Aug 21, 2043	DP			
ADAPALENE; BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - CABTREO								
N 216632	001		12616710	Jul 31, 2040	DP			
AFICAMTEN - MYQORZO								
N 219083	001		10836755	Jan 18, 2039	DS DP		U-4371	
			12370179	Jul 15, 2042			U-4371	
AFICAMTEN - MYQORZO								
N 219083	002		10836755	Jan 18, 2039	DS DP		U-4371	
			12370179	Jul 15, 2042			U-4371	
AFICAMTEN - MYQORZO								
N 219083	003		10836755	Jan 18, 2039	DS DP		U-4371	
			12370179	Jul 15, 2042			U-4371	
AFICAMTEN - MYQORZO								
N 219083	004		10836755	Jan 18, 2039	DS DP		U-4371	
			12370179	Jul 15, 2042			U-4371	
ALBUTEROL SULFATE - ALBUTEROL SULFATE								
A 219409	001						CGT	Dec 19, 2026
ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K - MULTIPLE VITAMINS INJECTION ADULT								
A 210672	001						CGT	Dec 01, 2026
AMIFAMPRIDINE PHOSPHATE - FIRDAPSE								
N 208078	001						ODE-553	Sep 29, 2029
AMIKACIN SULFATE - ARIKAYCE KIT								
N 207356	001		12616708	May 15, 2035			U-2414	
AMIODARONE HYDROCHLORIDE - NEXTERONE								
N 022325	002		10117951	Mar 13, 2029	DP			
			8410077	Mar 13, 2029	DP			
			9200088	Mar 13, 2029	DP			
			9493582	Feb 27, 2033	DP			
			9750822	Mar 13, 2029	DP			
AMIODARONE HYDROCHLORIDE - NEXTERONE								
N 022325	003		10117951	Mar 13, 2029	DP			
			8410077	Mar 13, 2029	DP			
			9200088	Mar 13, 2029	DP			
			9493582	Feb 27, 2033	DP			
			9750822	Mar 13, 2029	DP			
AMLODIPINE BESYLATE; INDAPAMIDE; TELMISARTAN - WIDAPLIK								
N 219423	003		12673047	Jan 23, 2038	DP			
AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE - VOQUEZNA TRIPLE PAK								
N 215152	001		7977488	Apr 10, 2030	DS			
APALUTAMIDE - ERLEADA								
N 210951	001		11723898	Jan 14, 2041			U-4449	
			12303497	Jan 30, 2040			U-4448	
			12303497	Jan 30, 2040			U-4494	
			8445507	Feb 14, 2032	DS DP		U-2237	
			8445507	Feb 14, 2032	DS DP		U-2624	
			RE50642	Sep 23, 2033			U-4450	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
APALUTAMIDE - ERLEADA						
N 210951 002	11723898	Jan 14, 2041	U-4449			
	12303497	Jan 30, 2040	U-4448			
	12303497	Jan 30, 2040	U-4494			
	8445507	Feb 14, 2032	DS DP U-2237			
	8445507	Feb 14, 2032	DS DP U-2624			
	RE50642	Sep 23, 2033	U-4450			
APREMILAST - OTEZLA						
N 205437 001	12576034	Nov 30, 2033	DP U-1858			
	12576034	Nov 30, 2033	DP U-4290			
	12576034	Nov 30, 2033	DP U-4291			
	12576034*PED	May 30, 2034				
APREMILAST - OTEZLA						
N 205437 002	12576034	Nov 30, 2033	DP U-1858			
	12576034	Nov 30, 2033	DP U-4290			
	12576034	Nov 30, 2033	DP U-4291			
	12576034*PED	May 30, 2034				
APREMILAST - OTEZLA						
N 205437 003	12576034	Nov 30, 2033	DP U-1858			
	12576034	Nov 30, 2033	DP U-4290			
	12576034	Nov 30, 2033	DP U-4291			
	12576034*PED	May 30, 2034				
ARIMOCLOMOL CITRATE - MIPLYFFA						
N 214927 001	11707456	Nov 19, 2041	DS DP U-4021			
ARIMOCLOMOL CITRATE - MIPLYFFA						
N 214927 002	11707456	Nov 19, 2041	DS DP U-4021			
ARIMOCLOMOL CITRATE - MIPLYFFA						
N 214927 003	11707456	Nov 19, 2041	DS DP U-4021			
ARIMOCLOMOL CITRATE - MIPLYFFA						
N 214927 004	11707456	Nov 19, 2041	DS DP U-4021			
ARIPIPRAZOLE LAUROXIL - ARISTADA						
N 207533 001	11097006	Sep 19, 2033	DP U-764			
	11969469	Apr 06, 2034	DP			
	12629366	Dec 06, 2032	DP U-764			
	>A> 12653822	Mar 19, 2035	U-2402			
ARIPIPRAZOLE LAUROXIL - ARISTADA						
N 207533 002	11097006	Sep 19, 2033	DP U-764			
	11969469	Apr 06, 2034	DP			
	12629366	Dec 06, 2032	DP U-764			
	>A> 12653822	Mar 19, 2035	U-2402			
ARIPIPRAZOLE LAUROXIL - ARISTADA						
N 207533 003	11097006	Sep 19, 2033	DP U-764			
	11969469	Apr 06, 2034	DP			
	12629366	Dec 06, 2032	DP U-764			
	>A> 12653822	Mar 19, 2035	U-2402			
ARIPIPRAZOLE LAUROXIL - ARISTADA						
N 207533 004	11097006	Sep 19, 2033	DP U-764			
	11969469	Apr 06, 2034	DP			
	12629366	Dec 06, 2032	DP U-764			
	>A> 12653822	Mar 19, 2035	U-2402			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARTESUNATE - ARTESUNATE						
N 213036 001	12390442	Feb 16, 2044	U-4433			
ARTICAINE HYDROCHLORIDE - CYKLX						
N 218643 001	11096922	Mar 27, 2039	DP U-4423			
	11826347	Mar 27, 2039	DP U-4423			
	12403126	Mar 27, 2039	DP U-4422			
ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K - MULTIPLE VITAMINS INJECTION PEDIATRIC						
A 210671 001					CGT	Dec 21, 2026
ATOGEPANT - QULIPTA						
N 215206 001	12622897	Sep 27, 2042	U-4536			
	8754096	Sep 28, 2035	DS DP U-3534			
ATOGEPANT - QULIPTA						
N 215206 002	12622897	Sep 27, 2042	U-4536			
	8754096	Sep 28, 2035	DS DP U-3534			
ATOGEPANT - QULIPTA						
N 215206 003	8754096	Sep 28, 2035	DS DP U-3534			
ATORVASTATIN CALCIUM - ATORVALIQ						
N 213260 001	12599553	Jun 07, 2037	DP			
ATRASENTAN HYDROCHLORIDE - VANRAFIA						
N 219208 001	12521369	Mar 02, 2041	U-3980			
	12582631	Mar 25, 2043	U-3980			
AVACINCAPTAD PEGOL SODIUM - IZERVAY						
N 217225 001	7579456	Feb 14, 2027	DS			
	9617546	Feb 14, 2027	DS U-3673			
AVACOPAN - TAVNEOS						
N 214487 001	8906938	Jan 06, 2034	DS DP			
AVATROMBOPAG MALEATE - DOPTELET						
N 210238 001					ODE-548	Jul 24, 2032
AVATROMBOPAG MALEATE - DOPTELET SPRINKLE						
N 219696 001					ODE-548	Jul 24, 2032
AVUTOMETINIB POTASSIUM; DEFACTINIB HYDROCHLORIDE - AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)						
N 219616 001	12509450	Dec 29, 2042	DP		ODE-525	May 08, 2032
AXITINIB - INLYTA						
N 202324 001	12534530	Feb 03, 2035	U-4411			
	12534530	Feb 03, 2035	U-4412			
	12534530*PED	Aug 03, 2035				
AXITINIB - INLYTA						
N 202324 002	12534530	Feb 03, 2035	U-4411			
	12534530	Feb 03, 2035	U-4412			
	12534530*PED	Aug 03, 2035				
AZILSARTAN KAMEDOXOMIL - AZILSARTAN MEDOXOMIL						
A 214489 001					PC	Dec 12, 2026
AZILSARTAN KAMEDOXOMIL - AZILSARTAN MEDOXOMIL						
A 214489 002					PC	Dec 12, 2026

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BALOXAVIR MARBOXIL - XOFLUZA							
N 210854 001		8987441	Oct 24, 2032	DS DP			
BALOXAVIR MARBOXIL - XOFLUZA							
N 210854 002		8987441	Oct 24, 2032	DS DP			
BALOXAVIR MARBOXIL - XOFLUZA							
N 210854 003		8987441	Oct 24, 2032	DS DP			
BALOXAVIR MARBOXIL - XOFLUZA							
N 214410 001		8987441	Oct 24, 2032	DS DP			
BALOXAVIR MARBOXIL - XOFLUZA							
N 214410 002		8987441	Oct 24, 2032	DS DP		M-187	Dec 19, 2027
BALOXAVIR MARBOXIL - XOFLUZA							
N 214410 003		8987441	Oct 24, 2032	DS DP		M-187	Dec 19, 2027
BAXDROSTAT - BAXFENDY							
N 219878 001		9353081	Feb 04, 2033	DS DP		NCE	May 15, 2031
BAXDROSTAT - BAXFENDY							
N 219878 002		9353081	Feb 04, 2033	DS DP		NCE	May 15, 2031
BECLOMETHASONE DIPROPIONATE; FORMOTEROL FUMARATE; GLYCOPYRROLATE - TRIMBOW							
N 219622 001		10159645	Dec 23, 2030	DP U-4538		NP	May 14, 2029
		10617638	Dec 23, 2034	DP U-4538			
		10806701	Dec 23, 2030	DP			
		11389401	Dec 23, 2030	DP			
		11590074	Dec 23, 2030	U-4538			
		12357568	Dec 23, 2030	DP U-4538			
BECLOMETHASONE DIPROPIONATE; FORMOTEROL FUMARATE; GLYCOPYRROLATE - TRIMBOW							
N 219622 002		10159645	Dec 23, 2030	DP U-4538		NP	May 14, 2029
		10617638	Dec 23, 2034	DP U-4538			
		10806701	Dec 23, 2030	DP			
		11389401	Dec 23, 2030	DP			
		11590074	Dec 23, 2030	U-4538			
		12357568	Dec 23, 2030	DP U-4538			
BELZUTIFAN - WELIREG							
N 215383 001	>A>	10335388	Apr 14, 2036	U-4565	>A>	I-994	Jun 12, 2029
	>A>	9908845	Sep 05, 2034	DS DP U-3201			
	>A>	9908845	Sep 05, 2034	DS DP U-4176			
	>A>	9908845	Sep 05, 2034	DS DP U-4195			
	>A>	9908845	Sep 05, 2034	DS DP U-4565			
	>A>	RE49948	Sep 05, 2034	DS DP U-3201			
	>A>	RE49948	Sep 05, 2034	DS DP U-4176			
	>A>	RE49948	Sep 05, 2034	DS DP U-4195			
	>A>	RE49948	Sep 05, 2034	DS DP U-4565			
BENZGALANTAMINE GLUCONATE - ZUNVEYL							
N 218549 001		12551491	Jul 23, 2045	U-713			
BENZGALANTAMINE GLUCONATE - ZUNVEYL							
N 218549 002		12551491	Jul 23, 2045	U-713			
BENZGALANTAMINE GLUCONATE - ZUNVEYL							
N 218549 003		12551491	Jul 23, 2045	U-713			
BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO							
N 214094 001		12545645	Nov 01, 2039	DS DP			
		12545645*PED	May 01, 2040				
		12545646	Nov 01, 2039	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO						
N 214094 001	12545646*PED	May 01, 2040				
	12545647	Nov 01, 2039	DS DP			
	12545647*PED	May 01, 2040				
	12552750	Nov 01, 2039	DS DP			
	12552750*PED	May 01, 2040				
	12590068	Nov 01, 2039	DS DP			
	12590068*PED	May 01, 2040				
	12590069	Nov 01, 2039	DS DP			
	12590069*PED	May 01, 2040				
BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO						
N 214094 002	12545645	Nov 01, 2039	DS DP			
	12545645*PED	May 01, 2040				
	12545646	Nov 01, 2039	DS DP			
	12545646*PED	May 01, 2040				
	12545647	Nov 01, 2039	DS DP			
	12545647*PED	May 01, 2040				
	12552750	Nov 01, 2039	DS DP			
	12552750*PED	May 01, 2040				
	12590068	Nov 01, 2039	DS DP			
	12590068*PED	May 01, 2040				
	12590069	Nov 01, 2039	DS DP			
	12590069*PED	May 01, 2040				
BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO						
N 219776 001	10125102	Apr 07, 2035	DS		U-4535	
	10125102*PED	Oct 07, 2035				
	10329260	Mar 09, 2035	DS			
	10329260*PED	Sep 09, 2035				
	10662160	Nov 01, 2039	DS		U-4535	
	10662160*PED	May 01, 2040				
	10689346	Mar 09, 2035			U-4535	
	10689346*PED	Sep 09, 2035				
	11117867	Nov 01, 2039	DP		U-4535	
	11117867*PED	May 01, 2040				
	11230530	Mar 09, 2035			U-4535	
	11230530*PED	Sep 09, 2035				
	11618733	Nov 01, 2039			U-4535	
	11618733*PED	May 01, 2040				
	11708333	Mar 09, 2035			U-4535	
	11708333*PED	Sep 09, 2035				
	12116346	Mar 09, 2035	DS			
	12116346*PED	Sep 09, 2035				
	12344585	Nov 01, 2039			U-4535	
	12344585*PED	May 01, 2040				
	12545645	Nov 01, 2039	DS DP			
	12545645*PED	May 01, 2040				
	12545646	Nov 01, 2039	DS DP			
	12545646*PED	May 01, 2040				
	12545647	Nov 01, 2039	DS DP			
	12545647*PED	May 01, 2040				
	12552750	Nov 01, 2039	DS DP			
	12552750*PED	May 01, 2040				
	12590068	Nov 01, 2039	DS DP			
	12590068*PED	May 01, 2040				
	12590069	Nov 01, 2039	DS DP			
	12590069*PED	May 01, 2040				
BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO						
N 219776 002	10125102	Apr 07, 2035	DS		U-4535	
	10125102*PED	Oct 07, 2035				
	10329260	Mar 09, 2035	DS			
	10329260*PED	Sep 09, 2035				
	10662160	Nov 01, 2039	DS		U-4535	
	10662160*PED	May 01, 2040				
	10689346	Mar 09, 2035			U-4535	
	10689346*PED	Sep 09, 2035				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO						
N 219776 002	11117867	Nov 01, 2039	DP		U-4535	
	11117867*PED	May 01, 2040				
	11230530	Mar 09, 2035			U-4535	
	11230530*PED	Sep 09, 2035				
	11618733	Nov 01, 2039			U-4535	
	11618733*PED	May 01, 2040				
	11708333	Mar 09, 2035			U-4535	
	11708333*PED	Sep 09, 2035				
	12116346	Mar 09, 2035	DS			
	12116346*PED	Sep 09, 2035				
	12344585	Nov 01, 2039			U-4535	
	12344585*PED	May 01, 2040				
	12545645	Nov 01, 2039	DS DP			
	12545645*PED	May 01, 2040				
	12545646	Nov 01, 2039	DS DP			
	12545646*PED	May 01, 2040				
	12545647	Nov 01, 2039	DS DP			
	12545647*PED	May 01, 2040				
	12552750	Nov 01, 2039	DS DP			
	12552750*PED	May 01, 2040				
	12590068	Nov 01, 2039	DS DP			
	12590068*PED	May 01, 2040				
	12590069	Nov 01, 2039	DS DP			
	12590069*PED	May 01, 2040				
BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO						
N 219776 003	10125102	Apr 07, 2035	DS		U-4535	
	10125102*PED	Oct 07, 2035				
	10329260	Mar 09, 2035	DS			
	10329260*PED	Sep 09, 2035				
	10662160	Nov 01, 2039	DS		U-4535	
	10662160*PED	May 01, 2040				
	10689346	Mar 09, 2035			U-4535	
	10689346*PED	Sep 09, 2035				
	11117867	Nov 01, 2039		DP	U-4535	
	11117867*PED	May 01, 2040				
	11230530	Mar 09, 2035			U-4535	
	11230530*PED	Sep 09, 2035				
	11618733	Nov 01, 2039			U-4535	
	11618733*PED	May 01, 2040				
	11708333	Mar 09, 2035			U-4535	
	11708333*PED	Sep 09, 2035				
	12116346	Mar 09, 2035	DS			
	12116346*PED	Sep 09, 2035				
	12344585	Nov 01, 2039			U-4535	
	12344585*PED	May 01, 2040				
	12545645	Nov 01, 2039	DS DP			
	12545645*PED	May 01, 2040				
	12545646	Nov 01, 2039	DS DP			
	12545646*PED	May 01, 2040				
	12545647	Nov 01, 2039	DS DP			
	12545647*PED	May 01, 2040				
	12552750	Nov 01, 2039	DS DP			
	12552750*PED	May 01, 2040				
	12590068	Nov 01, 2039	DS DP			
	12590068*PED	May 01, 2040				
	12590069	Nov 01, 2039	DS DP			
	12590069*PED	May 01, 2040				
BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO						
N 219776 004	10125102	Apr 07, 2035	DS		U-4535	
	10125102*PED	Oct 07, 2035				
	10329260	Mar 09, 2035	DS			
	10329260*PED	Sep 09, 2035				
	10662160	Nov 01, 2039	DS		U-4535	
	10662160*PED	May 01, 2040				
	10689346	Mar 09, 2035			U-4535	
	10689346*PED	Sep 09, 2035				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO						
N 219776 004	11117867	Nov 01, 2039	DP U-4535			
	11117867*PED	May 01, 2040				
	11230530	Mar 09, 2035	U-4535			
	11230530*PED	Sep 09, 2035				
	11618733	Nov 01, 2039	U-4535			
	11618733*PED	May 01, 2040				
	11708333	Mar 09, 2035	U-4535			
	11708333*PED	Sep 09, 2035				
	12116346	Mar 09, 2035	DS			
	12116346*PED	Sep 09, 2035				
	12344585	Nov 01, 2039	U-4535			
	12344585*PED	May 01, 2040				
	12545645	Nov 01, 2039	DS DP			
	12545645*PED	May 01, 2040				
	12545646	Nov 01, 2039	DS DP			
	12545646*PED	May 01, 2040				
	12545647	Nov 01, 2039	DS DP			
	12545647*PED	May 01, 2040				
	12552750	Nov 01, 2039	DS DP			
	12552750*PED	May 01, 2040				
	12590068	Nov 01, 2039	DS DP			
	12590068*PED	May 01, 2040				
	12590069	Nov 01, 2039	DS DP			
	12590069*PED	May 01, 2040				
BEXAGLIFLOZIN - BRENZAVVY						
N 214373 001	12594243	Oct 05, 2041	DP			
BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY						
N 210251 001	12594244	Nov 08, 2036	DP U-257		ODE-540	Jul 30, 2032
BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY						
N 210251 002	12594244	Nov 08, 2036	DP U-257		ODE-540	Jul 30, 2032
BINIMETINIB - MEKTOVI						
N 210498 001	7777050	Mar 13, 2027	DS DP			
BIRCH TRITERPENES - FILSUVEZ						
N 215064 001	8828444	Jun 21, 2027	DP			
BOSUTINIB MONOHYDRATE - BOSUTINIB MONOHYDRATE						
A 209543 001					>A> PC	Dec 08, 2026
BOSUTINIB MONOHYDRATE - BOSUTINIB MONOHYDRATE						
A 209543 002					>A> PC	Dec 08, 2026
BRIMONIDINE TARTRATE; CARBACHOL - YUVEZZI						
N 220142 001	12268662	Nov 10, 2042	DP U-3741		NP	Jan 28, 2029
	12268662	Nov 10, 2042	DP U-4419			
	12268662	Nov 10, 2042	DP U-4420			
	8455494	May 24, 2030	U-3741			
	8455494	May 24, 2030	U-4419			
	8455494	May 24, 2030	U-4420			
BRINCIDOFOVIR - TEMBEXA						
N 214460 001	9303051	Jul 30, 2034	DS DP U-3165			
BRINCIDOFOVIR - TEMBEXA						
N 214461 001	9303051	Jul 30, 2034	DS DP U-3165			
BUDESONIDE; FORMOTEROL FUMARATE - SYMBICORT AEROSPHERE						
N 216579 001	10716753	May 28, 2030	DP U-3203		I-988	Apr 27, 2029
	10716753	May 28, 2030	DP U-4513			
	9415009	May 28, 2030	U-3203			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUDESONIDE; FORMOTEROL FUMARATE - SYMBICORT AEROSPHERE							
N 216579	001	9415009	May 28, 2030	U-4513			
BUDESONIDE; FORMOTEROL FUMARATE - SYMBICORT AEROSPHERE							
N 216579	002	10716753	May 28, 2030	DP U-4513		NS	Apr 27, 2029
		9415009	May 28, 2030	U-4513			
BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE - BREZTRI AEROSPHERE							
N 212122	002	10716753	May 28, 2030	DP U-4503		NS	Apr 27, 2029
		11331442	Oct 05, 2038	DP			
		11833292	Oct 05, 2038	DP			
		8324266	May 28, 2030	U-4503			
		8703806	May 28, 2030	U-4503			
		8808713	May 28, 2030	DP U-4503			
		8815258	Mar 17, 2031	U-4503			
		9415009	May 28, 2030	U-4503			
		9463161	May 28, 2030	DP U-4503			
BUMETANIDE - ENBUMYST							
N 219500	001	12558330	May 14, 2045	DP U-4279			
BUPRENORPHINE - SUBLOCADE							
N 209819	001	12622904	Nov 06, 2035	U-4528			
BUPRENORPHINE - SUBLOCADE							
N 209819	002	12622904	Nov 06, 2035	U-4528			
BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY							
N 215430	001	10058518	Nov 05, 2034	U-3419		I-913	Apr 30, 2029
		10058518	Nov 05, 2034	U-4522			
		10064857	Nov 05, 2034	U-3419			
		10064857	Nov 05, 2034	U-4517			
		10080727	Nov 05, 2034	U-3419			
		10080727	Nov 05, 2034	U-4520			
		10092560	Nov 05, 2034	U-3419			
		10092560	Nov 05, 2034	U-4517			
		10092561	Nov 05, 2034	U-3419			
		10092561	Nov 05, 2034	U-4517			
		10105361	Nov 05, 2034	U-3419			
		10105361	Nov 05, 2034	U-4522			
		10251879	Nov 05, 2034	U-3419			
		10251879	Nov 05, 2034	U-4517			
		10463634	Nov 05, 2034	U-3419			
		10463634	Nov 05, 2034	U-4517			
		10512643	Nov 05, 2034	U-3419			
		10512643	Nov 05, 2034	U-4517			
		10596167	Nov 05, 2034	U-3419			
		10596167	Nov 05, 2034	U-4517			
		10780066	Nov 05, 2034	U-3419			
		10780066	Nov 05, 2034	U-4517			
		10786496	Nov 05, 2034	U-3419			
		10786496	Nov 05, 2034	U-4517			
		10806710	Nov 05, 2034	U-3419			
		10806710	Nov 05, 2034	U-4517			
		10881624	Nov 05, 2034	U-3419			
		10881624	Nov 05, 2034	U-4517			
		10966941	Nov 05, 2034	U-3419			
		10966941	Nov 05, 2034	U-4517			
		11007189	Nov 05, 2034	U-4516			
		11065248	Nov 05, 2034	U-3419			
		11065248	Nov 05, 2034	U-4517			
		11123344	Nov 05, 2034	U-3419			
		11123344	Nov 05, 2034	U-4517			
		11191739	Nov 05, 2034	DP U-3419			
		11191739	Nov 05, 2034	DP U-4516			
		11197839	Nov 05, 2034	DP U-3419			
		11197839	Nov 05, 2034	DP U-4516			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY						
N 215430 001	11207281	Nov 05, 2034			U-3419	
	11207281	Nov 05, 2034			U-4537	
	11234946	Nov 05, 2034			U-3419	
	11234946	Nov 05, 2034			U-4526	
	11253492	Nov 05, 2034			U-3419	
	11253492	Nov 05, 2034			U-4526	
	11273133	Nov 05, 2034			U-3419	
	11273133	Nov 05, 2034			U-4526	
	11273134	Nov 05, 2034			U-3419	
	11273134	Nov 05, 2034			U-4517	
	11285118	Nov 05, 2034			U-3419	
	11285118	Nov 05, 2034			U-4526	
	11285146	Nov 05, 2034			U-3419	
	11285146	Nov 05, 2034			U-4517	
	11291638	Nov 05, 2034			U-3419	
	11291638	Nov 05, 2034			U-4517	
	11291665	Nov 05, 2034			U-3419	
	11291665	Nov 05, 2034			U-4517	
	11298352	Nov 05, 2034			U-3419	
	11298352	Nov 05, 2034			U-4517	
	11344544	Nov 05, 2034			U-3419	
	11344544	Nov 05, 2034			U-4517	
	11357744	Nov 05, 2034			U-3419	
	11357744	Nov 05, 2034			U-4517	
	11382874	Nov 05, 2034			U-3419	
	11382874	Nov 05, 2034			U-4517	
	11419867	Nov 05, 2034			U-3419	
	11419867	Nov 05, 2034			U-4517	
	11426370	Nov 05, 2034			U-3419	
	11426370	Nov 05, 2034			U-4526	
	11426401	Nov 05, 2034			U-3419	
	11426401	Nov 05, 2034			U-4517	
	11433067	Nov 05, 2034		DP	U-3419	
	11433067	Nov 05, 2034		DP	U-4516	
	11439636	Nov 05, 2034			U-3419	
	11439636	Nov 05, 2034			U-4517	
	11534414	Nov 05, 2034		DP	U-3419	
	11534414	Nov 05, 2034		DP	U-4516	
	11571417	Nov 05, 2034			U-3419	
	11571417	Nov 05, 2034			U-4526	
	11576909	Nov 05, 2034			U-3419	
	11576909	Nov 05, 2034			U-4526	
	11590124	Nov 05, 2034			U-3419	
	11590124	Nov 05, 2034			U-4526	
	11617747	Nov 05, 2034			U-3563	
	11617747	Nov 05, 2034			U-4526	
	12194005	Jan 23, 2043			U-4523	
	12194036	Apr 20, 2043			U-4521	
	12239642	Jan 20, 2043			U-4515	
	12263161	Jan 20, 2043			U-4515	
	12364674	Jan 23, 2043			U-4516	
	12370154	Feb 15, 2043			U-4518	
	12433884	Jun 05, 2040			U-4514	
	12472155	Feb 23, 2043			U-4519	
	12472156	Jun 05, 2040			U-4516	
	12472174	Jan 20, 2043			U-4515	
	12478622	Jan 20, 2043			U-4515	
	12564587	Jan 20, 2043			U-4515	
	12576078	Jun 05, 2040			U-4516	
	12599576	Feb 15, 2043			U-4518	
>A>	12653795	Nov 28, 2043			U-4516	
>A>	12661408	Jan 20, 2043			U-3419	
>A>	12678506	Jan 20, 2043		DP		
	8569328	Jul 18, 2032		DP	U-3419	
	8569328	Jul 18, 2032		DP	U-4516	
	9168234	Nov 05, 2034			U-3419	
	9168234	Nov 05, 2034			U-4517	
	9198905	Nov 05, 2034			U-3419	
	9198905	Nov 05, 2034			U-4520	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY						
N 215430 001	9205083	Nov 05, 2034	U-3419			
	9205083	Nov 05, 2034	U-4520			
	9238032	Nov 05, 2034	U-3419			
	9238032	Nov 05, 2034	U-4520			
	9278095	Nov 05, 2034	U-3419			
	9278095	Nov 05, 2034	U-4517			
	9314462	Nov 05, 2034	U-3419			
	9314462	Nov 05, 2034	U-4517			
	9370513	Nov 05, 2034	U-3419			
	9370513	Nov 05, 2034	U-4520			
	9375429	Nov 05, 2034	U-3419			
	9375429	Nov 05, 2034	U-4517			
	9408815	Nov 05, 2034	U-3419			
	9408815	Nov 05, 2034	U-4517			
	9421176	Nov 05, 2034	U-3419			
	9421176	Nov 05, 2034	U-4517			
	9457023	Nov 05, 2034	U-3419			
	9457023	Nov 05, 2034	U-4517			
	9457025	Nov 05, 2034	U-3419			
	9457025	Nov 05, 2034	U-4517			
	9474731	Nov 05, 2034	U-3419			
	9474731	Nov 05, 2034	U-4520			
	9486450	Nov 05, 2034	U-3419			
	9486450	Nov 05, 2034	U-4517			
	9700528	Nov 05, 2034	U-3419			
	9700528	Nov 05, 2034	U-4517			
	9700553	Nov 05, 2034	U-3419			
	9700553	Nov 05, 2034	U-4517			
	9707191	Nov 05, 2034	U-3419			
	9707191	Nov 05, 2034	U-4522			
	9763932	Nov 05, 2034	U-3419			
	9763932	Nov 05, 2034	U-4517			
	9861595	Nov 05, 2034	U-3419			
	9861595	Nov 05, 2034	U-4517			
	9867819	Nov 05, 2034	U-3419			
	9867819	Nov 05, 2034	U-4517			
	9968568	Nov 05, 2034	U-3419			
	9968568	Nov 05, 2034	U-4517			
BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY						
N 215430 002	10058518	Nov 05, 2034	U-4522		I-913	Apr 30, 2029
	10064857	Nov 05, 2034	U-4517			
	10080727	Nov 05, 2034	U-4520			
	10092560	Nov 05, 2034	U-4517			
	10092561	Nov 05, 2034	U-4517			
	10105361	Nov 05, 2034	U-4522			
	10251879	Nov 05, 2034	U-4517			
	10463634	Nov 05, 2034	U-4517			
	10512643	Nov 05, 2034	U-4517			
	10780066	Nov 05, 2034	U-4517			
	10881624	Nov 05, 2034	U-4517			
	11007189	Nov 05, 2034	U-4516			
	11207281	Nov 05, 2034	U-4537			
	11234946	Nov 05, 2034	U-4526			
	11253492	Nov 05, 2034	U-4526			
	11273133	Nov 05, 2034	U-4526			
	11273134	Nov 05, 2034	U-4517			
	11285118	Nov 05, 2034	U-4526			
	11285146	Nov 05, 2034	U-4517			
	11291638	Nov 05, 2034	U-4517			
	11291665	Nov 05, 2034	U-4517			
	11298352	Nov 05, 2034	U-4517			
	11344544	Nov 05, 2034	U-4517			
	11382874	Nov 05, 2034	U-4517			
	11419867	Nov 05, 2034	U-4517			
	11426370	Nov 05, 2034	U-4526			
	11571417	Nov 05, 2034	U-4526			
	11590124	Nov 05, 2034	U-4526			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY							
N 215430 002		11617747	Nov 05, 2034	U-4526			
		12433884	Jun 05, 2040	U-4514			
		12472156	Jun 05, 2040	U-4516			
		12472174	Jan 20, 2043	U-4515			
		12576078	Jun 05, 2040	U-4516			
	>A>	12678506	Jan 20, 2043	DP			
		8569328	Jul 18, 2032	DP U-4516			
		9168234	Nov 05, 2034	U-4517			
		9198905	Nov 05, 2034	U-4520			
		9205083	Nov 05, 2034	U-4520			
		9238032	Nov 05, 2034	U-4520			
		9278095	Nov 05, 2034	U-4517			
		9314462	Nov 05, 2034	U-4517			
		9370513	Nov 05, 2034	U-4520			
		9375429	Nov 05, 2034	U-4517			
		9408815	Nov 05, 2034	U-4517			
		9421176	Nov 05, 2034	U-4517			
		9457023	Nov 05, 2034	U-4517			
		9457025	Nov 05, 2034	U-4517			
		9474731	Nov 05, 2034	U-4520			
		9486450	Nov 05, 2034	U-4517			
		9700528	Nov 05, 2034	U-4517			
		9700553	Nov 05, 2034	U-4517			
		9707191	Nov 05, 2034	U-4522			
		9763932	Nov 05, 2034	U-4517			
		9861595	Nov 05, 2034	U-4517			
		9867819	Nov 05, 2034	U-4517			
		9968568	Nov 05, 2034	U-4517			
CABAZITAXEL - JEVTANA KIT							
N 201023 001		10583110	Oct 27, 2030	U-2753			
		10583110*PED	Apr 27, 2031				
		10716777	Oct 27, 2030	U-2856			
		10716777*PED	Apr 27, 2031				
		12453712	Oct 27, 2030	U-4334			
		12453712*PED	Apr 27, 2031				
CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT							
N 212888 001		12636285	Oct 01, 2040	U-3348			
		12636286	Oct 01, 2040	U-3348			
CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT							
N 212888 002		12636285	Oct 01, 2040	U-3348			
		12636286	Oct 01, 2040	U-3348			
CABOZANTINIB S-MALATE - CABOMETYX							
N 208692 001						ODE-530	Mar 26, 2032
CABOZANTINIB S-MALATE - CABOMETYX							
N 208692 002						ODE-530	Mar 26, 2032
CABOZANTINIB S-MALATE - CABOMETYX							
N 208692 003						ODE-530	Mar 26, 2032
CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE - XYWAV							
N 212690 001		12582622	Feb 22, 2041	U-4044			
CANNABIDIOL - EPIDIOLEX							
N 210365 001	>A>	12661365	Sep 24, 2042	U-4573			
	>A>	12661365	Sep 24, 2042	U-4574			
	>A>	12661365	Sep 24, 2042	U-4575			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CAPIVASERTIB - TRUQAP							
N 218197	001	10039766	Apr 16, 2033	U-3762		I-991	Jun 12, 2029
		10039766	Apr 16, 2033	U-4559			
		11236095	Oct 10, 2028	U-4559			
		9492453	Oct 10, 2028	U-4559			
CAPIVASERTIB - TRUQAP							
N 218197	002	10039766	Apr 16, 2033	U-3762		I-991	Jun 12, 2029
		10039766	Apr 16, 2033	U-4559			
		11236095	Oct 10, 2028	U-4559			
		9492453	Oct 10, 2028	U-4559			
CARBIDOPA; LEVODOPA - CREXONT							
N 217186	001 >A>	12691074	Oct 07, 2034	DP			
CARBIDOPA; LEVODOPA - CREXONT							
N 217186	002 >A>	12691074	Oct 07, 2034	DP			
CARBIDOPA; LEVODOPA - CREXONT							
N 217186	003 >A>	12691074	Oct 07, 2034	DP			
CARBIDOPA; LEVODOPA - CREXONT							
N 217186	004 >A>	12691074	Oct 07, 2034	DP			
CARFILZOMIB - KYPROLIS							
N 202714	001	12636340	Apr 29, 2041	U-4551			
		12636340*PED	Oct 29, 2041				
CARFILZOMIB - KYPROLIS							
N 202714	002	12636340	Apr 29, 2041	U-4551			
		12636340*PED	Oct 29, 2041				
CARFILZOMIB - KYPROLIS							
N 202714	003	12636340	Apr 29, 2041	U-4551			
		12636340*PED	Oct 29, 2041				
CARIPRAZINE HYDROCHLORIDE - VRAYLAR							
N 204370	001	7737142	Sep 17, 2029	DS DP U-1750		M-14	Dec 18, 2028
		7737142	Sep 17, 2029	DS DP U-2543		NPP	Dec 18, 2028
		7737142	Sep 17, 2029	DS DP U-2544		PED	Jun 18, 2029
		7737142	Sep 17, 2029	DS DP U-2545		PED	Jun 18, 2029
		7737142	Sep 17, 2029	DS DP U-3503			
		7737142*PED	Mar 17, 2030				
		7943621	Dec 16, 2028	DS DP			
		7943621*PED	Jun 16, 2029				
		RE47350	Jul 16, 2029	U-1750			
		RE47350	Jul 16, 2029	U-2543			
		RE47350	Jul 16, 2029	U-2544			
		RE47350	Jul 16, 2029	U-2545			
		RE47350	Jul 16, 2029	U-3503			
		RE47350*PED	Jan 16, 2030				
		RE49110	Jul 16, 2029	U-2543			
		RE49110	Jul 16, 2029	U-2544			
		RE49110	Jul 16, 2029	U-2545			
		RE49110	Jul 16, 2029	U-3503			
		RE49110*PED	Jan 16, 2030				
		RE49302	Jul 16, 2029	U-2543			
		RE49302	Jul 16, 2029	U-2544			
		RE49302	Jul 16, 2029	U-2545			
		RE49302	Jul 16, 2029	U-3503			
		RE49302*PED	Jan 16, 2030				
CARIPRAZINE HYDROCHLORIDE - VRAYLAR							
N 204370	002	7737142	Sep 17, 2029	DS DP U-1750		M-14	Dec 18, 2028
		7737142	Sep 17, 2029	DS DP U-2543		NPP	Dec 18, 2028
		7737142	Sep 17, 2029	DS DP U-2544		PED	Jun 18, 2029

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CARIPRAZINE HYDROCHLORIDE - VRAYLAR						
N 204370 002	7737142	Sep 17, 2029	DS DP U-2545		PED	Jun 18, 2029
	7737142	Sep 17, 2029	DS DP U-3503			
	7737142*PED	Mar 17, 2030				
	7943621	Dec 16, 2028	DS DP			
	7943621*PED	Jun 16, 2029				
	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
	RE49110	Jul 16, 2029	U-3503			
	RE49110*PED	Jan 16, 2030				
	RE49302	Jul 16, 2029	U-2543			
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			
	RE49302*PED	Jan 16, 2030				
CARIPRAZINE HYDROCHLORIDE - VRAYLAR						
N 204370 003	7737142	Sep 17, 2029	DS DP U-1750		M-14	Dec 18, 2028
	7737142	Sep 17, 2029	DS DP U-2543		NPP	Dec 18, 2028
	7737142	Sep 17, 2029	DS DP U-2544		PED	Jun 18, 2029
	7737142*PED	Mar 17, 2030			PED	Jun 18, 2029
	7943621	Dec 16, 2028	DS DP			
	7943621*PED	Jun 16, 2029				
	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
	RE49110*PED	Jan 16, 2030				
	RE49302	Jul 16, 2029	U-2543			
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			
	RE49302*PED	Jan 16, 2030				
CARIPRAZINE HYDROCHLORIDE - VRAYLAR						
N 204370 004	7737142	Sep 17, 2029	DS DP U-1750		M-14	Dec 18, 2028
	7737142	Sep 17, 2029	DS DP U-2543		PED	Jun 18, 2029
	7737142	Sep 17, 2029	DS DP U-2544			
	7737142*PED	Mar 17, 2030				
	7943621	Dec 16, 2028	DS DP			
	7943621*PED	Jun 16, 2029				
	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
	RE49110*PED	Jan 16, 2030				
	RE49302	Jul 16, 2029	U-2543			
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			
	RE49302*PED	Jan 16, 2030				
CARIPRAZINE HYDROCHLORIDE - VRAYLAR						
N 204370 005	7737142	Sep 17, 2029	DS DP U-2543		M-14	Dec 18, 2028
	7737142	Sep 17, 2029	DS DP U-2544		NPP	Dec 18, 2028
	7737142	Sep 17, 2029	DS DP U-2545		PED	Jun 18, 2029
	7737142	Sep 17, 2029	DS DP U-3503		PED	Jun 18, 2029
	7737142*PED	Mar 17, 2030				
	7943621	Dec 20, 2028	DS DP			
	7943621*PED	Jun 20, 2029				
	RE47350	Jul 16, 2029	U-2543			
	RE47350	Jul 16, 2029	U-2544			
	RE47350	Jul 16, 2029	U-2545			
	RE47350	Jul 16, 2029	U-3503			
	RE47350*PED	Jan 16, 2030				
	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
	RE49110	Jul 16, 2029	U-3503			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CARIPRAZINE HYDROCHLORIDE - VRAYLAR						
N 204370 005	RE49110*PED	Jan 16, 2030				
CARIPRAZINE HYDROCHLORIDE - VRAYLAR						
N 204370 006	7737142	Sep 17, 2029	DS DP U-2543		M-14	Dec 18, 2028
	7737142	Sep 17, 2029	DS DP U-2544		NPP	Dec 18, 2028
	7737142	Sep 17, 2029	DS DP U-2545		PED	Jun 18, 2029
	7737142	Sep 17, 2029	DS DP U-3503		PED	Jun 18, 2029
	7737142*PED	Mar 17, 2030				
	7943621	Dec 20, 2028	DS DP			
	7943621*PED	Jun 20, 2029				
	RE47350	Jul 16, 2029	U-2543			
	RE47350	Jul 16, 2029	U-2544			
	RE47350	Jul 16, 2029	U-2545			
	RE47350	Jul 16, 2029	U-3503			
	RE47350*PED	Jan 16, 2030				
	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
	RE49110	Jul 16, 2029	U-3503			
	RE49110*PED	Jan 16, 2030				
CEDAZURIDINE; DECITABINE - INQOVI						
N 212576 001					I-990	May 13, 2029
CEFEPIME HYDROCHLORIDE; ZIDEBACTAM - ZAYNICH						
N 220787 001	8822450	Aug 24, 2032	DS DP		NCE	May 29, 2031
	8853197	Aug 24, 2032	DS		GAIN	May 29, 2036
	9132133	Aug 24, 2032	U-4558			
	9381200	Aug 24, 2032	DP			
	9657021	Oct 12, 2033	DS			
	9827235	Aug 24, 2032	DP U-4558			
	9834557	Oct 12, 2033	DS			
CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA						
N 206829 001	10028963	Sep 07, 2032	U-2565		NPP	May 12, 2029
	10028963	Sep 07, 2032	U-2566		PED	Nov 12, 2029
	10028963	Sep 07, 2032	U-4542			
	10028963	Sep 07, 2032	U-4543			
	10028963*PED	Mar 07, 2033				
	10125149	Aug 14, 2035	DP			
	10125149*PED	Feb 14, 2036				
	10376496	Sep 09, 2034	U-2610			
	10376496	Sep 09, 2034	U-2611			
	10376496	Sep 09, 2034	U-4548			
	10376496	Sep 09, 2034	U-4549			
	10376496*PED	Mar 09, 2035				
	10420841	Mar 14, 2034	U-1672			
	10420841	Mar 14, 2034	U-2631			
	10420841	Mar 14, 2034	U-3360			
	10420841	Mar 14, 2034	U-3361			
	10420841	Mar 14, 2034	U-4546			
	10420841	Mar 14, 2034	U-4547			
	10420841*PED	Sep 14, 2034				
	10933053	Sep 09, 2034	U-3090			
	10933053	Sep 09, 2034	U-3091			
	10933053	Sep 09, 2034	U-4544			
	10933053	Sep 09, 2034	U-4545			
	10933053*PED	Mar 09, 2035				
	11278622	Mar 14, 2034	U-3335			
	11278622	Mar 14, 2034	U-3336			
	11278622	Mar 14, 2034	U-4542			
	11278622	Mar 14, 2034	U-4543			
	11278622*PED	Sep 14, 2034				
	7129232	May 15, 2028	DS DP U-1676			
	7129232	May 15, 2028	DS DP U-3360			
	7129232	May 15, 2028	DS DP U-3361			
	7129232	May 15, 2028	DS DP U-36			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA							
N 206829	001	7129232	May 15, 2028	DS DP U-4542			
		7129232	May 15, 2028	DS DP U-4543			
		7129232	May 15, 2028	DS DP U-4547			
		7129232	May 15, 2028	DS DP U-4550			
		7129232*PED	Nov 15, 2028				
		8906898	May 28, 2034	DS DP			
		8906898*PED	Nov 28, 2034				
		8968753	Mar 14, 2034	U-1672			
		8968753	Mar 14, 2034	U-1673			
		8968753	Mar 14, 2034	U-3360			
		8968753	Mar 14, 2034	U-3361			
		8968753	Mar 14, 2034	U-4547			
		8968753	Mar 14, 2034	U-4550			
		8968753*PED	Sep 14, 2034				
		9320740	Mar 14, 2034	DP			
		9320740*PED	Sep 14, 2034				
		9724353	Sep 07, 2032	U-2565			
		9724353	Sep 07, 2032	U-2566			
		9724353	Sep 07, 2032	U-4542			
		9724353	Sep 07, 2032	U-4543			
		9724353*PED	Mar 07, 2033				
		9872906	Mar 14, 2034	DP			
		9872906*PED	Sep 14, 2034				
CELECOXIB - VYSCOXA							
N 211759	001	>A> 12678405	Sep 17, 2045	DP			
CHENODIOL - CTEXLI							
N 219488	001					ODE-523	Feb 21, 2032
CHLORTHALIDONE - HEMICLOR							
N 218647	001	12667554	Sep 04, 2045	DP			
CITALOPRAM HYDROBROMIDE - CITALOPRAM HYDROBROMIDE							
A 219985	001					CGT	Sep 16, 2026
CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - CLENPIQ							
N 209589	001	12576072	Jun 23, 2034	DP U-3261			
CLADRIBINE - MAVENCLAD							
N 022561	001	12533408	Sep 10, 2041	U-4395			
		12539329	Sep 10, 2041	U-4399			
CLOBETASOL PROPIONATE - IMPOYZ							
N 209483	001	11179465	Aug 31, 2030	DP U-1858			
CLONIDINE HYDROCHLORIDE - ONYDA XR							
N 217645	001	12576032	Jul 28, 2041	U-2357			
CLONIDINE HYDROCHLORIDE - QLONILIK							
N 221094	001	>A> 12551466	Aug 22, 2045	DP U-4581			
CLOTRIMAZOLE - CLOTIC							
N 217628	001					ODE-549	Sep 26, 2032
						GAIN	Sep 26, 2037
COBICISTAT - TYBOST							
N 203094	001				>A>	NPP	Jun 20, 2028
COBICISTAT - TYBOST							
N 203094	002				>A>	NS	Jun 20, 2028

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
COLCHICINE - GLOPERBA						
N 210942 001	12514819	Nov 22, 2036	U-2814			
COPPER - MIUDELLA						
N 218201 001	9180040	Mar 22, 2034	DP			
COPPER HISTIDINATE - ZYCUBO						
N 211241 001					NCE	Jan 12, 2031
					ODE-520	Jan 12, 2033
CRINECERFONT - CRENESSITY						
N 218808 001	12582634	Jan 12, 2043	DS			
CRINECERFONT - CRENESSITY						
N 218808 002	12582634	Jan 12, 2043	DS			
CRINECERFONT - CRENESSITY						
N 218808 003	12582634	Jan 12, 2043	DS			
CRINECERFONT - CRENESSITY						
N 218820 001	12582634	Jan 12, 2043	DS			
CYSTEINE HYDROCHLORIDE - NOURESS						
N 212535 001	12569514	Jan 15, 2039	DP			
CYTARABINE; DAUNORUBICIN - VYXEOS						
N 209401 001	10028912	Oct 15, 2032	DP U-3149		ODE-350	Mar 30, 2028
	10028912	Oct 15, 2032	DP U-3150		PED	Sep 30, 2028
	10028912*PED	Apr 15, 2033				
	10166184	Oct 15, 2032	DP U-3149			
	10166184*PED	Apr 15, 2033				
	10835492	Oct 15, 2032	U-3150			
	10835492*PED	Apr 15, 2033				
	7850990	Jan 23, 2027	DP U-3147			
	7850990*PED	Jul 23, 2027				
	8022279	Sep 14, 2027	DP U-3147			
	8022279*PED	Mar 14, 2028				
	8092828	Apr 01, 2029	U-3147			
	8092828*PED	Oct 01, 2029				
	9271931	Jan 23, 2027	DP			
	9271931*PED	Jul 23, 2027				
DAPAGLIFLOZIN - DAPAGLIFLOZIN						
A 211156 001					PC	Oct 03, 2026
DAPAGLIFLOZIN - DAPAGLIFLOZIN						
A 211156 002					PC	Oct 03, 2026
DAPAGLIFLOZIN - DAPAGLIFLOZIN						
A 211312 001					PC	Oct 03, 2026
DAPAGLIFLOZIN - DAPAGLIFLOZIN						
A 211312 002					PC	Oct 03, 2026
DAPAGLIFLOZIN - DAPAGLIFLOZIN						
A 211467 001					PC	Oct 03, 2026
DAPAGLIFLOZIN - DAPAGLIFLOZIN						
A 211467 002					PC	Oct 03, 2026
DAPAGLIFLOZIN - DAPAGLIFLOZIN						
A 211470 001					PC	Oct 03, 2026

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DAPAGLIFLOZIN - DAPAGLIFLOZIN						
A 211470 002					PC	Oct 03, 2026
DAPAGLIFLOZIN - DAPAGLIFLOZIN						
A 211482 001					PC	Oct 03, 2026
DAPAGLIFLOZIN - DAPAGLIFLOZIN						
A 211482 002					PC	Oct 03, 2026
DAPAGLIFLOZIN - DAPAGLIFLOZIN						
A 211523 001					PC	Oct 03, 2026
DAPAGLIFLOZIN - DAPAGLIFLOZIN						
A 211523 002					PC	Oct 03, 2026
DAPAGLIFLOZIN - DAPAGLIFLOZIN						
A 211541 001					PC	Oct 03, 2026
DAPAGLIFLOZIN - DAPAGLIFLOZIN						
A 211541 002					PC	Oct 03, 2026
DAPAGLIFLOZIN - DAPAGLIFLOZIN						
A 211545 001					PC	Oct 03, 2026
DAPAGLIFLOZIN - DAPAGLIFLOZIN						
A 211545 002					PC	Oct 03, 2026
DAPAGLIFLOZIN - DAPAGLIFLOZIN						
A 211560 001					PC	Oct 03, 2026
DAPAGLIFLOZIN - DAPAGLIFLOZIN						
A 211560 002					PC	Oct 03, 2026
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE						
A 211479 001					PC	Oct 03, 2026
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE						
A 211479 002					PC	Oct 03, 2026
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE						
A 211479 003					PC	Oct 03, 2026
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE						
A 211479 004					PC	Oct 03, 2026
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE						
A 211491 001					PC	Oct 03, 2026
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE						
A 211491 002					PC	Oct 03, 2026
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE						
A 211491 003					PC	Oct 03, 2026
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE						
A 211563 001					PC	Oct 03, 2026
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE						
A 211563 002					PC	Oct 03, 2026

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE						
A 211563 003					PC	Oct 03, 2026
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE						
A 211563 004					PC	Oct 03, 2026
DAPTOMYCIN - DAPTOMYCIN						
N 217415 001	12629337	Jan 09, 2043	DP			
DAPTOMYCIN - DAPTOMYCIN						
N 217415 002	12629337	Jan 09, 2043	DP			
DARIDOREXANT HYDROCHLORIDE - QUVIVIQ						
N 214985 001	>A> 9732075	Jun 03, 2033	DS DP U-620			
DARIDOREXANT HYDROCHLORIDE - QUVIVIQ						
N 214985 002	>A> 9732075	Jun 03, 2033	DS DP U-620			
DAROLUTAMIDE - NUBEQA						
N 212099 001	12329742	Jun 17, 2042	DP			
	12611397	Jul 02, 2040	DP			
DASATINIB - PHYRAGO						
N 216099 001	12544376	Jan 22, 2041	U-3767			
	12544376	Jan 22, 2041	U-3768			
	12544376	Jan 22, 2041	U-3769			
	12544376	Jan 22, 2041	U-3770			
	12544376	Jan 22, 2041	U-3771			
	12544376	Jan 22, 2041	U-3772			
DASATINIB - PHYRAGO						
N 216099 002	12544376	Jan 22, 2041	U-3767			
	12544376	Jan 22, 2041	U-3768			
	12544376	Jan 22, 2041	U-3769			
	12544376	Jan 22, 2041	U-3770			
	12544376	Jan 22, 2041	U-3771			
	12544376	Jan 22, 2041	U-3772			
DASATINIB - PHYRAGO						
N 216099 003	12544376	Jan 22, 2041	U-3767			
	12544376	Jan 22, 2041	U-3768			
	12544376	Jan 22, 2041	U-3769			
	12544376	Jan 22, 2041	U-3770			
	12544376	Jan 22, 2041	U-3771			
	12544376	Jan 22, 2041	U-3772			
DASATINIB - PHYRAGO						
N 216099 004	12544376	Jan 22, 2041	U-3767			
	12544376	Jan 22, 2041	U-3768			
	12544376	Jan 22, 2041	U-3769			
	12544376	Jan 22, 2041	U-3770			
	12544376	Jan 22, 2041	U-3771			
	12544376	Jan 22, 2041	U-3772			
DASATINIB - PHYRAGO						
N 216099 005	12544376	Jan 22, 2041	U-3767			
	12544376	Jan 22, 2041	U-3768			
	12544376	Jan 22, 2041	U-3769			
	12544376	Jan 22, 2041	U-3770			
	12544376	Jan 22, 2041	U-3771			
	12544376	Jan 22, 2041	U-3772			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DASATINIB - PHYRAGO						
N 216099 006	12544376	Jan 22, 2041	U-3767			
	12544376	Jan 22, 2041	U-3768			
	12544376	Jan 22, 2041	U-3769			
	12544376	Jan 22, 2041	U-3770			
	12544376	Jan 22, 2041	U-3771			
	12544376	Jan 22, 2041	U-3772			
DASIGLUCAGON HYDROCHLORIDE - ZEGALOGUE						
N 214231 001	10442847	Mar 22, 2035	DS DP		>A> NPP	Jun 18, 2029
DASIGLUCAGON HYDROCHLORIDE - ZEGALOGUE (AUTOINJECTOR)						
N 214231 002	10442847	Mar 22, 2035	DS DP		>A> NPP	Jun 18, 2029
DEFIBROTIDE SODIUM - DEFITELIO						
N 208114 001	12529052	Jun 22, 2032	DP			
	12534722	Jun 22, 2032	DP			
DEGARELIX ACETATE - FIRMAGON						
N 022201 001	12514898	Feb 20, 2029	U-1978			
	12533387	Feb 20, 2029	U-4417			
DEGARELIX ACETATE - FIRMAGON						
N 022201 002	12514898	Feb 20, 2029	U-1978			
	12533387	Feb 20, 2029	U-4417			
DEHYDRATED ALCOHOL - DEHYDRATED ALCOHOL						
N 214988 001					ODE-521	Oct 23, 2032
DELAFLOXACIN MEGLUMINE - BAXDELA						
N 208611 001	12558349	Mar 14, 2034	U-3967			
DESMOPRESSIN ACETATE - DESMODA						
N 219873 001	12214010	Apr 03, 2044	DP			
	12343372	Apr 03, 2044	DP U-4432			
DEUCRAVACITINIB - SOTYKTU						
N 214958 001	12521390	Feb 11, 2043	DP U-3434		I-986	Mar 06, 2029
	12521390	Feb 11, 2043	DP U-4451			
	RE47929	Nov 07, 2033	DS DP U-3434			
	RE47929	Nov 07, 2033	DS DP U-4452			
DEUTETRABENAZINE - AUSTEDO XR						
N 216354 001	12589075	Jun 10, 2041	U-1995			
	12589075	Jun 10, 2041	U-3055			
	12599598	Jun 10, 2041	U-1995			
	12599598	Jun 10, 2041	U-3055			
DEUTETRABENAZINE - AUSTEDO XR						
N 216354 002	12589075	Jun 10, 2041	U-1995			
	12589075	Jun 10, 2041	U-3055			
	12599598	Jun 10, 2041	U-1995			
	12599598	Jun 10, 2041	U-3055			
DEUTETRABENAZINE - AUSTEDO XR						
N 216354 003	12589075	Jun 10, 2041	U-1995			
	12589075	Jun 10, 2041	U-3055			
	12599598	Jun 10, 2041	U-1995			
	12599598	Jun 10, 2041	U-3055			
DEUTETRABENAZINE - AUSTEDO XR						
N 216354 004	12589075	Jun 10, 2041	U-1995			
	12589075	Jun 10, 2041	U-3055			
	12599598	Jun 10, 2041	U-1995			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEUTETRABENAZINE - AUSTEDO XR						
N 216354 004	12599598	Jun 10, 2041	U-3055			
DEUTETRABENAZINE - AUSTEDO XR						
N 216354 005	12589075	Jun 10, 2041	U-1995			
	12589075	Jun 10, 2041	U-3055			
	12599598	Jun 10, 2041	U-1995			
	12599598	Jun 10, 2041	U-3055			
DEUTETRABENAZINE - AUSTEDO XR						
N 216354 006	12589075	Jun 10, 2041	U-1995			
	12589075	Jun 10, 2041	U-3055			
	12599598	Jun 10, 2041	U-1995			
	12599598	Jun 10, 2041	U-3055			
DEUTETRABENAZINE - AUSTEDO XR						
N 216354 007	12589075	Jun 10, 2041	U-1995			
	12589075	Jun 10, 2041	U-3055			
	12599598	Jun 10, 2041	U-1995			
	12599598	Jun 10, 2041	U-3055			
DEUTETRABENAZINE - AUSTEDO XR						
N 216354 008	12589075	Jun 10, 2041	U-1995			
	12589075	Jun 10, 2041	U-3055			
	12599598	Jun 10, 2041	U-1995			
	12599598	Jun 10, 2041	U-3055			
DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM - ALYFTREK						
N 218730 001	10081621	Mar 25, 2031	DP U-4087		ODE-526	Dec 20, 2031
	10081621	Mar 25, 2031	DP U-4468		ODE-536	Mar 27, 2033
	10239867	Apr 09, 2027	DS DP U-4090			
	10239867	Apr 09, 2027	DS DP U-4464			
	11564916	Aug 13, 2029	U-4095			
	11564916	Aug 13, 2029	U-4466			
	11578062	Mar 25, 2031	DP U-4096			
	11578062	Mar 25, 2031	DP U-4465			
	11639347	Apr 09, 2027	DS DP U-4090			
	11639347	Apr 09, 2027	DS DP U-4464			
	11866450	Feb 14, 2039	U-4082			
	11866450	Feb 14, 2039	U-4463			
	11873300	Aug 13, 2040	DS DP U-4083			
	11873300	Aug 13, 2040	DS DP U-4462			
	8324242	Aug 05, 2027	U-4090			
	8324242	Aug 05, 2027	U-4464			
	8415387	Nov 12, 2027	U-4082			
	8415387	Nov 12, 2027	U-4463			
	8598181	May 01, 2027	U-4090			
	8598181	May 01, 2027	U-4463			
	9181192	May 17, 2032	DS DP U-4094			
	9181192	May 17, 2032	DS DP U-4472			
	9512079	May 17, 2032	DS DP U-4098			
	9512079	May 17, 2032	DS DP U-4471			
	9670163	Dec 28, 2026	DP U-4080			
	9670163	Dec 28, 2026	DP U-4470			
	9931334	Dec 28, 2026	DP U-4080			
	9931334	Dec 28, 2026	DP U-4469			
	9974781	Apr 09, 2027	DP U-4082			
	9974781	Apr 09, 2027	DP U-4463			
DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM - ALYFTREK						
N 218730 002	10081621	Mar 25, 2031	DP U-4087		ODE-526	Dec 20, 2031
	10081621	Mar 25, 2031	DP U-4468		ODE-536	Mar 27, 2033
	10206877	Apr 14, 2035	DP U-4092			
	10206877	Apr 14, 2035	DP U-4467			
	10239867	Apr 09, 2027	DS DP U-4090			
	10239867	Apr 09, 2027	DS DP U-4464			
	11564916	Aug 13, 2029	U-4095			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM - ALYFTREK							
N 218730	002	11564916	Aug 13, 2029			U-4466	
		11578062	Mar 25, 2031	DP		U-4096	
		11578062	Mar 25, 2031	DP		U-4465	
		11639347	Apr 09, 2027	DS DP		U-4090	
		11639347	Apr 09, 2027	DS DP		U-4464	
		11866450	Feb 14, 2039			U-4082	
		11866450	Feb 14, 2039			U-4463	
		11873300	Aug 13, 2040	DS DP		U-4083	
		11873300	Aug 13, 2040	DS DP		U-4462	
		11951212	Apr 14, 2035	DP		U-4089	
		11951212	Apr 14, 2035	DP		U-4461	
		12186306	Jan 10, 2043			U-4088	
		12186306	Jan 10, 2043			U-4460	
		8324242	Aug 05, 2027			U-4090	
		8324242	Aug 05, 2027			U-4464	
		8415387	Nov 12, 2027			U-4082	
		8415387	Nov 12, 2027			U-4463	
		8598181	May 01, 2027			U-4090	
		8598181	May 01, 2027			U-4463	
		9181192	May 17, 2032	DS DP		U-4094	
		9181192	May 17, 2032	DS DP		U-4472	
		9512079	May 17, 2032	DS DP		U-4098	
		9512079	May 17, 2032	DS DP		U-4471	
		9670163	Dec 28, 2026	DP		U-4080	
		9670163	Dec 28, 2026	DP		U-4470	
		9931334	Dec 28, 2026	DP		U-4080	
		9931334	Dec 28, 2026	DP		U-4469	
		9974781	Apr 09, 2027	DP		U-4082	
		9974781	Apr 09, 2027	DP		U-4463	
DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS							
N 212994	001	9079928	May 07, 2035	DP			
DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS							
N 212994	002	9079928	May 07, 2035	DP			
DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS							
N 212994	003	9079928	May 07, 2035	DP			
DEXTROAMPHETAMINE - XELSTRYM							
N 215401	001 >A>	12678504	Mar 12, 2034	DP		U-4583	
DEXTROAMPHETAMINE - XELSTRYM							
N 215401	002 >A>	12678504	Mar 12, 2034	DP		U-4583	
DEXTROAMPHETAMINE - XELSTRYM							
N 215401	003 >A>	12678504	Mar 12, 2034	DP		U-4583	
DEXTROAMPHETAMINE - XELSTRYM							
N 215401	004 >A>	12678504	Mar 12, 2034	DP		U-4583	
DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN; NAPROXEN SODIUM - MUCINEX 12HR COLD & FEVER MULTI-SYMPTOM							
N 217338	001	11278506	Oct 11, 2036	DP			
		12257218	Oct 11, 2036	DP			
		12370189	Oct 11, 2036	DP			
DIAZEPAM - VALTOCO							
N 211635	001	12521400	Mar 27, 2029	DP			
		12599611	Jun 10, 2042			U-4455	
DIAZEPAM - VALTOCO							
N 211635	002	12521400	Mar 27, 2029	DP			
		12599611	Jun 10, 2042			U-4455	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DIAZEPAM - VALTOCO							
N 211635 003		12521400	Mar 27, 2029	DP			
		12599611	Jun 10, 2042	U-4455			
DIAZOXIDE CHOLINE - VYKAT XR							
N 216665 001						ODE-532	Mar 26, 2032
DIAZOXIDE CHOLINE - VYKAT XR							
N 216665 002						ODE-532	Mar 26, 2032
DIAZOXIDE CHOLINE - VYKAT XR							
N 216665 003						ODE-532	Mar 26, 2032
DICLOFENAC EPOLAMINE - LICART							
N 206976 001						NPP	Mar 27, 2029
DIFAMILAST - ADQUEY							
N 219474 001		10588893	Dec 31, 2036	DS DP		NCE	Feb 12, 2031
		RE46792	Mar 01, 2028	DS DP U-4445			
DIFELIKEFALIN ACETATE - KORSUVA							
N 214916 001		7402564	Nov 12, 2032	DS DP U-3204			
DIHYDROERGOTAMINE MESYLATE - BREKIYA (AUTOINJECTOR)							
N 215400 001		11083712	Jun 30, 2039	DP U-2718			
		11083712	Jun 30, 2039	DP U-4508			
		11541043	Mar 20, 2039	DP			
		12329749	May 27, 2039	DP U-2718			
		12329749	May 27, 2039	DP U-4508			
		12414941	Aug 24, 2039	DP			
		12533351	Feb 26, 2039	DP			
DIHYDROERGOTAMINE MESYLATE - ATZUMI							
N 217901 001		12594273	Sep 24, 2033	DP			
DONIDALORSEN SODIUM - DAWNZERA (AUTOINJECTOR)							
N 219407 001						ODE-550	Aug 21, 2032
DORAVIRINE; ISLATRAVIR - IDVYNSO							
N 216964 001		7339053	May 31, 2027	DS		NCE	Apr 20, 2031
		8486975	Aug 30, 2032	DS DP U-4527			
DORDAVIPRONE HYDROCHLORIDE - MODEYSO							
N 219876 001						ODE-547	Aug 06, 2032
DUVELISIB - COPIKTRA							
N 211155 001		8193182	Sep 24, 2032	DS			
DUVELISIB - COPIKTRA							
N 211155 002		8193182	Sep 24, 2032	DS			
EDARAVONE - RADICAVA ORS							
N 215446 001		12527769	Nov 12, 2041	U-4111			
		12569469	Nov 12, 2041	U-4111			
		12599586	Nov 01, 2039	DP			
EFLORNITHINE HYDROCHLORIDE - IWILFIN							
N 215500 001		12582625	Feb 12, 2036	U-4444			
ELAFIBRANOR - IQIRVO							
N 218860 001		12589086	Mar 30, 2037	U-4473			
	>A>	12673035	Mar 05, 2044	DP U-1854			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELAMIPRETIDE HYDROCHLORIDE - FORZINITY						
N 215244 001	7576061	Jan 20, 2027	DS DP		ODE-551	Sep 19, 2032
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)						
N 212273 001	10081621	Mar 25, 2031	DP U-3032		ODE-543	Mar 27, 2033
	10081621	Mar 25, 2031	DP U-3157			
	10081621	Mar 25, 2031	DP U-4075			
	10081621	Mar 25, 2031	DP U-4480			
	10239867	Apr 09, 2027	DS DP U-3033			
	10239867	Apr 09, 2027	DS DP U-3158			
	10239867	Apr 09, 2027	DS DP U-4056			
	10239867	Apr 09, 2027	DS DP U-4475			
	10758534	Oct 06, 2035	DS DP U-3028			
	10758534	Oct 06, 2035	DS DP U-3144			
	10758534	Oct 06, 2035	DS DP U-4073			
	10758534	Oct 06, 2035	DS DP U-4475			
	10793547	Dec 08, 2037	DS DP U-3028			
	10793547	Dec 08, 2037	DS DP U-3144			
	10793547	Dec 08, 2037	DS DP U-4073			
	10793547	Dec 08, 2037	DS DP U-4475			
	11179367	Dec 08, 2037	DP U-3253			
	11179367	Dec 08, 2037	DP U-4071			
	11179367	Dec 08, 2037	DP U-4487			
	11426407	Oct 06, 2035	DS DP U-3425			
	11426407	Oct 06, 2035	DS DP U-4070			
	11426407	Oct 06, 2035	DS DP U-4475			
	11517564	Dec 08, 2037	DP U-3498			
	11517564	Dec 08, 2037	DP U-4067			
	11517564	Dec 08, 2037	DP U-4475			
	11564916	Aug 13, 2029	U-3525			
	11564916	Aug 13, 2029	U-4063			
	11564916	Aug 13, 2029	U-4491			
	11578062	Mar 25, 2031	DP U-3544			
	11578062	Mar 25, 2031	DP U-4054			
	11578062	Mar 25, 2031	DP U-4490			
	11639347	Apr 09, 2027	DS DP U-3587			
	11639347	Apr 09, 2027	DS DP U-4056			
	11639347	Apr 09, 2027	DS DP U-4475			
	12350262	Jul 17, 2038	U-4221			
	12350262	Jul 17, 2038	U-4475			
	12458635	Aug 13, 2029	DP U-4330			
	12458635	Aug 13, 2029	DP U-4486			
	8324242	Aug 05, 2027	U-3028			
	8324242	Aug 05, 2027	U-3144			
	8324242	Aug 05, 2027	U-4073			
	8324242	Aug 05, 2027	U-4475			
	8415387	Nov 12, 2027	U-3028			
	8415387	Nov 12, 2027	U-3144			
	8415387	Nov 12, 2027	U-4073			
	8415387	Nov 12, 2027	U-4475			
	8598181	May 01, 2027	U-3028			
	8598181	May 01, 2027	U-3144			
	8598181	May 01, 2027	U-4056			
	8598181	May 01, 2027	U-4475			
	9670163	Dec 28, 2026	DP U-3031			
	9670163	Dec 28, 2026	DP U-3155			
	9670163	Dec 28, 2026	DP U-4078			
	9670163	Dec 28, 2026	DP U-4477			
	9931334	Dec 28, 2026	DP U-3031			
	9931334	Dec 28, 2026	DP U-3155			
	9931334	Dec 28, 2026	DP U-4078			
	9931334	Dec 28, 2026	DP U-4479			
	9974781	Apr 09, 2027	DP U-3028			
	9974781	Apr 09, 2027	DP U-3144			
	9974781	Apr 09, 2027	DP U-4073			
	9974781	Apr 09, 2027	DP U-4475			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)						
N 212273 002	10081621	Mar 25, 2031	DP U-3157		ODE-543	Mar 27, 2033
	10081621	Mar 25, 2031	DP U-4075			
	10081621	Mar 25, 2031	DP U-4480			
	10239867	Apr 09, 2027	DS DP U-3158			
	10239867	Apr 09, 2027	DS DP U-4056			
	10239867	Apr 09, 2027	DS DP U-4475			
	10758534	Oct 06, 2035	DS DP U-3144			
	10758534	Oct 06, 2035	DS DP U-4073			
	10758534	Oct 06, 2035	DS DP U-4475			
	10793547	Dec 08, 2037	DS DP U-3144			
	10793547	Dec 08, 2037	DS DP U-4073			
	10793547	Dec 08, 2037	DS DP U-4475			
	11179367	Dec 08, 2037	DP U-3253			
	11179367	Dec 08, 2037	DP U-4071			
	11179367	Dec 08, 2037	DP U-4487			
	11426407	Oct 06, 2035	DS DP U-3425			
	11426407	Oct 06, 2035	DS DP U-4070			
	11426407	Oct 06, 2035	DS DP U-4475			
	11517564	Dec 08, 2037	DP U-3498			
	11517564	Dec 08, 2037	DP U-4069			
	11517564	Dec 08, 2037	DP U-4475			
	11564916	Aug 13, 2029	U-3525			
	11564916	Aug 13, 2029	U-4063			
	11564916	Aug 13, 2029	U-4491			
	11578062	Mar 25, 2031	DP U-3544			
	11578062	Mar 25, 2031	DP U-4054			
	11578062	Mar 25, 2031	DP U-4490			
	11639347	Apr 09, 2027	DS DP U-3587			
	11639347	Apr 09, 2027	DS DP U-4056			
	11639347	Apr 09, 2027	DS DP U-4475			
	12350262	Jul 17, 2038	U-4222			
	12350262	Jul 17, 2038	U-4475			
	12458635	Aug 13, 2029	DP U-4330			
	12458635	Aug 13, 2029	DP U-4486			
	8324242	Aug 05, 2027	U-3144			
	8324242	Aug 05, 2027	U-4073			
	8324242	Aug 05, 2027	U-4475			
	8415387	Nov 12, 2027	U-3144			
	8415387	Nov 12, 2027	U-4073			
	8415387	Nov 12, 2027	U-4475			
	8598181	May 01, 2027	U-3144			
	8598181	May 01, 2027	U-4056			
	8598181	May 01, 2027	U-4475			
	9670163	Dec 28, 2026	DP U-3155			
	9670163	Dec 28, 2026	DP U-4078			
	9670163	Dec 28, 2026	DP U-4477			
	9931334	Dec 28, 2026	DP U-3155			
	9931334	Dec 28, 2026	DP U-4078			
	9931334	Dec 28, 2026	DP U-4479			
	9974781	Apr 09, 2027	DP U-3144			
	9974781	Apr 09, 2027	DP U-4073			
	9974781	Apr 09, 2027	DP U-4475			
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)						
N 217660 001	10081621	Mar 25, 2031	DP U-3600		ODE-543	Mar 27, 2033
	10081621	Mar 25, 2031	DP U-4065			
	10081621	Mar 25, 2031	DP U-4481			
	10239867	Apr 09, 2027	DS DP U-3590			
	10239867	Apr 09, 2027	DS DP U-4053			
	10239867	Apr 09, 2027	DS DP U-4476			
	10272046	Feb 27, 2033	DP U-3599			
	10272046	Feb 27, 2033	DP U-4062			
	10272046	Feb 27, 2033	DP U-4482			
	10758534	Oct 06, 2035	DS DP U-3589			
	10758534	Oct 06, 2035	DS DP U-4066			
	10758534	Oct 06, 2035	DS DP U-4476			
	10793547	Dec 08, 2037	DS DP U-3588			
	10793547	Dec 08, 2037	DS DP U-4066			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)						
N 217660 001	10793547	Dec 08, 2037	DS DP U-4476			
	11147770	Feb 27, 2033	DP U-3598			
	11147770	Feb 27, 2033	DP U-4060			
	11147770	Feb 27, 2033	DP U-4483			
	11179367	Dec 08, 2037	DP U-3597			
	11179367	Dec 08, 2037	DP U-4059			
	11179367	Dec 08, 2037	DP U-4484			
	11426407	Oct 06, 2035	DS DP U-3595			
	11426407	Oct 06, 2035	DS DP U-4058			
	11426407	Oct 06, 2035	DS DP U-4476			
	11517564	Dec 08, 2037	DP U-3586			
	11517564	Dec 08, 2037	DP U-4057			
	11517564	Dec 08, 2037	DP U-4476			
	11564916	Aug 13, 2029	U-3585			
	11564916	Aug 13, 2029	U-4055			
	11564916	Aug 13, 2029	U-4485			
	11578062	Mar 25, 2031	DP U-3584			
	11578062	Mar 25, 2031	DP U-4054			
	11578062	Mar 25, 2031	DP U-4488			
	11639347	Apr 09, 2027	DS DP U-3583			
	11639347	Apr 09, 2027	DS DP U-4053			
	11639347	Apr 09, 2027	DS DP U-4476			
	11752106	Feb 27, 2033	DP U-3696			
	11752106	Feb 27, 2033	DP U-4052			
	11752106	Feb 27, 2033	DP U-4489			
	12214083	Feb 27, 2033	DP U-4141			
	12214083	Feb 27, 2033	DP U-4492			
	12458635	Aug 13, 2029	DP U-4333			
	12458635	Aug 13, 2029	DP U-4493			
	8324242	Aug 05, 2027	U-3589			
	8324242	Aug 05, 2027	U-4066			
	8324242	Aug 05, 2027	U-4476			
	8415387	Nov 12, 2027	U-3589			
	8415387	Nov 12, 2027	U-4066			
	8415387	Nov 12, 2027	U-4476			
	8598181	May 01, 2027	U-3589			
	8598181	May 01, 2027	U-4066			
	8598181	May 01, 2027	U-4476			
	9670163	Dec 28, 2026	DP U-3591			
	9670163	Dec 28, 2026	DP U-4068			
	9670163	Dec 28, 2026	DP U-4478			
	9931334	Dec 28, 2026	DP U-3591			
	9931334	Dec 28, 2026	DP U-4068			
	9931334	Dec 28, 2026	DP U-4478			
	9974781	Apr 09, 2027	DP U-3589			
	9974781	Apr 09, 2027	DP U-4066			
	9974781	Apr 09, 2027	DP U-4476			
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)						
N 217660 002	10081621	Mar 25, 2031	DP U-3600		ODE-543	Mar 27, 2033
	10081621	Mar 25, 2031	DP U-4065			
	10081621	Mar 25, 2031	DP U-4481			
	10239867	Apr 09, 2027	DS DP U-3590			
	10239867	Apr 09, 2027	DS DP U-4053			
	10239867	Apr 09, 2027	DS DP U-4476			
	10272046	Feb 27, 2033	DP U-3599			
	10272046	Feb 27, 2033	DP U-4062			
	10272046	Feb 27, 2033	DP U-4482			
	10758534	Oct 06, 2035	DS DP U-3589			
	10758534	Oct 06, 2035	DS DP U-4066			
	10758534	Oct 06, 2035	DS DP U-4476			
	10793547	Dec 08, 2037	DS DP U-3588			
	10793547	Dec 08, 2037	DS DP U-4066			
	10793547	Dec 08, 2037	DS DP U-4476			
	11147770	Feb 27, 2033	DP U-3598			
	11147770	Feb 27, 2033	DP U-4060			
	11147770	Feb 27, 2033	DP U-4483			
	11179367	Dec 08, 2037	DP U-3597			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)							
N 217660	002	11179367	Dec 08, 2037	DP		U-4059	
		11179367	Dec 08, 2037	DP		U-4484	
		11426407	Oct 06, 2035	DS DP		U-3595	
		11426407	Oct 06, 2035	DS DP		U-4058	
		11426407	Oct 06, 2035	DS DP		U-4476	
		11517564	Dec 08, 2037	DP		U-3586	
		11517564	Dec 08, 2037	DP		U-4057	
		11517564	Dec 08, 2037	DP		U-4476	
		11564916	Aug 13, 2029			U-3585	
		11564916	Aug 13, 2029			U-4055	
		11564916	Aug 13, 2029			U-4485	
		11578062	Mar 25, 2031	DP		U-3584	
		11578062	Mar 25, 2031	DP		U-4054	
		11578062	Mar 25, 2031	DP		U-4488	
		11639347	Apr 09, 2027	DS DP		U-3583	
		11639347	Apr 09, 2027	DS DP		U-4053	
		11639347	Apr 09, 2027	DS DP		U-4476	
		11752106	Feb 27, 2033	DP		U-3696	
		11752106	Feb 27, 2033	DP		U-4052	
		11752106	Feb 27, 2033	DP		U-4489	
		12214083	Feb 27, 2033	DP		U-4141	
		12214083	Feb 27, 2033	DP		U-4492	
		12350262	Jul 17, 2038			U-4220	
		12350262	Jul 17, 2038			U-4476	
		12458635	Aug 13, 2029	DP		U-4333	
		12458635	Aug 13, 2029	DP		U-4493	
		8324242	Aug 05, 2027			U-3589	
		8324242	Aug 05, 2027			U-4066	
		8324242	Aug 05, 2027			U-4476	
		8415387	Nov 12, 2027			U-3589	
		8415387	Nov 12, 2027			U-4066	
		8415387	Nov 12, 2027			U-4476	
		8598181	May 01, 2027			U-3589	
		8598181	May 01, 2027			U-4066	
		8598181	May 01, 2027			U-4476	
		9670163	Dec 28, 2026	DP		U-3591	
		9670163	Dec 28, 2026	DP		U-4068	
		9670163	Dec 28, 2026	DP		U-4478	
		9931334	Dec 28, 2026	DP		U-3591	
		9931334	Dec 28, 2026	DP		U-4068	
		9931334	Dec 28, 2026	DP		U-4478	
		9974781	Apr 09, 2027	DP		U-3589	
		9974781	Apr 09, 2027	DP		U-4066	
		9974781	Apr 09, 2027	DP		U-4476	
ELINZANETANT - LYNKUET							
N 219469	001	12533358	May 14, 2045			U-4402	
		7683056	Sep 15, 2027	DS DP			
EMPAGLIFLOZIN - JARDIANCE							
N 204629	001	12527810	Apr 22, 2033			U-4403	
		12527810*PED	Oct 22, 2033				
EMPAGLIFLOZIN - JARDIANCE							
N 204629	002	12527810	Apr 22, 2033			U-4403	
		12527810*PED	Oct 22, 2033				
EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR							
N 212614	001	>A> 12678442	Apr 02, 2029	DP			
EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR							
N 212614	002	>A> 12678442	Apr 02, 2029	DP			
EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR							
N 212614	003	>A> 12678442	Apr 02, 2029	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR							
N 212614 004	>A>	12678442	Apr 02, 2029	DP			
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY							
N 206111 001		12527810	Apr 22, 2033	U-4403			
		12527810*PED	Oct 22, 2033				
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY							
N 206111 002		12527810	Apr 22, 2033	U-4403			
		12527810*PED	Oct 22, 2033				
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY							
N 206111 003		12527810	Apr 22, 2033	U-4403			
		12527810*PED	Oct 22, 2033				
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY							
N 206111 004		12527810	Apr 22, 2033	U-4403			
		12527810*PED	Oct 22, 2033				
EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY							
N 208215 001		12629338	Jun 29, 2036	DP		>A> ODE-556	Jun 20, 2032
		12648911	Jun 29, 2036	U-1259			
		12648911	Jun 29, 2036	U-1663			
		12661323	Jun 29, 2036	DP			
	>A>	12678408	Jun 29, 2036	DP			
EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY							
N 208215 002		12661323	Jun 29, 2036	DP		>A> ODE-554	Jan 07, 2029
						>A> ODE-556	Jun 20, 2032
ENCORAFENIB - BRAFTOVI							
N 210496 002		10005761	Aug 27, 2030	U-2335			
		10005761	Aug 27, 2030	U-2802			
		10005761	Aug 27, 2030	U-2803			
		10005761	Aug 27, 2030	U-3738			
		10005761	Aug 27, 2030	U-4051			
		10005761	Aug 27, 2030	U-4440			
		10258622	Nov 21, 2032	U-2802			
		10258622	Nov 21, 2032	U-4051			
		10258622	Nov 21, 2032	U-4439			
		8541575	Feb 26, 2030	DS DP U-2335			
		8541575	Feb 26, 2030	DS DP U-2802			
		8541575	Feb 26, 2030	DS DP U-2803			
		8541575	Feb 26, 2030	DS DP U-3738			
		8541575	Feb 26, 2030	DS DP U-4051			
		8541575	Feb 26, 2030	DS DP U-4440			
		9314464	Jul 04, 2031	U-2336			
		9314464	Jul 04, 2031	U-2802			
		9314464	Jul 04, 2031	U-2803			
		9314464	Jul 04, 2031	U-3738			
		9314464	Jul 04, 2031	U-4051			
		9314464	Jul 04, 2031	U-4440			
		9474754	Aug 05, 2033	U-2802			
		9474754	Aug 05, 2033	U-4051			
		9474754	Aug 05, 2033	U-4440			
		9850230	Aug 27, 2030	U-2334			
		9850230	Aug 27, 2030	U-2802			
		9850230	Aug 27, 2030	U-2803			
		9850230	Aug 27, 2030	U-3738			
		9850230	Aug 27, 2030	U-4051			
		9850230	Aug 27, 2030	U-4440			
ENLICITIDE DECANOATE - LIPFENDRA							
N 220848 001	>A>	11427616	Feb 04, 2040	DS DP U-4585		>A> NCE	Jul 15, 2031

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ENSITRELVIR - XOCOVA							
N 220442	001	11814368	May 01, 2042	DS DP U-4553		NCE	May 29, 2031
		12559474	May 01, 2042	DS DP U-4553			
		9150546	Dec 12, 2030	DS DP			
EPINEPHRINE - EPINEPHRINE							
N 215425	001	12539283	Jan 17, 2045	DP			
EPLONTERSEN SODIUM - WAINUA							
N 217388	002	10683499	Aug 25, 2034	DS DP U-2378			
		9127276	May 01, 2034	DS			
		9181549	May 01, 2034	DS			
ERAVACYCLINE DIHYDROCHLORIDE - XERAVA							
N 211109	001	8906887	Aug 27, 2032	DP			
ERAVACYCLINE DIHYDROCHLORIDE - XERAVA							
N 211109	002	8906887	Aug 27, 2032	DP			
ERDAFITINIB - BALVERSA							
N 212018	001	>A> 12678498	Jun 13, 2036	U-4584			
ERDAFITINIB - BALVERSA							
N 212018	002	>A> 12678498	Jun 13, 2036	U-4584			
ERDAFITINIB - BALVERSA							
N 212018	003	>A> 12678498	Jun 13, 2036	U-4584			
ERTUGLIFLOZIN - STEGLATRO							
N 209803	001	8080580	Dec 19, 2031	DS DP U-2214			
ERTUGLIFLOZIN - STEGLATRO							
N 209803	002	8080580	Dec 19, 2031	DS DP U-2214			
ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET							
N 209806	001	8080580	Dec 19, 2031	DS DP U-2214			
ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET							
N 209806	002	8080580	Dec 19, 2031	DS DP U-2214			
ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET							
N 209806	003	8080580	Dec 19, 2031	DS DP U-2214			
ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET							
N 209806	004	8080580	Dec 19, 2031	DS DP U-2214			
ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN							
N 209805	001	8080580	Dec 19, 2031	DS DP U-2214			
ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN							
N 209805	002	8080580	Dec 19, 2031	DS DP U-2214			
ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX - MYFEMBREE							
N 214846	001	12551447	Nov 05, 2042	DP			
ETONOGESTREL - NEXPLANON							
N 021529	002					D-199	Jan 16, 2029
ETRIPAMIL - CARDAMYST							
N 218571	001	10010522	Jun 19, 2028	U-38			
		10010523	Jun 19, 2028	DS			
		10117848	Apr 13, 2036	DP U-4370			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ETRIPAMIL - CARDAMYST							
N 218571 001		12257224	Jul 15, 2042	U-4370			
		9227918	Jun 19, 2028	DP			
		9463179	Jun 19, 2028	U-4370			
FERRIC CARBOXYMALTOSE - INJECTAFER							
N 203565 001		7612109	Feb 05, 2027	DS DP			
FERRIC CARBOXYMALTOSE - INJECTAFER							
N 203565 002		7612109	Feb 05, 2027	DS DP			
FERRIC CARBOXYMALTOSE - INJECTAFER							
N 203565 003		7612109	Feb 05, 2027	DS DP			
FERRIC CARBOXYMALTOSE - INJECTAFER							
N 203565 004		7612109	Feb 05, 2027	DS DP			
FINERENONE - KERENDIA							
N 215341 001		8436180	Aug 26, 2033	DS DP			
FINERENONE - KERENDIA							
N 215341 002		8436180	Aug 26, 2033	DS DP			
FINERENONE - KERENDIA							
N 215341 003		8436180	Aug 26, 2033	DS DP			
FLIBANSERIN - ADDYI							
N 022526 001						I-983	Dec 13, 2028
FLURPIRIDAZ F-18 - FLYRCADO							
N 215168 001		12527884	May 13, 2042	DP U-4406			
FLUTICASONE PROPIONATE - FLUTICASONE PROPIONATE							
A 219602 001						CGT	Sep 20, 2026
FLUTICASONE PROPIONATE - XHANCE							
N 209022 001		12616806	Feb 23, 2036	U-4524			
		12616806	Feb 23, 2036	U-4525			
FOSFOMYCIN DISODIUM - CONTEPO							
N 212271 001						NP	Oct 22, 2028
						GAIN	Oct 22, 2033
FUROSEMIDE - LASIX ONYU							
N 217294 001	>A>	11246851	Jan 03, 2040	DP U-4576			
	>A>	12318363	Jan 03, 2040	DP			
	>A>	12403120	Jan 10, 2042	DP U-4576			
GADOPICLENOL - ELUCIREM							
N 216986 001		12064487	Jan 17, 2040	U-4424		NPP	Feb 20, 2029
	>A>	8114863	May 25, 2032	DS DP			
GADOPICLENOL - ELUCIREM							
N 216986 002		12064487	Jan 17, 2040	U-4424		NPP	Feb 20, 2029
	>A>	8114863	May 25, 2032	DS DP			
GADOPICLENOL - ELUCIREM							
N 216986 003		12064487	Jan 17, 2040	U-4424		NPP	Feb 20, 2029
	>A>	8114863	May 25, 2032	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GADOPICLENOL - ELUCIREM							
N 216986 004		12064487	Jan 17, 2040	U-4424		NPP	Feb 20, 2029
	>A>	8114863	May 25, 2032	DS DP			
GADOPICLENOL - ELUCIREM							
N 216986 005		12064487	Jan 17, 2040	U-4424		NPP	Feb 20, 2029
	>A>	8114863	May 25, 2032	DS DP			
GADOPICLENOL - ELUCIREM							
N 216986 006		12064487	Jan 17, 2040	U-4424		NPP	Feb 20, 2029
	>A>	8114863	May 25, 2032	DS DP			
GADOPICLENOL - ELUCIREM							
N 216986 007	>A>	8114863	May 25, 2032	DS DP		NPP	Feb 20, 2029
GADOQUATRANE - AMBELVIST							
N 219627 001	>A>	10137209	May 30, 2036	DS U-4424		NCE	Jun 12, 2031
	>A>	10722601	May 30, 2036	DS U-4424			
	>A>	11491245	May 30, 2036	DS			
	>A>	11944690	May 19, 2040	DP			
	>A>	12303573	Nov 21, 2039	DP			
	>A>	12478696	May 30, 2036	DS			
GADOQUATRANE - AMBELVIST							
N 219627 002	>A>	10137209	May 30, 2036	DS U-4424		NCE	Jun 12, 2031
	>A>	10722601	May 30, 2036	DS U-4424			
	>A>	11491245	May 30, 2036	DS			
	>A>	11944690	May 19, 2040	DP			
	>A>	12303573	Nov 21, 2039	DP			
	>A>	12478696	May 30, 2036	DS			
GADOQUATRANE - AMBELVIST							
N 219627 003	>A>	10137209	May 30, 2036	DS U-4424		NCE	Jun 12, 2031
	>A>	10722601	May 30, 2036	DS U-4424			
	>A>	11491245	May 30, 2036	DS			
	>A>	11944690	May 19, 2040	DP			
	>A>	12303573	Nov 21, 2039	DP			
	>A>	12478696	May 30, 2036	DS			
GADOQUATRANE - AMBELVIST							
N 219627 004	>A>	10137209	May 30, 2036	DS U-4424		NCE	Jun 12, 2031
	>A>	10722601	May 30, 2036	DS U-4424			
	>A>	11491245	May 30, 2036	DS			
	>A>	11944690	May 19, 2040	DP			
	>A>	12303573	Nov 21, 2039	DP			
	>A>	12478696	May 30, 2036	DS			
GADOQUATRANE - AMBELVIST							
N 219627 005	>A>	10137209	May 30, 2036	DS U-4424		NCE	Jun 12, 2031
	>A>	10722601	May 30, 2036	DS U-4424			
	>A>	11491245	May 30, 2036	DS			
	>A>	11944690	May 19, 2040	DP			
	>A>	12303573	Nov 21, 2039	DP			
	>A>	12478696	May 30, 2036	DS			
GADOQUATRANE - AMBELVIST							
N 219627 006	>A>	10137209	May 30, 2036	DS U-4424		NCE	Jun 12, 2031
	>A>	10722601	May 30, 2036	DS U-4424			
	>A>	11491245	May 30, 2036	DS			
	>A>	11944690	May 19, 2040	DP			
	>A>	12303573	Nov 21, 2039	DP			
	>A>	12478696	May 30, 2036	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GANAXOLONE - ZTALMY								
N 215904	001		8318714	Nov 28, 2031	DP			
GEDATOLISIB - REVTORPYK								
N 219908	001						>A> NCE	Jul 14, 2031
GEMCITABINE HYDROCHLORIDE - INLEXZO								
N 219683	001		12576253	Dec 17, 2030	DP			
			12636300	Nov 07, 2038	U-4552			
GEPOTIDACIN MESYLATE - BLUJEPA								
N 218230	001		12528809	Dec 13, 2042	DS DP U-4361			
			12528809	Dec 13, 2042	DS DP U-4408			
GIVINOSTAT HYDROCHLORIDE - DUVYZAT								
N 217865	001		12606519	May 03, 2040	DS DP			
			7329689	Jan 15, 2027	DS DP			
GLASDEGIB MALEATE - DAURISMO								
N 210656	001		8148401	Nov 21, 2032	DS DP			
GLASDEGIB MALEATE - DAURISMO								
N 210656	002		8148401	Nov 21, 2032	DS DP			
GLUCAGON - BAQSIMI								
N 210134	001						NPP	Mar 17, 2028
HYDROMORPHONE HYDROCHLORIDE - HYDROMORPHONE HYDROCHLORIDE								
N 217812	001	>A>	12653820	Jan 10, 2043	DP U-4571			
IBRUTINIB - IMBRUVICA								
N 210563	001		12551448	Mar 03, 2036	DP			
IBRUTINIB - IMBRUVICA								
N 210563	002		12551448	Mar 03, 2036	DP			
IBRUTINIB - IMBRUVICA								
N 210563	003		12551448	Mar 03, 2036	DP			
ICOTROKINRA HYDROCHLORIDE - ICOTYDE								
N 220149	001		11845808	Jan 14, 2041	DS U-4447		NCE	Mar 17, 2031
			11939361	Nov 19, 2041	DP U-4447			
			12552836	Jul 12, 2039	DS DP			
ILOPERIDONE - FANAPT								
N 022192	001		10563259	Jul 24, 2030	U-4562			
			10563259	Jul 24, 2030	U-4563			
			10570453	Mar 28, 2028	U-4562			
			10570453	Mar 28, 2028	U-4563			
			12606869	Sep 22, 2030	U-4504			
			12606869	Sep 22, 2030	U-4505			
ILOPERIDONE - FANAPT								
N 022192	002		10563259	Jul 24, 2030	U-4562			
			10563259	Jul 24, 2030	U-4563			
			10570453	Mar 28, 2028	U-4562			
			10570453	Mar 28, 2028	U-4563			
			12606869	Sep 22, 2030	U-4504			
			12606869	Sep 22, 2030	U-4505			
ILOPERIDONE - FANAPT								
N 022192	003		10563259	Jul 24, 2030	U-4562			
			10563259	Jul 24, 2030	U-4563			
			10570453	Mar 28, 2028	U-4562			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ILOPERIDONE - FANAPT						
N 022192 003	10570453	Mar 28, 2028	U-4563			
	12606869	Sep 22, 2030	U-4504			
	12606869	Sep 22, 2030	U-4505			
ILOPERIDONE - FANAPT						
N 022192 004	10563259	Jul 24, 2030	U-4562			
	10563259	Jul 24, 2030	U-4563			
	10570453	Mar 28, 2028	U-4562			
	10570453	Mar 28, 2028	U-4563			
	12606869	Sep 22, 2030	U-4504			
	12606869	Sep 22, 2030	U-4505			
ILOPERIDONE - FANAPT						
N 022192 005	10563259	Jul 24, 2030	U-4562			
	10563259	Jul 24, 2030	U-4563			
	10570453	Mar 28, 2028	U-4562			
	10570453	Mar 28, 2028	U-4563			
	12606869	Sep 22, 2030	U-4504			
	12606869	Sep 22, 2030	U-4505			
ILOPERIDONE - FANAPT						
N 022192 006	10563259	Jul 24, 2030	U-4562			
	10563259	Jul 24, 2030	U-4563			
	10570453	Mar 28, 2028	U-4562			
	10570453	Mar 28, 2028	U-4563			
	12606869	Sep 22, 2030	U-4504			
	12606869	Sep 22, 2030	U-4505			
ILOPERIDONE - FANAPT						
N 022192 007	10563259	Jul 24, 2030	U-4562			
	10563259	Jul 24, 2030	U-4563			
	10570453	Mar 28, 2028	U-4562			
	10570453	Mar 28, 2028	U-4563			
	12606869	Sep 22, 2030	U-4504			
	12606869	Sep 22, 2030	U-4505			
IMETELSTAT SODIUM - RYTELO						
N 217779 001	7494982	Dec 27, 2026	DS DP			
IMETELSTAT SODIUM - RYTELO						
N 217779 002	7494982	Dec 27, 2026	DS DP			
INCLISIRAN SODIUM - LEQVIO						
N 214012 001	10125369	Aug 18, 2034	DS DP U-4249		I-985	Feb 12, 2029
	10125369	Aug 18, 2034	DS DP U-4413		NPP	Feb 12, 2029
	10125369	Aug 18, 2034	DS DP U-4414		>A> ODE-555	Feb 12, 2033
	10131907	Aug 24, 2028	DS DP U-4249			
	10131907	Aug 24, 2028	DS DP U-4413			
	10131907	Aug 24, 2028	DS DP U-4414			
	10851377	Aug 25, 2036	U-4249			
	10851377	Aug 25, 2036	U-4413			
	10851377	Aug 25, 2036	U-4414			
	8106022	Dec 12, 2029	DS DP U-4249			
	8106022	Dec 12, 2029	DS DP U-4413			
	8106022	Dec 12, 2029	DS DP U-4414			
	8222222	Dec 29, 2027	U-4249			
	8222222	Dec 29, 2027	U-4413			
	8222222	Dec 29, 2027	U-4414			
	8809292	May 10, 2027	DS DP U-4249			
	8809292	May 10, 2027	DS DP U-4413			
	8809292	May 10, 2027	DS DP U-4414			
	8828956	Dec 04, 2028	DS DP U-4249			
	8828956	Dec 04, 2028	DS DP U-4413			
	8828956	Dec 04, 2028	DS DP U-4414			
	9370582	Dec 04, 2028	DS DP U-4249			
	9370582	Dec 04, 2028	DS DP U-4413			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
INCLISIRAN SODIUM - LEQVIO						
N 214012 001	9370582	Dec 04, 2028	DS DP U-4414			
INDOCYANINE GREEN - INDOCYANINE GREEN						
A 219139 001					>A> CGT	Jan 31, 2027
IOHEXOL - IOHEXOL						
A 217737 001					CGT	Jul 26, 2026
IPRATROPIUM BROMIDE - IPRATROPIUM BROMIDE						
A 217953 001					PC	Oct 13, 2026
IPTACOPAN HYDROCHLORIDE - FABHALTA						
N 218276 001					ODE-524	Mar 20, 2032
LAMOTRIGINE - SUBVENITE						
N 218879 001	12629377	May 29, 2040	DP U-4539			
	12629377	May 29, 2040	DP U-4540			
	12629377	May 29, 2040	DP U-4541			
	12636289	May 29, 2040	DP			
LANDIOLOL HYDROCHLORIDE - RAPIBLYK						
N 217202 001					NPP	Feb 13, 2029
LAZERTINIB MESYLATE - LAZCLUZE						
N 219008 001	12599606	May 14, 2040	U-4512			
LAZERTINIB MESYLATE - LAZCLUZE						
N 219008 002	12599606	May 14, 2040	U-4511			
LENACAPAVIR SODIUM - SUNLENCA						
N 215973 001	12594267	Jul 15, 2039	DP			
LENACAPAVIR SODIUM - YEZTUGO						
N 220018 001	12594267	Jul 15, 2039	DP			
LETROZOLE; RIBOCICLIB SUCCINATE - KISQALI FEMARA CO-PACK (COPACKAGED)						
N 209935 001	10799506	Apr 14, 2036	DP		I-951	Sep 17, 2027
	10799506*PED	Oct 14, 2036			PED	Mar 17, 2028
	12064434	Apr 14, 2036	DP			
	12064434*PED	Oct 14, 2036				
	12419894	Apr 14, 2036	DP			
	12419894*PED	Oct 14, 2036				
	12544380	Aug 07, 2034	U-3264			
	12544380	Aug 07, 2034	U-3998			
	12544380*PED	Feb 07, 2035				
	8324225	Jun 17, 2028	DS DP			
	8324225*PED	Dec 17, 2028				
	8415355	Mar 13, 2031	DS DP			
	8415355*PED	Sep 13, 2031				
	8685980	May 25, 2030	DS DP			
	8685980*PED	Nov 25, 2030				
	8962630	Dec 09, 2029	U-2505			
	8962630	Dec 09, 2029	U-3264			
	8962630	Dec 09, 2029	U-3998			
	8962630*PED	Jun 09, 2030				
	9193732	Nov 09, 2031	DS DP			
	9193732*PED	May 09, 2032				
	9416136	Aug 20, 2029	U-2505			
	9416136	Aug 20, 2029	U-3264			
	9416136	Aug 20, 2029	U-3998			
	9416136*PED	Feb 20, 2030				
	9868739	Nov 09, 2031	U-2505			
	9868739	Nov 09, 2031	U-3264			
	9868739	Nov 09, 2031	U-3998			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LETROZOLE; RIBOCICLIB SUCCINATE - KISQALI FEMARA CO-PACK (COPACKAGED)							
N 209935	001	9868739*PED	May 09, 2032				
LEUCOVORIN CALCIUM - VYKOURA							
N 220406	001	12564592	Dec 23, 2044	DP			
LEUCOVORIN CALCIUM - VYKOURA							
N 220406	002	12564592	Dec 23, 2044	DP			
LEUCOVORIN CALCIUM - VYKOURA							
N 220406	003	12564592	Dec 23, 2044	DP			
LEUPROLIDE MESYLATE - CAMCEVI KIT							
N 211488	001	9572857	Aug 02, 2029	DP			
LEUPROLIDE MESYLATE - CAMCEVI ETM							
N 219745	001	10646572	Jan 16, 2027	DP			
		11717555	Jan 01, 2039	DP			
		12133878	Dec 18, 2037	DP			
		9572857	Aug 02, 2029	DP			
		9744207	Jan 16, 2027	DP			
LEVOTHYROXINE SODIUM - TIROSINT							
N 021924	002	12564565	Sep 26, 2044	DP			
LEVOTHYROXINE SODIUM - TIROSINT							
N 021924	003	12564565	Sep 26, 2044	DP			
LEVOTHYROXINE SODIUM - TIROSINT							
N 021924	004	12564565	Sep 26, 2044	DP			
LEVOTHYROXINE SODIUM - TIROSINT							
N 021924	005	12564565	Sep 26, 2044	DP			
LEVOTHYROXINE SODIUM - TIROSINT							
N 021924	006	12564565	Sep 26, 2044	DP			
LEVOTHYROXINE SODIUM - TIROSINT							
N 021924	007	12564565	Sep 26, 2044	DP			
LEVOTHYROXINE SODIUM - TIROSINT							
N 021924	008	12564565	Sep 26, 2044	DP			
LEVOTHYROXINE SODIUM - TIROSINT							
N 021924	009	12564565	Sep 26, 2044	DP			
LEVOTHYROXINE SODIUM - TIROSINT							
N 021924	010	12564565	Sep 26, 2044	DP			
LEVOTHYROXINE SODIUM - TIROSINT							
N 021924	011	12564565	Sep 26, 2044	DP			
LEVOTHYROXINE SODIUM - TIROSINT							
N 021924	012	12564565	Sep 26, 2044	DP			
LEVOTHYROXINE SODIUM - TIROSINT							
N 021924	013	12564565	Sep 26, 2044	DP			
LEVOTHYROXINE SODIUM - TIROSINT							
N 021924	014	12564565	Sep 26, 2044	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEVOTHYROXINE SODIUM - TIROSINT						
N 021924 015	12564565	Sep 26, 2044	DP			
LEVOTHYROXINE SODIUM - TIROSINT						
N 021924 016	12564565	Sep 26, 2044	DP			
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 001	12564565	Sep 26, 2044	DP			
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 002	12564565	Sep 26, 2044	DP			
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 003	12564565	Sep 26, 2044	DP			
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 004	12564565	Sep 26, 2044	DP			
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 005	12564565	Sep 26, 2044	DP			
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 006	12564565	Sep 26, 2044	DP			
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 007	12564565	Sep 26, 2044	DP			
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 008	12564565	Sep 26, 2044	DP			
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 009	12564565	Sep 26, 2044	DP			
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 010	12564565	Sep 26, 2044	DP			
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 011	12564565	Sep 26, 2044	DP			
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 012	12564565	Sep 26, 2044	DP			
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 013	12564565	Sep 26, 2044	DP			
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 014	12564565	Sep 26, 2044	DP			
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 015	12564565	Sep 26, 2044	DP			
LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM						
N 210632 001	12636270	Dec 01, 2036	DP			
LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM						
N 210632 002	12636270	Dec 01, 2036	DP			
LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM						
N 210632 003	12636270	Dec 01, 2036	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LIDOCAINE; TETRACAINE - PLIAGLIS							
N 021717	001	12558328	Jan 14, 2031	U-4421			
LIFITEGRAST - XIIDRA							
N 208073	001	7314938	Jun 25, 2029	DS DP			
LINACLOTIDE - LINZESS							
N 202811	001					NPP	Nov 04, 2028
						PED	May 04, 2029
LINACLOTIDE - LINZESS							
N 202811	003	>A> 10702576	Aug 11, 2031	U-1516		NPP	May 21, 2029
		>A> 10702576	Aug 11, 2031	U-3644			
		>A> 10702576	Aug 11, 2031	U-4566			
		>A> 10702576*PED	Feb 11, 2032				
		>A> 7304036	Aug 30, 2026	DS DP U-1516			
		>A> 7304036	Aug 30, 2026	DS DP U-3644			
		>A> 7304036	Aug 30, 2026	DS DP U-4566			
		>A> 7304036*PED	Feb 28, 2027				
		>A> 8933030	Feb 17, 2031	DP U-1516			
		>A> 8933030	Feb 17, 2031	DP U-3644			
		>A> 8933030	Feb 17, 2031	DP U-4566			
		>A> 8933030*PED	Aug 17, 2031				
		>A> 9708371	Aug 16, 2033	DP U-1516			
		>A> 9708371	Aug 16, 2033	DP U-3644			
		>A> 9708371	Aug 16, 2033	DP U-4566			
		>A> 9708371*PED	Feb 16, 2034				
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO							
N 201281	001	>A> 12678442	Apr 02, 2029	DP			
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO							
N 201281	002	>A> 12678442	Apr 02, 2029	DP			
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO							
N 201281	003	>A> 12678442	Apr 02, 2029	DP			
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR							
N 208026	001	>A> 12678442	Apr 02, 2029	DP			
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR							
N 208026	002	>A> 12678442	Apr 02, 2029	DP			
LINERIXIBAT - LYNAVOY							
N 220295	001	9040518	Sep 06, 2031	DS DP		NCE	Mar 17, 2031
						ODE-517	Mar 17, 2033
LISDEXAMFETAMINE DIMESYLATE - ARYNTA							
N 219847	001	12582620	Apr 16, 2040	DP			
LOMITAPIDE MESYLATE - JUXTAPID							
N 203858	001	12472172	Jul 29, 2041	U-4438		NPP	Feb 25, 2029
LOMITAPIDE MESYLATE - JUXTAPID							
N 203858	002	12472172	Jul 29, 2041	U-4438		NPP	Feb 25, 2029
LOMITAPIDE MESYLATE - JUXTAPID							
N 203858	003	12472172	Jul 29, 2041	U-4438		NPP	Feb 25, 2029
LOMITAPIDE MESYLATE - JUXTAPID							
N 203858	004	12472172	Jul 29, 2041	U-4438		NPP	Feb 25, 2029

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LOMITAPIDE MESYLATE - JUXTAPID						
N 203858 005					NPP	Feb 25, 2029
LOMITAPIDE MESYLATE - JUXTAPID						
N 203858 007	12472172	Jul 29, 2041	U-4438		NS	Feb 25, 2029
	7932268	Aug 19, 2027	U-1316			
LOMUSTINE - LOMUSTINE						
A 219265 001					CGT	May 19, 2026
LOMUSTINE - LOMUSTINE						
A 219265 002					CGT	May 19, 2026
LOMUSTINE - LOMUSTINE						
A 219265 003					CGT	May 19, 2026
LOSARTAN POTASSIUM - ARBLI						
N 218772 001	12605365	Oct 07, 2041	DP U-4159			
	12605365	Oct 07, 2041	DP U-4160			
LOTEPREDNOL ETABONATE - LOTEMAX SM						
N 208219 001	12589069	Jan 26, 2036	DP U-2764			
LOTEPREDNOL ETABONATE; TOBRAMYCIN - LOTEPREDNOL ETABONATE AND TOBRAMYCIN						
A 217597 001					CGT	Jul 14, 2026
LUMATEPERONE TOSYLATE - CAPLYTA						
N 209500 001					M-319	Apr 24, 2029
LUMATEPERONE TOSYLATE - CAPLYTA						
N 209500 002					M-319	Apr 24, 2029
LUMATEPERONE TOSYLATE - CAPLYTA						
N 209500 003					M-319	Apr 24, 2029
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN - PLUVICTO						
N 215833 001	10398791	Mar 23, 2036	DS DP			
MACIMORELIN ACETATE - MACRILEN						
N 205598 001	8192719	Oct 12, 2027	U-2220			
	8192719*PED	Apr 12, 2028				
MACITENTAN - MACITENTAN						
A 211026 001					PC	Dec 03, 2026
MACITENTAN - MACITENTAN						
A 211120 001					PC	Dec 03, 2026
MACITENTAN - MACITENTAN						
A 211187 001					PC	Dec 03, 2026
MACITENTAN - MACITENTAN						
A 211224 001					PC	Dec 03, 2026
MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM SULFATE - SUFLAVE						
N 215344 001	12594298	Jun 14, 2044	DP			
MARALIXIBAT CHLORIDE - LIVMARLI						
N 214662 001	12599602	Feb 12, 2040	U-3290			
	12599602	Feb 12, 2040	U-3974			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MARIBAVIR - LIVTENCITY							
N 215596	001	12527771	Oct 11, 2043	DS DP			
	>A>	12661368	Oct 27, 2031	U-4572			
MELOXICAM; RIZATRIPTAN BENZOATE - SYMBRAVO							
N 215431	001	10265399	Apr 11, 2036	U-4509			
		10265400	Apr 11, 2036	U-4509			
		10307484	Apr 11, 2036	U-4509			
		10369225	Apr 11, 2036	U-4356			
		10456471	Apr 11, 2036	U-4509			
		11266657	Apr 11, 2036	U-1719			
		11433078	Apr 11, 2036	U-1719			
		11433079	Apr 11, 2036	U-1719			
		11944683	Apr 11, 2036	U-1719			
		12005118	Jan 25, 2043	U-1719			
		12544383	Mar 10, 2045	U-1719			
		12551488	May 28, 2040	U-1719			
		12551489	May 28, 2040	U-1719			
		12611413	Dec 29, 2041	U-1719			
		12616752	May 18, 2038	U-4510			
MEROPENEM; VABORBACTAM - VABOMERE							
N 209776	001	12533342	Apr 06, 2039	U-3421			
METAXALONE - METAXALONE							
N 022503	001	12485111	May 14, 2043	DP U-4453			
METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR							
N 200678	001					M-14	Oct 11, 2027
METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR							
N 200678	002					M-14	Oct 11, 2027
METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR							
N 200678	003					M-14	Oct 11, 2027
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - SITAGLIPTIN AND METFORMIN HYDROCHLORIDE							
A 202388	001					PC	Nov 24, 2026
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - SITAGLIPTIN AND METFORMIN HYDROCHLORIDE							
A 202388	002					PC	Nov 24, 2026
METHOTREXATE - JYLAMVO							
N 212479	001	12605385	Oct 25, 2035	DP			
MIGALASTAT HYDROCHLORIDE - GALAFOLD							
N 208623	001	12594268	May 23, 2041	U-2371			
		12599594	Jul 19, 2036	U-2371			
		12599595	Apr 28, 2028	U-2371			
MILSAPERIDONE - BYSANTI							
N 220358	001	10563259	Jul 24, 2030	U-4436		NCE	Feb 20, 2031
		10563259	Jul 24, 2030	U-4437			
		10570453	Mar 28, 2028	U-4436			
		10570453	Mar 28, 2028	U-4437			
		12478619	May 31, 2044	U-4434			
		12478619	May 31, 2044	U-4435			
		12606869	Sep 22, 2030	U-4506			
		12606869	Sep 22, 2030	U-4507			
		8999638	Oct 28, 2030	U-4436			
		8999638	Oct 28, 2030	U-4437			
		9072742	Jan 16, 2031	U-4436			
		9072742	Jan 16, 2031	U-4437			
		9074254	Dec 28, 2031	U-4436			
		9074254	Dec 28, 2031	U-4437			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MILSAPERIDONE - BYSANTI						
N 220358 001	9074255	Dec 17, 2030	U-4436			
	9074255	Dec 17, 2030	U-4437			
	9074256	Feb 10, 2031	U-4436			
	9074256	Feb 10, 2031	U-4437			
	9157121	Apr 05, 2030	U-4436			
	9157121	Apr 05, 2030	U-4437			
MILSAPERIDONE - BYSANTI						
N 220358 002	10563259	Jul 24, 2030	U-4436		NCE	Feb 20, 2031
	10563259	Jul 24, 2030	U-4437			
	10570453	Mar 28, 2028	U-4436			
	10570453	Mar 28, 2028	U-4437			
	12478619	May 31, 2044	U-4434			
	12478619	May 31, 2044	U-4435			
	12606869	Sep 22, 2030	U-4506			
	12606869	Sep 22, 2030	U-4507			
	8999638	Oct 28, 2030	U-4436			
	8999638	Oct 28, 2030	U-4437			
	9072742	Jan 16, 2031	U-4436			
	9072742	Jan 16, 2031	U-4437			
	9074254	Dec 28, 2031	U-4436			
	9074254	Dec 28, 2031	U-4437			
	9074255	Dec 17, 2030	U-4436			
	9074255	Dec 17, 2030	U-4437			
	9074256	Feb 10, 2031	U-4436			
	9074256	Feb 10, 2031	U-4437			
	9157121	Apr 05, 2030	U-4436			
	9157121	Apr 05, 2030	U-4437			
MILSAPERIDONE - BYSANTI						
N 220358 003	10563259	Jul 24, 2030	U-4436		NCE	Feb 20, 2031
	10563259	Jul 24, 2030	U-4437			
	10570453	Mar 28, 2028	U-4436			
	10570453	Mar 28, 2028	U-4437			
	12478619	May 31, 2044	U-4434			
	12478619	May 31, 2044	U-4435			
	12606869	Sep 22, 2030	U-4506			
	12606869	Sep 22, 2030	U-4507			
	8999638	Oct 28, 2030	U-4436			
	8999638	Oct 28, 2030	U-4437			
	9072742	Jan 16, 2031	U-4436			
	9072742	Jan 16, 2031	U-4437			
	9074254	Dec 28, 2031	U-4436			
	9074254	Dec 28, 2031	U-4437			
	9074255	Dec 17, 2030	U-4436			
	9074255	Dec 17, 2030	U-4437			
	9074256	Feb 10, 2031	U-4436			
	9074256	Feb 10, 2031	U-4437			
	9157121	Apr 05, 2030	U-4436			
	9157121	Apr 05, 2030	U-4437			
MILSAPERIDONE - BYSANTI						
N 220358 004	10563259	Jul 24, 2030	U-4436		NCE	Feb 20, 2031
	10563259	Jul 24, 2030	U-4437			
	10570453	Mar 28, 2028	U-4436			
	10570453	Mar 28, 2028	U-4437			
	12478619	May 31, 2044	U-4434			
	12478619	May 31, 2044	U-4435			
	12606869	Sep 22, 2030	U-4506			
	12606869	Sep 22, 2030	U-4507			
	8999638	Oct 28, 2030	U-4436			
	8999638	Oct 28, 2030	U-4437			
	9072742	Jan 16, 2031	U-4436			
	9072742	Jan 16, 2031	U-4437			
	9074254	Dec 28, 2031	U-4436			
	9074254	Dec 28, 2031	U-4437			
	9074255	Dec 17, 2030	U-4436			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MILSAPERIDONE - BYSANTI						
N 220358 004	9074255	Dec 17, 2030	U-4437			
	9074256	Feb 10, 2031	U-4436			
	9074256	Feb 10, 2031	U-4437			
	9157121	Apr 05, 2030	U-4436			
	9157121	Apr 05, 2030	U-4437			
MILSAPERIDONE - BYSANTI						
N 220358 005	10563259	Jul 24, 2030	U-4436		NCE	Feb 20, 2031
	10563259	Jul 24, 2030	U-4437			
	10570453	Mar 28, 2028	U-4436			
	10570453	Mar 28, 2028	U-4437			
	12478619	May 31, 2044	U-4434			
	12478619	May 31, 2044	U-4435			
	12606869	Sep 22, 2030	U-4506			
	12606869	Sep 22, 2030	U-4507			
	8999638	Oct 28, 2030	U-4436			
	8999638	Oct 28, 2030	U-4437			
	9072742	Jan 16, 2031	U-4436			
	9072742	Jan 16, 2031	U-4437			
	9074254	Dec 28, 2031	U-4436			
	9074254	Dec 28, 2031	U-4437			
	9074255	Dec 17, 2030	U-4436			
	9074255	Dec 17, 2030	U-4437			
	9074256	Feb 10, 2031	U-4436			
	9074256	Feb 10, 2031	U-4437			
	9157121	Apr 05, 2030	U-4436			
	9157121	Apr 05, 2030	U-4437			
MILSAPERIDONE - BYSANTI						
N 220358 006	10563259	Jul 24, 2030	U-4436		NCE	Feb 20, 2031
	10563259	Jul 24, 2030	U-4437			
	10570453	Mar 28, 2028	U-4436			
	10570453	Mar 28, 2028	U-4437			
	12478619	May 31, 2044	U-4434			
	12478619	May 31, 2044	U-4435			
	12606869	Sep 22, 2030	U-4506			
	12606869	Sep 22, 2030	U-4507			
	8999638	Oct 28, 2030	U-4436			
	8999638	Oct 28, 2030	U-4437			
	9072742	Jan 16, 2031	U-4436			
	9072742	Jan 16, 2031	U-4437			
	9074254	Dec 28, 2031	U-4436			
	9074254	Dec 28, 2031	U-4437			
	9074255	Dec 17, 2030	U-4436			
	9074255	Dec 17, 2030	U-4437			
	9074256	Feb 10, 2031	U-4436			
	9074256	Feb 10, 2031	U-4437			
	9157121	Apr 05, 2030	U-4436			
	9157121	Apr 05, 2030	U-4437			
MILSAPERIDONE - BYSANTI						
N 220358 007	10563259	Jul 24, 2030	U-4436		NCE	Feb 20, 2031
	10563259	Jul 24, 2030	U-4437			
	10570453	Mar 28, 2028	U-4436			
	10570453	Mar 28, 2028	U-4437			
	12478619	May 31, 2044	U-4434			
	12478619	May 31, 2044	U-4435			
	12606869	Sep 22, 2030	U-4506			
	12606869	Sep 22, 2030	U-4507			
	8999638	Oct 28, 2030	U-4436			
	8999638	Oct 28, 2030	U-4437			
	9072742	Jan 16, 2031	U-4436			
	9072742	Jan 16, 2031	U-4437			
	9074254	Dec 28, 2031	U-4436			
	9074254	Dec 28, 2031	U-4437			
	9074255	Dec 17, 2030	U-4436			
	9074255	Dec 17, 2030	U-4437			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MILSAPERIDONE - BYSANTI								
N 220358	007		9074256	Feb 10, 2031	U-4436			
			9074256	Feb 10, 2031	U-4437			
			9157121	Apr 05, 2030	U-4436			
			9157121	Apr 05, 2030	U-4437			
MINOCYCLINE HYDROCHLORIDE - ZILXI								
N 213690	001	>A>	12661407	Oct 01, 2030	U-1631			
MINOCYCLINE HYDROCHLORIDE - EMROSI								
N 219015	001		12594252	Jan 07, 2039	U-4043			
MIRDAMETINIB - GOMEKLI								
N 219379	001		12661330	Feb 05, 2044	U-4130			
MIRDAMETINIB - GOMEKLI								
N 219389	001		12661330	Feb 05, 2044	U-4130			
MIRDAMETINIB - GOMEKLI								
N 219389	002		12661330	Feb 05, 2044	U-4130			
MITAPIVAT SULFATE - PYRUKYND								
N 216196	001		RE49582	Apr 11, 2035	DS DP			
MITAPIVAT SULFATE - PYRUKYND								
N 216196	002		RE49582	Apr 11, 2035	DS DP			
MITAPIVAT SULFATE - PYRUKYND								
N 216196	003		RE49582	Apr 11, 2035	DS DP			
MITAPIVAT SULFATE - AQVESME								
N 216196	004		10632114	May 03, 2032	U-4391		NCE	Feb 17, 2027
			11254652	Nov 21, 2038	DS DP		NP	Dec 23, 2028
			11878049	Jul 31, 2041	U-4390		ODE-522	Dec 23, 2032
			9193701	Oct 26, 2032	U-4393			
			9682080	May 03, 2032	U-4392			
			RE49582	Apr 11, 2035	DS DP			
MOMELOTINIB DIHYDROCHLORIDE - OJJAARA								
N 216873	001		12576089	Aug 21, 2039	U-4441			
			8486941	Jan 03, 2035	DS DP U-1201			
MOMELOTINIB DIHYDROCHLORIDE - OJJAARA								
N 216873	002		12576089	Aug 21, 2039	U-4441			
			8486941	Jan 03, 2035	DS DP U-1201			
MOMELOTINIB DIHYDROCHLORIDE - OJJAARA								
N 216873	003		12576089	Aug 21, 2039	U-4441			
			8486941	Jan 03, 2035	DS DP U-1201			
MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE - RYALTRIS								
N 211746	001	>A>	12653833	Nov 21, 2044	DP U-4564	>A>	NPP	Jul 07, 2029
MOXIDECTIN - MOXIDECTIN								
N 210867	001						ODE-528	Feb 07, 2032
NALOXONE HYDROCHLORIDE - REZENOPY								
N 215487	001		12514854	Feb 05, 2041	U-4397			
			12622903	Feb 05, 2041	DP			
NAVEPEGRITIDE - YUVIWEL								
N 219164	001		10835578	Jan 05, 2037	DS DP U-4425		NCE	Feb 27, 2031
			11154593	Jan 05, 2037	DS DP U-4425		ODE-516	Feb 27, 2033

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NAVEPEGRITIDE - YUVIWEL						
N 219164 001	11224661	Jan 05, 2037	DS DP			
	11311604	Jan 05, 2037	DS DP U-4425			
	11389510	Jan 05, 2037	DS DP			
	11389511	Jan 05, 2037	DP U-4425			
	11413351	Jan 05, 2037	DS DP			
	12083182	Jan 05, 2037	U-4425			
	12156917	Jan 05, 2037	U-4425			
	12239689	Jan 05, 2037	U-4425			
	12377133	Nov 12, 2042	DP U-4425			
	8906847	Apr 30, 2031	DS DP U-4425			
NAVEPEGRITIDE - YUVIWEL						
N 219164 002	10835578	Jan 05, 2037	DS DP U-4425		NCE	Feb 27, 2031
	11154593	Jan 05, 2037	DS DP U-4425		ODE-516	Feb 27, 2033
	11224661	Jan 05, 2037	DS DP			
	11311604	Jan 05, 2037	DS DP U-4425			
	11389510	Jan 05, 2037	DS DP			
	11389511	Jan 05, 2037	DP U-4425			
	11413351	Jan 05, 2037	DS DP			
	12083182	Jan 05, 2037	U-4425			
	12156917	Jan 05, 2037	U-4425			
	12239689	Jan 05, 2037	U-4425			
	12377133	Nov 12, 2042	DP U-4425			
	8906847	Apr 30, 2031	DS DP U-4425			
NAVEPEGRITIDE - YUVIWEL						
N 219164 003	10835578	Jan 05, 2037	DS DP U-4425		NCE	Feb 27, 2031
	11154593	Jan 05, 2037	DS DP U-4425		ODE-516	Feb 27, 2033
	11224661	Jan 05, 2037	DS DP			
	11311604	Jan 05, 2037	DS DP U-4425			
	11389510	Jan 05, 2037	DS DP			
	11389511	Jan 05, 2037	DP U-4425			
	11413351	Jan 05, 2037	DS DP			
	12083182	Jan 05, 2037	U-4425			
	12156917	Jan 05, 2037	U-4425			
	12239689	Jan 05, 2037	U-4425			
	12377133	Nov 12, 2042	DP U-4425			
	8906847	Apr 30, 2031	DS DP U-4425			
NEDOSIRAN SODIUM - RIVFLOZA						
N 215842 001					ODE-531	Mar 27, 2032
NEDOSIRAN SODIUM - RIVFLOZA						
N 215842 002					ODE-531	Mar 27, 2032
NEDOSIRAN SODIUM - RIVFLOZA						
N 215842 003					ODE-531	Mar 27, 2032
NERANDOMILAST - JASCAYD						
N 218764 001	11406638	Oct 22, 2038	U-4297		I-979	Dec 19, 2028
	11406638	Oct 22, 2038	U-4373		ODE-546	Oct 07, 2032
	11813266	Oct 22, 2038	U-4292			
	11813266	Oct 22, 2038	U-4372			
NERANDOMILAST - JASCAYD						
N 218764 002	11406638	Oct 22, 2038	U-4297		I-979	Dec 19, 2028
	11406638	Oct 22, 2038	U-4373		ODE-546	Oct 07, 2032
	11813266	Oct 22, 2038	U-4292			
	11813266	Oct 22, 2038	U-4372			
NILOTINIB - CAVHANZA						
N 217379 001	11389450	Jan 29, 2041	U-4556			
	11389450	Jan 29, 2041	U-4557			
	11559485	Apr 30, 2041	DP			
	12016861	Jan 29, 2041	U-4554			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NILOTINIB - CAVHANZA						
N 217379 001	12016861	Jan 29, 2041	U-4555			
	12029740	Jan 29, 2041	DP			
NILOTINIB - CAVHANZA						
N 217379 002	11389450	Jan 29, 2041	U-4556			
	11389450	Jan 29, 2041	U-4557			
	11559485	Apr 30, 2041	DP			
	12016861	Jan 29, 2041	U-4554			
	12016861	Jan 29, 2041	U-4555			
	12029740	Jan 29, 2041	DP			
NILOTINIB TARTRATE - DANZITEN						
N 219293 001	12629369	Feb 18, 2040	DP			
NILOTINIB TARTRATE - DANZITEN						
N 219293 002	12629369	Feb 18, 2040	DP			
NIROGACESTAT HYDROBROMIDE - OGSIVEO						
N 217677 001	12599587	Jul 08, 2042	DP			
NIROGACESTAT HYDROBROMIDE - OGSIVEO						
N 217677 002	12599587	Jul 08, 2042	DP			
NIROGACESTAT HYDROBROMIDE - OGSIVEO						
N 217677 003	12599587	Jul 08, 2042	DP			
NITISINONE - HARLIKU						
N 209449 004					ODE-529	Jun 10, 2032
NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE						
N 215700 004	10888534	Apr 26, 2039	DP			
	RE49422	Feb 26, 2035	DP			
	RE49443	Feb 26, 2035	DP			
NUSINERSEN SODIUM - SPINRAZA						
N 209531 002	7838657	Jul 11, 2027	DS DP		NS	Mar 27, 2029
	8361977	Dec 23, 2030	DS DP			
	8980853	Nov 24, 2030	U-1941			
	9717750	Jun 17, 2030	U-1942			
	9717750	Jun 17, 2030	U-1943			
	9717750	Jun 17, 2030	U-2093			
	9717750	Jun 17, 2030	U-2094			
NUSINERSEN SODIUM - SPINRAZA						
N 209531 003	7838657	Jul 11, 2027	DS DP		NS	Mar 27, 2029
	8361977	Dec 23, 2030	DS DP			
	8980853	Nov 24, 2030	U-1941			
	9717750	Jun 17, 2030	U-1942			
	9717750	Jun 17, 2030	U-1943			
	9717750	Jun 17, 2030	U-2093			
	9717750	Jun 17, 2030	U-2094			
OCTREOTIDE ACETATE - OCTREOTIDE ACETATE						
A 216589 001					CGT	Aug 02, 2026
OCTREOTIDE ACETATE - OCTREOTIDE ACETATE						
A 216589 002					CGT	Jul 27, 2026
OCTREOTIDE ACETATE - OCTREOTIDE ACETATE						
A 216589 003					CGT	Jul 27, 2026

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ODEVIXIBAT - BYLVAY								
N 215498 001		12508234	Jun 20, 2039		U-3186			
		12508234	Jun 20, 2039		U-3648			
		12545705	Nov 08, 2031		U-3186			
		12545705	Nov 08, 2031		U-3648			
		9694018	Mar 18, 2034		U-3186			
		9694018	Mar 18, 2034		U-3648			
ODEVIXIBAT - BYLVAY								
N 215498 002		12508234	Jun 20, 2039		U-3186			
		12508234	Jun 20, 2039		U-3648			
		12545705	Nov 08, 2031		U-3186			
		12545705	Nov 08, 2031		U-3648			
		9694018	Mar 18, 2034		U-3186			
		9694018	Mar 18, 2034		U-3648			
ODEVIXIBAT - BYLVAY								
N 215498 003		12508234	Jun 20, 2039		U-3186			
		12508234	Jun 20, 2039		U-3648			
		12545705	Nov 08, 2031		U-3186			
		12545705	Nov 08, 2031		U-3648			
		9694018	Mar 18, 2034		U-3186			
		9694018	Mar 18, 2034		U-3648			
ODEVIXIBAT - BYLVAY								
N 215498 004		12508234	Jun 20, 2039		U-3186			
		12508234	Jun 20, 2039		U-3648			
		12545705	Nov 08, 2031		U-3186			
		12545705	Nov 08, 2031		U-3648			
		9694018	Mar 18, 2034		U-3186			
		9694018	Mar 18, 2034		U-3648			
OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI								
N 213378 001		10300054	May 31, 2033		DP U-3140			
		10300054	May 31, 2033		DP U-3141			
OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI								
N 213378 002		10300054	May 31, 2033		DP U-3140			
		10300054	May 31, 2033		DP U-3141			
OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI								
N 213378 003		10300054	May 31, 2033		DP U-3140			
		10300054	May 31, 2033		DP U-3141			
OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI								
N 213378 004		10300054	May 31, 2033		DP U-3140			
		10300054	May 31, 2033		DP U-3141			
OLEZARSEN SODIUM - TRYNGOLZA (AUTOINJECTOR)								
N 218614 001	>A>	12509684	May 01, 2034		U-4050		>A> I-992	Jun 24, 2029
	>A>	12509684	May 01, 2034		U-4580			
	>A>	9157082	Apr 27, 2032		U-4050			
	>A>	9157082	Apr 27, 2032		U-4580			
OLEZARSEN SODIUM - TRYNGOLZA (AUTOINJECTOR)								
N 218614 002	>A>	12509684	May 01, 2034		U-4580		>A> NS	Jun 24, 2029
	>A>	9127276	May 01, 2034	DS				
	>A>	9157082	Apr 27, 2032		U-4580			
	>A>	9163239	May 01, 2034	DS				
	>A>	9181549	May 01, 2034	DS				
OMADACYCLINE TOSYLATE - NUZYRA								
N 209816 001							M-320	May 13, 2029

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OMADACYCLINE TOSYLATE - NUZYRA						
N 209817 001					M-320	May 13, 2029
OMEPRAZOLE - OMEPRAZOLE						
N 022032 001	12599565	Jan 31, 2030	DP			
OPICAPONE - ONGENTYS						
N 212489 001	8168793	Oct 10, 2027	DS DP U-3869			
OPICAPONE - ONGENTYS						
N 212489 002	8168793	Oct 10, 2027	DS DP U-3869			
ORFORGLIPRON CALCIUM - FOUNDAYO						
N 220934 001	RE50455	Sep 26, 2037	DS DP U-4474		NCE	Apr 01, 2031
ORFORGLIPRON CALCIUM - FOUNDAYO						
N 220934 002	RE50455	Sep 26, 2037	DS DP U-4474		NCE	Apr 01, 2031
ORFORGLIPRON CALCIUM - FOUNDAYO						
N 220934 003	RE50455	Sep 26, 2037	DS DP U-4474		NCE	Apr 01, 2031
ORFORGLIPRON CALCIUM - FOUNDAYO						
N 220934 004	RE50455	Sep 26, 2037	DS DP U-4474		NCE	Apr 01, 2031
ORFORGLIPRON CALCIUM - FOUNDAYO						
N 220934 005	RE50455	Sep 26, 2037	DS DP U-4474		NCE	Apr 01, 2031
ORFORGLIPRON CALCIUM - FOUNDAYO						
N 220934 006	RE50455	Sep 26, 2037	DS DP U-4474		NCE	Apr 01, 2031
ORITAVANCIN DIPHOSPHATE - ORBACTIV						
N 206334 001	12514899	Aug 29, 2029	U-4398			
ORITAVANCIN DIPHOSPHATE - KIMYRSA						
N 214155 001	12514899	Aug 29, 2029	U-4398			
OSILODROSTAT PHOSPHATE - ISTURISA						
N 212801 001	10709691	Oct 12, 2035	U-4529		ODE-535	Apr 15, 2032
	8314097	May 20, 2033	DS DP			
	8609862	Jan 13, 2031	U-4529			
OSILODROSTAT PHOSPHATE - ISTURISA						
N 212801 002	10709691	Oct 12, 2035	U-4529		ODE-535	Apr 15, 2032
	8314097	May 20, 2033	DS DP			
	8609862	Jan 13, 2031	U-4529			
OSILODROSTAT PHOSPHATE - ISTURISA						
N 212801 003					ODE-535	Apr 15, 2032
OXYCODONE - XTAMPZA ER						
N 208090 001	7771707	Oct 09, 2028	DP			
OXYCODONE - XTAMPZA ER						
N 208090 002	7771707	Oct 09, 2028	DP			
OXYCODONE - XTAMPZA ER						
N 208090 003	7771707	Oct 09, 2028	DP			
OXYCODONE - XTAMPZA ER						
N 208090 004	7771707	Oct 09, 2028	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OXYCODONE - XTAMPZA ER						
N 208090 005	7771707	Oct 09, 2028	DP			
OXYMETAZOLINE HYDROCHLORIDE - UPNEEQ						
N 212520 001	12605363	Dec 16, 2039	DP			
	12648930	Dec 16, 2039	U-2849			
PAFOLACIANINE SODIUM - CYTALUX						
N 214907 001	9061057	Nov 29, 2035	DS DP U-3291			
PALBOCICLIB - IBRANCE						
N 207103 001					>A> I-995	Jun 24, 2029
PALBOCICLIB - IBRANCE						
N 207103 002					>A> I-995	Jun 24, 2029
PALBOCICLIB - IBRANCE						
N 207103 003					>A> I-995	Jun 24, 2029
PALBOCICLIB - IBRANCE						
N 212436 001					>A> I-995	Jun 24, 2029
PALBOCICLIB - IBRANCE						
N 212436 002					>A> I-995	Jun 24, 2029
PALBOCICLIB - IBRANCE						
N 212436 003					>A> I-995	Jun 24, 2029
PALTUSOTINE HYDROCHLORIDE - PALSONIFY						
N 219070 001					ODE-537	Sep 25, 2032
PALTUSOTINE HYDROCHLORIDE - PALSONIFY						
N 219070 002					ODE-537	Sep 25, 2032
PEGCETACOPLAN - EMPAVELI						
N 215014 001					ODE-533	Jul 28, 2032
					ODE-539	Jul 28, 2032
PEGCETACOPLAN - SYFOVRE						
N 217171 001	12528836	Oct 07, 2036	U-4394			
PEMIGATINIB - PEMAZYRE						
N 213736 001	12552792	Oct 03, 2040	DS DP			
PEMIGATINIB - PEMAZYRE						
N 213736 002	12552792	Oct 03, 2040	DS DP			
PEMIGATINIB - PEMAZYRE						
N 213736 003	12552792	Oct 03, 2040	DS DP			
PERAMPANEL - PERAMPANEL						
A 218152 001					PC	Jun 14, 2026
PHENOBARBITAL SODIUM - SEZABY						
N 215910 001	12636254	Apr 07, 2042	DP U-3779			
PHENTOLAMINE MESYLATE - RYZUMVI						
N 217064 001	12201615	Oct 25, 2039	U-3804			
	12576066	Oct 25, 2039	U-3804			
	12576067	Oct 25, 2039	U-3804			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PHENYLEPHRINE HYDROCHLORIDE - PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE						
N 216830 001	12564561	Aug 08, 2044	DP			
PIFLUFOLASTAT F-18 - PYLARIFY TRUVU						
N 220089 001	10947197	Jun 09, 2037	DS DP U-3317		NCE	May 26, 2026
	11851407	Jun 09, 2037	DS DP U-3317			
	12070513	Jul 31, 2029	DS DP U-3317			
	8487129	Nov 07, 2027	DS DP			
	8778305	Sep 21, 2030	DS DP U-3317			
	9861713	Jul 31, 2029	DS DP U-3317			
PIMAVANSERIN TARTRATE - NUPLAZID						
N 207318 001	7601740	Apr 29, 2030	DS DP		M-14	Apr 27, 2029
	7601740*PED	Oct 29, 2030			PED	Oct 27, 2029
	7732615	Jun 03, 2028	DS DP			
	7732615*PED	Dec 03, 2028				
PIMAVANSERIN TARTRATE - NUPLAZID						
N 207318 002	10517860	Mar 23, 2037	U-1974		M-14	Apr 27, 2029
	10517860*PED	Sep 23, 2037			PED	Oct 27, 2029
	10953000	Mar 23, 2037	U-1974			
	10953000*PED	Sep 23, 2037				
	7601740	Apr 29, 2030	DS DP			
	7601740*PED	Oct 29, 2030				
	7732615	Jun 03, 2028	DS DP			
	7732615*PED	Dec 03, 2028				
PIMAVANSERIN TARTRATE - NUPLAZID						
N 210793 001	10449185	Aug 27, 2038	DP		M-14	Apr 27, 2029
	10449185*PED	Feb 27, 2039			PED	Oct 27, 2029
	10646480	Aug 27, 2038	DP			
	10646480*PED	Feb 27, 2039				
	10849891	Aug 27, 2038	DP U-1974			
	10849891*PED	Feb 27, 2039				
	11452721	Aug 27, 2038	DP			
	11452721*PED	Feb 27, 2039				
	7601740	Apr 29, 2030	DS DP			
	7601740*PED	Oct 29, 2030				
	7732615	Jun 03, 2028	DS DP			
	7732615*PED	Dec 03, 2028				
PIMOZIDE - PIMOZIDE						
A 219897 001					CGT	Oct 18, 2026
PIMOZIDE - PIMOZIDE						
A 219897 002					CGT	Oct 18, 2026
PIRTOBRUTINIB - JAYPIRCA						
N 216059 001					I-981	Dec 02, 2028
					ODE-518	Dec 03, 2032
PIRTOBRUTINIB - JAYPIRCA						
N 216059 002					I-981	Dec 02, 2028
					ODE-518	Dec 03, 2032
PITOLISANT HYDROCHLORIDE - WAKIX						
N 211150 001					ODE-519	Feb 13, 2033
PITOLISANT HYDROCHLORIDE - WAKIX						
N 211150 002					ODE-519	Feb 13, 2033
PLOZASIRAN SODIUM - REDEMPLO						
N 219947 001					ODE-541	Nov 18, 2032

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
POMALIDOMIDE - POMALIDOMIDE							
A 210111 001						PC	Aug 29, 2026
POMALIDOMIDE - POMALIDOMIDE							
A 210111 002						PC	Aug 29, 2026
POMALIDOMIDE - POMALIDOMIDE							
A 210111 003						PC	Aug 29, 2026
POMALIDOMIDE - POMALIDOMIDE							
A 210111 004						PC	Aug 29, 2026
POSACONAZOLE - NOXAFIL							
N 205053 001						NPP	Jan 27, 2029
POSACONAZOLE - NOXAFIL							
N 205596 001		9023790	Jul 04, 2031	DP U-1698		NPP	Jan 27, 2029
		9023790	Jul 04, 2031	DP U-3160			
		9023790	Jul 04, 2031	DP U-3171			
		9023790	Jul 04, 2031	DP U-4415			
		9023790	Jul 04, 2031	DP U-4416			
		9358297	Jun 24, 2031	DP U-3160			
		9358297	Jun 24, 2031	DP U-3171			
		9358297	Jun 24, 2031	DP U-4415			
		9358297	Jun 24, 2031	DP U-4416			
POSACONAZOLE - NOXAFIL POWDERMIX KIT							
N 214770 001						I-984	Jan 27, 2029
POTASSIUM CHLORI DE - POTASSIUM CHLORIDE							
N 206814 001		12539314	Mar 07, 2039	DP			
POTASSIUM CHLORI DE - POTASSIUM CHLORIDE							
N 206814 002		12539314	Mar 07, 2039	DP			
POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC - POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE							
N 218343 001	>A>	11925661	Oct 12, 2041	DP U-4185			
PRALSETINIB - GAVRETO							
N 213721 001		12448366	Jul 07, 2042	DS			
		12539303	Apr 03, 2039	U-2828			
	>A>	12655128	Nov 01, 2036	DS DP			
PROBENECID; SULOPENEM ETZADROXIL - ORLYNVAH							
N 213972 001		12544337	Dec 23, 2039	DP U-4026			
RELACORILANT - LIFYORLI (COPACKAGED)							
N 220641 001		10456392	May 24, 2033	U-4457		NCE	Mar 25, 2031
		11285145	May 26, 2041	U-4457			
		11285145	May 26, 2041	U-4458			
		11285145	May 26, 2041	U-4459			
		11464764	Apr 14, 2040	DP			
		11576907	May 24, 2033	DS DP U-4457			
		11576907	May 24, 2033	DS DP U-4458			
		11576907	May 24, 2033	DS DP U-4459			
		11925626	Dec 18, 2039	DP			
		12152028	Dec 22, 2041	DP U-4457			
		12152028	Dec 22, 2041	DP U-4458			
		12152028	Dec 22, 2041	DP U-4459			
		12514849	Dec 18, 2039	DP			
		12589094	May 26, 2041	U-4457			
		12589094	May 26, 2041	U-4458			
		12589094	May 26, 2041	U-4459			
		8859774	May 24, 2033	DS DP			
		9273047	May 24, 2033	U-4457			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RELACORILANT - LIFYORLI (COPACKAGED)								
N 220641	001		9273047	May 24, 2033	U-4458			
			9273047	May 24, 2033	U-4459			
RELUGOLIX - ORGOVYX								
N 214621	001		12629370	Sep 29, 2037	U-3020			
REMDESIVIR - VEKLURY								
N 214787	001	>A>	10065958	Nov 18, 2032	DS			
		>A>	10065958*PED	May 18, 2033				
REMDESIVIR - VEKLURY								
N 214787	002	>A>	10065958	Nov 18, 2032	DS			
		>A>	10065958*PED	May 18, 2033				
REMIBRUTINIB - RHAPSIDO								
N 218436	001		12419889	Jan 19, 2043	U-4281			
RESMETIROM - REZDIFFRA								
N 217785	001	>A>	12661359	Jan 28, 2042	U-4568			
		>A>	12667575	Feb 04, 2045	U-4567			
		>A>	7452882	Sep 12, 2027	DS DP			
RESMETIROM - REZDIFFRA								
N 217785	002	>A>	12661359	Jan 28, 2042	U-4568			
		>A>	12667575	Feb 04, 2045	U-4567			
		>A>	7452882	Sep 12, 2027	DS DP			
RESMETIROM - REZDIFFRA								
N 217785	003	>A>	12661359	Jan 28, 2042	U-4568			
		>A>	7452882	Sep 12, 2027	DS DP			
REVUMENIB CITRATE - REVUFORJ								
N 218944	001		12564590	Dec 18, 2042	DP U-4045			
			12564590	Dec 18, 2042	DP U-4327			
REVUMENIB CITRATE - REVUFORJ								
N 218944	002		12564590	Dec 18, 2042	DP U-4045			
			12564590	Dec 18, 2042	DP U-4327			
REVUMENIB CITRATE - REVUFORJ								
N 218944	003		12564590	Dec 18, 2042	DP U-4045			
			12564590	Dec 18, 2042	DP U-4327			
REZAFUNGIN ACETATE - REZZAYO								
N 217417	001		8722619	May 09, 2036	DS DP U-3566			
RIBOCICLIB SUCCINATE - KISQALI								
N 209092	001		10799506	Apr 14, 2036	DP		I-950	Sep 17, 2027
			10799506*PED	Oct 14, 2036			PED	Mar 17, 2028
			12064434	Apr 14, 2036	DP			
			12064434*PED	Oct 14, 2036				
			12419894	Apr 14, 2036	DP			
			12419894*PED	Oct 14, 2036				
			12544379	Aug 07, 2034	U-3975			
			12544379*PED	Feb 07, 2035				
			12544380	Aug 07, 2034	U-4404			
			12544380	Aug 07, 2034	U-4405			
			12544380*PED	Feb 07, 2035				
			8324225	Jun 17, 2028	DS DP			
			8324225*PED	Dec 17, 2028				
			8415355	Mar 13, 2031	DS DP			
			8415355*PED	Sep 13, 2031				
			8685980	May 25, 2030	DS DP			
			8685980*PED	Nov 25, 2030				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RIBOCICLIB SUCCINATE - KISQALI							
N 209092	001	8962630	Dec 09, 2029	U-1981			
		8962630	Dec 09, 2029	U-2355			
		8962630	Dec 09, 2029	U-2356			
		8962630	Dec 09, 2029	U-3265			
		8962630	Dec 09, 2029	U-3266			
		8962630	Dec 09, 2029	U-3975			
		8962630	Dec 09, 2029	U-3999			
		8962630*PED	Jun 09, 2030				
		9193732	Nov 09, 2031	DS DP			
		9193732*PED	May 09, 2032				
		9416136	Aug 20, 2029	U-1981			
		9416136	Aug 20, 2029	U-2355			
		9416136	Aug 20, 2029	U-2356			
		9416136	Aug 20, 2029	U-3265			
		9416136	Aug 20, 2029	U-3266			
		9416136	Aug 20, 2029	U-3975			
		9416136	Aug 20, 2029	U-3999			
		9416136*PED	Feb 20, 2030				
		9868739	Nov 09, 2031	U-1981			
		9868739	Nov 09, 2031	U-2355			
		9868739	Nov 09, 2031	U-2356			
		9868739	Nov 09, 2031	U-3265			
		9868739	Nov 09, 2031	U-3266			
		9868739	Nov 09, 2031	U-3975			
		9868739	Nov 09, 2031	U-3999			
		9868739*PED	May 09, 2032				
RILZABRUTINIB - WAYRILZ							
N 219685	001					ODE-552	Aug 29, 2032
RIOCIGUAT - ADEMPAS							
N 204819	001	12503469	Feb 18, 2034	DP U-2834			
		12503469	Feb 18, 2034	DP U-2835			
RIOCIGUAT - ADEMPAS							
N 204819	002	12503469	Feb 18, 2034	DP U-2834			
		12503469	Feb 18, 2034	DP U-2835			
RIOCIGUAT - ADEMPAS							
N 204819	003	12503469	Feb 18, 2034	DP U-2834			
		12503469	Feb 18, 2034	DP U-2835			
RIOCIGUAT - ADEMPAS							
N 204819	004	12503469	Feb 18, 2034	DP U-2834			
		12503469	Feb 18, 2034	DP U-2835			
RIOCIGUAT - ADEMPAS							
N 204819	005	12503469	Feb 18, 2034	DP U-2834			
		12503469	Feb 18, 2034	DP U-2835			
ROFLUMILAST - ZORYVE							
N 215985	001	>A> 11129818	Aug 25, 2037	U-3408		>A> NPP	Jun 29, 2029
		>A> 11129818	Aug 25, 2037	U-3712			
		>A> 11129818	Aug 25, 2037	U-4578			
		>A> 11819496	Jun 07, 2037	U-3748			
		>A> 11819496	Jun 07, 2037	U-4578			
		>A> 11992480	Jun 07, 2037	U-3748			
		>A> 11992480	Jun 07, 2037	U-4578			
		>A> 12005051	Jun 07, 2037	U-3748			
		>A> 12005051	Jun 07, 2037	U-4578			
		>A> 12310956	Jun 07, 2037	U-3748			
		>A> 12310956	Jun 07, 2037	U-4578			
		>A> 9907788	Jun 07, 2037	U-3408			
		>A> 9907788	Jun 07, 2037	U-3712			
		>A> 9907788	Jun 07, 2037	U-4578			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ROFLUMILAST - ZORYVE							
N 215985	001	>A> 11129818	Aug 25, 2037	U-3408		>A> NPP	Jun 29, 2029
		>A> 11129818	Aug 25, 2037	U-3712			
		>A> 11129818	Aug 25, 2037	U-4578			
		>A> 11819496	Jun 07, 2037	U-3748			
		>A> 11819496	Jun 07, 2037	U-4578			
		>A> 11992480	Jun 07, 2037	U-3748			
		>A> 11992480	Jun 07, 2037	U-4578			
		>A> 12005051	Jun 07, 2037	U-3748			
		>A> 12005051	Jun 07, 2037	U-4578			
		>A> 12310956	Jun 07, 2037	U-3748			
		>A> 12310956	Jun 07, 2037	U-4578			
		>A> 9907788	Jun 07, 2037	U-3408			
		>A> 9907788	Jun 07, 2037	U-3712			
		>A> 9907788	Jun 07, 2037	U-4578			
ROMIDEPSIN - ROMIDEPSIN							
A 219099	001					CGT	Dec 07, 2026
RUCAPARIB CAMSYLATE - RUBRACA							
N 209115	001					I-982	Dec 17, 2028
RUCAPARIB CAMSYLATE - RUBRACA							
N 209115	002					I-982	Dec 17, 2028
RUCAPARIB CAMSYLATE - RUBRACA							
N 209115	003					I-982	Dec 17, 2028
RUXOLITINIB PHOSPHATE - OPZELURA							
N 215309	001	12544381	May 20, 2031	DP			
		12564593	May 20, 2031	DP			
		12589096	Sep 04, 2040	U-3505			
RUXOLITINIB PHOSPHATE - JAKAFI XR							
N 217180	001	10016429	Jun 12, 2028	U-3226		ODE*	Sep 22, 2028
		10016429	Jun 12, 2028	U-3230		PED	Mar 22, 2029
		10016429*PED	Dec 12, 2028				
		10874616	Nov 14, 2033	DP			
		10874616*PED	May 14, 2034				
		11213528	Jun 12, 2028	DP			
		11213528*PED	Dec 12, 2028				
		11337927	Jan 17, 2034	U-3226			
		11337927	Jan 17, 2034	U-3227			
		11337927	Jan 17, 2034	U-3228			
		11337927	Jan 17, 2034	U-3230			
		11337927*PED	Jul 17, 2034				
		11576864	Nov 14, 2033	U-3226			
		11576864	Nov 14, 2033	U-3227			
		11576864	Nov 14, 2033	U-3228			
		11576864	Nov 14, 2033	U-3230			
		11576864*PED	May 14, 2034				
		11576865	Nov 14, 2033	DP U-3226			
		11576865	Nov 14, 2033	DP U-3227			
		11576865	Nov 14, 2033	DP U-3228			
		11576865	Nov 14, 2033	DP U-3230			
		11576865*PED	May 14, 2034				
		11744832	Dec 12, 2026	U-3226			
		11744832	Dec 12, 2026	U-3230			
		11896717	Nov 14, 2033	DP U-3226			
		11896717	Nov 14, 2033	DP U-3227			
		11896717	Nov 14, 2033	DP U-3228			
		11896717	Nov 14, 2033	DP U-3230			
		11896717*PED	May 14, 2034				
		7598257	Dec 24, 2027	DS DP U-3227			
		7598257	Dec 24, 2027	DS DP U-3228			
		7598257*PED	Jun 24, 2028				
		8415362	Dec 24, 2027	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RUXOLITINIB PHOSPHATE - JAKAFI XR						
N 217180 001	8415362*PED	Jun 24, 2028				
	8530485	Dec 12, 2026	DP			
	8722693	Jun 12, 2028	DS DP			
	8722693*PED	Dec 12, 2028				
	8822481	Jun 12, 2028	U-3226			
	8822481	Jun 12, 2028	U-3227			
	8822481	Jun 12, 2028	U-3228			
	8822481	Jun 12, 2028	U-3230			
	8822481*PED	Dec 12, 2028				
	8829013	Jun 12, 2028	U-3227			
	8829013	Jun 12, 2028	U-3228			
	8829013*PED	Dec 12, 2028				
	9079912	Dec 12, 2026	U-3226			
	9079912	Dec 12, 2026	U-3227			
	9079912	Dec 12, 2026	U-3228			
	9079912	Dec 12, 2026	U-3230			
	9206187	Dec 12, 2026	U-3227			
	9206187	Dec 12, 2026	U-3228			
	9814722	Dec 12, 2026	U-3226			
	9814722	Dec 12, 2026	U-3230			
RUXOLITINIB PHOSPHATE - JAKAFI XR						
N 217180 002	10016429	Jun 12, 2028	U-3226		ODE*	Sep 22, 2028
	10016429	Jun 12, 2028	U-3230		PED	Mar 22, 2029
	10016429*PED	Dec 12, 2028				
	10874616	Nov 14, 2033	DP			
	10874616*PED	May 14, 2034				
	11213528	Jun 12, 2028	DP			
	11213528*PED	Dec 12, 2028				
	11337927	Jan 17, 2034	U-3226			
	11337927	Jan 17, 2034	U-3227			
	11337927	Jan 17, 2034	U-3228			
	11337927	Jan 17, 2034	U-3230			
	11337927*PED	Jul 17, 2034				
	11576864	Nov 14, 2033	U-3226			
	11576864	Nov 14, 2033	U-3227			
	11576864	Nov 14, 2033	U-3228			
	11576864	Nov 14, 2033	U-3230			
	11576864*PED	May 14, 2034				
	11576865	Nov 14, 2033	DP U-3226			
	11576865	Nov 14, 2033	DP U-3227			
	11576865	Nov 14, 2033	DP U-3228			
	11576865	Nov 14, 2033	DP U-3230			
	11576865*PED	May 14, 2034				
	11744832	Dec 12, 2026	U-3226			
	11744832	Dec 12, 2026	U-3230			
	11896717	Nov 14, 2033	DP U-3226			
	11896717	Nov 14, 2033	DP U-3227			
	11896717	Nov 14, 2033	DP U-3228			
	11896717	Nov 14, 2033	DP U-3230			
	11896717*PED	May 14, 2034				
	7598257	Dec 24, 2027	DS DP U-3227			
	7598257	Dec 24, 2027	DS DP U-3228			
	7598257*PED	Jun 24, 2028				
	8415362	Dec 24, 2027	DS DP			
	8415362*PED	Jun 24, 2028				
	8530485	Dec 12, 2026	DP			
	8722693	Jun 12, 2028	DS DP			
	8722693*PED	Dec 12, 2028				
	8822481	Jun 12, 2028	U-3226			
	8822481	Jun 12, 2028	U-3227			
	8822481	Jun 12, 2028	U-3228			
	8822481	Jun 12, 2028	U-3230			
	8822481*PED	Dec 12, 2028				
	8829013	Jun 12, 2028	U-3227			
	8829013	Jun 12, 2028	U-3228			
	8829013*PED	Dec 12, 2028				
	9079912	Dec 12, 2026	U-3226			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RUXOLITINIB PHOSPHATE - JAKAFI XR						
N 217180 002	9079912	Dec 12, 2026	U-3227			
	9079912	Dec 12, 2026	U-3228			
	9079912	Dec 12, 2026	U-3230			
	9206187	Dec 12, 2026	U-3227			
	9206187	Dec 12, 2026	U-3228			
	9814722	Dec 12, 2026	U-3226			
	9814722	Dec 12, 2026	U-3230			
RUXOLITINIB PHOSPHATE - JAKAFI XR						
N 217180 003	10016429	Jun 12, 2028	U-3226		ODE*	Sep 22, 2028
	10016429	Jun 12, 2028	U-3230		PED	Mar 22, 2029
	10016429*PED	Dec 12, 2028				
	10874616	Nov 14, 2033	DP			
	10874616*PED	May 14, 2034				
	11213528	Jun 12, 2028	DP			
	11213528*PED	Dec 12, 2028				
	11337927	Jan 17, 2034	U-3226			
	11337927	Jan 17, 2034	U-3227			
	11337927	Jan 17, 2034	U-3228			
	11337927	Jan 17, 2034	U-3230			
	11337927*PED	Jul 17, 2034				
	11576864	Nov 14, 2033	U-3226			
	11576864	Nov 14, 2033	U-3227			
	11576864	Nov 14, 2033	U-3228			
	11576864	Nov 14, 2033	U-3230			
	11576864*PED	May 14, 2034				
	11576865	Nov 14, 2033	DP U-3226			
	11576865	Nov 14, 2033	DP U-3227			
	11576865	Nov 14, 2033	DP U-3228			
	11576865	Nov 14, 2033	DP U-3230			
	11576865*PED	May 14, 2034				
	11744832	Dec 12, 2026	U-3226			
	11744832	Dec 12, 2026	U-3230			
	11896717	Nov 14, 2033	DP U-3226			
	11896717	Nov 14, 2033	DP U-3227			
	11896717	Nov 14, 2033	DP U-3228			
	11896717	Nov 14, 2033	DP U-3230			
	11896717*PED	May 14, 2034				
	7598257	Dec 24, 2027	DS DP U-3227			
	7598257	Dec 24, 2027	DS DP U-3228			
	7598257*PED	Jun 24, 2028				
	8415362	Dec 24, 2027	DS DP			
	8415362*PED	Jun 24, 2028				
	8530485	Dec 12, 2026	DP			
	8722693	Jun 12, 2028	DS DP			
	8722693*PED	Dec 12, 2028				
	8822481	Jun 12, 2028	U-3226			
	8822481	Jun 12, 2028	U-3227			
	8822481	Jun 12, 2028	U-3228			
	8822481	Jun 12, 2028	U-3230			
	8822481*PED	Dec 12, 2028				
	8829013	Jun 12, 2028	U-3227			
	8829013	Jun 12, 2028	U-3228			
	8829013*PED	Dec 12, 2028				
	9079912	Dec 12, 2026	U-3226			
	9079912	Dec 12, 2026	U-3227			
	9079912	Dec 12, 2026	U-3228			
	9079912	Dec 12, 2026	U-3230			
	9206187	Dec 12, 2026	U-3227			
	9206187	Dec 12, 2026	U-3228			
	9814722	Dec 12, 2026	U-3226			
	9814722	Dec 12, 2026	U-3230			
RUXOLITINIB PHOSPHATE - JAKAFI XR						
N 217180 004	10016429	Jun 12, 2028	U-3226		ODE*	Sep 22, 2028
	10016429	Jun 12, 2028	U-3230		PED	Mar 22, 2029
	10016429*PED	Dec 12, 2028				
	10874616	Nov 14, 2033	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RUXOLITINIB PHOSPHATE - JAKAFI XR						
N 217180 004	10874616*PED	May 14, 2034				
	11213528	Jun 12, 2028	DP			
	11213528*PED	Dec 12, 2028				
	11337927	Jan 17, 2034	U-3226			
	11337927	Jan 17, 2034	U-3227			
	11337927	Jan 17, 2034	U-3228			
	11337927	Jan 17, 2034	U-3230			
	11337927*PED	Jul 17, 2034				
	11576864	Nov 14, 2033	U-3226			
	11576864	Nov 14, 2033	U-3227			
	11576864	Nov 14, 2033	U-3228			
	11576864	Nov 14, 2033	U-3230			
	11576864*PED	May 14, 2034				
	11576865	Nov 14, 2033	DP U-3226			
	11576865	Nov 14, 2033	DP U-3227			
	11576865	Nov 14, 2033	DP U-3228			
	11576865	Nov 14, 2033	DP U-3230			
	11576865*PED	May 14, 2034				
	11744832	Dec 12, 2026	U-3226			
	11744832	Dec 12, 2026	U-3230			
	11896717	Nov 14, 2033	DP U-3226			
	11896717	Nov 14, 2033	DP U-3227			
	11896717	Nov 14, 2033	DP U-3228			
	11896717	Nov 14, 2033	DP U-3230			
	11896717*PED	May 14, 2034				
	7598257	Dec 24, 2027	DS DP U-3227			
	7598257	Dec 24, 2027	DS DP U-3228			
	7598257*PED	Jun 24, 2028				
	8415362	Dec 24, 2027	DS DP			
	8415362*PED	Jun 24, 2028				
	8530485	Dec 12, 2026	DP			
	8722693	Jun 12, 2028	DS DP			
	8722693*PED	Dec 12, 2028				
	8822481	Jun 12, 2028	U-3226			
	8822481	Jun 12, 2028	U-3227			
	8822481	Jun 12, 2028	U-3228			
	8822481	Jun 12, 2028	U-3230			
	8822481*PED	Dec 12, 2028				
	8829013	Jun 12, 2028	U-3227			
	8829013	Jun 12, 2028	U-3228			
	8829013*PED	Dec 12, 2028				
	9079912	Dec 12, 2026	U-3226			
	9079912	Dec 12, 2026	U-3227			
	9079912	Dec 12, 2026	U-3228			
	9079912	Dec 12, 2026	U-3230			
	9206187	Dec 12, 2026	U-3227			
	9206187	Dec 12, 2026	U-3228			
	9814722	Dec 12, 2026	U-3226			
	9814722	Dec 12, 2026	U-3230			
RUXOLITINIB PHOSPHATE - JAKAFI XR						
N 217180 005	10016429	Jun 12, 2028	U-3226		ODE*	Sep 22, 2028
	10016429	Jun 12, 2028	U-3230		PED	Mar 22, 2029
	10016429*PED	Dec 12, 2028				
	10874616	Nov 14, 2033	DP			
	10874616*PED	May 14, 2034				
	11213528	Jun 12, 2028	DP			
	11213528*PED	Dec 12, 2028				
	11337927	Jan 17, 2034	U-3226			
	11337927	Jan 17, 2034	U-3227			
	11337927	Jan 17, 2034	U-3228			
	11337927	Jan 17, 2034	U-3230			
	11337927*PED	Jul 17, 2034				
	11576864	Nov 14, 2033	U-3226			
	11576864	Nov 14, 2033	U-3227			
	11576864	Nov 14, 2033	U-3228			
	11576864	Nov 14, 2033	U-3230			
	11576864*PED	May 14, 2034				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RUXOLITINIB PHOSPHATE - JAKAFI XR						
N 217180 005	11576865	Nov 14, 2033	DP U-3226			
	11576865	Nov 14, 2033	DP U-3227			
	11576865	Nov 14, 2033	DP U-3228			
	11576865	Nov 14, 2033	DP U-3230			
	11576865*PED	May 14, 2034				
	11744832	Dec 12, 2026	U-3226			
	11744832	Dec 12, 2026	U-3230			
	11896717	Nov 14, 2033	DP U-3226			
	11896717	Nov 14, 2033	DP U-3227			
	11896717	Nov 14, 2033	DP U-3228			
	11896717	Nov 14, 2033	DP U-3230			
	11896717*PED	May 14, 2034				
	7598257	Dec 24, 2027	DS DP U-3227			
	7598257	Dec 24, 2027	DS DP U-3228			
	7598257*PED	Jun 24, 2028				
	8415362	Dec 24, 2027	DS DP			
	8415362*PED	Jun 24, 2028				
	8530485	Dec 12, 2026	DP			
	8722693	Jun 12, 2028	DS DP			
	8722693*PED	Dec 12, 2028				
	8822481	Jun 12, 2028	U-3226			
	8822481	Jun 12, 2028	U-3227			
	8822481	Jun 12, 2028	U-3228			
	8822481	Jun 12, 2028	U-3230			
	8822481*PED	Dec 12, 2028				
	8829013	Jun 12, 2028	U-3227			
	8829013	Jun 12, 2028	U-3228			
	8829013*PED	Dec 12, 2028				
	9079912	Dec 12, 2026	U-3226			
	9079912	Dec 12, 2026	U-3227			
	9079912	Dec 12, 2026	U-3228			
	9079912	Dec 12, 2026	U-3230			
	9206187	Dec 12, 2026	U-3227			
	9206187	Dec 12, 2026	U-3228			
	9814722	Dec 12, 2026	U-3226			
	9814722	Dec 12, 2026	U-3230			
SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA						
N 022350 001					>A> M-14	Oct 11, 2027
SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA						
N 022350 002					>A> M-14	Oct 11, 2027
SEBETRALSTAT - EKTERLY						
N 219301 001					ODE-534	Jul 03, 2032
SELEXIPAG - UPTRAVI						
N 207947 001	10821108	Dec 01, 2036	DP U-2992		NPP	May 23, 2029
	10821108*PED	Jun 01, 2037			PED	Nov 23, 2029
	10828298	Dec 01, 2036	DP U-2991			
	10828298*PED	Jun 01, 2037				
	7205302	Oct 31, 2026	DS DP U-1797			
	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				
	9173881	Aug 12, 2029	U-1798			
	9173881*PED	Feb 12, 2030				
	9284280	Jun 25, 2030	U-1831			
	9284280*PED	Dec 25, 2030				
SELEXIPAG - UPTRAVI						
N 207947 002	10821108	Dec 01, 2036	DP U-2992		NPP	May 23, 2029
	10821108*PED	Jun 01, 2037			PED	Nov 23, 2029
	10828298	Dec 01, 2036	DP U-2991			
	10828298*PED	Jun 01, 2037				
	7205302	Oct 31, 2026	DS DP U-1797			
	7205302*PED	Apr 30, 2027				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SELEXIPAG - UPTRAVI						
N 207947 002	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				
	9173881	Aug 12, 2029	U-1798			
	9173881*PED	Feb 12, 2030				
	9284280	Jun 25, 2030	U-1831			
	9284280*PED	Dec 25, 2030				
SELEXIPAG - UPTRAVI						
N 207947 003	10821108	Dec 01, 2036	DP U-2992		NPP	May 23, 2029
	10821108*PED	Jun 01, 2037			PED	Nov 23, 2029
	10828298	Dec 01, 2036	DP U-2991			
	10828298*PED	Jun 01, 2037				
	7205302	Oct 31, 2026	DS DP U-1797			
	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				
	9173881	Aug 12, 2029	U-1798			
	9173881*PED	Feb 12, 2030				
	9284280	Jun 25, 2030	U-1831			
	9284280*PED	Dec 25, 2030				
SELEXIPAG - UPTRAVI						
N 207947 004	10821108	Dec 01, 2036	DP U-2992		NPP	May 23, 2029
	10821108*PED	Jun 01, 2037			PED	Nov 23, 2029
	10828298	Dec 01, 2036	DP U-2991			
	10828298*PED	Jun 01, 2037				
	7205302	Oct 31, 2026	DS DP U-1797			
	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				
	9173881	Aug 12, 2029	U-1798			
	9173881*PED	Feb 12, 2030				
	9284280	Jun 25, 2030	U-1831			
	9284280*PED	Dec 25, 2030				
SELEXIPAG - UPTRAVI						
N 207947 005	10821108	Dec 01, 2036	DP U-2992		NPP	May 23, 2029
	10821108*PED	Jun 01, 2037			PED	Nov 23, 2029
	10828298	Dec 01, 2036	DP U-2991			
	10828298*PED	Jun 01, 2037				
	7205302	Oct 31, 2026	DS DP U-1797			
	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				
	9173881	Aug 12, 2029	U-1798			
	9173881*PED	Feb 12, 2030				
	9284280	Jun 25, 2030	U-1831			
	9284280*PED	Dec 25, 2030				
SELEXIPAG - UPTRAVI						
N 207947 006	10821108	Dec 01, 2036	DP U-2992		NPP	May 23, 2029
	10821108*PED	Jun 01, 2037			PED	Nov 23, 2029
	10828298	Dec 01, 2036	DP U-2991			
	10828298*PED	Jun 01, 2037				
	7205302	Oct 31, 2026	DS DP U-1797			
	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				
	9173881	Aug 12, 2029	U-1798			
	9173881*PED	Feb 12, 2030				
	9284280	Jun 25, 2030	U-1831			
	9284280*PED	Dec 25, 2030				
SELEXIPAG - UPTRAVI						
N 207947 007	10821108	Dec 01, 2036	DP U-2992		NPP	May 23, 2029
	10821108*PED	Jun 01, 2037			PED	Nov 23, 2029
	10828298	Dec 01, 2036	DP U-2991			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SELEXIPAG - UPTRAVI						
N 207947 007	10828298*PED	Jun 01, 2037				
	7205302	Oct 31, 2026	DS DP U-1797			
	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				
	9173881	Aug 12, 2029	U-1798			
	9173881*PED	Feb 12, 2030				
	9284280	Jun 25, 2030	U-1831			
	9284280*PED	Dec 25, 2030				
SELEXIPAG - UPTRAVI						
N 207947 008	10821108	Dec 01, 2036	DP U-2992		NPP	May 23, 2029
	10821108*PED	Jun 01, 2037			PED	Nov 23, 2029
	10828298	Dec 01, 2036	DP U-2991			
	10828298*PED	Jun 01, 2037				
	7205302	Oct 31, 2026	DS DP U-1797			
	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				
	9173881	Aug 12, 2029	U-1798			
	9173881*PED	Feb 12, 2030				
	9284280	Jun 25, 2030	U-1831			
	9284280*PED	Dec 25, 2030				
SELEXIPAG - UPTRAVI						
N 207947 010	10821108	Dec 01, 2036	DP U-2992		NS	May 23, 2029
	10821108*PED	Jun 01, 2037			PED	Nov 23, 2029
	10828298	Dec 01, 2036	DP U-2991			
	10828298*PED	Jun 01, 2037				
	7205302	Oct 31, 2026	DS DP U-1797			
	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				
	9173881	Aug 12, 2029	U-1798			
	9173881*PED	Feb 12, 2030				
	9284280	Jun 25, 2030	U-1831			
	9284280*PED	Dec 25, 2030				
SELEXIPAG - UPTRAVI						
N 207947 011	10821108	Dec 01, 2036	DP U-2992		NS	May 23, 2029
	10821108*PED	Jun 01, 2037			PED	Nov 23, 2029
	10828298	Dec 01, 2036	DP U-2991			
	10828298*PED	Jun 01, 2037				
	7205302	Oct 31, 2026	DS DP U-1797			
	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				
	9173881	Aug 12, 2029	U-1798			
	9173881*PED	Feb 12, 2030				
	9284280	Jun 25, 2030	U-1831			
	9284280*PED	Dec 25, 2030				
SELEXIPAG - UPTRAVI						
N 214275 001	7205302	Oct 31, 2026	DS DP U-1797			
	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				
	9173881	Aug 12, 2029	U-1798			
	9173881*PED	Feb 12, 2030				
	9284280	Jun 25, 2030	U-1831			
	9284280*PED	Dec 25, 2030				
SELINEXOR - XPOVIO						
N 212306 001	10519139	Aug 14, 2035	DS DP U-2584			
	10519139	Aug 14, 2035	DS DP U-3018			
	11746102	Aug 14, 2035	U-2584			
	11746102	Aug 14, 2035	U-3018			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SELINEXOR - XPOVIO						
N 212306 001	11753401	Aug 14, 2035	DP U-2584			
	11753401	Aug 14, 2035	DP U-3018			
	11787771	Jul 26, 2032	U-2584			
	11787771	Jul 26, 2032	U-2855			
	11787771	Jul 26, 2032	U-3018			
	12291508	Jul 26, 2032	U-2584			
	12291508	Jul 26, 2032	U-3018			
	9079865	Jul 26, 2032	U-2584			
	9079865	Jul 26, 2032	U-3018			
SELINEXOR - XPOVIO						
N 212306 002	10519139	Aug 14, 2035	DS DP U-2584			
	10519139	Aug 14, 2035	DS DP U-3018			
	11746102	Aug 14, 2035	U-2584			
	11746102	Aug 14, 2035	U-3018			
	11753401	Aug 14, 2035	DP U-2584			
	11753401	Aug 14, 2035	DP U-3018			
	11787771	Jul 26, 2032	U-2584			
	11787771	Jul 26, 2032	U-3018			
	12291508	Jul 26, 2032	U-2584			
	12291508	Jul 26, 2032	U-3018			
	9079865	Jul 26, 2032	U-2584			
	9079865	Jul 26, 2032	U-3018			
SELINEXOR - XPOVIO						
N 212306 003	10519139	Aug 14, 2035	DS DP U-2584			
	10519139	Aug 14, 2035	DS DP U-3018			
	11746102	Aug 14, 2035	U-2584			
	11746102	Aug 14, 2035	U-3018			
	11753401	Aug 14, 2035	DP U-2584			
	11753401	Aug 14, 2035	DP U-3018			
	11787771	Jul 26, 2032	U-2584			
	11787771	Jul 26, 2032	U-3018			
	12291508	Jul 26, 2032	U-2584			
	12291508	Jul 26, 2032	U-3018			
	9079865	Jul 26, 2032	U-2584			
	9079865	Jul 26, 2032	U-3018			
SELINEXOR - XPOVIO						
N 212306 004	10519139	Aug 14, 2035	DS DP U-2584			
	10519139	Aug 14, 2035	DS DP U-3018			
	11746102	Aug 14, 2035	U-2584			
	11746102	Aug 14, 2035	U-3018			
	11753401	Aug 14, 2035	DP U-2584			
	11753401	Aug 14, 2035	DP U-3018			
	11787771	Jul 26, 2032	U-2584			
	11787771	Jul 26, 2032	U-3018			
	12291508	Jul 26, 2032	U-2584			
	12291508	Jul 26, 2032	U-3018			
	9079865	Jul 26, 2032	U-2584			
	9079865	Jul 26, 2032	U-3018			
SELINEXOR - XPOVIO						
N 212306 005	10519139	Aug 14, 2035	DS DP U-2584			
	10519139	Aug 14, 2035	DS DP U-3018			
	11746102	Aug 14, 2035	U-2584			
	11746102	Aug 14, 2035	U-3018			
	11753401	Aug 14, 2035	DP U-2584			
	11753401	Aug 14, 2035	DP U-3018			
	11787771	Jul 26, 2032	U-2584			
	11787771	Jul 26, 2032	U-3018			
	12291508	Jul 26, 2032	U-2584			
	12291508	Jul 26, 2032	U-3018			
	9079865	Jul 26, 2032	U-2584			
	9079865	Jul 26, 2032	U-3018			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SELUMETINIB SULFATE - KOSELUGO						
N 213756 001					ODE-545	Nov 19, 2032
SELUMETINIB SULFATE - KOSELUGO						
N 213756 002					ODE-545	Nov 19, 2032
SELUMETINIB SULFATE - KOSELUGO						
N 219943 001					ODE*	Nov 19, 2032
SELUMETINIB SULFATE - KOSELUGO						
N 219943 002					ODE*	Nov 19, 2032
SEMAGLUTIDE - OZEMPIC						
N 209637 001	9457154	Sep 29, 2027	DP	Y		
SEMAGLUTIDE - OZEMPIC						
N 209637 002	12295988	Oct 10, 2038	U-1852			
	12569543	Apr 28, 2037	U-4446			
	9457154	Sep 29, 2027	DP	Y		
SEMAGLUTIDE - OZEMPIC						
N 209637 003	12569543	Apr 28, 2037	U-4446			
	9457154	Sep 29, 2027	DP	Y		
SEMAGLUTIDE - OZEMPIC						
N 209637 004	12295988	Oct 10, 2038	U-1852			
	12569543	Apr 28, 2037	U-4446			
	9457154	Sep 29, 2027	DP	Y		
SEMAGLUTIDE - OZEMPIC						
N 209637 005	10888605	Aug 24, 2038	DP U-1852			
	11318191	Feb 17, 2041	DP U-1852			
	11318191	Feb 17, 2041	DP U-4561			
	11752198	Aug 24, 2038	DP U-1852			
	12214017	Aug 24, 2038	DP U-1852			
	12569543	Apr 28, 2037	U-4446			
	8129343	Dec 05, 2031	DS DP U-3355			
SEMAGLUTIDE - OZEMPIC						
N 209637 006	10888605	Aug 24, 2038	DP U-1852			
	11318191	Feb 17, 2041	DP U-1852			
	11318191	Feb 17, 2041	DP U-4561			
	11752198	Aug 24, 2038	DP U-1852			
	12214017	Aug 24, 2038	DP U-1852			
	12569543	Apr 28, 2037	U-4446			
	8129343	Dec 05, 2031	DS DP U-3355			
SEMAGLUTIDE - OZEMPIC						
N 209637 007	10335462	Jun 21, 2033	U-1852			
	10888605	Aug 24, 2038	DP U-1852			
	11318191	Feb 17, 2041	DP U-1852			
	11318191	Feb 17, 2041	DP U-4561			
	11752198	Aug 24, 2038	DP U-1852			
	12214017	Aug 24, 2038	DP U-1852			
	12295988	Oct 10, 2038	U-1852			
	12569543	Apr 28, 2037	U-4446			
	8129343	Dec 05, 2031	DS DP U-3355			
SEMAGLUTIDE - RYBELSUS						
N 213051 001	11033499	Jun 19, 2033	DP U-2628			
	12514822	May 02, 2034	U-2628			
	12594326	Mar 15, 2033	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SEMAGLUTIDE - RYBELSUS						
N 213051 002	11033499	Jun 19, 2033	DP U-2628			
	12514822	May 02, 2034	U-2628			
	12594326	Mar 15, 2033	DP			
SEMAGLUTIDE - RYBELSUS						
N 213051 003	11033499	Jun 19, 2033	DP U-2628			
	12514822	May 02, 2034	U-2628			
	12594326	Mar 15, 2033	DP			
SEMAGLUTIDE - OZEMPIC						
N 213051 004	11033499	Jun 19, 2033	DP U-2628			
	12514822	May 02, 2034	U-2628			
SEMAGLUTIDE - OZEMPIC						
N 213051 005	11033499	Jun 19, 2033	DP U-2628			
	12514822	May 02, 2034	U-2628			
SEMAGLUTIDE - OZEMPIC						
N 213051 006	11033499	Jun 19, 2033	DP U-2628			
	12514822	May 02, 2034	U-2628			
SEMAGLUTIDE - WEGOVY						
N 215256 005	12551536	Oct 10, 2038	U-4418			
SEMAGLUTIDE - WEGOVY HD						
N 215256 006	10888605	Aug 24, 2038	DP U-4418		NS	Mar 19, 2029
	11318191	Feb 17, 2041	DP U-4418			
	11752198	Aug 24, 2038	DP U-4418			
	12029779	Oct 10, 2038	U-4418			
	12214017	Aug 24, 2038	DP U-4418			
	12551536	Oct 10, 2038	U-4418			
	8129343	Dec 05, 2031	DS DP			
	9764003	Jun 21, 2033	U-4418			
SEMAGLUTIDE - WEGOVY						
N 215256 007	10888605	Aug 24, 2038	DP U-3162			
	11318191	Feb 17, 2041	DP U-3162			
	11318191	Feb 17, 2041	DP U-4443			
	11318191	Feb 17, 2041	DP U-4560			
	11478533	May 13, 2040	U-3861			
	11752198	Aug 24, 2038	DP U-3162			
	12029779	Oct 10, 2038	U-3162			
	12214017	Aug 24, 2038	DP U-3162			
	12551536	Oct 10, 2038	U-4418			
	12569543	Apr 28, 2037	U-4443			
	8129343	Dec 05, 2031	DS DP			
	9764003	Jun 21, 2033	U-3161			
SEMAGLUTIDE - WEGOVY						
N 215256 008	10888605	Aug 24, 2038	DP U-3162			
	11318191	Feb 17, 2041	DP U-3162			
	11318191	Feb 17, 2041	DP U-4443			
	11318191	Feb 17, 2041	DP U-4560			
	11478533	May 13, 2040	U-3861			
	11752198	Aug 24, 2038	DP U-3162			
	12029779	Oct 10, 2038	U-3162			
	12214017	Aug 24, 2038	DP U-3162			
	12551536	Oct 10, 2038	U-4418			
	12569543	Apr 28, 2037	U-4443			
	8129343	Dec 05, 2031	DS DP			
	9764003	Jun 21, 2033	U-3161			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SEMAGLUTIDE - WEGOVY							
N 215256 009		10888605	Aug 24, 2038	DP U-3162			
		11318191	Feb 17, 2041	DP U-3162			
		11318191	Feb 17, 2041	DP U-4443			
		11318191	Feb 17, 2041	DP U-4560			
		11478533	May 13, 2040	U-3861			
		11752198	Aug 24, 2038	DP U-3162			
		12029779	Oct 10, 2038	U-3162			
		12214017	Aug 24, 2038	DP U-3162			
		12551536	Oct 10, 2038	U-4418			
		12569543	Apr 28, 2037	U-4443			
		8129343	Dec 05, 2031	DS DP			
		9764003	Jun 21, 2033	U-3161			
SEMAGLUTIDE - WEGOVY							
N 215256 010		10888605	Aug 24, 2038	DP U-3162			
		11318191	Feb 17, 2041	DP U-3162			
		11318191	Feb 17, 2041	DP U-4443			
		11318191	Feb 17, 2041	DP U-4560			
		11478533	May 13, 2040	U-3861			
		11752198	Aug 24, 2038	DP U-3162			
		12029779	Oct 10, 2038	U-3162			
		12214017	Aug 24, 2038	DP U-3162			
		12551536	Oct 10, 2038	U-4418			
		12569543	Apr 28, 2037	U-4443			
		8129343	Dec 05, 2031	DS DP			
		9764003	Jun 21, 2033	U-3161			
SEMAGLUTIDE - WEGOVY							
N 215256 011		10888605	Aug 24, 2038	DP U-3162			
		11318191	Feb 17, 2041	DP U-3162			
		11318191	Feb 17, 2041	DP U-4443			
		11318191	Feb 17, 2041	DP U-4560			
		11478533	May 13, 2040	U-3861			
		11752198	Aug 24, 2038	DP U-3162			
		12029779	Oct 10, 2038	U-3162			
		12214017	Aug 24, 2038	DP U-3162			
		12551536	Oct 10, 2038	U-4418			
		12569543	Apr 28, 2037	U-4443			
		8129343	Dec 05, 2031	DS DP			
		9764003	Jun 21, 2033	U-3161			
SEMAGLUTIDE - WEGOVY FLEXTOUCH							
N 215256 012	>A>	11478533	May 13, 2040	U-3861		>A> I-935	Mar 08, 2027
	>A>	12029779	Oct 10, 2038	U-3162		>A> I-973	Aug 15, 2028
	>A>	12551536	Oct 10, 2038	U-4418			
	>A>	8129343	Dec 05, 2031	DS DP			
	>A>	9764003	Jun 21, 2033	U-3161			
SEMAGLUTIDE - WEGOVY							
N 218316 001		10278923	May 02, 2034	U-4389		I-935	Mar 08, 2027
		11033499	Jun 19, 2033	DP U-4496		NP	Dec 22, 2028
		11382957	Dec 16, 2031	DP			
		11833248	Feb 01, 2039	DP U-4387			
		12239739	May 02, 2034	U-4388			
		12396953	Feb 01, 2039	DP U-4387			
		8129343	Dec 05, 2031	DS DP			
		8536122	Mar 20, 2026	DS DP			
SEMAGLUTIDE - WEGOVY							
N 218316 002		10278923	May 02, 2034	U-4389		I-935	Mar 08, 2027
		11033499	Jun 19, 2033	DP U-4496		NP	Dec 22, 2028
		11382957	Dec 16, 2031	DP			
		11833248	Feb 01, 2039	DP U-4387			
		12239739	May 02, 2034	U-4388			
		12396953	Feb 01, 2039	DP U-4387			
		8129343	Dec 05, 2031	DS DP			
		8536122	Mar 20, 2026	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SEMAGLUTIDE - WEGOVY						
N 218316 002	10278923	May 02, 2034	U-4389		I-935	Mar 08, 2027
	11033499	Jun 19, 2033	DP U-4496		NP	Dec 22, 2028
	11382957	Dec 16, 2031	DP			
	11833248	Feb 01, 2039	DP U-4387			
	12239739	May 02, 2034	U-4388			
	12396953	Feb 01, 2039	DP U-4387			
	8129343	Dec 05, 2031	DS DP			
	8536122	Mar 20, 2026	DS DP			
SEMAGLUTIDE - WEGOVY						
N 218316 003	10278923	May 02, 2034	U-4389		I-935	Mar 08, 2027
	11033499	Jun 19, 2033	DP U-4496		NP	Dec 22, 2028
	11382957	Dec 16, 2031	DP			
	11833248	Feb 01, 2039	DP U-4387			
	12239739	May 02, 2034	U-4388			
	12396953	Feb 01, 2039	DP U-4387			
	8129343	Dec 05, 2031	DS DP			
	8536122	Mar 20, 2026	DS DP			
	9278123	Dec 16, 2031	DP U-4389			
SEMAGLUTIDE - WEGOVY						
N 218316 004	10278923	May 02, 2034	U-4389		I-935	Mar 08, 2027
	11033499	Jun 19, 2033	DP U-4496		NP	Dec 22, 2028
	11382957	Dec 16, 2031	DP			
	11833248	Feb 01, 2039	DP U-4387			
	12239739	May 02, 2034	U-4388			
	12396953	Feb 01, 2039	DP U-4387			
	8129343	Dec 05, 2031	DS DP			
	8536122	Mar 20, 2026	DS DP			
	9278123	Dec 16, 2031	DP U-4389			
SEPIAPTERIN - SEPHIENCE						
N 219666 001					ODE-542	Jul 28, 2032
SEPIAPTERIN - SEPHIENCE						
N 219666 002					ODE-542	Jul 28, 2032
SETMELANOTIDE ACETATE - IMCIVREE						
N 213793 001					I-987	Mar 19, 2029
SEVABERTINIB - HYRNUO						
N 219972 001	10428063	Oct 10, 2035	DS DP			
>A>	12679836	Nov 14, 2043	DS DP U-4582			
SILDENAFIL CITRATE - VYBRIQUE						
N 210858 001	11123287	Dec 16, 2033	DP		NP	Dec 16, 2028
SILDENAFIL CITRATE - VYBRIQUE						
N 210858 002	11123287	Dec 16, 2033	DP		NP	Dec 16, 2028
SILDENAFIL CITRATE - VYBRIQUE						
N 210858 003	11123287	Dec 16, 2033	DP		NP	Dec 16, 2028
SILDENAFIL CITRATE - VYBRIQUE						
N 210858 004	11123287	Dec 16, 2033	DP		NP	Dec 16, 2028
SIPONIMOD - MAYZENT						
N 209884 001	12533340	Apr 23, 2036	U-4407			
SIPONIMOD - MAYZENT						
N 209884 002	12533340	Apr 23, 2036	U-4407			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SIPONIMOD - MAYZENT						
N 209884 003	12533340	Apr 23, 2036	U-4407			
SITAGLIPTIN PHOSPHATE - SITAGLIPTIN PHOSPHATE						
A 202387 001					PC	Nov 24, 2026
SITAGLIPTIN PHOSPHATE - SITAGLIPTIN PHOSPHATE						
A 202387 002					PC	Nov 24, 2026
SITAGLIPTIN PHOSPHATE - SITAGLIPTIN PHOSPHATE						
A 202387 003					PC	Nov 24, 2026
SITAGLIPTIN PHOSPHATE - SITAGLIPTIN PHOSPHATE						
A 202425 001					PC	Nov 24, 2026
SITAGLIPTIN PHOSPHATE - SITAGLIPTIN PHOSPHATE						
A 202425 002					PC	Nov 24, 2026
SITAGLIPTIN PHOSPHATE - SITAGLIPTIN PHOSPHATE						
A 202425 003					PC	Nov 24, 2026
SONROTOCLAX - BEQALZI						
N 220711 001	11420968	Apr 29, 2039	DS DP		NCE	May 13, 2031
SONROTOCLAX - BEQALZI						
N 220711 002	11420968	Apr 29, 2039	DS DP		NCE	May 13, 2031
SONROTOCLAX - BEQALZI						
N 220711 003	11420968	Apr 29, 2039	DS DP		NCE	May 13, 2031
SONROTOCLAX - BEQALZI						
N 220711 004	11420968	Apr 29, 2039	DS DP		NCE	May 13, 2031
SOTALOL HYDROCHLORIDE - SOTALOL HYDROCHLORIDE						
N 022306 001	12569183	Apr 05, 2039	U-4456			
SPARSENTAN - FILSPARI						
N 216403 001	9662312	Mar 29, 2030	U-4495		I-989	Apr 13, 2029
	9993461	Mar 29, 2030	U-3269			
	9993461	Mar 29, 2030	U-3993			
	9993461	Mar 29, 2030	U-4495			
SPARSENTAN - FILSPARI						
N 216403 002	9662312	Mar 29, 2030	U-4495		I-989	Apr 13, 2029
	9993461	Mar 29, 2030	U-3269			
	9993461	Mar 29, 2030	U-3993			
	9993461	Mar 29, 2030	U-4495			
SUVOREXANT - BELSOMRA						
N 204569 001	12599610	May 29, 2033	DP			
SUVOREXANT - BELSOMRA						
N 204569 002	12599610	May 29, 2033	DP			
SUVOREXANT - BELSOMRA						
N 204569 003	12599610	May 29, 2033	DP			
SUVOREXANT - BELSOMRA						
N 204569 004	12599610	May 29, 2033	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TADALAFIL - TADLIQ									
N 214522	001	>A>	12691120	Dec 24, 2038		DP U-3397			
		>A>	12697338	Dec 24, 2038		DP U-3397			
TAFENOQUINE SUCCINATE - ARAKODA									
N 210607	001		12616689	Dec 02, 2035		U-2582			
TALETRECTINIB ADIPATE - IBTROZI									
N 219713	001							ODE-544	Jun 11, 2032
TAPINAROF - VTAMA									
N 215272	001		10195160	May 23, 2036		DP			
			12569453	Dec 18, 2039		U-4048			
TEBIPENEM PIVOXIL HYDROBROMIDE - UTEBZI									
N 215960	001	>A>	10889587	Feb 06, 2038	DS	DP U-4570		>A> NCE	Jun 17, 2031
		>A>	12226403	Dec 15, 2037		DP U-4569		>A> GAIN	Jun 17, 2036
TECHNETIUM TC-99M LABELED CARBON - TECHNEGAS KIT									
N 022335	001		7722856	Feb 24, 2031		U-4442			
TENAPANOR HYDROCHLORIDE - IBSRELA									
N 211801	001		12539299	Nov 26, 2042		DP			
TENAPANOR HYDROCHLORIDE - XPHOZAH									
N 213931	001		12539299	Nov 26, 2042		DP			
TENAPANOR HYDROCHLORIDE - XPHOZAH									
N 213931	002		12539299	Nov 26, 2042		DP			
TENAPANOR HYDROCHLORIDE - XPHOZAH									
N 213931	003		12539299	Nov 26, 2042		DP			
TENOFOVIR ALAFENAMIDE FUMARATE - VEMLIDY									
N 208464	001							NPP	Mar 27, 2027
TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)									
N 209863	001		12629483	Aug 07, 2035		DP			
TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)									
N 209863	002		12629483	Aug 07, 2035		DP			
TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)									
N 209863	003		12629483	Aug 07, 2035		DP			
TESTOSTERONE UNDECANOATE - JATENZO									
N 206089	001		12605391	Apr 12, 2039		U-1103			
TESTOSTERONE UNDECANOATE - JATENZO									
N 206089	002		12605391	Apr 12, 2039		U-1103			
TESTOSTERONE UNDECANOATE - JATENZO									
N 206089	003		12605391	Apr 12, 2039		U-1103			
THIOTEPA - TEPADINA AND SODIUM CHLORIDE									
N 208264	004		9931458	May 31, 2037		DP			
THIOTEPA - TEPYLUTE									
N 216984	001		12622921	Aug 16, 2041		U-4530			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
THIOTEPA - TEPYLUTE							
N 216984 002		12622921	Aug 16, 2041	U-4530			
TIRBANIBULIN - KLISYRI							
N 213189 001	>A>	12667576	Mar 12, 2038	U-4577			
TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)							
N 215866 001		12343382	Jul 22, 2039	U-4229		NPP	Dec 19, 2028
		12343382	Jul 22, 2039	U-4230			
		12343382	Jul 22, 2039	U-4231			
		12343382	Jul 22, 2039	U-4232			
		12343382	Jul 22, 2039	U-4400			
		12343382	Jul 22, 2039	U-4401			
		12453755	Jun 14, 2039	U-4375			
		12453755	Jun 14, 2039	U-4376			
		12453755	Jun 14, 2039	U-4377			
		12453755	Jun 14, 2039	U-4378			
		12453755	Jun 14, 2039	U-4379			
		12453755	Jun 14, 2039	U-4380			
		12453755	Jun 14, 2039	U-4381			
		12453755	Jun 14, 2039	U-4382			
		12453755	Jun 14, 2039	U-4383			
		12453755	Jun 14, 2039	U-4384			
		12453755	Jun 14, 2039	U-4385			
		12453755	Jun 14, 2039	U-4386			
		12616740	Jul 22, 2039	U-4500			
		12616740	Jul 22, 2039	U-4501			
		12616740	Jul 22, 2039	U-4502			
		12629404	Jun 14, 2039	U-4533	DP		
		12629404	Jun 14, 2039	U-4534	DP		
	>A>	9474780	May 13, 2036	U-4374	DS DP		
TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)							
N 215866 002		12343382	Jul 22, 2039	U-4229		NPP	Dec 19, 2028
		12343382	Jul 22, 2039	U-4230			
		12343382	Jul 22, 2039	U-4231			
		12343382	Jul 22, 2039	U-4232			
		12343382	Jul 22, 2039	U-4400			
		12343382	Jul 22, 2039	U-4401			
		12453755	Jun 14, 2039	U-4375			
		12453755	Jun 14, 2039	U-4376			
		12453755	Jun 14, 2039	U-4377			
		12453755	Jun 14, 2039	U-4378			
		12453755	Jun 14, 2039	U-4379			
		12453755	Jun 14, 2039	U-4380			
		12453755	Jun 14, 2039	U-4381			
		12453755	Jun 14, 2039	U-4382			
		12453755	Jun 14, 2039	U-4383			
		12453755	Jun 14, 2039	U-4384			
		12453755	Jun 14, 2039	U-4385			
		12453755	Jun 14, 2039	U-4386			
		12616740	Jul 22, 2039	U-4500			
		12616740	Jul 22, 2039	U-4501			
		12616740	Jul 22, 2039	U-4502			
		12629404	Jun 14, 2039	U-4533	DP		
		12629404	Jun 14, 2039	U-4534	DP		
	>A>	9474780	May 13, 2036	U-4374	DS DP		
TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)							
N 215866 003		12343382	Jul 22, 2039	U-4229		NPP	Dec 19, 2028
		12343382	Jul 22, 2039	U-4230			
		12343382	Jul 22, 2039	U-4231			
		12343382	Jul 22, 2039	U-4232			
		12343382	Jul 22, 2039	U-4400			
		12343382	Jul 22, 2039	U-4401			
		12453755	Jun 14, 2039	U-4375			
		12453755	Jun 14, 2039	U-4376			
		12453755	Jun 14, 2039	U-4377			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)						
N 215866 003	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	12616740	Jul 22, 2039	U-4500			
	12616740	Jul 22, 2039	U-4501			
	12616740	Jul 22, 2039	U-4502			
	12629404	Jun 14, 2039	DP U-4533			
	12629404	Jun 14, 2039	DP U-4534			
	>A> 9474780	May 13, 2036	DS DP U-4374			
TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)						
N 215866 004	12343382	Jul 22, 2039	U-4229		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	12616740	Jul 22, 2039	U-4500			
	12616740	Jul 22, 2039	U-4501			
	12616740	Jul 22, 2039	U-4502			
	12629404	Jun 14, 2039	DP U-4533			
	12629404	Jun 14, 2039	DP U-4534			
	>A> 9474780	May 13, 2036	DS DP U-4374			
TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)						
N 215866 005	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	12616740	Jul 22, 2039	U-4500			
	12616740	Jul 22, 2039	U-4501			
	12616740	Jul 22, 2039	U-4502			
	12629404	Jun 14, 2039	DP U-4533			
	12629404	Jun 14, 2039	DP U-4534			
	>A> 9474780	May 13, 2036	DS DP U-4374			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)						
N 215866 005	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	12616740	Jul 22, 2039	U-4500			
	12616740	Jul 22, 2039	U-4501			
	12616740	Jul 22, 2039	U-4502			
	12629404	Jun 14, 2039	DP U-4533			
	12629404	Jun 14, 2039	DP U-4534			
>A>	9474780	May 13, 2036	DS DP U-4374			
TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)						
N 215866 006	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	12616740	Jul 22, 2039	U-4500			
	12616740	Jul 22, 2039	U-4501			
	12616740	Jul 22, 2039	U-4502			
	12629404	Jun 14, 2039	DP U-4533			
	12629404	Jun 14, 2039	DP U-4534			
>A>	9474780	May 13, 2036	DS DP U-4374			
TIRZEPATIDE - MOUNJARO						
N 215866 007	12343382	Jul 22, 2039	U-4229		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TIRZEPATIDE - MOUNJARO						
N 215866 007	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	12616740	Jul 22, 2039	U-4500			
	12616740	Jul 22, 2039	U-4501			
	12616740	Jul 22, 2039	U-4502			
	12629404	Jun 14, 2039	DP U-4533			
	12629404	Jun 14, 2039	DP U-4534			
	>A> 9474780	May 13, 2036	DS DP U-4374			
TIRZEPATIDE - MOUNJARO						
N 215866 008	12343382	Jul 22, 2039	U-4229		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	12616740	Jul 22, 2039	U-4500			
	12616740	Jul 22, 2039	U-4501			
	12616740	Jul 22, 2039	U-4502			
	12629404	Jun 14, 2039	DP U-4533			
	12629404	Jun 14, 2039	DP U-4534			
	>A> 9474780	May 13, 2036	DS DP U-4374			
TIRZEPATIDE - MOUNJARO						
N 215866 009	12343382	Jul 22, 2039	U-4229		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	12616740	Jul 22, 2039	U-4500			
	12616740	Jul 22, 2039	U-4501			
	12616740	Jul 22, 2039	U-4502			
	12629404	Jun 14, 2039	DP U-4533			
	12629404	Jun 14, 2039	DP U-4534			
	>A> 9474780	May 13, 2036	DS DP U-4374			
TIRZEPATIDE - MOUNJARO						
N 215866 010	12343382	Jul 22, 2039	U-4229		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TIRZEPATIDE - MOUNJARO						
N 215866 010	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	12616740	Jul 22, 2039	U-4500			
	12616740	Jul 22, 2039	U-4501			
	12616740	Jul 22, 2039	U-4502			
	12629404	Jun 14, 2039	U-4533	DP		
	12629404	Jun 14, 2039	U-4534	DP		
	>A> 9474780	May 13, 2036	U-4374	DS DP		
TIRZEPATIDE - MOUNJARO						
N 215866 011	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	12616740	Jul 22, 2039	U-4500			
	12616740	Jul 22, 2039	U-4501			
	12616740	Jul 22, 2039	U-4502			
	12629404	Jun 14, 2039	U-4533	DP		
	12629404	Jun 14, 2039	U-4534	DP		
	>A> 9474780	May 13, 2036	U-4374	DS DP		
TIRZEPATIDE - MOUNJARO						
N 215866 012	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	12616740	Jul 22, 2039	U-4500			
	12616740	Jul 22, 2039	U-4501			
	12616740	Jul 22, 2039	U-4502			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TIRZEPATIDE - MOUNJARO						
N 215866 012	12629404	Jun 14, 2039	DP U-4533			
	12629404	Jun 14, 2039	DP U-4534			
	>A> 9474780	May 13, 2036	DS DP U-4374			
TIRZEPATIDE - MOUNJARO						
N 215866 013	12295987	Dec 30, 2041	U-4192		NCE	May 13, 2027
	12295987	Dec 30, 2041	U-4193		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12616740	Jul 22, 2039	U-4500			
	12616740	Jul 22, 2039	U-4501			
	12616740	Jul 22, 2039	U-4502			
	>A> 9474780	May 13, 2036	DS DP U-4374			
TIRZEPATIDE - MOUNJARO						
N 215866 014	12295987	Dec 30, 2041	U-4192		NCE	May 13, 2027
	12295987	Dec 30, 2041	U-4193		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12616740	Jul 22, 2039	U-4500			
	12616740	Jul 22, 2039	U-4501			
	12616740	Jul 22, 2039	U-4502			
	>A> 9474780	May 13, 2036	DS DP U-4374			
TIRZEPATIDE - MOUNJARO						
N 215866 015	12295987	Dec 30, 2041	U-4192		NCE	May 13, 2027
	12295987	Dec 30, 2041	U-4193		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12616740	Jul 22, 2039	U-4500			
	12616740	Jul 22, 2039	U-4501			
	12616740	Jul 22, 2039	U-4502			
	>A> 9474780	May 13, 2036	DS DP U-4374			
TIRZEPATIDE - MOUNJARO						
N 215866 016	12295987	Dec 30, 2041	U-4192		NCE	May 13, 2027
	12295987	Dec 30, 2041	U-4193		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12616740	Jul 22, 2039	U-4500			
	12616740	Jul 22, 2039	U-4501			
	12616740	Jul 22, 2039	U-4502			
	>A> 9474780	May 13, 2036	DS DP U-4374			
TIRZEPATIDE - MOUNJARO						
N 215866 017	12295987	Dec 30, 2041	U-4192		NCE	May 13, 2027
	12295987	Dec 30, 2041	U-4193		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TIRZEPATIDE - MOUNJARO						
N 215866 017	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12616740	Jul 22, 2039	U-4500			
	12616740	Jul 22, 2039	U-4501			
	12616740	Jul 22, 2039	U-4502			
	>A> 9474780	May 13, 2036	DS DP U-4374			
TIRZEPATIDE - MOUNJARO						
N 215866 018	12295987	Dec 30, 2041	U-4192		NCE	May 13, 2027
	12295987	Dec 30, 2041	U-4193		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12616740	Jul 22, 2039	U-4500			
	12616740	Jul 22, 2039	U-4501			
	12616740	Jul 22, 2039	U-4502			
	>A> 9474780	May 13, 2036	DS DP U-4374			
TIRZEPATIDE - MOUNJARO KWIKPEN						
N 215866 019	12295987	Dec 30, 2041	U-4192		NCE	May 13, 2027
	12295987	Dec 30, 2041	U-4193		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12616740	Jul 22, 2039	U-4500			
	12616740	Jul 22, 2039	U-4501			
	12616740	Jul 22, 2039	U-4502			
	>A> 9474780	May 13, 2036	DS DP U-4374			
TIRZEPATIDE - MOUNJARO KWIKPEN						
N 215866 020	12295987	Dec 30, 2041	U-4192		NCE	May 13, 2027
	12295987	Dec 30, 2041	U-4193		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12616740	Jul 22, 2039	U-4500			
	12616740	Jul 22, 2039	U-4501			
	12616740	Jul 22, 2039	U-4502			
	>A> 9474780	May 13, 2036	DS DP U-4374			
TIRZEPATIDE - MOUNJARO KWIKPEN						
N 215866 021	12295987	Dec 30, 2041	U-4192		NCE	May 13, 2027
	12295987	Dec 30, 2041	U-4193		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12616740	Jul 22, 2039	U-4500			
	12616740	Jul 22, 2039	U-4501			
	12616740	Jul 22, 2039	U-4502			
	>A> 9474780	May 13, 2036	DS DP U-4374			
TIRZEPATIDE - MOUNJARO KWIKPEN						
N 215866 022	12295987	Dec 30, 2041	U-4192		NCE	May 13, 2027
	12295987	Dec 30, 2041	U-4193		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4229			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TIRZEPATIDE - MOUNJARO KWIKPEN							
N 215866 022		12343382	Jul 22, 2039	U-4230			
		12343382	Jul 22, 2039	U-4231			
		12343382	Jul 22, 2039	U-4232			
		12343382	Jul 22, 2039	U-4400			
		12343382	Jul 22, 2039	U-4401			
		12616740	Jul 22, 2039	U-4500			
		12616740	Jul 22, 2039	U-4501			
		12616740	Jul 22, 2039	U-4502			
	>A>	9474780	May 13, 2036	DS DP U-4374			
TIRZEPATIDE - MOUNJARO KWIKPEN							
N 215866 023		12295987	Dec 30, 2041	U-4192		NCE	May 13, 2027
		12295987	Dec 30, 2041	U-4193			
		12343382	Jul 22, 2039	U-4229			
		12343382	Jul 22, 2039	U-4230			
		12343382	Jul 22, 2039	U-4231			
		12343382	Jul 22, 2039	U-4232			
		12343382	Jul 22, 2039	U-4400			
		12343382	Jul 22, 2039	U-4401			
		12616740	Jul 22, 2039	U-4500			
		12616740	Jul 22, 2039	U-4501			
		12616740	Jul 22, 2039	U-4502			
	>A>	9474780	May 13, 2036	DS DP U-4374			
TIRZEPATIDE - MOUNJARO KWIKPEN							
N 215866 024		12295987	Dec 30, 2041	U-4192		NCE	May 13, 2027
		12295987	Dec 30, 2041	U-4193			
		12343382	Jul 22, 2039	U-4229			
		12343382	Jul 22, 2039	U-4230			
		12343382	Jul 22, 2039	U-4231			
		12343382	Jul 22, 2039	U-4232			
		12343382	Jul 22, 2039	U-4400			
		12343382	Jul 22, 2039	U-4401			
		12616740	Jul 22, 2039	U-4500			
		12616740	Jul 22, 2039	U-4501			
		12616740	Jul 22, 2039	U-4502			
	>A>	9474780	May 13, 2036	DS DP U-4374			
TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)							
N 217806 001		12343382	Jul 22, 2039	U-4227			
		12343382	Jul 22, 2039	U-4228			
		12343382	Jul 22, 2039	U-4409			
		12343382	Jul 22, 2039	U-4410			
		12616740	Jul 22, 2039	U-4497			
		12616740	Jul 22, 2039	U-4498			
		12616740	Jul 22, 2039	U-4499			
		12629404	Jun 14, 2039	DP U-4531			
		12629404	Jun 14, 2039	DP U-4532			
	>A>	9474780	May 13, 2036	DS DP			
TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)							
N 217806 002		12343382	Jul 22, 2039	U-4227			
		12343382	Jul 22, 2039	U-4228			
		12343382	Jul 22, 2039	U-4409			
		12343382	Jul 22, 2039	U-4410			
		12616740	Jul 22, 2039	U-4497			
		12616740	Jul 22, 2039	U-4498			
		12616740	Jul 22, 2039	U-4499			
		12629404	Jun 14, 2039	DP U-4531			
		12629404	Jun 14, 2039	DP U-4532			
	>A>	9474780	May 13, 2036	DS DP			
TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)							
N 217806 003		12343382	Jul 22, 2039	U-4227			
		12343382	Jul 22, 2039	U-4228			
		12343382	Jul 22, 2039	U-4409			
		12343382	Jul 22, 2039	U-4410			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)						
N 217806 003	12616740	Jul 22, 2039			U-4497	
	12616740	Jul 22, 2039			U-4498	
	12616740	Jul 22, 2039			U-4499	
	12629404	Jun 14, 2039	DP		U-4531	
	12629404	Jun 14, 2039	DP		U-4532	
	>A> 9474780	May 13, 2036	DS DP			
TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)						
N 217806 004	12343382	Jul 22, 2039			U-4227	
	12343382	Jul 22, 2039			U-4228	
	12343382	Jul 22, 2039			U-4409	
	12343382	Jul 22, 2039			U-4410	
	12616740	Jul 22, 2039			U-4497	
	12616740	Jul 22, 2039			U-4498	
	12616740	Jul 22, 2039			U-4499	
	12629404	Jun 14, 2039	DP		U-4531	
	12629404	Jun 14, 2039	DP		U-4532	
	>A> 9474780	May 13, 2036	DS DP			
TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)						
N 217806 005	12343382	Jul 22, 2039			U-4227	
	12343382	Jul 22, 2039			U-4228	
	12343382	Jul 22, 2039			U-4409	
	12343382	Jul 22, 2039			U-4410	
	12616740	Jul 22, 2039			U-4497	
	12616740	Jul 22, 2039			U-4498	
	12616740	Jul 22, 2039			U-4499	
	12629404	Jun 14, 2039	DP		U-4531	
	12629404	Jun 14, 2039	DP		U-4532	
	>A> 9474780	May 13, 2036	DS DP			
TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)						
N 217806 006	12343382	Jul 22, 2039			U-4227	
	12343382	Jul 22, 2039			U-4228	
	12343382	Jul 22, 2039			U-4409	
	12343382	Jul 22, 2039			U-4410	
	12616740	Jul 22, 2039			U-4497	
	12616740	Jul 22, 2039			U-4498	
	12616740	Jul 22, 2039			U-4499	
	12629404	Jun 14, 2039	DP		U-4531	
	12629404	Jun 14, 2039	DP		U-4532	
	>A> 9474780	May 13, 2036	DS DP			
TIRZEPATIDE - ZEPBOUND						
N 217806 007	12343382	Jul 22, 2039			U-4227	
	12343382	Jul 22, 2039			U-4228	
	12343382	Jul 22, 2039			U-4409	
	12343382	Jul 22, 2039			U-4410	
	12616740	Jul 22, 2039			U-4497	
	12616740	Jul 22, 2039			U-4498	
	12616740	Jul 22, 2039			U-4499	
	12629404	Jun 14, 2039	DP		U-4531	
	12629404	Jun 14, 2039	DP		U-4532	
	>A> 9474780	May 13, 2036	DS DP			
TIRZEPATIDE - ZEPBOUND						
N 217806 008	12343382	Jul 22, 2039			U-4227	
	12343382	Jul 22, 2039			U-4228	
	12343382	Jul 22, 2039			U-4409	
	12343382	Jul 22, 2039			U-4410	
	12616740	Jul 22, 2039			U-4497	
	12616740	Jul 22, 2039			U-4498	
	12616740	Jul 22, 2039			U-4499	
	12629404	Jun 14, 2039	DP		U-4531	
	12629404	Jun 14, 2039	DP		U-4532	
	>A> 9474780	May 13, 2036	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TIRZEPATIDE - ZEPBOUND						
N 217806 008	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
	12616740	Jul 22, 2039	U-4497			
	12616740	Jul 22, 2039	U-4498			
	12616740	Jul 22, 2039	U-4499			
	12629404	Jun 14, 2039	DP U-4531			
	12629404	Jun 14, 2039	DP U-4532			
	>A> 9474780	May 13, 2036	DS DP			
TIRZEPATIDE - ZEPBOUND						
N 217806 009	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
	12616740	Jul 22, 2039	U-4497			
	12616740	Jul 22, 2039	U-4498			
	12616740	Jul 22, 2039	U-4499			
	12629404	Jun 14, 2039	DP U-4531			
	12629404	Jun 14, 2039	DP U-4532			
	>A> 9474780	May 13, 2036	DS DP			
TIRZEPATIDE - ZEPBOUND						
N 217806 010	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
	12616740	Jul 22, 2039	U-4497			
	12616740	Jul 22, 2039	U-4498			
	12616740	Jul 22, 2039	U-4499			
	12629404	Jun 14, 2039	DP U-4531			
	12629404	Jun 14, 2039	DP U-4532			
	>A> 9474780	May 13, 2036	DS DP			
TIRZEPATIDE - ZEPBOUND						
N 217806 011	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
	12616740	Jul 22, 2039	U-4497			
	12616740	Jul 22, 2039	U-4498			
	12616740	Jul 22, 2039	U-4499			
	12629404	Jun 14, 2039	DP U-4531			
	12629404	Jun 14, 2039	DP U-4532			
	>A> 9474780	May 13, 2036	DS DP			
TIRZEPATIDE - ZEPBOUND						
N 217806 012	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
	12616740	Jul 22, 2039	U-4497			
	12616740	Jul 22, 2039	U-4498			
	12616740	Jul 22, 2039	U-4499			
	12629404	Jun 14, 2039	DP U-4531			
	12629404	Jun 14, 2039	DP U-4532			
	>A> 9474780	May 13, 2036	DS DP			
TIRZEPATIDE - ZEPBOUND						
N 217806 013	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228		M-82	Oct 18, 2027
	12343382	Jul 22, 2039	U-4409		NCE	May 13, 2027
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TIRZEPATIDE - ZEPBOUND						
N 217806 013	12453758	Jul 22, 2039	U-4311			
	12616740	Jul 22, 2039	U-4497			
	12616740	Jul 22, 2039	U-4498			
	12616740	Jul 22, 2039	U-4499			
	>A> 9474780	May 13, 2036	DS DP			
TIRZEPATIDE - ZEPBOUND						
N 217806 014	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228		M-82	Oct 18, 2027
	12343382	Jul 22, 2039	U-4409		NCE	May 13, 2027
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	12616740	Jul 22, 2039	U-4497			
	12616740	Jul 22, 2039	U-4498			
	12616740	Jul 22, 2039	U-4499			
	>A> 9474780	May 13, 2036	DS DP			
TIRZEPATIDE - ZEPBOUND						
N 217806 015	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228		M-82	Oct 18, 2027
	12343382	Jul 22, 2039	U-4409		NCE	May 13, 2027
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	12616740	Jul 22, 2039	U-4497			
	12616740	Jul 22, 2039	U-4498			
	12616740	Jul 22, 2039	U-4499			
	>A> 9474780	May 13, 2036	DS DP			
TIRZEPATIDE - ZEPBOUND						
N 217806 016	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228		M-82	Oct 18, 2027
	12343382	Jul 22, 2039	U-4409		NCE	May 13, 2027
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	12616740	Jul 22, 2039	U-4497			
	12616740	Jul 22, 2039	U-4498			
	12616740	Jul 22, 2039	U-4499			
	>A> 9474780	May 13, 2036	DS DP			
TIRZEPATIDE - ZEPBOUND						
N 217806 017	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228		M-82	Oct 18, 2027
	12343382	Jul 22, 2039	U-4409		NCE	May 13, 2027
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	12616740	Jul 22, 2039	U-4497			
	12616740	Jul 22, 2039	U-4498			
	12616740	Jul 22, 2039	U-4499			
	>A> 9474780	May 13, 2036	DS DP			
TIRZEPATIDE - ZEPBOUND						
N 217806 018	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228		M-82	Oct 18, 2027
	12343382	Jul 22, 2039	U-4409		NCE	May 13, 2027
	12343382	Jul 22, 2039	U-4410			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TIRZEPATIDE - ZEPBOUND						
N 217806 018	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	12616740	Jul 22, 2039	U-4497			
	12616740	Jul 22, 2039	U-4498			
	12616740	Jul 22, 2039	U-4499			
	>A> 9474780	May 13, 2036	DS DP			
TIRZEPATIDE - ZEPBOUND KWIKPEN						
N 217806 019	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228		M-82	Oct 18, 2027
	12343382	Jul 22, 2039	U-4409		NCE	May 13, 2027
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	12616740	Jul 22, 2039	U-4497			
	12616740	Jul 22, 2039	U-4498			
	12616740	Jul 22, 2039	U-4499			
	>A> 9474780	May 13, 2036	DS DP			
TIRZEPATIDE - ZEPBOUND KWIKPEN						
N 217806 020	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228		M-82	Oct 18, 2027
	12343382	Jul 22, 2039	U-4409		NCE	May 13, 2027
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	12616740	Jul 22, 2039	U-4497			
	12616740	Jul 22, 2039	U-4498			
	12616740	Jul 22, 2039	U-4499			
	>A> 9474780	May 13, 2036	DS DP			
TIRZEPATIDE - ZEPBOUND KWIKPEN						
N 217806 021	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228		M-82	Oct 18, 2027
	12343382	Jul 22, 2039	U-4409		NCE	May 13, 2027
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	12616740	Jul 22, 2039	U-4497			
	12616740	Jul 22, 2039	U-4498			
	12616740	Jul 22, 2039	U-4499			
	>A> 9474780	May 13, 2036	DS DP			
TIRZEPATIDE - ZEPBOUND KWIKPEN						
N 217806 022	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228		M-82	Oct 18, 2027
	12343382	Jul 22, 2039	U-4409		NCE	May 13, 2027
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	12616740	Jul 22, 2039	U-4497			
	12616740	Jul 22, 2039	U-4498			
	12616740	Jul 22, 2039	U-4499			
	>A> 9474780	May 13, 2036	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TIRZEPATIDE - ZEPBOUND KWIKPEN						
N 217806 023	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228		M-82	Oct 18, 2027
	12343382	Jul 22, 2039	U-4409		NCE	May 13, 2027
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	12616740	Jul 22, 2039	U-4497			
	12616740	Jul 22, 2039	U-4498			
	12616740	Jul 22, 2039	U-4499			
	>A> 9474780	May 13, 2036	DS DP			
TIRZEPATIDE - ZEPBOUND KWIKPEN						
N 217806 024	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228		M-82	Oct 18, 2027
	12343382	Jul 22, 2039	U-4409		NCE	May 13, 2027
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	12616740	Jul 22, 2039	U-4497			
	12616740	Jul 22, 2039	U-4498			
	12616740	Jul 22, 2039	U-4499			
	>A> 9474780	May 13, 2036	DS DP			
TRABECTEDIN - EVDI						
N 220837 001	12303506	Feb 18, 2043	DP			
TRADIPITANT - NEREUS						
N 220152 001	10772880	Mar 04, 2036	U-4396			
	10821099	Mar 04, 2036	U-4396			
	11324735	Mar 04, 2036	U-4396			
	12318375	Aug 09, 2036	U-4396			
TREOSULFAN - GRAFAPEX						
N 214759 001	7199162	Oct 12, 2026	U-4142			
TREOSULFAN - GRAFAPEX						
N 214759 002	7199162	Oct 12, 2026	U-4142			
TRIENTINE TETRAHYDROCHLORIDE - CUVRIOR						
N 215760 001	12662445	May 03, 2039	DS DP U-4262			
TRIHEPTANOIN - DOJOLVI						
N 213687 001	12551461	Nov 14, 2034	DP			
TRILACICLIB DIHYDROCHLORIDE - COSELA						
N 214200 001	12527798	Dec 05, 2037	U-3504			
TROFINETIDE - DAYBUE						
N 217026 001	11370755	Aug 03, 2040	DS DP		NCE	Mar 10, 2028
	11370755*PED	Feb 03, 2041			ODE-425	Mar 10, 2030
	11827600	Jul 12, 2042	DS DP U-3556		PED	Sep 10, 2028
	11827600*PED	Jan 12, 2043			PED	Sep 10, 2030
	12492167	Jul 12, 2042	DS DP U-3556			
	12492167*PED	Jan 12, 2043				
	9212204	Jan 27, 2032	U-3556			
	9212204*PED	Jul 27, 2032				
TROFINETIDE - DAYBUE STIX						
N 219884 001	11370755	Aug 03, 2040	DS DP		NCE	Mar 10, 2028
	11370755*PED	Feb 03, 2041			ODE*	Mar 10, 2030
	11827600	Jul 12, 2042	DS DP U-3556		PED	Sep 10, 2028

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TROFINETIDE - DAYBUE STIX						
N 219884 001	11827600*PED	Jan 12, 2043			PED	Sep 10, 2030
	12492167	Jul 12, 2042	DS DP U-3556			
	12492167*PED	Jan 12, 2043				
	9212204	Jan 27, 2032	U-3556			
	9212204*PED	Jul 27, 2032				
TROFINETIDE - DAYBUE STIX						
N 219884 002	11370755	Aug 03, 2040	DS DP		NCE	Mar 10, 2028
	11370755*PED	Feb 03, 2041			ODE*	Mar 10, 2030
	11827600	Jul 12, 2042	DS DP U-3556		PED	Sep 10, 2028
	11827600*PED	Jan 12, 2043			PED	Sep 10, 2030
	12492167	Jul 12, 2042	DS DP U-3556			
	12492167*PED	Jan 12, 2043				
	9212204	Jan 27, 2032	U-3556			
	9212204*PED	Jul 27, 2032				
TROFINETIDE - DAYBUE STIX						
N 219884 003	11370755	Aug 03, 2040	DS DP		NCE	Mar 10, 2028
	11370755*PED	Feb 03, 2041			ODE*	Mar 10, 2030
	11827600	Jul 12, 2042	DS DP U-3556		PED	Sep 10, 2028
	11827600*PED	Jan 12, 2043			PED	Sep 10, 2030
	12492167	Jul 12, 2042	DS DP U-3556			
	12492167*PED	Jan 12, 2043				
	9212204	Jan 27, 2032	U-3556			
	9212204*PED	Jul 27, 2032				
TROSPIUM CHLORIDE; XANOMELINE TARTRATE - COBENFY						
N 216158 001	12558317	Oct 29, 2039	DP			
TROSPIUM CHLORIDE; XANOMELINE TARTRATE - COBENFY						
N 216158 002	12558317	Oct 29, 2039	DP			
TROSPIUM CHLORIDE; XANOMELINE TARTRATE - COBENFY						
N 216158 003	12558317	Oct 29, 2039	DP			
TUCATINIB - TUKYSA						
N 213411 001	8648087	Apr 17, 2034	DS DP			
TUCATINIB - TUKYSA						
N 213411 002	8648087	Apr 17, 2034	DS DP			
UPADACITINIB - RINVOQ						
N 211675 001	12570664	Oct 17, 2036	U-4454		ODE-538	Apr 28, 2032
VADADUSTAT - VAFSEO						
N 215192 001	12569474	Jun 04, 2034	U-3876			
VADADUSTAT - VAFSEO						
N 215192 002	12569474	Jun 04, 2034	U-3876			
VADADUSTAT - VAFSEO						
N 215192 003	12569474	Jun 04, 2034	U-3876			
VARENICLINE TARTRATE - TYRVAYA						
N 213978 001	12576080	Oct 19, 2035	U-1900			
	12653824	Oct 19, 2035	DP			
VEPDEGESTRANT - VEPPANU						
N 219835 001	10647698	Jan 30, 2038	DS DP		NCE	May 01, 2031
	10899742	Dec 01, 2037	U-4278			
	11597720	Dec 01, 2037	DS DP U-4278			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VEPDEGESTRANT - VEPPANU							
N 219835	002	10647698	Jan 30, 2038	DS DP		NCE	May 01, 2031
		10899742	Dec 01, 2037	U-4278			
		11597720	Dec 01, 2037	DS DP U-4278			
VERICIGUAT - VERQUVO							
N 214377	001					D-198	Jan 21, 2029
VERICIGUAT - VERQUVO							
N 214377	002					D-198	Jan 21, 2029
VERICIGUAT - VERQUVO							
N 214377	003					D-198	Jan 21, 2029
VIGABATRIN - VIGAFYDE							
N 217684	001	12576054	Jun 08, 2043	DP			
VIMSELTINIB - ROMVIMZA							
N 219304	001	12509443	Apr 30, 2045	DP			
		12528787	Dec 06, 2044	DS DP			
		12551483	Dec 06, 2044	DP			
		12582655	Dec 23, 2039	U-4145			
		12617775	Dec 06, 2044	DS DP			
		12643883	Dec 06, 2044	DS DP			
	>A>	12686672	Apr 30, 2045	DP			
VIMSELTINIB - ROMVIMZA							
N 219304	002	12509443	Apr 30, 2045	DP			
		12528787	Dec 06, 2044	DS DP			
		12551483	Dec 06, 2044	DP			
		12582655	Dec 23, 2039	U-4145			
		12617775	Dec 06, 2044	DS DP			
		12643883	Dec 06, 2044	DS DP			
	>A>	12686672	Apr 30, 2045	DP			
VIMSELTINIB - ROMVIMZA							
N 219304	003	12509443	Apr 30, 2045	DP			
		12528787	Dec 06, 2044	DS DP			
		12551483	Dec 06, 2044	DP			
		12582655	Dec 23, 2039	U-4145			
		12617775	Dec 06, 2044	DS DP			
		12643883	Dec 06, 2044	DS DP			
	>A>	12686672	Apr 30, 2045	DP			
VOCLOSPORIN - LUPKYNIS							
N 213716	001	7332472	Oct 17, 2027	DS DP U-3056			
VONOPRAZAN FUMARATE - VOQUEZNA							
N 215151	001	7977488	Apr 10, 2030	DS			
VONOPRAZAN FUMARATE - VOQUEZNA							
N 215151	002	7977488	Apr 10, 2030	DS			
VOSORITIDE - VOXZOGO							
N 214938	001	12514906	Aug 01, 2036	DP U-3927			
		8198242	Jun 11, 2035	DS DP U-3927			
VOSORITIDE - VOXZOGO							
N 214938	002	12514906	Aug 01, 2036	DP U-3927			
		8198242	Jun 11, 2035	DS DP U-3927			
VOSORITIDE - VOXZOGO							
N 214938	003	12514906	Aug 01, 2036	DP U-3927			
		8198242	Jun 11, 2035	DS DP U-3927			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2026

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VOSORITIDE - VOXZOGO							
N 214938 003		12514906	Aug 01, 2036	DP U-3927			
		8198242	Jun 11, 2035	DS DP U-3927			
VUTRISIRAN SODIUM - AMVUTTRA							
N 215515 001						ODE-527	Mar 20, 2032
ZAVEGEPANT HYDROCHLORIDE - ZAVZPRET							
N 216386 001		8481546	Jun 26, 2034	DS DP U-3555			
ZIDESAMTINIB - JIDEYTRO							
N 220185 001	>A>	11542278	May 05, 2041	DS DP			
	>A>	12043626	Sep 30, 2042	DS DP			
	>A>	12054498	May 05, 2041	U-4579			
	>A>	12630560	Sep 30, 2042	U-4579			
ZIDESAMTINIB - JIDEYTRO							
N 220185 002	>A>	11542278	May 05, 2041	DS DP			
	>A>	12043626	Sep 30, 2042	DS DP			
	>A>	12054498	May 05, 2041	U-4579			
	>A>	12630560	Sep 30, 2042	U-4579			
ZIFTOMENIB - KOMZIFTI							
N 220305 001		12521396	Jul 16, 2044	DP			
ZOLIFLODACIN - NUZOLVENCE							
N 219491 001		8658641	Jun 20, 2030	DS			
		8889671	Jan 21, 2034	DS U-4369			
		9040528	Oct 13, 2029	U-4369			
		9187495	Jan 21, 2034	DS U-4369			
		9540394	Jan 21, 2034	U-4369			
		9839641	Jan 21, 2034	U-4369			
ZONISAMIDE - ZONISADE							
N 214273 001	>A>	12685723	Aug 18, 2038	DP			

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 46TH Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm